
<html lang="en"     class="pb-page"  data-request-id="9e66202c-100d-4721-88ff-cebddea95f30"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;article:article:10.1021/jm9011142;ctype:string:Journal Content;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2010.53.issue-4;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Single Agents with Designed Combination Chemotherapy Potential: Synthesis and Evaluation of Substituted Pyrimido[4,5-b]indoles as Receptor Tyrosine Kinase and Thymidylate Synthase Inhibitors and as Antitumor Agents" /></meta><meta name="dc.Creator" content="Aleem  Gangjee" /></meta><meta name="dc.Creator" content="Nilesh  Zaware" /></meta><meta name="dc.Creator" content="Sudhir  Raghavan" /></meta><meta name="dc.Creator" content="Michael  Ihnat" /></meta><meta name="dc.Creator" content="Satyendra  Shenoy" /></meta><meta name="dc.Creator" content="Roy L.  Kisliuk" /></meta><meta name="dc.Description" content="Combinations of antiangiogenic agents (AAs) with cytotoxic agents have shown significant promise in cancer treatment, and several such clinical trials are currently underway. We have designed, synt..." /></meta><meta name="Description" content="Combinations of antiangiogenic agents (AAs) with cytotoxic agents have shown significant promise in cancer treatment, and several such clinical trials are currently underway. We have designed, synt..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="January 21, 2010" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm9011142" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2010 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm9011142" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm9011142" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm9011142" /></link>
        
    
    

<title>Single Agents with Designed Combination Chemotherapy Potential: Synthesis and Evaluation of Substituted Pyrimido[4,5-b]indoles as Receptor Tyrosine Kinase and Thymidylate Synthase Inhibitors and as Antitumor Agents | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm9011142" /></meta><meta property="og:title" content="Single Agents with Designed Combination Chemotherapy Potential: Synthesis and Evaluation of Substituted Pyrimido[4,5-b]indoles as Receptor Tyrosine Kinase and Thymidylate Synthase Inhibitors and as Antitumor Agents" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0005.jpeg" /></meta><meta property="og:description" content="Combinations of antiangiogenic agents (AAs) with cytotoxic agents have shown significant promise in cancer treatment, and several such clinical trials are currently underway. We have designed, synthesized, and evaluated two compounds that each inhibit vascular endothelial growth factor receptor-2 (VEGFR-2) and platelet-derived growth factor receptor-β (PDGFR-β) for antiangiogenic effects and also inhibit human thymidylate synthase (hTS) for cytotoxic effects in single agents. The synthesis of these compounds involved the nucleophilic displacement of the common intermediate 5-chloro-9H-pyrimido[4,5-b]indole-2,4-diamine with appropriate benzenethiols. The inhibitory potency of both these single agents against VEGFR-2, PDGFR-β, and hTS is better than or close to standards. In a COLO-205 xenograft mouse model, one of the analogs significantly decreased tumor growth (tumor growth inhibition (TGI) = 76% at 35 mg/kg), liver metastases, and tumor blood vessels compared with a standard drug and with control and thus demonstrated potent tumor growth inhibition, inhibition of metastasis, and antiangiogenic effects in vivo. These compounds afford combination chemotherapeutic potential in single agents." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm9011142"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm9011142">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm9011142&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm9011142&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm9011142&amp;href=/doi/10.1021/jm9011142" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2010</span><span class="cit-fg-volume">, 53</span><span class="cit-fg-issue">, 4</span><span class="cit-fg-pageRange">, 1563-1578</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/53/4" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm901084f" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm901228u" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Single Agents with Designed Combination Chemotherapy Potential: Synthesis and Evaluation of Substituted Pyrimido[4,5-<i>b</i>]indoles as Receptor Tyrosine Kinase and Thymidylate Synthase Inhibitors and as Antitumor Agents</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Aleem++Gangjee">Aleem Gangjee</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nilesh++Zaware">Nilesh Zaware</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sudhir++Raghavan">Sudhir Raghavan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Ihnat">Michael Ihnat</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Satyendra++Shenoy">Satyendra Shenoy</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Roy+L.++Kisliuk">Roy L. Kisliuk</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, 600 Forbes Avenue, Pittsburgh, Pennsylvania 15282</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Department of Cell Biology, The University of Oklahoma Health Science Center, Oklahoma City, Oklahoma 73104</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Department of Biochemistry, Tufts University School of Medicine, 136 Harrison Avenue, Boston, Massachusetts 02111</span></div><div class="corresp-info"><strong>*</strong>To whom correspondence should be addressed. Telephone: 412-396-6070. Fax: 412-396-5593. E-mail address: <a href="/cdn-cgi/l/email-protection#27404649404d42426743525609424352"><span class="__cf_email__" data-cfemail="3354525d54595656735746421d565746">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm9011142&amp;href=/doi/10.1021%2Fjm9011142" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2010</span></span><span class="cit-volume">, 53</span><span class="cit-issue">, 4</span><span class="cit-pageRange">, 1563–1578</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 21, 2010</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>27 July 2009</li><li><span class="item_label"><b>Published</b> online</span>21 January 2010</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 February 2010</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm9011142" title="DOI URL">https://doi.org/10.1021/jm9011142</a></div><div class="article_header-article-copyright"><strong>Copyright © 2010 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1563%26pageCount%3D16%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAleem%2BGangjee%252C%2BNilesh%2BZaware%252C%2BSudhir%2BRaghavan%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D53%26issueNum%3D4%26contentID%3Djm9011142%26title%3DSingle%2BAgents%2Bwith%2BDesigned%2BCombination%2BChemotherapy%2BPotential%253A%2BSynthesis%2Band%2BEvaluation%2Bof%2BSubstituted%2BPyrimido%255B4%252C5-b%255Dindoles%2Bas%2BReceptor%2BTyrosine%2BKinase%2Band%2BThymidylate%2BSynthase%2BInhibitors%2Band%2Bas%2BAntitumor%2BAgents%26numPages%3D16%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1578%26publicationDate%3DFebruary%2B2010">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm9011142"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2965</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">40</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm9011142" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Single Agents with Designed Combination Chemotherapy Potential: Synthesis and Evaluation of Substituted Pyrimido[4,5-b]indoles as Receptor Tyrosine Kinase and Thymidylate Synthase Inhibitors and as Antitumor Agents&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Aleem&quot;,&quot;last_name&quot;:&quot;Gangjee&quot;},{&quot;first_name&quot;:&quot;Nilesh&quot;,&quot;last_name&quot;:&quot;Zaware&quot;},{&quot;first_name&quot;:&quot;Sudhir&quot;,&quot;last_name&quot;:&quot;Raghavan&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Ihnat&quot;},{&quot;first_name&quot;:&quot;Satyendra&quot;,&quot;last_name&quot;:&quot;Shenoy&quot;},{&quot;first_name&quot;:&quot;Roy&quot;,&quot;last_name&quot;:&quot;L. Kisliuk&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2010&quot;,&quot;month&quot;:&quot;01&quot;,&quot;day&quot;:&quot;21&quot;,&quot;issue&quot;:&quot;4&quot;,&quot;volume&quot;:&quot;53&quot;,&quot;pages&quot;:&quot;1563-1578&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm9011142&quot;},&quot;abstract&quot;:&quot;Combinations of antiangiogenic agents (AAs) with cytotoxic agents have shown significant promise in cancer treatment, and several such clinical trials are currently underway. We have designed, synthesized, and evaluated two compounds that each inhibit vascular endothelial growth factor receptor-2 (VEGFR-2) and platelet-derived growth factor receptor-β (PDGFR-β) for antiangiogenic effects and also inhibit human thymidylate synthase (hTS) for cytotoxic effects in single agents. The synthesis of these compounds involved the nucleophilic displacement of the common intermediate 5-chloro-9H-pyrimido[4,5-b]indole-2,4-diamine with appropriate benzenethiols. The inhibitory potency of both these single agents against VEGFR-2, PDGFR-β, and hTS is better than or close to standards. In a COLO-205 xenograft mouse model, one of the analogs significantly decreased tumor growth (tumor growth inhibition (TGI) = 76% at 35 mg/kg), liver metastases, and tumor blood vessels compared with a standard drug and with control and thus d&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm9011142&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm9011142" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm9011142&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm9011142" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm9011142&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm9011142" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm9011142&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm9011142&amp;href=/doi/10.1021/jm9011142" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm9011142" /></input><a href="/doi/pdf/10.1021/jm9011142" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm9011142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm9011142%26sid%3Dliteratum%253Aachs%26pmid%3D20092323%26genre%3Darticle%26aulast%3DGangjee%26date%3D2010%26atitle%3DSingle%2BAgents%2Bwith%2BDesigned%2BCombination%2BChemotherapy%2BPotential%253A%2BSynthesis%2Band%2BEvaluation%2Bof%2BSubstituted%2BPyrimido%255B4%252C5-b%255Dindoles%2Bas%2BReceptor%2BTyrosine%2BKinase%2Band%2BThymidylate%2BSynthase%2BInhibitors%2Band%2Bas%2BAntitumor%2BAgents%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D53%26issue%3D4%26spage%3D1563%26epage%3D1578%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=290808" title="Toxicity">Toxicity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/53/4" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/medium/jm-2009-011142_0005.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9011142&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Combinations of antiangiogenic agents (AAs) with cytotoxic agents have shown significant promise in cancer treatment, and several such clinical trials are currently underway. We have designed, synthesized, and evaluated two compounds that each inhibit vascular endothelial growth factor receptor-2 (VEGFR-2) and platelet-derived growth factor receptor-β (PDGFR-β) for antiangiogenic effects and also inhibit human thymidylate synthase (hTS) for cytotoxic effects in single agents. The synthesis of these compounds involved the nucleophilic displacement of the common intermediate 5-chloro-9<i>H</i>-pyrimido[4,5-<i>b</i>]indole-2,4-diamine with appropriate benzenethiols. The inhibitory potency of both these single agents against VEGFR-2, PDGFR-β, and hTS is better than or close to standards. In a COLO-205 xenograft mouse model, one of the analogs significantly decreased tumor growth (tumor growth inhibition (TGI) = 76% at 35 mg/kg), liver metastases, and tumor blood vessels compared with a standard drug and with control and thus demonstrated potent tumor growth inhibition, inhibition of metastasis, and antiangiogenic effects in vivo. These compounds afford combination chemotherapeutic potential in single agents.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div id="ac_i1" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i1"> </h2><div class="NLM_p">Antiangiogenic agents (AA)<a class="ref internalNav" href="#abbr1" aria-label="a">a</a> have established a new paradigm in cancer chemotherapy and have allowed significant progress toward the control and treatment of various cancers.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Normal cell angiogenesis is initiated under conditions of injured or hypoxic tissues, occurs in wound healing, menstrual cycle and pregnancy, and is promoted by vascular endothelial growth factor (VEGF) and similar growth factors. Except for these conditions, angiogenesis is mostly absent in normal tissues.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Heterogeneous solid growing tumors however are in a state of angiogenesis and continually overexpress growth factors.<div class="NLM_fn" id="abbr1">a<p class="last">Abbreviations: AA, antiangiogenic agents; VEGF, vascular endothelial growth factor; RTK, receptor tyrosine kinases; EGFR, epidermal growth factor receptor; PDGFR, platelet-derived growth factor receptor; <i>abl</i>, abelson proto-oncogene; c-kit, stem cell factor receptor; CSF-1R, colony stimulating factor 1 receptor; Flt-3, FMS-like tyrosine kinase 3; ErbB-2, human epidermal growth factor receptor 2; hTS, human thymidylate synthase; hDHFR, human dihydrofolate reductase; GARFT, glycinamide−ribonucleotide formyl transferase; AICARFT, aminoimidazole-4-carboxamide-ribonucleotide formyl transferase; 5-FU, 5-fluorouracil; PMX, pemetrexed; RTX, raltitrexed; MTX, methotrexate; TMQ, trimetrexate; PDB, protein data bank; DMSO<sub>2</sub>, methyl sulfone; DMAP, 4-dimethylaminopyridine; DMF, dimethylformamide; POCl<sub>3</sub>, phosphorus oxychloride; NMP, <i>N</i>-methyl-2-pyrrolidone; PI3K, phosphatidylinositol 3-kinase; CAM, chorioallantoic membrane; TGI, tumor growth inhibition; MTD, maximum tolerated dose; ADR, adverse drug reaction.</p></div></div><div class="NLM_p">Receptor tyrosine kinases (RTKs) are a subclass of cell surface growth factor receptors with intrinsic, ligand-controlled tyrosine kinase activity.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a> Epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), and vascular endothelial growth factor receptor (VEGFR) families of receptors are all RTKs and, despite their diverse biological roles, share similarities in structure and domain arrangement.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/medium/jm-2009-011142_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0006.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Single and multitargeted RTK inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9011142&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Clinically useful RTK inhibitors have resulted from small molecule ATP competitive inhibitors (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) that target the kinase domain of RTKs. While RTK inhibitors have afforded a new mechanism for the treatment of a variety of cancers, it was quickly realized that single RTK inhibitors allowed the development of resistance by point mutations in the ATP binding site. In addition, the molecular pathways responsible for tumor growth, survival, and metastasis are redundant and adaptable between individual patients and within tumors in the same patient. Thus treatment targeting a single RTK would be highly unlikely to provide long-term tumor control in most patients. Proangiogenic growth factors are redundantly expressed by both tumor and stromal cells.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Thus there is now a paradigm shift in the utility of RTK inhibitors for cancer treatment in that rather than single RTK inhibition it is now desirable to use multitargeted RTK inhibitors to overcome possible resistance and thwart the escape mechanism of alternative pathways for tumor growth. Recent FDA approvals of just such multitargeted RTK inhibitors sorafenib (VEGFR-2, PDGFR-β, FMS-like tyrosine kinase 3 (Flt-3), raf kinase, and stem cell factor receptor (c-kit)) and sunitinib (VEGFR-1, -2, and -3, PDGFR-β and -α, Flt-3, and colony stimulating factor 1 receptor (CSF-1R)) attest to the importance of this new paradigm in cancer chemotherapy.<a onclick="showRef(event, 'ref3 ref4 ref5 ref6 ref7 ref8 ref9 ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5 ref6 ref7 ref8 ref9 ref10 ref11 ref12">(3-12)</a> In addition, vandetanib is a VEGFR-2 inhibitor that combines EGFR (rather than PDGFR-β) inhibitory activity, and lapatinib also combines EGFR and human epidermal growth factor receptor-2 (ErbB-2) inhibitory activity. All of these multitargeting RTK inhibitors have some monotherapy potential but are mostly cytostatic (some cytotoxicity has been observed via apoptosis in a limited number of tumor types); thus for optimal benefit they must be combined with cytotoxic, conventional chemotherapeutic agents, radiation therapy, or both.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> The rationale and mechanisms for the success of these combinations continues to provide discussion in the literature.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13, 14)</a> Hundreds of such ongoing clinical trials (clinicaltrials.gov) attest to the importance of the concept and the individual drugs, both cytostatic and cytotoxic, in the combinations.</div><div class="NLM_p">Combination therapy with VEGFR-2 (endothelial cell inhibition) along with PDGFR-β inhibition (pericytes inhibition) increases the antiangiogenic effect even in the often intractable late state of solid tumors.<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15, 16)</a> Thus targeting both VEGFR-2 and PDGFR-β simultaneously is a desirable goal for AAs that have cytostatic and perhaps cytotoxic activity. The clinical success of sunitinib<a onclick="showRef(event, 'ref9 ref11'); return false;" href="javascript:void(0);" class="ref ref9 ref11">(9, 11)</a> and sorafenib<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> that target both VEGFR and PDGFR attests to the viability of this combination in single agent multi-RTK inhibitors. Preclinical and clinical evidence indicates that combinations of AAs with conventional cytotoxic agents, radiation therapy, or both results in additive or even synergistic antitumor effects<a onclick="showRef(event, 'ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17">(15-17)</a> and that monotherapy is usually unsuccessful with antiangiogenic agents. Rapid vascular regrowth in tumors after the removal of AAs attests to their cytostatic mechanism.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18, 19)</a></div><div class="NLM_p">Combination cancer chemotherapy is not a new idea. Recent studies indicate that the combination of antiangiogenic agents with cytotoxic agents is more effective in cancer treatment.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> However, what would be novel is if a single agent could be found that had both antiangiogenic activity by multitargeting RTKs and also possessed cytotoxic activity to afford combination chemotherapy in a single agent. We<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> synthesized such agents with VEGFR-2, PDGFR-β, and dihydrofolate reductase (DHFR) inhibition with good results. However, the potency of the cytotoxic component in these agents was extremely low.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Thus we elected to structurally engineer multi-RTK inhibitory attributes along with the deliberate design of cytotoxicity in single agents as a second iteration of our previous report. Such single agents would circumvent the pharmacokinetic problems of multiple agents, would avoid drug−drug interactions, could be used at lower doses to alleviate toxicity, could be devoid of overlapping toxicities, and could delay or prevent tumor cell resistance. Most importantly providing the cytotoxic agent, by structural design, in the same molecule allows the cytotoxicity to be mainfested as soon as the antiangiogenic effects are operable. A separately dosed cytotoxic agent may miss the timing window and hence preclude the intent of the combination. Such multitargeted agents could exert their cytotoxic action as soon as or even during transient tumor vasculature normalization<a onclick="showRef(event, 'ref13 ref22'); return false;" href="javascript:void(0);" class="ref ref13 ref22">(13, 22)</a> due to the antiangiogenic effects. Thus such agents might not need to be as potent as conventional separately dosed cytotoxic agents. Dosing of such an antiangiogenic multitargeted RTK inhibitor with a built-in cytotoxic mechanism would be tantamount to providing a combination of multitargeted RTK inhibitors along with a metronomic dosing of a cytotoxic agent. Thus these single agents would be in keeping with the two important mechanisms that explain the rationale for the success of separate antiangiogenic and cytotoxic chemotherapeutic agents in combination for cancer chemotherapy.<a onclick="showRef(event, 'ref13 ref22 ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref13 ref22 ref23 ref24 ref25">(13, 22-25)</a> Other advantages of such single agents are in the reduced cost and increased patient compliance, which are sometimes as significant contributors to chemotherapy failure as resistance, toxicity, and lack of efficacy.</div><div class="NLM_p">The antiangiogenic component is usually targeted to tumor cells and is, under most circumstances, not targeted to normal cells. However, the cytotoxic component is targeted to the tumor cells but not exclusively. Thus the challenge in designing single agents with a cytotoxic component is that the cytotoxic component should be potent enough to kill tumor cells that have been compromised via the antiangiogenic effect but not potent enough to cause serious toxicity to normal cells not affected by the antiangiogenic effect. Clearly one of the problems with conventional cytotoxic chemotherapeutic agents is dose-limiting toxicities. These single agents should avoid these toxicities since they do not need to be as potent as conventional chemotherapeutic agents.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/medium/jm-2009-011142_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0007.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Target compounds <b>1</b> and <b>2</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9011142&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/medium/jm-2009-011142_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0008.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Dihydrofolate reductase and thymidylate synthase inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9011142&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We have designed and synthesized compounds <b>1</b> and <b>2</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>), which each target VEGFR-2 and PDGFR-β and provide antiangiogenic effects in vivo and also have human thymidylate synthase (hTS) inhibitory activity to afford the cytotoxic component in vivo in single agents. The choice of VEGFR-2<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> and PDGFR-β<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> inhibition for antiangiogenic activity was obvious since these are the principal direct and indirect mediators of angiogenesis. The choice of inhibition of human dihydrofolate reductase (hDHFR) or hTS as the cytotoxic component was based in part on our long-standing interest in inhibitors of folate metabolizing enzymes and on structural, architectural, and molecular modeling considerations in the design of the molecules. In addition, the successful clinical and preclinical combinations of capecitibine,<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28, 29)</a> 5-FU<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> (TS inhibitors) and pemetrexed (PMX)<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31, 32)</a> (TS and DHFR inhibitor) (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>) with AAs in combination therapy with and without radiation was also an important factor in selecting TS or DHFR as the possible cytotoxic targets in the design of <b>1</b> and <b>2</b>.</div><div class="NLM_p">DHFR carries out the reduction of dihydrofolate to tetrahydrofolate and maintains the pool of reduced folate cofactors that function in one carbon transfers in a variety of metabolic transformations crucial for cell survival.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Thus inhibitors of DHFR such as methotrexate (MTX) and PMX (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>) have found utility as antitumor agents. TS carries out the sole de novo biosynthesis of TMP from dUMP. It utilizes 5,10-methylenetetrahydrofolate as a cofactor to transfer the methyl group to dUMP.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Because of its pivotal role in DNA synthesis and cell growth, it is a viable target for several clinically used cancer chemotherapeutic agents.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The fluoropyrimidine 5-FU and its derivatives, in particular, capecitabine (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>), have found extensive utility in ovarian, breast, colon, and several other cancers alone and in combinations and are a mainstay in cancer chemotherapy.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Folate-based TS inhibitor antimetabolites (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>) that are clinically used alone or in combination in a variety of cancers include PMX<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> and in Europe raltitrexed (RTX) a derivative of PDDF. In addition, <b>3</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>), also a TS inhibitor, and its derivatives are in various stages of clinical development alone and in combinations against a variety of cancers.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></div><div class="NLM_p">Tricyclic scaffolds reported in the literature with appropriate 4-anilino substitutions have shown excellent RTK inhibition.<a onclick="showRef(event, 'ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref39 ref40">(39, 40)</a> An example of such an analog is presented in Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>A.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> In a general RTK model, it was shown<a onclick="showRef(event, 'ref41 ref42 ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref41 ref42 ref43 ref44">(41-44)</a> that the 2-NH<sub>2</sub>, the N3, and the 4-anilino nitrogen of the pyrimidine ring of RTK inhibitors H-bond with the hinge region as depicted in Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>A. In addition, the phenyl ring of the 4-anilino moiety lies in the hydrophobic region 1, and the tricyclic scaffold mimics the purine ring of ATP.<a onclick="showRef(event, 'ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref39 ref40">(39, 40)</a> We reasoned that transposing the phenyl ring from the 4-position (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>A) to the 5-position of the tricyclic scaffold as shown in Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>B maintains access to hydrophobic region 1 and allows the H-bonds with the hinge region. Such compounds with phenyl substitutions in the 5-position should maintain RTK inhibitory activity. However, moving the phenyl ring from the 4- to the 5-position unveils a 2,4-diaminopyrimidine motif on the tricyclic scaffold (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>B) that is highly conducive for DHFR or TS inhibition or both.<a onclick="showRef(event, 'ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref45 ref46">(45, 46)</a> MTX and trimetrexate (TMQ) (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>) are well-known 2,4-diamino fused pyrimidines with hDHFR inhibition and for MTX hTS inhibitory activity as well.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Usually DHFR and TS inhibitors have a 2,4-diamino and a 2-amino-4-oxo substitution on the pyrimidine ring, respectively. There are however reports where analogs with a 2,4-diamino substitution have TS and DHFR inhibitory activity<a onclick="showRef(event, 'ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref45 ref46">(45, 46)</a> while a 2-amino-4-oxo substitution provides DHFR and TS inhibitory activity.<a onclick="showRef(event, 'ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref48 ref49">(48, 49)</a> Thus we designed 2,4-diamino-5-thio phenyl substituted pyrimido[4,5-<i>b</i>]indoles as potential RTK inhibitors with DHFR or TS inhibitory attributes or both.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/medium/jm-2009-011142_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0009.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Rationale for the synthesis of target molecules.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9011142&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/medium/jm-2009-011142_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0010.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Stereoview (SYBYL7.3) of the pyrimidine ring of <b>1</b> superimposed on the pyrimidine ring of the DHFR inhibitor in the X-ray crystal structure of hDHFR (<a href="https://" class="ext-link">1PDB</a>).<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9011142&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Molecular modeling with hDHFR confirmed that the third ring of the tricyclic scaffold could afford additional interaction with Ile60 of hDHFR<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> over the previously synthesized bicyclic analogs.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Modeling (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>) using SYBYL7.3<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> and superimposition of one of the energy-minimized conformations of <b>1</b> with the pyrimidine ring of <b>1</b> on the X-ray crystal structure of the pyrimidine ring of the pyrido[2,3-<i>d</i>]pyrimidine inhibitor (not shown) (<a href="https://" class="ext-link">1PDB</a>)<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> in hDHFR shows that the 2,4-diamino motif is maintained for hDHFR inhibitory activity as is the S-Ph, which mimics the phenyl ring of MTX<a onclick="showRef(event, 'ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref52 ref53">(52, 53)</a> and TMQ.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> The 2NH<sub>2</sub> and N1 make a salt bridge with Glu30 in hDHFR and the S-Ph ring makes hydrophobic contact with Phe31 and Val115 much like TMQ and MTX and the third ring of the tricyclic scaffold contacts Ile60. The conformation of the phenyl ring of <b>1</b> in Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a> is not the usual conformation of this ring in other reported hDHFR inhibitors. With this exception all other interactions of the scaffold of <b>1</b> were similar to the pteridine of MTX and the quinazoline of TMQ. Thus we anticipated DHFR inhibitory activity for <b>1</b>.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/medium/jm-2009-011142_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0011.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Stereoview (SYBYL7.3) of <b>1</b> superimposed on the X-ray crystal structure of pemetrexed (green) in hTS. (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1JU6">1JU6</a>).<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9011142&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">For TS inhibitory activity, modeling <b>1</b> by superimposing the pyrimidine ring of the energy minimized <b>1</b> (yellow) onto the pyrimidine ring of the X-ray crystal structure of PMX (green) in hTS (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1JU6">1JU6</a>),<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a> (SYBYL 7.3), showed that the superimposition is perfect for the two scaffolds. In the molecular modeling, the hydrophobic interactions of the tricyclic C-ring of <b>1</b> with Trp109 (bottom right) are somewhat better than those of the bicyclic B-ring of PMX. In addition, the S-phenyl ring of <b>1</b> and its close proximity to the benzoyl ring of PMX (green) is evident, as are the hydrophobic interactions with Ile108, Leu221, and Phe225 (top center) (and Met311 not shown). Also evident is the stacking interaction of <b>1</b> and dUMP (directly below <b>1</b>). Thus on the basis of molecular modeling, we anticipated compound <b>1</b> to have DHFR or TS inhibitory activity or both.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/medium/jm-2009-011142_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0012.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Stereoview (SYBYL7.3) of <b>1</b> superimposed on furo[2,3-<i>d</i>]pyrimidine X-ray crystal structure (not shown) in VEGFR2. Hinge region, 4NH<sub>2</sub>−Glu915 (C═O), N3−Cys917 (N−H), 2NH<sub>2</sub>−Cys917 (C═O); hydrophobic region 1, 5-thiophenyl−(Leu1033, Cys1043) (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1YWN">1YWN</a>).<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9011142&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>, energy-minimized <b>1</b> was superimposed (SYBYL7.3) onto a furo[2,3-<i>d</i>]pyrimidine<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> inhibitor (not shown) of VEGFR-2 in the X-ray crystal structure of VEGFR-2 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1YWN">1YWN</a>)<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> that indicated the hinge region binding of the 4NH<sub>2</sub> group of <b>1</b> with Glu915 (C═O); N3 with Cys917 (N−H); 2NH<sub>2</sub> with Cys917 (C═O). The 5-thiophenyl ring lies in hydrophobic region 1 and interacts with Val897, Leu1033, and Cys1043. Thus molecular modeling supports the inhibition of VEGFR-2 by <b>1</b>.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/medium/jm-2009-011142_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0013.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Stereoview of a docked pose of <b>1</b> in the putative PDGFR-β active site model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9011142&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">There is currently no crystal structure of PDGFR-β bound to a ligand. Using the structure of colony-stimulating factor-1 receptor (cFMS) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PKG">1PKG</a>, chain A)<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> as the template, a homology model of inactive PDGFR-β was generated using the Molecular Operating Environment (MOE 2007.09)<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> suite and methods indicated in the literature.<a onclick="showRef(event, 'ref58 ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref58 ref59 ref60">(58-60)</a> A conformational database was built for <b>1</b> and minimized and docked into the homology-modeled active site shown in Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>. The docked poses were then ranked. The 2- and 4-NH<sub>2</sub> groups of <b>1</b> form hydrogen bonds with the backbone residues of the hinge region (Tyr683, Cys684). Additionally, the 5-S-Ph is involved in a cation−π interaction (10−15 kcal/mol stabilization) with the protonated Arg604. Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a> shows only one of the low-energy binding poses of <b>1</b> with PDGFR-β and provides a working model for binding to PDGFR-β.</div><div class="NLM_p last">Thus we anticipated that the synthesis and evaluation of <b>1</b> and <b>2</b> would afford VEGFR-2 or PDGFR-β inhibition or both and that these compounds would also possess DHFR or TS inhibitory activity or both, thus providing combination chemotherapy potential in single molecules.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86703" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86703" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/medium/jm-2009-011142_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0014.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. <sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9011142&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) EtO<sub>2</sub>CCH<sub>2</sub>CN, <i>t</i>-BuOK, THF, reflux, 48 h; (b) Zn, HOAc, 50−55 °C, 2 h, 30 min; (c) methyl sulfone, 110 °C, 30 min; (d) 2,2-dimethylpropanoic anhydride, DMAP, NEt<sub>3</sub>, DMF, 60 °C, 48 h; (e) POCl<sub>3</sub>, reflux, 4 h; (f) NH<sub>3</sub>/CH<sub>3</sub>OH, sealed vessel, 130 °C, 48 h; (g) K<sub>2</sub>CO<sub>3</sub>, NMP, microwave, 250 °C, 30 min.</p></p></figure><div class="NLM_p last">The synthesis of the target compounds is outlined in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. Condensation of 1,2-dichloro-3-nitro-benzene <b>4</b> with the potassium salt of ethyl cyanoacetate anion provided adduct 2-(2-chloro-6-nitrophenyl)-2-cyanoacetate <b>5</b>. Zinc dust reduction of <b>5</b>, utilizing literature conditions,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> furnished ethyl 2-amino-4-chloro-1<i>H</i>-indole-3-carboxylate <b>6</b>. Cyclocondensation of <b>6</b> with carbamimidic chloride hydrochloride<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> afforded 2-amino-5-chloro-3<i>H</i>-pyrimido[4,5-<i>b</i>]indol-4(9<i>H</i>)-one <b>7</b>. Protection of the 2-amino group of <b>7</b> using 2,2-dimethyl propanoic anhydride provided <b>8</b>. The 4-chloro derivative <b>9</b> was prepared by treating <b>8</b> with phosphorus oxychloride at reflux. Displacement of the 4-chloro group with ammonia and concomitant deprotection of the 2-amino group of <b>9</b> was achieved by means of a sealed vessel reaction; thus the 2,4-diamino compound <b>10</b> was obtained as the common intermediate. Treatment of <b>10</b> with the appropriate substituted benzenethiols in a microwave apparatus (from Biotage) provided target compounds <b>1</b> and <b>2</b>.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Biological Evaluation and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31342" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31342" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Discrepancies in IC<sub>50</sub> values obtained from isolated RTK inhibitory assays compared with IC<sub>50</sub> values obtained against whole tumor cell assays are sometimes quite large (as much as 1000-fold). There are several reasons for this, and the conditions (e.g., ATP concentrations for ATP competitive agents) of the assay dictate the IC<sub>50</sub> values. Variations in assay conditions afford different IC<sub>50</sub> values. Thus we have elected to evaluate the RTK inhibitory activity of our compounds using human tumor cells known to express high levels of the appropriate RTK.</div><figure id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/medium/jm-2009-011142_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0015.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Standard drugs and control agents.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9011142&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We believe that tumor cell inhibitory assays are the most meaningful assays of the activity of the analogs evaluated and allow the most appropriate extrapolation regarding candidate selection and chances of success for in vivo evaluations. In addition to this, we recognize that the IC<sub>50</sub>'s of standard compounds also vary under different assay conditions, thus we use a standard (control) compound in each of our assays. These standard compounds were evaluated side by side with our analogs and afford direct comparison of IC<sub>50</sub>'s of our analogs with the standard compounds.</div><div class="NLM_p">Compounds <b>1</b> and <b>2</b> were evaluated as inhibitors of EGFR, VEGFR-1, VEGFR-2, PDGFR-β, phosphatidylinositol 3-kinase (PI3K), and Flt-3 and for antiproliferative activity against the A431 tumor cell line that overexpresses EGFR. For the RTK and PI3K assays, cells overexpresssing each kinase were exposed to compound followed by the ligand for each RTK as described in the <a class="ref internalNav" href="#sec6" aria-label="Detailed Methods">Detailed Methods</a> section. This was followed by a “cytoblot”, or in-cell ELISA, developed by our laboratory for the evaluation of kinase activity.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> The compounds were compared with standards <i>N</i>-(3-bromophenyl)-6,7-dimethoxyquinazolin-4-amine (<b>13</b>) for EGFR (Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>), semaxinib for VEGFR-2, <i>N</i>-(4-chloro-2-fluorophenyl)-6,7-dimethoxyquinazolin-4-amine (<b>14</b>) for VEGFR-1, (<i>Z</i>)-3-((4-dimethylamino)benzylidene)indolin-2-one (DMBI) for PDGFR-β, cisplatin (CDDP) for A431, 2-morpholino-8-phenyl-4<i>H</i>-chromen-4-one (<b>15</b>) for P13K, and 2-(3,4-dimethoxybenzamido)-4,5,6,7-tetrahydrobenzo[<i>b</i>]thiophene-3-carboxamide (<b>16)</b> for Flt-3 (Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>). The results are listed in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>. The compounds are active against VEGFR-2 and within 2−4-fold of the standard semaxinib with <b>1</b> more potent than <b>2</b>. Against PDGFR-β, <b>1</b> is somewhat more potent than the standard DMBI and <b>2</b> is about 11-fold less potent. Against the growth of A431 tumor cells in culture <b>2</b> is similar to cisplatin while <b>1</b> is much less potent. Since neither compound is a potent EGFR inhibitor compared with standard <b>13</b>, the marginal inhibitory activity against A431 tumor cells of <b>1</b> and <b>2</b> was not surprising. The involvement of Flt-3<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> inhibition for both sorafenib and sunitinib in addition to other RTKs prompted the modeling of <b>1</b> in the X-ray crystal structure of Flt-3.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> This afforded an excellent docked conformation, and hence we initiated the whole cell assay for Flt-3 kinase for <b>1</b> and <b>2</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). Compounds <b>1</b> and <b>2</b> were about 13-fold less active against Flt-3 compared with standard <b>16</b>. Due to the importance of PI3K in tumor growth,<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> we also evaluated <b>1</b> and <b>2</b> in the PI3K assay using <b>15</b> as the standard (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>); compounds <b>1</b> and <b>2</b> are 8-fold and 11-fold less active, respectively, than the standard <b>15</b> against PI3K.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. IC<sub>50</sub> Values (μM) of Kinase Inhibition and in the A431 Cytotoxicity Assay and EC<sub>50</sub> (μM) against P13K<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top"><th align="center">compd no.</th><th align="center" char=".">EGFR kinase inhibition</th><th align="center" char=".">VEGFR-2 (Flk-1) kinase inhibition</th><th align="center" char=".">VEGFR-1 (Flt-1) kinase inhibition</th><th align="center" char=".">PDGFR-β kinase inhibition</th><th align="center" char=".">A431 cytotoxicity</th><th align="center" char=".">PI3K activity</th><th align="center" char=".">Flt-3 activity</th></tr></thead><tbody><tr valign="top"><td align="left"><b>1</b></td><td align="char" char=".">15.07 ± 3.1</td><td align="char" char=".">22.6 ± 4.5</td><td align="char" char=".">118.1 ± 19.4</td><td align="char" char=".">2.8 ± 0.42</td><td align="char" char=".">49.2 ± 4.7</td><td align="char" char=".">21.6</td><td align="char" char=".">41.2 ± 5.7</td></tr><tr valign="top"><td align="left"><b>2</b></td><td align="char" char=".">10.41 ± 1.2</td><td align="char" char=".">56.3 ± 7.1</td><td align="char" char=".">160.1 ± 28.9</td><td align="char" char=".">40.3 ± 5.1</td><td align="char" char=".">14.1 ± 2.0</td><td align="char" char=".">12.2</td><td align="char" char=".">39.6 ± 4.1</td></tr><tr valign="top"><td align="left"><b>13</b></td><td align="char" char=".">0.23 ± 0.05</td><td align="char" char="."> </td><td align="char" char="."> </td><td align="char" char="."> </td><td align="char" char="."> </td><td align="char" char="."> </td><td align="char" char="."> </td></tr><tr valign="top"><td align="left">semaxinib</td><td align="char" char="."> </td><td align="char" char=".">12.9 ± 2.9</td><td align="char" char="."> </td><td align="char" char="."> </td><td align="char" char="."> </td><td align="char" char="."> </td><td align="char" char="."> </td></tr><tr valign="top"><td align="left"><b>14</b></td><td align="char" char="."> </td><td align="char" char="."> </td><td align="char" char=".">14.1 ± 2.8</td><td align="char" char="."> </td><td align="char" char="."> </td><td align="char" char="."> </td><td align="char" char="."> </td></tr><tr valign="top"><td align="left">DMBI</td><td align="char" char="."> </td><td align="char" char="."> </td><td align="char" char="."> </td><td align="char" char=".">3.75 ± 0.31</td><td align="char" char="."> </td><td align="char" char="."> </td><td align="char" char="."> </td></tr><tr valign="top"><td align="left">cisplatin</td><td align="char" char="."> </td><td align="char" char="."> </td><td align="char" char="."> </td><td align="char" char="."> </td><td align="char" char=".">10.6 ± 3.5</td><td align="char" char="."> </td><td align="char" char="."> </td></tr><tr valign="top"><td align="left"><b>15</b></td><td align="char" char="."> </td><td align="char" char="."> </td><td align="char" char="."> </td><td align="char" char="."> </td><td align="char" char="."> </td><td align="char" char=".">1.5</td><td align="char" char="."> </td></tr><tr valign="top"><td align="left"><b>16</b></td><td align="char" char="."> </td><td align="char" char="."> </td><td align="char" char="."> </td><td align="char" char="."> </td><td align="char" char="."> </td><td align="char" char="."> </td><td align="char" char=".">2.9 ± 0.031</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">In-cell kinase activity was assessed by a “cytoblot” developed in our laboratory using A431 cells, which overexpress EGFR, SF539 cells for PDGFRβ, U251 cells for VEGFR2, A498 cells for VEGFR1, MV 3:11 cells for Flt-3, and HeLa cells for PI3K as described in the <a class="ref internalNav" href="#sec6" aria-label="Detailed Methods">Detailed Methods</a> section.</p></div></div></div><div class="NLM_p">The compounds were also evaluated against isolated DHFR and TS for the cytotoxic component. The results are listed in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> and are compared with standards for DHFR (MTX, trimethoprim (TMP)) and TS (PMX, RTX). The compounds were potent inhibitors of hTS at submicromolar levels that were 54-fold (<b>1</b>) and 76-fold (<b>2</b>) more active than clinically used PMX as its monoglutamate and comparable to RTX. The better hTS inhibitory activity of both <b>1</b> and <b>2</b> compared with PMX could be due to a better C-ring interaction with Trp109.</div><div class="NLM_p">However <b>1</b> and <b>2</b> were not appreciably potent against hDHFR as well as other DHFR. Why was <b>1</b> poorly active against hDHFR? Molecular modeling had suggested that superimposition of <b>1</b> onto DHFR inhibitors in X-ray crystal structures (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>) should afford inhibition of hDHFR. The modeling provides the 5-S-phenyl of <b>1</b> in a binding mode that is at 90° to other hDHFR inhibitor (such as MTX<a onclick="showRef(event, 'ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref52 ref53">(52, 53)</a> and TMQ<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a>) side chain phenyl rings. On the basis of molecular modeling, other binding modes of <b>1</b> afford clashes of the C-ring with side chains and backbone of hDHFR. This could perhaps explain, in part, the poor activity against hDHFR.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Inhibitory Concentrations (IC<sub>50</sub>, μM) against DHFR and TS</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="rowsep1"><th class="rowsep1" align="center"> </th><th class="colsep1 rowsep1" colspan="3" align="center" char=".">TS inhibitory activity,<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> IC<sub>50</sub> (μM)</th><th class="rowsep1" colspan="3" align="center" char=".">DHFR inhibitory activity,<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> IC<sub>50</sub> (μM)</th></tr><tr valign="top"><th align="center">compd</th><th align="center" char=".">human<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th><th align="center" char="."><i>Escherichia coli</i><a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th><th align="center" char="."><i>Toxoplasma gondii</i><a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></th><th align="center" char=".">human<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></th><th align="center" char="."><i>Escherichia coli</i><a class="ref internalNav" href="#t2fn6" aria-label="f">f</a></th><th align="center" char="."><i>Toxoplasma gondii</i><a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></th></tr></thead><tbody><tr valign="top"><td align="left"><b>1</b></td><td align="char" char=".">0.54</td><td align="char" char=".">>27</td><td align="char" char=".">0.11</td><td align="char" char=" ">>33 (17)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td align="char" char=" ">>33 (35)</td><td align="char" char=".">33</td></tr><tr valign="top"><td align="left"><b>2</b></td><td align="char" char=".">0.39</td><td align="char" char=".">>26</td><td align="char" char=".">>26</td><td align="char" char=" ">>31 (7)</td><td align="char" char=" ">>31 (27)</td><td align="char" char=" ">>31 (22)</td></tr><tr valign="top"><td align="left">pemetrexed<a class="ref internalNav" href="#t2fn7" aria-label="g">g</a></td><td align="char" char=".">29.0</td><td align="char" char=".">15</td><td align="char" char=".">14</td><td align="char" char="."> </td><td align="char" char="."> </td><td align="char" char="."> </td></tr><tr valign="top"><td align="left">raltitrexed<a class="ref internalNav" href="#t2fn8" aria-label="h">h</a></td><td align="char" char=".">0.29</td><td align="char" char=".">2.3</td><td align="char" char=".">0.48</td><td align="char" char="."> </td><td align="char" char="."> </td><td align="char" char="."> </td></tr><tr valign="top"><td align="left">MTX</td><td align="char" char="."> </td><td align="char" char="."> </td><td align="char" char="."> </td><td align="char" char=".">0.022</td><td align="char" char=".">0.0066</td><td align="char" char=".">0.019</td></tr><tr valign="top"><td align="left">trimethoprim</td><td align="char" char="."> </td><td align="char" char="."> </td><td align="char" char="."> </td><td align="char" char=".">680</td><td align="char" char=".">0.02</td><td align="char" char=".">2.9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">The percent inhibition was determined at a minimum of four inhibitor concentrations within 20% of the 50% point. The standard deviations for determination of 50% points were within ±10% of the value given.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">Numbers in parentheses indicate the percent inhibition at the stated concentration.</p></div><div class="footnote" id="t2fn3"><sup>c</sup><p class="last">Kindly provided by Dr. Frank Maley, New York State Department of Health.</p></div><div class="footnote" id="t2fn4"><sup>d</sup><p class="last">Kindly provided by Dr. Karen Anderson, Yale University, New Haven, CT.</p></div><div class="footnote" id="t2fn5"><sup>e</sup><p class="last">Kindly provided by Dr. Andre Rosowsky, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.</p></div><div class="footnote" id="t2fn6"><sup>f</sup><p class="last">Kindly provided by Dr. R. L. Blakley, St. Jude Children’s Hospital, Memphis, TN.</p></div><div class="footnote" id="t2fn7"><sup>g</sup><p class="last">Kindly provided by Dr. Chuan Shih, Eli Lilly and Co.</p></div><div class="footnote" id="t2fn8"><sup>h</sup><p class="last">Kindly provided by Dr. Ann Jackman, CRC Centre for Cancer Therapeutics, Surrey SM2 5NG, England.</p></div></div></div><div class="NLM_p">Thus <b>1</b> and <b>2</b> were good to moderate inhibitors of VEGFR-2 and PDGFR-β, comparable or better than the standards (except <b>2</b> for PDGFR-β) for RTK inhibition and potential antiangiogenic activity, and also had hTS inhibitory activity (IC<sub>50</sub>) in the submicromolar range to provide the cytotoxic effects needed for combination chemotherapy potential in single agents. The hTS IC<sub>50</sub> values were not in the single digit nanomolar range and hence should not cause severe toxicity to normal cells not compromised by the antiangiogenic effects of <b>1</b> and <b>2</b>. The usual next step is to determine the inhibitory activity against tumor cells in culture. The NCI preclinical 60 tumor panel was the obvious choice; however since angiogenesis is not part of these tumors in culture, only the cytotoxic effects were expected to play a role in the inhibition of these cells in culture. Compound <b>1</b> was evaluated against the growth of the NCI 60 tumor cell lines, and the results were as anticipated; <b>1</b> inhibited the tumors at GI<sub>50</sub> values of 1−10 μM. This was about 10-fold less than the isolated hTS inhibitory activity (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>) and indicates a relatively low potency completely in keeping with the absence of the antiangiogenic component and perhaps an indication of low toxicity to normal cells.</div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Pharmacodynamic (PD) Data in MDA-MB-435 Cells</h3><div class="NLM_p">Compounds <b>1</b> and <b>2</b> were evaluated for cell viability (IC<sub>50</sub> of cell kill) in several cell types (Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>). In addition, MDA MB 435 metastatic dermal breast cancer cells were exposed to 20 μM of <b>1</b> and <b>2</b> for cell cycle analysis (Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a>), and cell signaling analysis (Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a>) was carried out. First, cell viability was evaluated on cells serum-starved overnight before the addition of 1% FCS to the cancer cells, 200 ng/mL hrVEGF-165 to the endothelial cells, and 100 ng/mL hrPDGF-BB to the SMC variants together with drug for 24 h followed by 24 h incubation in serum-containing media and a cell viability assay carried out as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. It was found that <b>1</b> had varied effects (Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>) on three cancer cell lines (MDA-MB-435, A431, Capan-1) and fairly consistent effects on two endothelial cell types (HUVEC, HMEC-1). Human retinal pericytes (Huperi-3)<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> (not human aortic SMCs) were very sensitive to <b>1</b> cell kill (Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>, left panel). Compound <b>2</b> had a different profile of sensitivity than did <b>1</b> with tumor cells being the most sensitive, endothelial cells falling someplace in the middle, and SMC variants being the least sensitive to <b>2</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>, right panel). For cell cycle analysis, it was found that after 24 h exposure, <b>1</b> resulted in a buildup in G<sub>2</sub>/M (Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a>, right panel) while <b>2</b> resulted in an increase in S phase (Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a>, left panel). Next, a cell signaling experiment was performed on the MDA-MB-435 breast cells exposed for either 1 or 4 h to 20 μM <b>1</b> or <b>2</b>. The same cells exposed to 30 J/m<sup>2</sup> UV-B for 4 h were used as a positive control. The first downstream target of RTKs was activated phospho-p42/44 MAPkinase (ERK 1/2), a MAP kinase member involved in cell proliferation in many cancers. It was found that both <b>1</b> and <b>2</b> reduced levels of activated ERK 1/2, but not to the same extent as UV-B exposure (Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a>; top gel). In contrast, exposure to neither agent resulted in increased levels of activated phospho-Akt, a cell survival pathway also downstream of RTKs with levels of (nonphospho) Akt used as a loading control (Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a>, middle two gels). Finally, neither 20 μM <b>1</b> nor 20 μM <b>2</b> resulted in increased levels of cleaved caspase 3, the terminal step in apoptosis (Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a>; bottom most gel).</div><figure id="fig10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/medium/jm-2009-011142_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0016.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Cell viability assay after 48 h treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9011142&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/medium/jm-2009-011142_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0001.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Cell cycle analysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9011142&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig12" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/medium/jm-2009-011142_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0002.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Cell signaling.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9011142&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> MDA-MB-435 Chorioallantoic Membrane (CAM) Xenograft</h3><div class="NLM_p">We have developed an intermediate systemic in vivo xenograft system using the chicken embryo CAM. This method allows for in vivo testing of more compounds in a given time and cost than the mouse tumor xenograft studies. For the CAM xenograft model, MDA-MB-435 cells (250 000) were implanted under the vascularized CAM of 10 days of incubation (DI) chicken embryos, and then the embryos were treated systemically with 25 mg/kg <b>1</b> on days one and two, and CAMs were fixed, excised, and imaged with representative images shown from five to six CAMs (Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a>). It was found that <b>1</b> reduced both the size and the vascularity of resulting tumors, at least to the same extent as the standard VEGFR2 kinase inhibitor semaxanib at 10 mg/kg (Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a>). These results indicate the antitumor and antiangiogenic activity of <b>1</b>. Taken together the preliminary in vitro and the in vivo results (see below) suggest that compound <b>1</b> has profound antiangiogenic activity both in vitro and in vivo. Further, these data indicate that 1 may act more on the vasculature to decrease RTK growth factor signaling perhaps decreasing cell proliferation. The data from compound <b>2</b> are more complex; it appears that this compound acts both on the tumor and on cells of the vasculature to decrease RTK and MAPK signaling. The increase in S phase content observed in response to <b>2</b> could indicate that cells enter into DNA synthesis but cannot exit into G<sub>2</sub>, a phenomenon consistent with TS inhibition.</div><figure id="fig13" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/medium/jm-2009-011142_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0003.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. MDA-MB-435 CAM 72 h xenograft.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9011142&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The logical next step was to demonstrate antitumor activity of <b>1</b> via an in vivo animal model. Compound <b>1</b> was the first choice over <b>2</b> mainly because of its better PDGFR-β inhibitory activity. To determine the antitumor effect of <b>1</b> in vivo, athymic mice were first implanted with COLO-205 metastatic colon cancer cells, shown to overexpress PDGFR-β.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> At day 9 after implantation, treatment was initiated with the PDGFR-β inhibitor DMBI<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> at the MTD of 15 mg/kg three times weekly and with <b>1</b> at two doses, 25 and 35 mg/kg three times weekly. Tumor growth was measured using calipers. It was found that DMBI and <b>1</b> resulted in significant decreases in primary tumor growth rate (Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a>A,B) and that <b>1</b> resulted in a further significant decrease in tumor growth rate compared with the control compound, DMBI. At the end of the experiment, tumors were taken and stained for blood vessels. It was found that <b>1</b> at 35 mg/kg three times weekly resulted in a significant decrease in primary tumor vascularity compared with control treated animals (Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a>C) suggesting an antiangiogenic effect in vivo. Finally, livers were stained for the presence of metastases, and it was found that <b>1</b> at both 25 and 35 mg/kg, but not DMBI, resulted in significantly reduced numbers of COLO-205 metastases to the liver (Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a>D). TGI for <b>1</b> is 76% at 35 mg/kg in this study. No MTD was determined for <b>1</b>; doses up to 75 mg/kg were well tolerated without any visual ADRs or loss in weight. Thus in vivo compound <b>1</b> has considerable antitumor activity, antiangiogenic activity, and antimetastatic activity. Further in vitro and in vivo studies are currently underway to afford further evidence of the triple mechanism(s) of action of <b>1</b> and <b>2</b> with a triple combination of a VEGFR2, a PDGFR-β, and a hTS inhibitor as standard as well as a combination of two of these standards together to determine the mechanism of action, in vivo, of <b>1</b> and <b>2</b> responsible for the in vivo antitumor, antiangiogenic, and antimetastatic activities of <b>1</b>.</div><figure id="fig14" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/medium/jm-2009-011142_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0004.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Tumor growth: (A) primary tumor volume, (B) primary tumor growth rate, (C) primary tumor vascularity, and (D) liver metastasis of COLO-205 tumor xenografts after various treatments. COLO-205 cells were implanted into male athymic mice as in the <a class="ref internalNav" href="#sec6" aria-label="Detailed Methods">Detailed Methods</a> section. Compounds were administered at the listed doses three times weekly, and tumor growth was measured using calipers. At the experiment end, tumors were stained for vascularity and livers were stained for metastases as in the <a class="ref internalNav" href="#sec6" aria-label="Detailed Methods">Detailed Methods</a> section. Data represent the average ± SD of 7−11 animals: ∗, <i>P</i> > 0.05; ∗∗, <i>P</i> < 0.01; ∗∗∗, <i>P</i> < 0.001 by one-way ANOVA and Neuman−Keuls post-test. The average tumor growth rate for control treated animals (B) is 58.9 mm<sup>3</sup>/day, average number of tumor vessels in control-treated animals (C) is 11.2/field, and average metastases in control treated animals (D) are 0.65/lobe.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9011142&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">We designed, synthesized, and discovered two compounds, <b>1</b> and <b>2</b>, that inhibit VEGFR-2 and PDGFR-β in whole cells at IC<sub>50</sub> values comparable to standard compounds. In addition, <b>1</b> and <b>2</b> also inhibit isolated hTS better than the monoglutamate of clinically used PMX. Thus remarkably <b>1</b> and <b>2</b> possess both multi-RTK inhibitory activity (VEGFR-2 and PDGFR-β) for antiangiogenic effects and hTS inhibitory activity (cytotoxic effects) comparable to or better than clinically used single agents. Compound <b>1</b> in vivo in a COLO-205 metastatic colon cancer xenograft mouse model, at both 25 and 35 mg/kg, showed significantly decreased tumor growth, significantly decreased liver metastasis, and significantly decreased primary tumor blood vessels (angiogenesis), remarkably without any toxicity, compared with untreated control and a standard PDGFR-β inhibitor DMBI. The combination chemotherapeutic attributes of <b>1</b> and <b>2</b> of VEGFR-2, PDGFR-β, and hTS inhibitory activity makes them unique and distinct from all other known agents in clinical or investigational use. The relevance of this combination of activities in a single agent is that it mimics the clinically relevant combinations of RTK inhibitors with TS inhibitors. In addition, the in vivo antitumor, antiangiogenic, and antimetastatic activity of <b>1</b> supports the optimization and development of this agent and design of analogs as potential clinically useful antitumor agents that afford combination chemotherapy potential in single agents. Such single agents are designed to be used as monotherapy but could also be used with other antitumor agents or radiation as part of the therapy for cancers.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22724" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22724" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Analytical samples were dried in vacuo (0.2 mmHg) in a CHEM-DRY drying apparatus over P<sub>2</sub>O<sub>5</sub> at 80 °C. Melting points were determined on a MEL-TEMP II melting point apparatus with FLUKE 51 K/J electronic thermometer and are uncorrected. Nuclear magnetic resonance spectra for proton (<sup>1</sup>H NMR) were recorded on a Bruker WH-300 (300 MHz) spectrometer. The chemical shift values are expressed in ppm (parts per million) relative to tetramethylsilane as an internal standard: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad singlet. Thin-layer chromatography (TLC) was performed on Whatman Sil G/UV254 silica gel plates with a fluorescent indicator, and the spots were visualized under 254 and 366 nm illumination. Proportions of solvents used for TLC are by volume. Column chromatography was performed on a 230−400 mesh silica gel (Fisher, Somerville, NJ) column. Elemental analyses were performed by Atlantic Microlab, Inc., Norcross, GA. Element compositions are within ±0.4% of the calculated values. Fractional moles of water or organic solvents frequently found in some analytical samples of antifolates could not be prevented despite 24−48 h of drying in vacuo and were confirmed where possible by their presence in the <sup>1</sup>H NMR spectra. Elemental analysis was used to determine the purity of the final compounds <b>1</b> and <b>2</b>. All solvents and chemicals were purchased from Aldrich Chemical Co. or Fisher Scientific and were used as received. Purity of the final compounds <b>1</b> and <b>2</b> were >95% and were determined by elemental (C, H, N, S) analysis.</div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Ethyl 2-Amino-4-chloro-1<i>H</i>-indole-3-carboxylate (<b>6</b>)</h3><div class="NLM_p">To an ice-cold solution of ethyl cyanoacetate (10.9 mL, 102.4 mmol) in anhydrous THF (170 mL) under N<sub>2</sub> was added potassium <i>tert-</i>butoxide (12.07 g, 107.5 mmol). The formed white suspension was stirred for 15 min then treated with 1,2-dichloro-3-nitrobenzene <b>4</b> (9.83 g, 51.2 mmol). The suspension was heated at reflux for 48 h. The resulting reddish brown solution was poured into H<sub>2</sub>O, and the aqueous mixture was acidified to pH 2 with concentrated HCl. The mixture was extracted with ether (3×), and then the combined organic phases were dried using sodium sulfate and concentrated to give ethyl (2-chloro-2-nitrophenyl)(cyano)acetate <b>5</b> as a dark oil. The oil was purified by column chromatography eluting with 10:1 hexane/EtOAc. TLC <i>R</i><sub><i>f</i></sub> 0.23 (hexane/EtOAc, 3:1). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 1.17−1.22 (t, 3 H, CH<sub>3</sub>), 4.18−4.25 (q, 2 H, CH<sub>2</sub>), 6.36 (bs, 2 H, 2-NH<sub>2</sub>, exch), 7.75−7.81 (t, <i>J</i> = 8.1 Hz, 1 H, C4-CH), 8.04−8.06 (dd, <i>J</i> = 6.9, 1.2 Hz, 1 H, Ar), 8.13−8.16 (dd, <i>J</i> = 6.9, 1.2 Hz, 1 H, Ar). The material was used directly for the next step.</div><div class="NLM_p last">A solution of impure <b>5</b> (18 g, 67 mmol) in glacial AcOH (185 mL) was treated with a single charge of Zn dust (12.1 g, 185 mmol). The mixture was heated at 55 °C for 45 min, then treated with more Zn dust (6 g). After heating for another 105 min, the mixture was filtered through a pad of Celite. The pad was washed well with AcOH, and the filtrate was concentrated to a residue that was distributed between CHCl<sub>3</sub> and H<sub>2</sub>O. The organic phase was washed with 5% aq NaHCO<sub>3</sub> and concentrated to a residue that was purified by column chromatography, eluting sequentially with 0%, 5%, and 10% EtOAc in CHCl<sub>3</sub>. The fractions containing the pure product (TLC) were pooled and evaporated to give a pink solid. The overall yield from <b>4</b> to <b>6</b> was 63% (7.7 g of <b>6</b> was obtained). TLC <i>R</i><sub><i>f</i></sub> 0.18 (hexane/CHCl<sub>3</sub>, 1:1); mp 140−142 °C; <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 1.26−1.30 (t, 3 H, CH<sub>3</sub>), 4.15−4.23 (q, 2 H, CH<sub>2</sub>), 6.82−6.87 (t, <i>J</i> = 7.8 Hz, 1 H, C6-CH), 6.92−6.96 (dd, <i>J</i> = 7.8 Hz, 1 H, Ar), 6.96 (bs, 2 H, 2-NH<sub>2</sub>, exch), 7.05−7.08 (dd, <i>J</i> = 7.8 Hz, 1 H, Ar), 11.35 (bs, 1 H, 9-NH, exch). Anal. (C<sub>11</sub>H<sub>11</sub>ClN<sub>2</sub>O<sub>2</sub>) C, H, N.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> 2-Amino-5-chloro-3,9-dihydro-4<i>H</i>-pyrimido[4,5-<i>b</i>]indol-4-one (<b>7</b>)</h3><div class="NLM_p last">A mixture of ethyl 2-amino-4-chloro-1<i>H</i>-indole-3-carboxylate (<b>6</b>) (200 mg, 0.837 mmol), carbamimidic chloride hydrochloride<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> (106.22 mg, 1.37 mmol), and methyl sulfone (1 g) was stirred and heated at 110−120 °C for 30 min. About 10 mL of water was added to quench the reaction. Ammonia−water was added to neutralize the reaction mixture. The precipitated solid was filtered, dissolved in chloroform and methanol, and dried (Na<sub>2</sub>SO<sub>4</sub>), the solvent was evaporated, and the solid was recrystallized from chloroform and methanol (1:1) in overall yield of 78%. TLC <i>R</i><sub><i>f</i></sub> 0.33 (CHCl<sub>3</sub>/MeOH, 1:1); mp >250 °C; <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 6.58 (bs, 2 H, 2-NH<sub>2</sub>, exch), 7.04−7.06 (t, <i>J</i> = 3.3 Hz, 1 H, C7-CH), 7.17−7.20 (m, 2 H, Ar), 10.42 (s, 1 H, 3-NH, exch), 11.65 (s, 1 H, 9-NH, exch). HRMS calcd for C<sub>10</sub>H<sub>7</sub>ClN<sub>4</sub>O 234.0309, found 234.0308.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> <i>N</i>-(5-Chloro-4-oxo-4,9-dihydro-3<i>H</i>-pyrimido[4,5-<i>b</i>]indol-2-yl)-2,2-dimethyl Propanamide (<b>8</b>)</h3><div class="NLM_p last">To a round bottomed flask were added <b>7</b> (300 mg, 1.27 mmol), 2,2-dimethylpropanoic anhydride (713.32 mg, 3.83 mmol), dimethylaminopyridine (7 mg, 0.06 mmol), and triethylamine (514.05 mg, 5.08 mmol), along with 30 mL of DMF. The mixture was stirred at 60 °C for 48 h. The DMF was removed using an oil pump to afford a residue, which was purified by column chromatography, eluting sequentially with 0%, 1%, and 5% CH<sub>3</sub>OH in CHCl<sub>3</sub>. Fractions containing the product <b>8</b> (TLC) were pooled and evaporated to give solid compound. The yield was 40% (163 mg). TLC <i>R</i><sub><i>f</i></sub> 0.45 (CHCl<sub>3</sub>/MeOH, 10:1); mp 185.8−190.1 °C; <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 1.27 (s, 9 H, C(CH<sub>3</sub>)<sub>3</sub>), 7.18−7,21 (t, <i>J</i> = 2.4 Hz, 1 H, C7-CH), 7.24−7.26 (dd, <i>J</i> = 7.5 Hz, 1 H, Ar), 7.37−7.40 (dd, <i>J</i> = 6.3 Hz, 1 H, Ar), 11.15 (s, 1 H, 3-NH, exch), 11.93 (s, 1 H, 2-NH, exch), 12.11 (s, 1 H, 9-NH,exch). HRMS calcd for C<sub>15</sub>H<sub>15</sub>ClN<sub>4</sub>O<sub>2</sub> [M + Na]<sup>+</sup> 341.0757, found 341.0781.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> <i>N</i>-(4,5-Dichloro-9<i>H</i>-pyrimido[4,5-<i>b</i>]indol-2-yl)-2,2-dimethyl Propanamide (<b>9</b>)</h3><div class="NLM_p last">Compound <b>8</b> (2 g, 6.274 mmol) was added to a round bottomed flask and dissolved in 30 mL of POCl<sub>3</sub>. The reaction mixture was refluxed at 110−120 °C for 4 h. After evaporation of the POCl<sub>3</sub>, ice-cold water was added. The reaction mixture was neutralized with NH<sub>3</sub>·H<sub>2</sub>O and extracted with CHCl<sub>3</sub>. The organic phase was dried with Na<sub>2</sub>SO<sub>4</sub>. The crude mixture was then purified by column chromatography, eluting sequentially with 0%, 1%, and 5% methanol in chloroform. Fractions containing the product <b>9</b> (TLC) were pooled and evaporated to give a solid. The yield was 70% (1.48 g). TLC <i>R</i><sub><i>f</i></sub> 0.86 (CHCl<sub>3</sub>/MeOH, 5:1); mp 245.6−246.1 °C; <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 1.25 (s, 9 H, C(CH<sub>3</sub>)<sub>3</sub>), 7.36−7.39 (t, <i>J</i> = 4.5 Hz, 1 H, C7−CH), 7.49−7.51 (m, 2 H, Ar), 10.30 (s, 1 H, 9-NH, exch), 12.96 (s, 1 H, 2-NH, exch). HRMS calcd for C<sub>15</sub>H<sub>14</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>2</sub> [M + Na]<sup>+</sup> 359.0428, found 359.0442.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> 5-Chloro-9<i>H</i>-pyrimido[4,5-<i>b</i>]indole-2,4-diamine Propanamide (<b>10</b>)</h3><div class="NLM_p last">Compound <b>9</b> (200 mg, 0.6 mmol) was added to 5 mL of methanol saturated with ammonia. The solution was stirred at 130 °C for 2 days in a sealed vessel. The methanol was evaporated to give a solid that was purified by column chromatography, eluting sequentially with 0% and 1% methanol in chloroform. Fractions containing the product <b>10</b> (TLC) were pooled and evaporated to give a solid. The yield was 39% (54 mg). TLC <i>R</i><sub><i>f</i></sub> 0.43 (CHCl<sub>3</sub>/MeOH, 5:1); mp 245.2−246.3 °C; <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 6.15 (bs, 2 H, 4-NH<sub>2</sub>, exch), 6.85 (bs, 2 H, 2-NH<sub>2</sub>, exch), 7.10−7.15 (t, <i>J</i> = 7.2 Hz, 1 H, C7-CH), 7.15−7.18 (dd, <i>J</i> = 9 Hz, 1 H, Ar), 7.22−7.24 (dd, <i>J</i> = 6.9 Hz, 1 H, Ar), 11.54 (bs, 1 H, 9-NH, exch). Anal. (C<sub>10</sub>H<sub>8</sub>ClN<sub>5</sub>) C, H, N, Cl.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> General Procedure for the Synthesis of 5-Substituted (Phenylthio)-9<i>H</i>-pyrimido[4,5-<i>b</i>]indole-2,4-diamines <b>1</b> and <b>2</b></h3><div class="NLM_p">Compound <b>10</b> (50 mg, 0.2 mmol), the appropriate thiol (0.9 mmol), and potassium carbonate (120 mg, 0.9 mmol) were added to a 2−5 mL biotage microwave vial. Three milliliters of NMP was added as solvent, and the tube was sealed. The reaction was run in a microwave for 30 min at 250 °C. After cooling to room temperature, the reaction mixture was transferred on top of a silica gel column and eluted with 0% and 4% methanol in chloroform. Fractions containing the product (TLC) were pooled and evaporated to afford the products <b>1</b> and <b>2</b>.</div><div id="sec4_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> 5-(Phenylthio)-9<i>H</i>-pyrimido[4,5-<i>b</i>]indole-2,4-diamine (<b>1</b>)</h4><div class="NLM_p last">Using the general procedure described above, the reaction of <b>10</b> with benzene thiol <b>11</b> afforded <b>1</b> as an off-white solid: yield 97% (64 mg). TLC <i>R</i><sub><i>f</i></sub> 0.23 (CHCl<sub>3</sub>/MeOH 10:1); mp 251 °C; <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 6.04 (bs, 2 H, 4-NH<sub>2</sub>, exch), 7.03−7.04 (d, <i>J</i> = 4.5 Hz, 2 H, Ar), 7.13−7.16 (t, <i>J</i> = 4.2 Hz, 1 H, C7-CH), 7.21−7.27 (m, 2 H, Ar), 7.24 (bs, 2 H, 2-NH<sub>2</sub>, exch), 7.32−7.33 (dd, <i>J</i> = 4.2 Hz, 1 H, Ar), 7.40−7.42 (dd, <i>J</i> = 4.5 Hz, 1 H, Ar), 11.49 (bs, 1 H, 9-NH, exch). Anal. (C<sub>16</sub>H<sub>13</sub>N<sub>5</sub>S) C, H, N, S.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> 5-[(4-Methylphenyl)thio]-9<i>H</i>-pyrimido[4,5-<i>b</i>]indole-2,4-diamine (<b>2</b>)</h4><div class="NLM_p last">Using the general procedure described above, the reaction of <b>10</b> with 4-methyl benzene thiol <b>12</b> afforded <b>2</b> as an off-white solid: yield 87% (60 mg). TLC <i>R</i><sub><i>f</i></sub> 0.54 (CHCl<sub>3</sub>/MeOH 5:1); mp >250 °C; <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 2.19 (s, 3 H, CH<sub>3</sub>), 6.02 (bs, 2 H, 4-NH<sub>2</sub>, exch); 7.19 (bs, 2 H, 2-NH<sub>2</sub>, exch), 6.95−6.97 (d, <i>J</i> = 6 Hz, 2 H, Ar), 7.05−7.07 (d, <i>J</i> = 6 Hz, 2 H, Ar), 7.18−7.22 (t, <i>J</i> = 6 Hz, 1 H, C7-CH), 7.29−7.31 (dd, <i>J</i> = 5.7 Hz, 1 H, Ar), 7.38−7.40 (dd, <i>J</i> = 5.7 Hz, 1 H, Ar), 11.46 (bs, 1 H, 9-NH, exch). Anal. (C<sub>17</sub>H<sub>15</sub>N<sub>5</sub>S·0.4H<sub>2</sub>O) C, H, N, S.</div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Molecular Modeling</h3><div class="NLM_p">There is currently no known crystal structure of PDGFR-β bound to a ligand. A homology model was hence built for evaluating the binding of <b>1</b> in PDGFR-β. The amino acid sequence of the PDGFR-β kinase domain was obtained from the SWISS-PROT database (ID PGFRB_HUMAN [<a href="https://P09619" class="ext-link">P09619</a>]). As has been reported earlier in the literature,<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> a DISOPRED2.0<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> analysis of the amino acid sequence was performed to predict the ordered and disordered regions. The results from this analysis predicted amino acids 700−792 were disordered. A homology model was then built using MOE 2007.09 using the structure of c-KIT kinase complex (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PKG">1PKG</a>, chain A) as the template. A BLASTP<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> search indicated that chain A of the c-KIT kinase complex shows high sequence similarity with PDGFR-β (E-value: 1e-58). Sequence alignment was performed using MOE_Align using the “actual secondary structure” option in MOE. Using the “actual secondary structure” option in MOE was necessary to correctly identify the disordered kinase insertion domain (amino acids 700−792). The final homology model returned by the program was subjected to further energy minimization using Amber99 as the forcefield and a 0.5 rms gradient. A Ramachandran plot of the model showed the presence of six outlying residues (Tyr562, Glu563, Asp590, Ser623, Ser642, Glu911). Since these residues were not in the proximity of the ATP binding site, the model was used without further refinement. Docking studies were performed using the docking suite of MOE 2007.09. After addition of hydrogen atoms, the protein was then “prepared” using the LigX function in MOE. LigX is a graphical interface and collection of procedures for conducting interactive ligand modification and energy minimization in the active site of a flexible receptor. In LigX calculations, the receptor atoms far from the ligand are constrained and not allowed to move while receptor atoms in the active site of the protein are allowed to move but are subject to tether restraints that discourage gross movement. The procedure was performed with the default settings.</div><div class="NLM_p">Ligands were built using the molecule builder function in MOE and were energy-minimized to their local minima using the MMF94X forcefield to a constant of 0.05 kcal/mol.</div><div class="NLM_p last">Ligands were docked into the active site of the prepared protein using the docking suite as implemented in MOE. The docking was restricted to the active site pocket residues using the Alpha triangle placement method. Refinement of the docked poses was carried out using the Forcefield refinement scheme and scored using the Affinity dG scoring system. Around 30 poses were returned for each compound at the end of each docking run. The docked poses were manually examined in the binding pocket to ensure quality of docking and to confirm absence of steric clashes with the amino acid residues of the binding pocket.</div></div><div id="sec6" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Detailed Methods</h3><div id="sec6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> Specific Assays</h4><div id="sec6_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i21" class="anchor-spacer"></div><h5 class="article-section__title" id="_i21"> CYQUANT Cell Proliferation Marker Assay</h5><div class="NLM_p last">As a measure of cell proliferation, the CYQUANT cell counting/proliferation assay was used as previously described.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> We have found that this assay is comparable in sensitivity to a clonogenic (colony-forming) assay<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> and lacks many of the problems associated with metabolic-based assays. For the CYQUANT assay, cells were serum-starved overnight; 1% FCS was then added along with drug to the media of cancer cells (MDA-MB-435, Capan-1, J82, A431, U251), 200 ng/mL hrVEGF-165 was added with drug to the media of endothelial cells (HUVEC, HMEC-1), and 100 ng/mL hrPDGF-BB was added to the media of SMCs (HASMCs, HuPeri-3) for 24 h; then media were replaced with fresh (drug-free) completed media for an additional 24 h. The cells were then lysed, and the CYQUANT dye, which intercalates into the DNA of cells, was added, and after 5 min, the fluorescence of each well was measured using a plate reader. A positive control used for cytotoxicity was cisplatin. Data are graphed as a percent of cells receiving no compound, and IC<sub>50</sub> values were estimated from two to three separate experiments (<i>n</i> = 6−15) using sigmoidal dose−response analysis with Prism 3.0 (GraphPad software, San Diego).</div></div><div id="sec6_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i22" class="anchor-spacer"></div><h5 class="article-section__title" id="_i22"> Phosphotyrosine (PY) Cell-Based ELISA</h5><div class="NLM_p last">Because of the need for screening many compounds in multiple replicates, a higher throughput 96-well phosphotyrosine (PY) ELISA was developed.<a onclick="showRef(event, 'ref71 ref72'); return false;" href="javascript:void(0);" class="ref ref71 ref72">(71, 72)</a> Briefly, cells at 60−75% confluence were placed in serum-free medium for 18 h to reduce the background of phosphorylation. Cells used for these experiments have been shown to overexpress particular RTKs; specifically A431 for EGFR, SF539 for PDGFRβ, U251 for VEGFR2, A498 for VEGFR1, and MV 3:11 cells for Flt-3 (but not VEGFR1/2). Cells were then pretreated for 60 min with 10, 3.33, 1.11, 0.37, and 0.12 μM compound followed by an optimized dose and time of purified growth factor (EGF, PDGF-β, VEGF). The reaction was stopped, and cells were permeabilized by quickly removing the media from the cells and adding ice-cold Tris-buffered saline (TBS) containing 0.05% triton X-100, protease inhibitor cocktail, and tyrosine phosphatase inhibitor cocktail (both from Sigma Chemical). The TBS solution was then removed, and cells were fixed to the plate by heat and further incubation in 70% ethanol. Cells were further exposed to block (TBS with 1% BSA) and washed, and then a horseradish peroxidase (HRP)-conjugated phosphotyrosine antibody was added. The antibody was removed; cells were washed again and exposed to an enhanced luminol ELISA substrate, and light emission was measured using a plate reader. The known RTK-specific kinase inhibitors (PD153035, SU5416, CB67645, DMBI, and compound <b>16</b>) discussed above were used as positive controls for kinase inhibition. Data were graphed as a percent of cells receiving growth factor alone, and EC<sub>50</sub> values were estimated from two to three separate experiments (<i>n</i> = 8−24) using sigmoidal dose−response relations in Prism 3.0 software (GraphPad). In every case, the activity of a positive control inhibitor did not deviate more than 10% from the EC<sub>50</sub> values historically collected in this assay.<a onclick="showRef(event, 'ref21 ref42 ref73'); return false;" href="javascript:void(0);" class="ref ref21 ref42 ref73">(21, 42, 73)</a></div></div><div id="sec6_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i23" class="anchor-spacer"></div><h5 class="article-section__title" id="_i23"> PI3 Kinase Assay</h5><div class="NLM_p last">The PI3 kinase assay is a cytoblot for the phosphorylated (active) form of the p85 subunit of PI3K. HeLa cells have been shown to possess large PI3K activity without any stimulus,<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> so for these studies, no inducer is necessary. HeLa cells grown in log phase for one day after passaging in serum-containing media were exposed as above to various concentrations of unknown compounds or the known PI3K inhibitor, LY294002 for 1 h at 37 °C. As above, cells were permeabilized with Triton, fixed by heat and ethanol and blocked, and a phospho-(Tyr) p85 PI3K binding motif antibody (Cell Signaling) was added at a 1:100 dilution overnight at 4 °C. The antibody was then removed, and an anti-rabbit HRP-conjugated secondary antibody was then added (Pierce Chemical) for 30 min at RT, the antibody was removed, cells were washed again and exposed to an enhanced luminol ELISA substrate, and light emission was measured using a chemiluminescent plate reader.</div></div><div id="sec6_1_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i24" class="anchor-spacer"></div><h5 class="article-section__title" id="_i24"> Dihydrofolate Reductase (DHFR) Assay<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a></h5><div class="NLM_p last">All enzymes were assayed spectrophotometrically in a solution containing 50 μM dihydrofolate, 80 μM NADPH, 50 mM Tris-HCl, 0.001 M 2-mercaptoethanol, and 0.001 M EDTA at pH 7.4 at 30 °C. The reaction was initiated with an amount of enzymes yielding a change in optical density at 340 nm of 0.015 units/min.</div></div><div id="sec6_1_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i25" class="anchor-spacer"></div><h5 class="article-section__title" id="_i25"> Thymidylate Synthase (TS) Assay</h5><div class="NLM_p last">TS was assayed spectrophotometrically at 30 °C and pH 7.4 in a mixture containing 0.1 M 2-mercaptoethanol, 0.0003 M (6<i>R</i>,<i>S</i>)-tetrahydrofolate, 0.012 M formaldehyde, 0.02 M MgCl<sub>2</sub>, 0.001 M dUMP, 0.04 M Tris-HCl, and 0.000 75 M NaEDTA. This was the assay described by Wahba and Friedkin<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> except that the dUMP concentration was increased 25-fold according to the method of Davisson et al.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> The reaction was initiated by the addition of an amount of enzyme yielding a change in absorbance at 340 nm of 0.016 units/min in the absence of inhibitor.</div></div></div><div id="sec6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> In Vitro Pharmacodynamic Studies</h4><div id="sec6_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i27" class="anchor-spacer"></div><h5 class="article-section__title" id="_i27"> Cell Cycle Analysis</h5><div class="NLM_p last">After exposure to drug, cells were fixed in 50% ethanol overnight, permeabilized, and labeled with PBS containing 0.1% Triton X-100, 100 μg/mL Rnase A, and 25 μg/mL propidium iodide for 45 min to 1 h at 37 °C before being subjected to flow cytometry as previously described.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Cell cycle analysis of mean fluorescence data was performed using MODFIT software to generate percent S phase, G1/G0 phase, and G2/M phase (Verity Software, Topsham, ME). Aphidicolin (250 ng/mL), an agent that inhibits DNA polymerase, was used as a control for G1 arrest,<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> and 50 ng/mL nocodazole, a reversible mitotic spindle poison, was used as a control for G2/M arrest (data not shown).<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a></div></div><div id="sec6_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28"> Cell Signaling Analysis</h5><div class="NLM_p last">Cells were treated with compounds at around the IC<sub>50</sub> dose for 1 and 4 h, and whole cell lysates were prepared using M-PER reagent (Pierce Chemical, Rockford, IL) with 300 mM NaCl to lyse the nucleus. Western blots against phosphorylated (activated) (ERK1/2 (Cell Signaling cat. no. 4370)) and against phospho (Cell Signaling cat. no. 4060) and nonphosphorylated Akt (Cell Signaling cat. no. 2920), two major signaling pathways downstream of RTKs, were done per manufacturer’s instructions. Additionaly, cleaved caspase 3 (Cell Signaling cat. no. 9661) was assessed as a marker of apoptosis.</div></div><div id="sec6_2_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> Chorioallantoic Membrane (CAM) Xenograft Assay</h5><div class="NLM_p last">The procedure used was a modification of a previously published procedure<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> Fertile Leghorn chicken eggs (CBT Farms, Chestertown, MD) were incubated until 10 DI, eggs were candled for viability, then a small window was made in the superior shell to expose the chorion and CAM. The CAM was then candled to visualize the vasculature, and a small mark was made on the chorion in a location away from major vessels. Human MDA-MB-435 cancer cells (American Type Culture Collection, Manassas, VA), 250 000 in 50 μL of inert extracellular matrix (Humatrix, Care-Tech Laboratories, St Louis, MO), were implanted just under the CAM using a 1 mL syringe with a 25G needle. Neomycin−polymyxin ointment was then applied to the injection site, and the shell hole was covered with Micropore surgical tape (3M, St. Paul, MN). Four hours and 48 h after tumor implantation, the tape was partially removed and drug or solvent (DMSO in SWFI) was placed onto the chorion using a micropipettor, yielding a systemic dose to the embryo. In an initial dose-finding experiment, either semaxanib or compound <b>1</b> were given at doses of 2.5, 5, 10, 15, 25, and 35 mg/kg embryo body weight<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> and at 3 days after injection embryo lethality was evaluated. It was found that 10 mg/kg of gemcitabine and 25 mg/kg of compound <b>1</b> were the highest doses resulting in no lethality or overt toxicity in embryos; thus these doses were used in subsequent experiments. Three days after tumor implantation, CAMs were fixed in situ by pipetting on a solution of 0.1% Triton X-100 in 4% paraformaldehyde for 1 min. The solution was removed and CAM/chorion were excised in an area surrounding the tumor implantation site. The CAM/chorion were placed into 4% paraformaldehyde and allowed to fix an addition 2 min, and the chorion was separated from the CAM. CAMs were removed to 6-well plates containing 4% paraformaldehyde. CAMs were spread gently to remove wrinkles, and images were captured at 6.25× magnification using a brightfield dissecting microcope (Wild M400 photomakroscop, Bern, Switzerland) connected to a cooled camera (QImaging, Burnaby, BC, Canada). Images were then converted to gray scale, the number of vessels surrounding the tumor was manually counted, and the size of the tumor was determined using NIH Image J densitometry software.</div></div><div id="sec6_2_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> Animal Numbers</h5><div class="NLM_p last">Consulting with the Biostatistics Program at OUHSC and using StatMate software (<a href="http://www.graphpad.com" class="extLink">www.graphpad.com</a>) and a power analysis, we have found that a sample size of 10 animals is optimal for 80% power, a significance level of 0.05 in a (two-tailed) unpaired <i>t</i> test, and an expected SD of 24 (from previous experiments). Four animals per treatment group are used for short-term toxicity studies, and five animals per group are used for the longer term toxicity studies.</div></div><div id="sec6_2_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> Whole Animal Toxicity Assay</h5><div class="NLM_p last">To first determine the maximal tolerated dose (MTD) of a drug, male NCr nu/nu mice at 8 weeks of age without tumors were injected with 5, 10, 12.5, 15, 17.5, and 20 mg/kg compound <b>1</b> or the PDGFR-β kinase inhibitor DMBI three times weekly, on Monday morning, Wednesday noon, and Friday afternoon. Weights were taken, and animals were observed for acute distress during the first 96 h after injection and in a 3 and 6 week period. Significance in weights was calculated after each weighing using one-way ANOVA and Neuman−Keuls post-test with the null hypothesis rejected if <i>P</i> < 0.05. Animals with significant (>7%) weight loss were humanely euthanized and inspected for any overt toxicity, and organs (heart, lung, kidney, liver, colon) were removed for inspection by a veterinarian pathologist at OUHSC.</div></div><div id="sec6_2_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> COLO-205 Human Metastatic Colon Mouse Xenograft</h5><div class="NLM_p last">It has been shown that the natural killer (NK) T cell activity in athymic mice affects the metastasis of human tumor xenografts.<a onclick="showRef(event, 'ref82 ref83'); return false;" href="javascript:void(0);" class="ref ref82 ref83">(82, 83)</a> Thus for these experiments, NIH-III nude mice, deficient in NK cells, were used. One million COLO-205 (liver colonizing; ATCC) human metastatic colon cancer cells were injected subcutaneously (SQ) in the lateral flank of athymic NIH-III male mice, 8 weeks in age. Animals are monitored every other day for the presence of tumors. At the time in which most tumors are measurable by calipers (day 9 after implantation), animals with tumors were randomly sorted into treatment groups. DMSO stocks (30 mM) of drugs were further dissolved into sterile water for injection, and the optimal dose (from toxicity studies) was injected intraperitoneally (IP). The length (long side), width (short side), and depth of the tumors were measured using digital Vernier calipers each Monday, Wednesday, and Friday. Tumor volume was calculated using the formula length × width × depth. Tumor growth rate was then calculated using a linear regression analysis algorithm with the software GraphPad Prism 4.0.c. At the experiment’s end, animals were humanly euthanized, tumors and liver were excised, fixed in 20% neutral buffered formalin for 8−10 h, and embedded into paraffin, and hematoxylin−eosin (H&E) stain of three separate tissue sections was completed to span the tumor and liver. Together with the OUHSC Department of Pathology core, metastases per liver lobe were counted using the H&E stained sections. The metastases can be seen as purple clusters of disorganized cells on the highly organized largely pink liver. Together with the OUHSC Department of Pathology core, blood vessels per unit area on primary tumors were also counted in five fields at 100× magnification and averaged. Tumor growth rate per day, tumor vascularity, and liver metastases were calculated, and significance was determined from the growth curves using two-way ANOVA with a repeated measures post-test, and the null hypothesis was rejected if <i>P</i> < 0.05.</div></div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i34"><a href="/doi/suppl/10.1021/jm9011142">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64544" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64544" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Results from elemental analysis and high-resolution mass spectrometry. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm9011142/suppl_file/jm9011142_si_001.pdf">jm9011142_si_001.pdf (33.02 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm9011142" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53034" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53034" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aleem Gangjee</span> - <span class="hlFld-Affiliation affiliation">Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, 600 Forbes Avenue, Pittsburgh, Pennsylvania 15282</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#2443454a434e4141644051550a414051"><span class="__cf_email__" data-cfemail="5334323d34393636133726227d363726">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nilesh Zaware</span> - <span class="hlFld-Affiliation affiliation">Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, 600 Forbes Avenue, Pittsburgh, Pennsylvania 15282</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sudhir Raghavan</span> - <span class="hlFld-Affiliation affiliation">Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, 600 Forbes Avenue, Pittsburgh, Pennsylvania 15282</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Ihnat</span> - <span class="hlFld-Affiliation affiliation">Department of Cell Biology, The University of Oklahoma Health Science Center, Oklahoma City, Oklahoma 73104</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Satyendra Shenoy</span> - <span class="hlFld-Affiliation affiliation">Department of Cell Biology, The University of Oklahoma Health Science Center, Oklahoma City, Oklahoma 73104</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Roy L. Kisliuk</span> - <span class="hlFld-Affiliation affiliation">Department of Biochemistry, Tufts University School of Medicine, 136 Harrison Avenue, Boston, Massachusetts 02111</span></div></li></ul></li><li></li><li></li><li></li></ul></div><div class="ack"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i33">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35658" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35658" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported, in part, by a grant from the National Institutes of Health, National Cancer Institute (Grant CA136944 (A.G.)).</p></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10862" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10862" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 83 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Davis, D. W.; Herbst, R. S.; Abbruzzese, J. L.</span> <span class="citation_source-book">Antiangiogenic Cancer Therapy</span>; <span class="NLM_publisher-name">CRC Press, Taylor and Francis Group</span>: <span class="NLM_publisher-loc">Boca Raton, FL</span>:<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span>p  <span class="NLM_fpage">841</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=841&author=D.+W.+Davis&author=R.+S.+Herbst&author=J.+L.+Abbruzzese&title=Antiangiogenic+Cancer+Therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DD.%2BW.%26btitle%3DAntiangiogenic%2520Cancer%2520Therapy%26pub%3DCRC%2520Press%252C%2520Taylor%2520and%2520Francis%2520Group%26date%3D2008%26spage%3D841" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Folkman, J.</span><span> </span><span class="NLM_article-title">Angiogenesis</span> <span class="citation_source-journal">Annu. Rev. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">18</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2006&pages=1-18&author=J.+Folkman&title=Angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFolkman%26aufirst%3DJ.%26atitle%3DAngiogenesis%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2006%26volume%3D57%26spage%3D1%26epage%3D18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Fabbro, D.; McCormick, F.</span>, Eds.  <span class="citation_source-book">Protein Tyrosine Kinases: From Inhibitors to Useful Drugs</span>; <span class="NLM_publisher-name">Humana Press</span>, <span class="NLM_publisher-loc">Totowa, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">2006</span><span class="NLM_x">; </span>290 pp.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=D.+Fabbro&author=F.+McCormick&title=Protein+Tyrosine+Kinases%3A+From+Inhibitors+to+Useful+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DFabbro%26aufirst%3DD.%26btitle%3DProtein%2520Tyrosine%2520Kinases%253A%2520From%2520Inhibitors%2520to%2520Useful%2520Drugs%26pub%3DHumana%2520Press%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Gschwind, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span> </span><span class="NLM_article-title">Timeline: The discovery of receptor tyrosine kinases: Targets for cancer therapy</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">361</span><span class="NLM_x">–</span> <span class="NLM_lpage">370</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1038%2Fnrc1360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=15122207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsFSlu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=361-370&author=A.+Gschwindauthor=O.+M.+Fischerauthor=A.+Ullrich&title=Timeline%3A+The+discovery+of+receptor+tyrosine+kinases%3A+Targets+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Timeline: The discovery of receptor tyrosine kinases: targets for cancer therapy</span></div><div class="casAuthors">Gschwind, Andreas; Fischer, Oliver M.; Ullrich, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">361-370</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinases are a subclass of cell-surface growth-factor receptors with an intrinsic, ligand-controlled tyrosine-kinase activity.  They regulate diverse functions in normal cells and have a crucial role in oncogenesis.  Twenty years ago, the 1st primary structure of a receptor Tyr kinase, the epidermal growth factor receptor, was elucidated.  The characterization of both the mol. architecture of receptor Tyr kinases and the main functions of these proteins and their ligands in tumorigenesis opened the door to a new era in mol. oncol. and paved the way to the development of the 1st target-specific cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1NLVNn4dw37Vg90H21EOLACvtfcHk0licM_xHnQGaqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsFSlu7g%253D&md5=ea24c0ccaea68b743b5da9587ed19406</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrc1360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1360%26sid%3Dliteratum%253Aachs%26aulast%3DGschwind%26aufirst%3DA.%26aulast%3DFischer%26aufirst%3DO.%2BM.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DTimeline%253A%2520The%2520discovery%2520of%2520receptor%2520tyrosine%2520kinases%253A%2520Targets%2520for%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D361%26epage%3D370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Carmeliet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, R. K.</span><span> </span><span class="NLM_article-title">Angiogenesis in cancer and other diseases</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">407</span><span class="NLM_x">, </span> <span class="NLM_fpage">249</span><span class="NLM_x">–</span> <span class="NLM_lpage">257</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1038%2F35025220" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=11001068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmvVSls74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=407&publication_year=2000&pages=249-257&author=P.+Carmelietauthor=R.+K.+Jain&title=Angiogenesis+in+cancer+and+other+diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Angiogenesis in cancer and other diseases</span></div><div class="casAuthors">Carmeliet, Peter; Jain, Rakesh K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">407</span>
        (<span class="NLM_cas:issue">6801</span>),
    <span class="NLM_cas:pages">249-257</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with 75 refs.  Pathol. angiogenesis is a hallmark of cancer and various ischemic and inflammatory diseases.  Concd. efforts in this area of research are leading to the discovery of a growing no. of pro- and anti-angiogenic mols., some of which are already in clin. trials.  The complex interactions among these mols. and how they affect vascular structure and function in different environments are now beginning to be elucidated.  This integrated understanding is leading to the development of a no. of exciting and bold approaches to treat cancer and other diseases.  But owing to several unanswered questions, caution is needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPQMelW0OMYbVg90H21EOLACvtfcHk0ljmmqtUMgzlig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmvVSls74%253D&md5=703cbcdbd32292a9238f0394220c853c</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2F35025220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35025220%26sid%3Dliteratum%253Aachs%26aulast%3DCarmeliet%26aufirst%3DP.%26aulast%3DJain%26aufirst%3DR.%2BK.%26atitle%3DAngiogenesis%2520in%2520cancer%2520and%2520other%2520diseases%26jtitle%3DNature%26date%3D2000%26volume%3D407%26spage%3D249%26epage%3D257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Gorre, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammed, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellwood, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquette, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">293</span><span class="NLM_x">, </span> <span class="NLM_fpage">876</span><span class="NLM_x">–</span> <span class="NLM_lpage">880</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=293&publication_year=2001&pages=876-880&author=M.+E.+Gorreauthor=M.+Mohammedauthor=K.+Ellwoodauthor=N.+Hsuauthor=R.+Paquetteauthor=P.+N.+Raoauthor=C.+L.+Sawyers&title=Clinical+resistance+to+STI-571+cancer+therapy+caused+by+BCR-ABL+gene+mutation+or+amplification"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGorre%26aufirst%3DM.%2BE.%26aulast%3DMohammed%26aufirst%3DM.%26aulast%3DEllwood%26aufirst%3DK.%26aulast%3DHsu%26aufirst%3DN.%26aulast%3DPaquette%26aufirst%3DR.%26aulast%3DRao%26aufirst%3DP.%2BN.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DClinical%2520resistance%2520to%2520STI-571%2520cancer%2520therapy%2520caused%2520by%2520BCR-ABL%2520gene%2520mutation%2520or%2520amplification%26jtitle%3DScience%26date%3D2001%26volume%3D293%26spage%3D876%26epage%3D880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Gorre, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia</span> <span class="citation_source-journal">Curr. Opin. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">303</span><span class="NLM_x">–</span> <span class="NLM_lpage">307</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1097%2F00062752-200207000-00007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=12042704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A280%3ADC%252BD38zgtFSgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2002&pages=303-307&author=M.+E.+Gorreauthor=C.+L.+Sawyers&title=Molecular+mechanisms+of+resistance+to+STI571+in+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia</span></div><div class="casAuthors">Gorre Mercedes E; Sawyers Charles L</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in hematology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">303-7</span>
        ISSN:<span class="NLM_cas:issn">1065-6251</span>.
    </div><div class="casAbstract">Therapeutic use of the recently FDA-approved drug STI571 has been successful in the treatment of Philadelphia chromosome-positive leukemias.  STI571 is a small molecule inhibitor with activity against BCR-ABL, the deregulated tyrosine kinase responsible for initiation and maintenance of the disease in the chronic phase of chronic myeloid leukemia (CML).  Clinical trials demonstrated the ability of STI571 to induce remissions in patients with chronic phase CML with only rare relapses after 18 months of follow-up.  However, in patients with more advanced stages of disease, responses to STI571 were less common and often transient.  Studies investigating the molecular mechanisms of resistance to this novel compound have progressed rapidly and point to the continued importance of BCR-ABL in disease maintenance even at its latest stages.  Here the authors review recent work aimed at elucidating the nature of STI51 resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQFpKjX-b8FPSsZ1x6zOs0vfW6udTcc2eYnmzYCnJnRvbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38zgtFSgtQ%253D%253D&md5=63a02d15bd7f0917778618d4835d9aa3</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1097%2F00062752-200207000-00007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00062752-200207000-00007%26sid%3Dliteratum%253Aachs%26aulast%3DGorre%26aufirst%3DM.%2BE.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DMolecular%2520mechanisms%2520of%2520resistance%2520to%2520STI571%2520in%2520chronic%2520myeloid%2520leukemia%26jtitle%3DCurr.%2520Opin.%2520Hematol.%26date%3D2002%26volume%3D9%26spage%3D303%26epage%3D307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Hurwitz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fehrenbacher, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novotny, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cartwright, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hainsworth, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heim, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berlin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffing, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmgren, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fyfe, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kabbinavar, F.</span><span> </span><span class="NLM_article-title">Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x">, </span> <span class="NLM_fpage">2335</span><span class="NLM_x">–</span> <span class="NLM_lpage">2342</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1056%2FNEJMoa032691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=15175435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD2cXks1Gjt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2004&pages=2335-2342&author=H.+Hurwitzauthor=L.+Fehrenbacherauthor=W.+Novotnyauthor=T.+Cartwrightauthor=J.+Hainsworthauthor=W.+Heimauthor=J.+Berlinauthor=A.+Baronauthor=S.+Griffingauthor=E.+Holmgrenauthor=N.+Ferraraauthor=G.+Fyfeauthor=B.+Rogersauthor=R.+Rossauthor=F.+Kabbinavar&title=Bevacizumab+plus+irinotecan%2C+fluorouracil%2C+and+leucovorin+for+metastatic+colorectal+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer</span></div><div class="casAuthors">Hurwitz, Herbert; Fehrenbacher, Louis; Novotny, William; Cartwright, Thomas; Hainsworth, John; Heim, William; Berlin, Jordan; Baron, Ari; Griffing, Susan; Holmgren, Eric; Ferrara, Napoleone; Fyfe, Gwen; Rogers, Beth; Ross, Robert; Kabbinavar, Fairooz</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2335-2342</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclin. and clin. activity against metastatic colorectal cancer, particularly in combination with chemotherapy.  Of 813 patients with previously untreated metastatic colorectal cancer, we randomly assigned 402 to receive irinotecan, bolus fluorouracil, and leucovorin (IFL) plus bevacizumab (5 mg per kg of body wt. every two weeks) and 411 to receive IFL plus placebo.  The primary end point was overall survival.  Secondary end points were progression-free survival, the response rate, the duration of the response, safety, and the quality of life.  The median duration of survival was 20.3 mo in the group given IFL plus bevacizumab, as compared with 15.6 mo in the group given IFL plus placebo, corresponding to a hazard ratio for death of 0.66 (P<0.001).  The median duration of progression-free survival was 10.6 mo in the group given IFL plus bevacizumab, as compared with 6.2 mo in the group given IFL plus placebo (hazard ratio for disease progression, 0.54; P<0.001); the corresponding rates of response were 44.8 % and 34.8 % (P = 0.004).  The median duration of the response was 10.4 mo in the group given IFL plus bevacizumab, as compared with 7.1 mo in the group given IFL plus placebo (hazard ratio for progression, 0.62; P = 0.001).  Grade 3 hypertension was more common during treatment with IFL plus bevacizumab than with IFL plus placebo (11.0 % vs. 2.3 %) but was easily managed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5r6uP5oxZU7Vg90H21EOLACvtfcHk0ljmmqtUMgzlig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXks1Gjt74%253D&md5=6a1289cdbf1501f121eb0482e5a1f536</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa032691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa032691%26sid%3Dliteratum%253Aachs%26aulast%3DHurwitz%26aufirst%3DH.%26aulast%3DFehrenbacher%26aufirst%3DL.%26aulast%3DNovotny%26aufirst%3DW.%26aulast%3DCartwright%26aufirst%3DT.%26aulast%3DHainsworth%26aufirst%3DJ.%26aulast%3DHeim%26aufirst%3DW.%26aulast%3DBerlin%26aufirst%3DJ.%26aulast%3DBaron%26aufirst%3DA.%26aulast%3DGriffing%26aufirst%3DS.%26aulast%3DHolmgren%26aufirst%3DE.%26aulast%3DFerrara%26aufirst%3DN.%26aulast%3DFyfe%26aufirst%3DG.%26aulast%3DRogers%26aufirst%3DB.%26aulast%3DRoss%26aufirst%3DR.%26aulast%3DKabbinavar%26aufirst%3DF.%26atitle%3DBevacizumab%2520plus%2520irinotecan%252C%2520fluorouracil%252C%2520and%2520leucovorin%2520for%2520metastatic%2520colorectal%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D350%26spage%3D2335%26epage%3D2342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Oestman, A.</span><span> </span><span class="NLM_article-title">PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma</span> <span class="citation_source-journal">Cytokine Growth Factor Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">275</span><span class="NLM_x">–</span> <span class="NLM_lpage">286</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1016%2Fj.cytogfr.2004.03.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=15207817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltVKhtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2004&pages=275-286&author=A.+Oestman&title=PDGF+receptors-mediators+of+autocrine+tumor+growth+and+regulators+of+tumor+vasculature+and+stroma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma</span></div><div class="casAuthors">Oestman, Arne</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">275-286</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review with refs.  PDGFs and their cognate tyrosine kinase α- and β-receptors are involved in multiple tumor-assocd. processes including autocrine growth stimulation of tumor cells, stimulation of tumor angiogenesis and recruitment and regulation of tumor fibroblasts.  The recent development of clin. useful PDGF antagonists, like STI571/Glivec, has increased the interest in PDGF receptors as cancer drug targets.  Autocrine PDGF receptor signaling occurs in certain malignancies characterized by mutational activation of PDGF or PDGF receptors, for instance, dermatofibrosarcoma protuberans, gastrointestinal stromal tumors, and hypereosinophilic syndrome.  The roles of PDGF in regulation of tumor angiogenesis and tumor fibroblasts are more general, and probably occur in most common solid tumors.  Concerning tumor angiogenesis recent studies have predominantly focused on the importance of PDGF receptor signaling for tumor pericyte recruitment.  PDGF receptors in the tumor stroma have also attracted attention as interesting drug targets because of their function as regulators of tumor interstitial fluid pressure, tumor trans-vascular transport and tumor drug uptake.  In summary, the improved understanding of the role of PDGF signaling in tumor biol., and the introduction of PDGF antagonists, has set the stage for a continued development of PDGF antagonists as novel cancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8-4CVipxax7Vg90H21EOLACvtfcHk0ljzCUPDXuIdJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltVKhtLw%253D&md5=1acb20873a7a3b8e18799bb255792a46</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.cytogfr.2004.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cytogfr.2004.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DOestman%26aufirst%3DA.%26atitle%3DPDGF%2520receptors-mediators%2520of%2520autocrine%2520tumor%2520growth%2520and%2520regulators%2520of%2520tumor%2520vasculature%2520and%2520stroma%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2004%26volume%3D15%26spage%3D275%26epage%3D286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Pearson, M.; Garcia-Echeverria, C.; Fabbro, D.</span><span> </span><span class="NLM_article-title">Protein Tyrosine Kinases as Targets for Cancer and Other Indications in Protein Tyrosine Kinases</span>. In  <span class="citation_source-book">From Inhibitors to Useful Drugs</span>; <span class="NLM_contrib-group">Fabbro, D.,; McCormick, F.</span>, Eds.; <span class="NLM_publisher-name">Human Press</span>, <span class="NLM_publisher-loc">Totowa, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">2005</span><span class="NLM_x">, </span>pp  <span class="NLM_fpage">1</span>− <span class="NLM_lpage">29</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&pages=1-29&author=M.+Pearson&author=C.+Garcia-Echeverria&author=D.+Fabbroauthor=D.+Fabbro&author=F.+McCormick&title=From+Inhibitors+to+Useful+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DPearson%26aufirst%3DM.%26atitle%3DProtein%2520Tyrosine%2520Kinases%2520as%2520Targets%2520for%2520Cancer%2520and%2520Other%2520Indications%2520in%2520Protein%2520Tyrosine%2520Kinases%26btitle%3DFrom%2520Inhibitors%2520to%2520Useful%2520Drugs%26aulast%3DFabbro%26aufirst%3DD.%26pub%3DHuman%2520Press%26date%3D2005%26spage%3D1%26epage%3D29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Stein, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span> </span><span class="NLM_article-title">CCR drug updates: Sorafenib and sunitinib in renal cell carcinoma</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">3765</span><span class="NLM_x">–</span> <span class="NLM_lpage">3770</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1158%2F1078-0432.CCR-06-2844" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=17606705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD2sXntFymsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=3765-3770&author=M.+N.+Steinauthor=K.+T.+Flaherty&title=CCR+drug+updates%3A+Sorafenib+and+sunitinib+in+renal+cell+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">CCR drug updates: Sorafenib and sunitinib in renal cell carcinoma</span></div><div class="casAuthors">Stein, Mark N.; Flaherty, Keith T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3765-3770</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The role of sorafenib and sunitinib antagonize VEGF receptor tyrosine kinases of these agents as VEGFR inhibitors in renal cell carcinoma (RCC) and their unique spectra of activity are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqchkyOioqfkLVg90H21EOLACvtfcHk0ljzCUPDXuIdJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXntFymsb4%253D&md5=45c121fccb373ff7784a48cd33380383</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-2844&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-2844%26sid%3Dliteratum%253Aachs%26aulast%3DStein%26aufirst%3DM.%2BN.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26atitle%3DCCR%2520drug%2520updates%253A%2520Sorafenib%2520and%2520sunitinib%2520in%2520renal%2520cell%2520carcinoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D3765%26epage%3D3770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Tabernero, J.</span><span> </span><span class="NLM_article-title">The role of VEGF and EGFR inhibition: Implications for combining anti-VEGF and anti-EGFR agents</span> <span class="citation_source-journal">Mol. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">203</span><span class="NLM_x">–</span> <span class="NLM_lpage">220</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1158%2F1541-7786.MCR-06-0404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=17374728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjt1Srsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2007&pages=203-220&author=J.+Tabernero&title=The+role+of+VEGF+and+EGFR+inhibition%3A+Implications+for+combining+anti-VEGF+and+anti-EGFR+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of VEGF and EGFR Inhibition: Implications for Combining Anti-VEGF and Anti-EGFR Agents</span></div><div class="casAuthors">Tabernero, Josep</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">203-220</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Multiple cellular pathways influence the growth and metastatic potential of tumors.  This creates heterogeneity, redundancy, and the potential for tumors to bypass signaling pathway blockade, resulting in primary or acquired resistance.  Combining therapies that inhibit different signaling pathways has the potential to be more effective than inhibition of a single pathway and to overcome tumor resistance.  Vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) inhibitors have become key therapies in several tumor types.  Close relationships between these factors exist: VEGF signaling is up-regulated by EGFR expression and, conversely, VEGF up-regulation independent of EGFR signaling seems to contribute to resistance to EGFR inhibition.  Therefore, inhibition of both pathways could improve antitumor efficacy and overcome resistance to EGFR inhibition.  Preclin. studies have shown that VEGF and EGFR inhibitors can have additive effects and that combined inhibition is effective in EGFR inhibitor-resistant cell lines.  Clin. trials have also produced promising data: combining the anti-VEGF monoclonal antibody bevacizumab with the anti-EGFR antibody cetuximab or the EGFR tyrosine kinase inhibitor erlotinib increases benefit compared with either of these anti-EGFR agents alone or combined with chemotherapy.  The potential of this novel approach to anticancer therapy will be elucidated by large, ongoing clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgvbskfTKTarVg90H21EOLACvtfcHk0ljzCUPDXuIdJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjt1Srsbo%253D&md5=af3b3a51f6836322379eac8e1427cec4</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-06-0404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-06-0404%26sid%3Dliteratum%253Aachs%26aulast%3DTabernero%26aufirst%3DJ.%26atitle%3DThe%2520role%2520of%2520VEGF%2520and%2520EGFR%2520inhibition%253A%2520Implications%2520for%2520combining%2520anti-VEGF%2520and%2520anti-EGFR%2520agents%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2007%26volume%3D5%26spage%3D203%26epage%3D220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Jain, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duda, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loeffler, J. S.</span><span> </span><span class="NLM_article-title">Lessons from phase III clinical trials on anti-VEGF therapy for cancer</span> <span class="citation_source-journal">Nat. Clin. Pract. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">24</span><span class="NLM_x">–</span> <span class="NLM_lpage">40</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1038%2Fncponc0403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=16407877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVynsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2006&pages=24-40&author=R.+K.+Jainauthor=D.+G.+Dudaauthor=J.+W.+Clarkauthor=J.+S.+Loeffler&title=Lessons+from+phase+III+clinical+trials+on+anti-VEGF+therapy+for+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons from phase III clinical trials on anti-VEGF therapy for cancer</span></div><div class="casAuthors">Jain, Rakesh K.; Duda, Dan G.; Clark, Jeffrey W.; Loeffler, Jay S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Clinical Practice Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">24-40</span>CODEN:
                <span class="NLM_cas:coden">NCPOB5</span>;
        ISSN:<span class="NLM_cas:issn">1743-4254</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In randomized phase III trials two anti-vascular endothelial growth factor (VEGF) approaches have yielded survival benefit in patients with metastatic cancer.  In one approach, the addn. of bevacizumab, a VEGF-specific antibody, to std. chemotherapy improved overall survival in colorectal and lung cancer patients and progression-free survival in breast cancer patients.  In the second approach, multitargeted tyrosine kinase inhibitors that block VEGF receptor and other kinases in both endothelial and cancer cells, demonstrated survival benefit in gastrointestinal stromal tumor and renal-cell-carcinoma patients.  By contrast, adding bevacizumab to chemotherapy failed to increase survival in patients with previously treated and refractory metastatic breast cancer.  Furthermore, addn. of vatalanib, a kinase inhibitor developed as a VEGF receptor-selective agent, to chemotherapy did not show a similar benefit in metastatic colorectal cancer patients.  These contrasting responses raise crit. questions about how these agents work and how to combine them optimally.  We summarize three of the many potential mechanisms of action of anti-VEGF agents, and also discuss progress relating to the identification of potential biomarkers for anti-VEGF-agent efficacy in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzdONgbUWNUrVg90H21EOLACvtfcHk0ljL1saE33TjIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVynsL0%253D&md5=dfcfbf8ab8060df6b65c359b0bf8ef77</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fncponc0403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncponc0403%26sid%3Dliteratum%253Aachs%26aulast%3DJain%26aufirst%3DR.%2BK.%26aulast%3DDuda%26aufirst%3DD.%2BG.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DLoeffler%26aufirst%3DJ.%2BS.%26atitle%3DLessons%2520from%2520phase%2520III%2520clinical%2520trials%2520on%2520anti-VEGF%2520therapy%2520for%2520cancer%26jtitle%3DNat.%2520Clin.%2520Pract.%2520Oncol.%26date%3D2006%26volume%3D3%26spage%3D24%26epage%3D40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Slamon, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leyland-Jones, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shak, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuchs, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paton, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajamonde, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleming, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiermann, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pegram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norton, L.</span><span> </span><span class="NLM_article-title">Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">344</span><span class="NLM_x">, </span> <span class="NLM_fpage">783</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1056%2FNEJM200103153441101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=11248153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD3MXisVGktrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2001&pages=783-792&author=D.+J.+Slamonauthor=B.+Leyland-Jonesauthor=S.+Shakauthor=H.+Fuchsauthor=V.+Patonauthor=A.+Bajamondeauthor=T.+Flemingauthor=W.+Eiermannauthor=J.+Wolterauthor=M.+Pegramauthor=J.+Baselgaauthor=L.+Norton&title=Use+of+chemotherapy+plus+a+monoclonal+antibody+against+HER2+for+metastatic+breast+cancer+that+overexpresses+HER2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2</span></div><div class="casAuthors">Slamon, Dennis J.; Leyland-Jones, Brian; Shak, Steven; Fuchs, Hank; Paton, Virginia; Bajamonde, Alex; Fleming, Thomas; Eiermann, Wolfgang; Wolter, Janet; Pegram, Mark; Baselga, Jose; Norton, Larry</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">783-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The HER2 gene, which encodes the growth factor receptor HER2, is amplified and HER2 is overexpressed in 25 to 30 % of breast cancers, increasing the aggressiveness of the tumor.  We evaluated the efficacy and safety of trastuzumab, a recombinant monoclonal antibody against HER2, in women with metastatic breast cancer that overexpressed HER2.  We randomly assigned 234 patients to receive std. chemotherapy plus trastuzumab.  Patients who had not previously received adjuvant (postoperative) therapy with an anthracycline were treated with doxorubicin (or epirubicin in the case of 36 women) and cyclophosphamide with (143 women) or without trastuzumab (138 women).  Patients who had previously received adjuvant anthracycline were treated with paclitaxel alone (96 women) or paclitaxel with trastuzumab (92 women).  The addn. of trastuzumab to chemotherapy was assocd. with a longer time to disease progression (median, 7.4 vs. 4.6 mo; P<0.001), a higher rate of objective response (50 % vs. 32 %, P<0.001), a longer duration of response (median, 9.1 vs. 6.1 mo; P<0.001), a lower rate of death at 1 yr (22 % vs. 33 %, P=0.008), longer survival (median survival, 25.1 vs. 20.3 mo; P=0.046), and a 20 % redn. in the risk of death.  The most important adverse event was cardiac dysfunction, which occurred in 27 % of the group given an anthracycline, cyclophosphamide, and trastuzumab; 8 % of the group given an anthracycline and cyclophosphamide alone; 13 % of the group given paclitaxel and trastuzumab; and 1 % of the group given paclitaxel alone.  Although the cardiotoxicity was potentially severe and, in some cases, life-threatening, the symptoms generally improved with std. medical management.  Trastuzumab increases the clin. benefit of first-line chemotherapy in metastatic breast cancer that overexpresses HER2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGK_4WWRZLKLVg90H21EOLACvtfcHk0ljL1saE33TjIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXisVGktrc%253D&md5=81112f11ffc66fc3a898b61e104322b6</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1056%2FNEJM200103153441101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200103153441101%26sid%3Dliteratum%253Aachs%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26aulast%3DLeyland-Jones%26aufirst%3DB.%26aulast%3DShak%26aufirst%3DS.%26aulast%3DFuchs%26aufirst%3DH.%26aulast%3DPaton%26aufirst%3DV.%26aulast%3DBajamonde%26aufirst%3DA.%26aulast%3DFleming%26aufirst%3DT.%26aulast%3DEiermann%26aufirst%3DW.%26aulast%3DWolter%26aufirst%3DJ.%26aulast%3DPegram%26aufirst%3DM.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DNorton%26aufirst%3DL.%26atitle%3DUse%2520of%2520chemotherapy%2520plus%2520a%2520monoclonal%2520antibody%2520against%2520HER2%2520for%2520metastatic%2520breast%2520cancer%2520that%2520overexpresses%2520HER2%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2001%26volume%3D344%26spage%3D783%26epage%3D792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Bergers, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer-Morse, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergsland, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanahan, D.</span><span> </span><span class="NLM_article-title">Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">1287</span><span class="NLM_x">–</span> <span class="NLM_lpage">1295</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2003&pages=1287-1295&author=G.+Bergersauthor=S.+Songauthor=N.+Meyer-Morseauthor=E.+Bergslandauthor=D.+Hanahan&title=Benefits+of+targeting+both+pericytes+and+endothelial+cells+in+the+tumor+vasculature+with+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBergers%26aufirst%3DG.%26aulast%3DSong%26aufirst%3DS.%26aulast%3DMeyer-Morse%26aufirst%3DN.%26aulast%3DBergsland%26aufirst%3DE.%26aulast%3DHanahan%26aufirst%3DD.%26atitle%3DBenefits%2520of%2520targeting%2520both%2520pericytes%2520and%2520endothelial%2520cells%2520in%2520the%2520tumor%2520vasculature%2520with%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2003%26volume%3D111%26spage%3D1287%26epage%3D1295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Carmeliet, P.</span><span> </span><span class="NLM_article-title">Angiogenesis in life, disease and medicine</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">438</span><span class="NLM_x">, </span> <span class="NLM_fpage">932</span><span class="NLM_x">–</span> <span class="NLM_lpage">936</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1038%2Fnature04478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=16355210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSksrjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=438&publication_year=2005&pages=932-936&author=P.+Carmeliet&title=Angiogenesis+in+life%2C+disease+and+medicine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Angiogenesis in life, disease and medicine</span></div><div class="casAuthors">Carmeliet, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">438</span>
        (<span class="NLM_cas:issue">7070</span>),
    <span class="NLM_cas:pages">932-936</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The growth of blood vessels (a process known as angiogenesis) is essential for organ growth and repair.  An imbalance in this process contributes to numerous malignant, inflammatory, ischemic, infectious and immune disorders.  Recently, the first anti-angiogenic agents have been approved for the treatment of cancer and blindness.  Angiogenesis research will probably change the face of medicine in the next decades, with more than 500 million people worldwide predicted to benefit from pro- or anti-angiogenesis treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor5NqkaUGRfrVg90H21EOLACvtfcHk0ljL1saE33TjIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSksrjF&md5=e196d7203fa60d5ecd9182fa023cd30e</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnature04478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04478%26sid%3Dliteratum%253Aachs%26aulast%3DCarmeliet%26aufirst%3DP.%26atitle%3DAngiogenesis%2520in%2520life%252C%2520disease%2520and%2520medicine%26jtitle%3DNature%26date%3D2005%26volume%3D438%26spage%3D932%26epage%3D936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Gasparini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teicher, B. A.</span><span> </span><span class="NLM_article-title">Combination of antiangiogenic therapy with other anticancer therapies: Results, challenges, and open questions</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1295</span><span class="NLM_x">–</span> <span class="NLM_lpage">1311</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1200%2FJCO.2005.10.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=15718328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitl2gu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=1295-1311&author=G.+Gaspariniauthor=R.+Longoauthor=M.+Fanelliauthor=B.+A.+Teicher&title=Combination+of+antiangiogenic+therapy+with+other+anticancer+therapies%3A+Results%2C+challenges%2C+and+open+questions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of antiangiogenic therapy with other anticancer therapies: Results, challenges, and open questions</span></div><div class="casAuthors">Gasparini, Giampietro; Longo, Raffaele; Fanelli, Massimo; Teicher, Beverly A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1295-1311</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Angiogenesis is necessary for tumor growth.  Drug discovery efforts have identified several potential therapeutic targets on endothelial cells and selective inhibitors capable of slowing tumor growth or producing tumor regression by blocking angiogenesis in in vivo tumor models.  Certain antiangiogenic therapeutics increase the activity of cytotoxic anticancer treatments in preclin. models.  More than 75 antiangiogenic compds. have entered clin. trials.  Most of the early clin. testing was conducted in patients with advanced disease resistant to std. therapies.  Several phase III trials have been undertaken to compare the efficacy of std. chemotherapy vs. the same in combination with an exptl. angiogenesis inhibitor.  Preliminary results of the clin. studies suggest that single-agent antiangiogenic therapy is poorly active in advanced tumors.  Although some of the results of combination trials are controversial, recent pos. outcomes with an antivascular endothelial growth factor antibody combined with chemotherapy as front-line therapy of metastatic colorectal cancer have renewed enthusiasm for this therapeutic strategy.  This article presents an overview of exptl. and clin. studies of combined therapy with antiangiogenic agents and highlights the challenges related to the appropriate strategies for selection of the patients, study design, and choice of proper end points for preclin. and clin. studies using these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi3tg_F1HebrVg90H21EOLACvtfcHk0lhBR4xkpdbbBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitl2gu74%253D&md5=7d365a736bcd2aabc130d9d5f9c60eed</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.10.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.10.022%26sid%3Dliteratum%253Aachs%26aulast%3DGasparini%26aufirst%3DG.%26aulast%3DLongo%26aufirst%3DR.%26aulast%3DFanelli%26aufirst%3DM.%26aulast%3DTeicher%26aufirst%3DB.%2BA.%26atitle%3DCombination%2520of%2520antiangiogenic%2520therapy%2520with%2520other%2520anticancer%2520therapies%253A%2520Results%252C%2520challenges%252C%2520and%2520open%2520questions%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D1295%26epage%3D1311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Casanovas, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicklin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergers, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanahan, D.</span><span> </span><span class="NLM_article-title">Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">299</span><span class="NLM_x">–</span> <span class="NLM_lpage">309</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2005&pages=299-309&author=O.+Casanovasauthor=D.+J.+Hicklinauthor=G.+Bergersauthor=D.+Hanahan&title=Drug+resistance+by+evasion+of+antiangiogenic+targeting+of+VEGF+signaling+in+late-stage+pancreatic+islet+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCasanovas%26aufirst%3DO.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26aulast%3DBergers%26aufirst%3DG.%26aulast%3DHanahan%26aufirst%3DD.%26atitle%3DDrug%2520resistance%2520by%2520evasion%2520of%2520antiangiogenic%2520targeting%2520of%2520VEGF%2520signaling%2520in%2520late-stage%2520pancreatic%2520islet%2520tumors%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D8%26spage%3D299%26epage%3D309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Mancuso, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norberg, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Brien, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sennino, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakahara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freimark, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shalinsky, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu-Lowe, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, D. M.</span><span> </span><span class="NLM_article-title">Rapid vascular regrowth in tumors after reversal of VEGF inhibition</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">2610</span><span class="NLM_x">–</span> <span class="NLM_lpage">2621</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2006&pages=2610-2621&author=M.+R.+Mancusoauthor=R.+Davisauthor=S.+M.+Norbergauthor=S.+O%27Brienauthor=B.+Senninoauthor=T.+Nakaharaauthor=V.+J.+Yaoauthor=T.+Inaiauthor=P.+Brooksauthor=B.+Freimarkauthor=D.+R.+Shalinskyauthor=D.+D.+Hu-Loweauthor=D.+M.+McDonald&title=Rapid+vascular+regrowth+in+tumors+after+reversal+of+VEGF+inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMancuso%26aufirst%3DM.%2BR.%26aulast%3DDavis%26aufirst%3DR.%26aulast%3DNorberg%26aufirst%3DS.%2BM.%26aulast%3DO%2527Brien%26aufirst%3DS.%26aulast%3DSennino%26aufirst%3DB.%26aulast%3DNakahara%26aufirst%3DT.%26aulast%3DYao%26aufirst%3DV.%2BJ.%26aulast%3DInai%26aufirst%3DT.%26aulast%3DBrooks%26aufirst%3DP.%26aulast%3DFreimark%26aufirst%3DB.%26aulast%3DShalinsky%26aufirst%3DD.%2BR.%26aulast%3DHu-Lowe%26aufirst%3DD.%2BD.%26aulast%3DMcDonald%26aufirst%3DD.%2BM.%26atitle%3DRapid%2520vascular%2520regrowth%2520in%2520tumors%2520after%2520reversal%2520of%2520VEGF%2520inhibition%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2006%26volume%3D116%26spage%3D2610%26epage%3D2621" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Ma, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waxman, D. J.</span><span> </span><span class="NLM_article-title">Combination of antiangiogenesis with chemotherapy for more effective cancer treatment</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">3670</span><span class="NLM_x">–</span> <span class="NLM_lpage">3684</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1158%2F1535-7163.MCT-08-0715" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=19074844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsV2iurnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=3670-3684&author=J.+Maauthor=D.+J.+Waxman&title=Combination+of+antiangiogenesis+with+chemotherapy+for+more+effective+cancer+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of antiangiogenesis with chemotherapy for more effective cancer treatment</span></div><div class="casAuthors">Ma, Jie; Waxman, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3670-3684</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Angiogenesis is a hallmark of tumor development and metastasis and is now a validated target for cancer treatment.  However, the survival benefits of antiangiogenic drugs have thus far been rather modest, stimulating interest in developing more effective ways to combine antiangiogenic drugs with established chemotherapies.  This review discusses recent progress and emerging challenges in this field; interactions between antiangiogenic drugs and conventional chemotherapeutic agents are examd., and strategies for the optimization of combination therapies are discussed.  Antiangiogenic drugs such as the anti-vascular endothelial growth factor antibody bevacizumab can induce a functional normalization of the tumor vasculature that is transient and can potentiate the activity of coadministered chemoradiotherapies.  However, chronic angiogenesis inhibition typically reduces tumor uptake of coadministered chemotherapeutics, indicating a need to explore new approaches, including intermittent treatment schedules and provascular strategies to increase chemotherapeutic drug exposure.  In cases where antiangiogenesis-induced tumor cell starvation augments the intrinsic cytotoxic effects of a conventional chemotherapeutic drug, combination therapy may increase antitumor activity despite a decrease in cytotoxic drug exposure.  As new angiogenesis inhibitors enter the clinic, reliable surrogate markers are needed to monitor the progress of antiangiogenic therapies and to identify responsive patients.  New targets for antiangiogenesis continue to be discovered, increasing the opportunities to interdict tumor angiogenesis and circumvent resistance mechanisms that may emerge with chronic use of these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFuKsU4WlEmLVg90H21EOLACvtfcHk0lhBR4xkpdbbBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsV2iurnN&md5=187b65f71cce4580756ae01973ca758f</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-0715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-0715%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DWaxman%26aufirst%3DD.%2BJ.%26atitle%3DCombination%2520of%2520antiangiogenesis%2520with%2520chemotherapy%2520for%2520more%2520effective%2520cancer%2520treatment%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D3670%26epage%3D3684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Gangjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihnat, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warnke, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kisliuk, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, F.-T.</span><span> </span><span class="NLM_article-title">Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">5475</span><span class="NLM_x">–</span> <span class="NLM_lpage">5491</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2005&pages=5475-5491&author=A.+Gangjeeauthor=Y.+Zengauthor=M.+Ihnatauthor=L.+A.+Warnkeauthor=D.+W.+Greenauthor=R.+L.+Kisliukauthor=F.-T.+Lin&title=Novel+5-substituted%2C+2%2C4-diaminofuro%5B2%2C3-d%5Dpyrimidines+as+multireceptor+tyrosine+kinase+and+dihydrofolate+reductase+inhibitors+with+antiangiogenic+and+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DZeng%26aufirst%3DY.%26aulast%3DIhnat%26aufirst%3DM.%26aulast%3DWarnke%26aufirst%3DL.%2BA.%26aulast%3DGreen%26aufirst%3DD.%2BW.%26aulast%3DKisliuk%26aufirst%3DR.%2BL.%26aulast%3DLin%26aufirst%3DF.-T.%26atitle%3DNovel%25205-substituted%252C%25202%252C4-diaminofuro%255B2%252C3-d%255Dpyrimidines%2520as%2520multireceptor%2520tyrosine%2520kinase%2520and%2520dihydrofolate%2520reductase%2520inhibitors%2520with%2520antiangiogenic%2520and%2520antitumor%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2005%26volume%3D13%26spage%3D5475%26epage%3D5491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Fukumura, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, R. K.</span><span> </span><span class="NLM_article-title">Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalization</span> <span class="citation_source-journal">Microvasc. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">72</span><span class="NLM_x">–</span> <span class="NLM_lpage">84</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1016%2Fj.mvr.2007.05.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=17560615" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1ykur7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2007&pages=72-84&author=D.+Fukumuraauthor=R.+K.+Jain&title=Tumor+microvasculature+and+microenvironment%3A+Targets+for+anti-angiogenesis+and+normalization"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalization</span></div><div class="casAuthors">Fukumura, Dai; Jain, Rakesh K.</div><div class="citationInfo"><span class="NLM_cas:title">Microvascular Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">72-84</span>CODEN:
                <span class="NLM_cas:coden">MIVRA6</span>;
        ISSN:<span class="NLM_cas:issn">0026-2862</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  A solid tumor forms an organ-like entity comprised of neoplastic cells and non-transformed host stromal cells embedded in an extracellular matrix.  Similar to normal tissues, blood vessels nourish cells residing in tumors.  However, unlike normal blood vessels, tumor vasculature has abnormal organization, structure, and function.  Tumor vessels are leaky and blood flow is heterogeneous and often compromised.  Vascular hyperpermeability and the lack of functional lymphatic vessels inside tumors cause elevation of interstitial fluid pressure in solid tumors.  Each of these abnormalities forms a physiol. barrier to the delivery of therapeutic agents to tumors.  Furthermore, elevated tumor interstitial fluid pressure increases fluid flow from the tumor margin into the peri-tumor area and may facilitate peri-tumor lymphatic hyperplasia and metastasis.  Abnormal microcirculation in tumors also leads to a hostile microenvironment characterized by hypoxia and acidosis, which hinder the effectiveness of anti-tumor treatments such as radiation therapy and chemotherapy.  In addn., host-tumor interactions regulate expression of pro- and anti-angiogenic factors and hence contribute to their imbalance and resulting pathophysiol. characteristics of the tumor.  Restoration of pro- and anti-angiogenic balance in tumors may "normalize" tumor vasculature and thus improve its function.  Indeed, anti-angiogenic treatments directly targeting angiogenic signaling pathways as well as indirectly modulating angiogenesis show normalization of tumor vasculature and microenvironment at least transiently in both preclin. and clin. settings.  Combination of cytotoxic therapy and anti-angiogenic treatment during the vascular normalization exhibits synergistic effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDTVgfrwwDFLVg90H21EOLACvtfcHk0lg1WBV2d8VZyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1ykur7E&md5=c5d718292cb56e9762af981656db45bf</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.mvr.2007.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mvr.2007.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DFukumura%26aufirst%3DD.%26aulast%3DJain%26aufirst%3DR.%2BK.%26atitle%3DTumor%2520microvasculature%2520and%2520microenvironment%253A%2520Targets%2520for%2520anti-angiogenesis%2520and%2520normalization%26jtitle%3DMicrovasc.%2520Res.%26date%3D2007%26volume%3D74%26spage%3D72%26epage%3D84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Browder, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butterfield, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraling, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Reilly, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folkman, J.</span><span> </span><span class="NLM_article-title">Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">1878</span><span class="NLM_x">–</span> <span class="NLM_lpage">1886</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=1878-1886&author=T.+Browderauthor=C.+E.+Butterfieldauthor=B.+M.+Kralingauthor=B.+Shiauthor=B.+Marshallauthor=M.+S.+O%27Reillyauthor=J.+Folkman&title=Antiangiogenic+scheduling+of+chemotherapy+improves+efficacy+against+experimental+drug-resistant+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrowder%26aufirst%3DT.%26aulast%3DButterfield%26aufirst%3DC.%2BE.%26aulast%3DKraling%26aufirst%3DB.%2BM.%26aulast%3DShi%26aufirst%3DB.%26aulast%3DMarshall%26aufirst%3DB.%26aulast%3DO%2527Reilly%26aufirst%3DM.%2BS.%26aulast%3DFolkman%26aufirst%3DJ.%26atitle%3DAntiangiogenic%2520scheduling%2520of%2520chemotherapy%2520improves%2520efficacy%2520against%2520experimental%2520drug-resistant%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2000%26volume%3D60%26spage%3D1878%26epage%3D1886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Ferrara, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerbel, R. S.</span><span> </span><span class="NLM_article-title">Angiogenesis as a therapeutic target</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">438</span><span class="NLM_x">, </span> <span class="NLM_fpage">967</span><span class="NLM_x">–</span> <span class="NLM_lpage">974</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1038%2Fnature04483" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=16355214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSksrnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=438&publication_year=2005&pages=967-974&author=N.+Ferraraauthor=R.+S.+Kerbel&title=Angiogenesis+as+a+therapeutic+target"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Angiogenesis as a therapeutic target</span></div><div class="casAuthors">Ferrara, Napoleone; Kerbel, Robert S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">438</span>
        (<span class="NLM_cas:issue">7070</span>),
    <span class="NLM_cas:pages">967-974</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Inhibiting angiogenesis is a promising strategy for treatment of cancer and several other disorders, including age-related macular degeneration.  Major progress towards a treatment has been achieved over the past few years, and the first antiangiogenic agents have been recently approved for use in several countries.  Therapeutic angiogenesis (promoting new vessel growth to treat ischemic disorders) is an exciting frontier of cardiovascular medicine, but further understanding of the mechanisms of vascular morphogenesis is needed first.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdP_T905faXLVg90H21EOLACvtfcHk0lg1WBV2d8VZyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSksrnI&md5=05a90bd29a0fb34f9c20a825f899d04c</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnature04483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04483%26sid%3Dliteratum%253Aachs%26aulast%3DFerrara%26aufirst%3DN.%26aulast%3DKerbel%26aufirst%3DR.%2BS.%26atitle%3DAngiogenesis%2520as%2520a%2520therapeutic%2520target%26jtitle%3DNature%26date%3D2005%26volume%3D438%26spage%3D967%26epage%3D974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Klement, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baruchel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Man, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicklin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohlen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerbel, R. S.</span><span> </span><span class="NLM_article-title">Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">R15</span><span class="NLM_x">–</span> <span class="NLM_lpage">R24</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2000&pages=R15-R24&author=G.+Klementauthor=S.+Baruchelauthor=J.+Rakauthor=S.+Manauthor=K.+Clarkauthor=D.+J.+Hicklinauthor=P.+Bohlenauthor=R.+S.+Kerbel&title=Continuous+low-dose+therapy+with+vinblastine+and+VEGF+receptor-2+antibody+induces+sustained+tumor+regression+without+overt+toxicity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKlement%26aufirst%3DG.%26aulast%3DBaruchel%26aufirst%3DS.%26aulast%3DRak%26aufirst%3DJ.%26aulast%3DMan%26aufirst%3DS.%26aulast%3DClark%26aufirst%3DK.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26aulast%3DBohlen%26aufirst%3DP.%26aulast%3DKerbel%26aufirst%3DR.%2BS.%26atitle%3DContinuous%2520low-dose%2520therapy%2520with%2520vinblastine%2520and%2520VEGF%2520receptor-2%2520antibody%2520induces%2520sustained%2520tumor%2520regression%2520without%2520overt%2520toxicity%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2000%26volume%3D105%26spage%3DR15%26epage%3DR24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Ho, Q. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, C. J.</span><span> </span><span class="NLM_article-title">Vascular endothelial growth factor: Biology and therapeutic applications</span> <span class="citation_source-journal">Int. J. Biochem. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1349</span><span class="NLM_x">–</span> <span class="NLM_lpage">1357</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1016%2Fj.biocel.2007.04.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=17537667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2007&pages=1349-1357&author=Q.+T.+Hoauthor=C.+J.+Kuo&title=Vascular+endothelial+growth+factor%3A+Biology+and+therapeutic+applications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular endothelial growth factor: Biology and therapeutic applications</span></div><div class="casAuthors">Ho, Quoc T.; Kuo, Calvin J.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry & Cell Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">1349-1357</span>CODEN:
                <span class="NLM_cas:coden">IJBBFU</span>;
        ISSN:<span class="NLM_cas:issn">1357-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  While the development of anti-angiogenic therapy, as it pertains to cancer treatment, may still be in its infancy relative to well-established modalities such as chemotherapy, radiation, and surgery, major strides made in the past several decades have allowed translation of basic science discoveries in this field into clin. reality.  The discovery of key mol. modulators of angiogenesis, notably vascular endothelial growth factor (VEGF), has catalyzed the development of numerous neutralizing therapeutic agents.  The validity of VEGF inhibition as a therapeutic strategy has been well supported in randomized clin. trials, as well as U.S.  Food and Drug Administration approval of the VEGF antagonists bevacizumab, sunitinib malate, sorafenib, pegaptinib and ranibizumab.  Accordingly, this review will (1) briefly review the basic mol. biol. of VEGF and (2) summarize recent progress in targeting the VEGF mol. pathway as therapy for angiogenic diseases such as cancer and age-related macular degeneration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraJnUIpAfpmbVg90H21EOLACvtfcHk0lg1WBV2d8VZyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWltLs%253D&md5=b802e1610699a5619e56f3720ef17bac</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.biocel.2007.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biocel.2007.04.010%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DQ.%2BT.%26aulast%3DKuo%26aufirst%3DC.%2BJ.%26atitle%3DVascular%2520endothelial%2520growth%2520factor%253A%2520Biology%2520and%2520therapeutic%2520applications%26jtitle%3DInt.%2520J.%2520Biochem.%2520Cell%2520Biol.%26date%3D2007%26volume%3D39%26spage%3D1349%26epage%3D1357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27a"><span><span class="NLM_contrib-group">Lindahl, P. J. B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levéen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Betsholtz, C.</span><span> </span><span class="NLM_article-title">Pericyte Loss and Microaneurysm Formation in PDGF-B-Deficient Mice</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x"> (</span><span class="NLM_issue">5323</span><span class="NLM_x">) </span> <span class="NLM_fpage">242</span><span class="NLM_x">–</span> <span class="NLM_lpage">245</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=1997&pages=242-245&issue=5323&author=P.+J.+B.+R.+Lindahlauthor=P.+Lev%C3%A9enauthor=C.+Betsholtz&title=Pericyte+Loss+and+Microaneurysm+Formation+in+PDGF-B-Deficient+Mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLindahl%26aufirst%3DP.%2BJ.%2BB.%2BR.%26aulast%3DLev%25C3%25A9en%26aufirst%3DP.%26aulast%3DBetsholtz%26aufirst%3DC.%26atitle%3DPericyte%2520Loss%2520and%2520Microaneurysm%2520Formation%2520in%2520PDGF-B-Deficient%2520Mice%26jtitle%3DScience%26date%3D1997%26volume%3D277%26issue%3D5323%26spage%3D242%26epage%3D245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit27b"><span><span class="NLM_contrib-group">Sjöblom, T. P., K.; Östman, A.; Heldin, C.-H.</span><span> </span><span class="NLM_article-title">Platelet-derived growth factor. Normal function, role in disease and application of PDGF antagonists</span>. In  <span class="citation_source-book">Protein Tyrosine Kinases: From Inhibitors to Useful Drugs</span>; <span class="NLM_contrib-group">Fabbra, D., ; McCormick, F.</span>, Eds.; <span class="NLM_publisher-name">Humana Press</span>, <span class="NLM_publisher-loc">Totowa, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">2006</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">161</span>− <span class="NLM_lpage">186</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=161-186&author=T.+P.%2C+K.+Sj%C3%B6blom&author=A.+%C3%96stman&author=C.-H.+Heldinauthor=D.+Fabbra&author=F.+McCormick&title=Protein+Tyrosine+Kinases%3A+From+Inhibitors+to+Useful+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DSj%25C3%25B6blom%26aufirst%3DT.%2BP.%252C%2BK.%26atitle%3DPlatelet-derived%2520growth%2520factor.%2520Normal%2520function%252C%2520role%2520in%2520disease%2520and%2520application%2520of%2520PDGF%2520antagonists%26btitle%3DProtein%2520Tyrosine%2520Kinases%253A%2520From%2520Inhibitors%2520to%2520Useful%2520Drugs%26aulast%3DFabbra%26aufirst%3DD.%26pub%3DHumana%2520Press%26date%3D2006%26spage%3D161%26epage%3D186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="ref28_1"><span>Clinical Trials: Combination of Capecitabine with Kinase Inhibitors: Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer. <a href="http://www.clinicaltrials.gov/ct2/show/NCT00496366?term=capecitabine&amp;rank=4" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00496366?term=capecitabine&rank=4</a>; <a href="http://www.clinicaltrials.gov/ct2/show/NCT00496366?term=capecitabine&amp;rank=4" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00496366?term=capecitabine&rank=4</a>; A study of Sunitinib in Combination with Capecitabine Compared with Capecitabine in Patients with Breast Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00435409?term=capecitabine&amp;rank=5" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00435409?term=capecitabine&rank=5</a>; Study of Sunitinib in Combination with Cisplatin/Capecitabine or Oxaliplatin/Capecitabine in Patients with Advanced Gastric Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00555620?term=capecitabine&amp;rank=6" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00555620?term=capecitabine&rank=6</a>; Bevacizumab, Erlotinib and Capecitabine for Locally Advanced Rectal Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00543842?term=capecitabine&amp;rank=15" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00543842?term=capecitabine&rank=15</a>; Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabinie/Erlotnib Followed of Capecitabine, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00440167" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00440167</a>; A Phase I Trial of Capecitabine in Combination with Gemcitabine and Erlotinib for Advanced Pancreatic Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00480584" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00480584</a>; Gemcitabine/Vinorelbine versus Gemcitabine/Cisplatin versus Gemcitabine/Capecitabine in Metastatic Breast Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00480597" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00480597</a>; A Phase II Trial of Gemcitabine, Capecitabine and Bevacizumab in Metastatic Renal Cell Carcinoma, <a href="http://www.clinicaltrials.gov/ct2/show/NCT0000523640" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT0000523640</a>; Brain Mets - Capecitabine and WBRT, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00570908?term=capecitabine&amp;rank=19" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00570908?term=capecitabine&rank=19</a>; Combination Study of Capecitabine and Erlotinib Concurrent with Radiotherapy for Non-operable Advanced Pancreatic Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00565487?term=capecitabine&amp;rank=30" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00565487?term=capecitabine&rank=30</a>; Phase I Vandetanib Plau Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00532909?term=capecitabine&amp;rank=44" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00532909?term=capecitabine&rank=44</a>; Phase I Study of Lapatinib in combination with Oxaliplatin and Capecitabine in Sugjects with Advanced Colorectal Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00536809?term=capecitabine&amp;rank=74" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00536809?term=capecitabine&rank=74</a>; Enzastaurin in combination of Capecitabine to Treat Breat Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00437294?term=capecitabine&amp;rank=92" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00437294?term=capecitabine&rank=92</a>; Imatinib Mesylate, Gemcitabine and Capecitabine in Treating Patients with Advanced Solid Tumors, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00483366?term=capecitabine&amp;rank=93" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00483366?term=capecitabine&rank=93</a>; Lapatinib + Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women from China, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00508274?term=capecitabine&amp;rank=101" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00508274?term=capecitabine&rank=101</a>; A Clinical Trial Comparing Efficacy and Safety of Sunitinib and Capecitabine, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00373113?term=capecitabine&amp;rank=150" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00373113?term=capecitabine&rank=150</a>; Study for Patients with Untreated Gastric Cancer Who Will Receive Capecitabine and Lapatinib, <a href="http://www.clinicaltrials.gov/ct2/show/NCT0000570908?term=capecitabine&amp;rank=152" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT0000570908?term=capecitabine&rank=152</a>; EAP (Expanded Access Protocol) of Lapatinib Combinied with Capecitabine in Metastatic Breast Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00338247?term=capecitabine&amp;rank=167" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00338247?term=capecitabine&rank=167</a>; Phase I/II XP + Sorafenib in AGC, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00565370?term=capecitabine&amp;rank=250" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00565370?term=capecitabine&rank=250</a>. A Brain Metastases in ErbB2-Positive Breast Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00437073?term=capecitabine&amp;rank=267" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00437073?term=capecitabine&rank=267</a>; Lapatinib in Combination with Capecitabine in Japanese Patients with Metastatic Breast Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00477464?term=capecitabine&amp;rank=309" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00477464?term=capecitabine&rank=309</a>; Clinical Trial on the Mixture of Gemcitabine, Capecitabine and Sorafenib (Bay 43-9006) in the Treatment of Patients with Renal Cell Carcinoma (RCC) (SOGUG-02-06), <a href="http://www.clinicaltrials.gov/ct2/show/NCT00496301?term=capecitabine&amp;rank=311" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00496301?term=capecitabine&rank=311</a>; Erlotinib, Combination Chemotherapy and Radiation Therapy in Treating Patients with Stage I or Stage II Pancreatic Cancer that can be Removed by Surgery, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00313560?term=capecitabine&amp;rank=352" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00313560?term=capecitabine&rank=352</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical+Trials%3A+Combination+of+Capecitabine+with+Kinase+Inhibitors%3A+Capecitabine+%28Xeloda%29+and+Lapatinib+%28Tykerb%29+as+First-line+Therapy+in+HER2%2FNeu-positive+Breast+Cancer.+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00496366%3Fterm%3Dcapecitabine%26rank%3D4%3B+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00496366%3Fterm%3Dcapecitabine%26rank%3D4%3B+A+study+of+Sunitinib+in+Combination+with+Capecitabine+Compared+with+Capecitabine+in+Patients+with+Breast+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00435409%3Fterm%3Dcapecitabine%26rank%3D5%3B+Study+of+Sunitinib+in+Combination+with+Cisplatin%2FCapecitabine+or+Oxaliplatin%2FCapecitabine+in+Patients+with+Advanced+Gastric+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00555620%3Fterm%3Dcapecitabine%26rank%3D6%3B+Bevacizumab%2C+Erlotinib+and+Capecitabine+for+Locally+Advanced+Rectal+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00543842%3Fterm%3Dcapecitabine%26rank%3D15%3B+Capecitabine%2FErlotinib+Followed+of+Gemcitabine+Versus+Gemcitabinie%2FErlotnib+Followed+of+Capecitabine%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00440167%3B+A+Phase+I+Trial+of+Capecitabine+in+Combination+with+Gemcitabine+and+Erlotinib+for+Advanced+Pancreatic+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00480584%3B+Gemcitabine%2FVinorelbine+versus+Gemcitabine%2FCisplatin+versus+Gemcitabine%2FCapecitabine+in+Metastatic+Breast+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00480597%3B+A+Phase+II+Trial+of+Gemcitabine%2C+Capecitabine+and+Bevacizumab+in+Metastatic+Renal+Cell+Carcinoma%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT0000523640%3B+Brain+Mets+-+Capecitabine+and+WBRT%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00570908%3Fterm%3Dcapecitabine%26rank%3D19%3B+Combination+Study+of+Capecitabine+and+Erlotinib+Concurrent+with+Radiotherapy+for+Non-operable+Advanced+Pancreatic+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00565487%3Fterm%3Dcapecitabine%26rank%3D30%3B+Phase+I+Vandetanib+Plau+Capecitabine%2C+Oxaliplatin+and+Bevacizumab+for+Metastatic+Colorectal+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00532909%3Fterm%3Dcapecitabine%26rank%3D44%3B+Phase+I+Study+of+Lapatinib+in+combination+with+Oxaliplatin+and+Capecitabine+in+Sugjects+with+Advanced+Colorectal+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00536809%3Fterm%3Dcapecitabine%26rank%3D74%3B+Enzastaurin+in+combination+of+Capecitabine+to+Treat+Breat+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00437294%3Fterm%3Dcapecitabine%26rank%3D92%3B+Imatinib+Mesylate%2C+Gemcitabine+and+Capecitabine+in+Treating+Patients+with+Advanced+Solid+Tumors%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00483366%3Fterm%3Dcapecitabine%26rank%3D93%3B+Lapatinib+%2B+Capecitabine+Treatment+for+Advanced+Metastatic+Breast+Cancer+in+Women+from+China%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00508274%3Fterm%3Dcapecitabine%26rank%3D101%3B+A+Clinical+Trial+Comparing+Efficacy+and+Safety+of+Sunitinib+and+Capecitabine%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00373113%3Fterm%3Dcapecitabine%26rank%3D150%3B+Study+for+Patients+with+Untreated+Gastric+Cancer+Who+Will+Receive+Capecitabine+and+Lapatinib%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT0000570908%3Fterm%3Dcapecitabine%26rank%3D152%3B+EAP+%28Expanded+Access+Protocol%29+of+Lapatinib+Combinied+with+Capecitabine+in+Metastatic+Breast+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00338247%3Fterm%3Dcapecitabine%26rank%3D167%3B+Phase+I%2FII+XP+%2B+Sorafenib+in+AGC%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00565370%3Fterm%3Dcapecitabine%26rank%3D250.+A+Brain+Metastases+in+ErbB2-Positive+Breast+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00437073%3Fterm%3Dcapecitabine%26rank%3D267%3B+Lapatinib+in+Combination+with+Capecitabine+in+Japanese+Patients+with+Metastatic+Breast+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00477464%3Fterm%3Dcapecitabine%26rank%3D309%3B+Clinical+Trial+on+the+Mixture+of+Gemcitabine%2C+Capecitabine+and+Sorafenib+%28Bay+43-9006%29+in+the+Treatment+of+Patients+with+Renal+Cell+Carcinoma+%28RCC%29+%28SOGUG-02-06%29%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00496301%3Fterm%3Dcapecitabine%26rank%3D311%3B+Erlotinib%2C+Combination+Chemotherapy+and+Radiation+Therapy+in+Treating+Patients+with+Stage+I+or+Stage+II+Pancreatic+Cancer+that+can+be+Removed+by+Surgery%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00313560%3Fterm%3Dcapecitabine%26rank%3D352."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=ref28_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Tripathy, D.</span><span> </span><span class="NLM_article-title">Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: underlying rationale and results of clinical trials</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">375</span><span class="NLM_x">–</span> <span class="NLM_lpage">389</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=375-389&author=D.+Tripathy&title=Capecitabine+in+combination+with+novel+targeted+agents+in+the+management+of+metastatic+breast+cancer%3A+underlying+rationale+and+results+of+clinical+trials"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTripathy%26aufirst%3DD.%26atitle%3DCapecitabine%2520in%2520combination%2520with%2520novel%2520targeted%2520agents%2520in%2520the%2520management%2520of%2520metastatic%2520breast%2520cancer%253A%2520underlying%2520rationale%2520and%2520results%2520of%2520clinical%2520trials%26jtitle%3DOncologist%26date%3D2007%26volume%3D12%26spage%3D375%26epage%3D389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="ref30_1"><span>Clinical Trials Combination of 5-FU with Kinase Inhibitors: Bevacizumab, Erlotinib and 5-Fluorouracil with External Beam Radiation Therapy in Locally Advanced Rectal Cancer,. <a href="http://www.clinicaltrials.gov/ct2/show/NCT00307736" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00307736</a>; Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00591123" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00591123</a>; Sunitinib, Irinotecan, Fluorouracil and Leucovorini in Treating Patients with Advanced Stomach Cancer or Gastroesophageal Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00524186" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00524186</a>; A Phase I Study of Sunitinib in combination with Cisplatin and 5-Fluorouracil in Patients with Advanced Gastric Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00555672" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00555672</a>; Oxaliplatin, Fluorouracil, Erlotinib and Radiation Therapy before Surgery and Erlotinib After Sursery in Treating Patients with Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00499564" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00499564</a>; Cisplatin, Fluorouracil, Gefitinib and Radiation Therapy in Treating Patients with Locally Advanced Head and Neck Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00352105" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00352105</a>; Study of FOLFIRI Chemotherapy with or without Sunitinib in Patients with Metastatic Colorectal Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00457691" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00457691</a>; Docetaxel and Lapatinib with or without Combination Chemotherapy or Docetaxel and Trastuzumab with Combination Chemotherapy in Treating Women with Locally Advanced, Inflammatory or Resectable Breast Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00450892" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00450892</a>; Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00393068" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00393068</a>; Combination Chemotherapy and Radiation therapy with or without Lapatinib in Treating Patients with Locally Advanced Cancer of the Larynx or Hypopharynx That Can Be Removed by Surgery, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00498953" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00498953</a>; Lapatinib +/- Trastuzumab in addition to Standard Neoadjuvant Breast Cancer Therapy, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00524303" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00524303</a>; Chemotherapy & Erlotinib in Treating Patients with Esophageal or Gastroesophageal Cancer That Cannot be Removed by Surgery, <a href="http://www.clinicaltrials.gov/ct2/show/NCT0000539617" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT0000539617</a>; A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in combination with FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00500292" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00500292</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical+Trials+Combination+of+5-FU+with+Kinase+Inhibitors%3A+Bevacizumab%2C+Erlotinib+and+5-Fluorouracil+with+External+Beam+Radiation+Therapy+in+Locally+Advanced+Rectal+Cancer%2C.+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00307736%3B+Study+of+Erlotinib+and+Chemotherapy+for+Unresectable+or+Metastatic+Cancer+of+the+Esophagus+and+Gastric+Cardia%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00591123%3B+Sunitinib%2C+Irinotecan%2C+Fluorouracil+and+Leucovorini+in+Treating+Patients+with+Advanced+Stomach+Cancer+or+Gastroesophageal+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00524186%3B+A+Phase+I+Study+of+Sunitinib+in+combination+with+Cisplatin+and+5-Fluorouracil+in+Patients+with+Advanced+Gastric+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00555672%3B+Oxaliplatin%2C+Fluorouracil%2C+Erlotinib+and+Radiation+Therapy+before+Surgery+and+Erlotinib+After+Sursery+in+Treating+Patients+with+Locally+Advanced+Cancer+of+the+Esophagus+or+Gastroesophageal+Junction%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00499564%3B+Cisplatin%2C+Fluorouracil%2C+Gefitinib+and+Radiation+Therapy+in+Treating+Patients+with+Locally+Advanced+Head+and+Neck+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00352105%3B+Study+of+FOLFIRI+Chemotherapy+with+or+without+Sunitinib+in+Patients+with+Metastatic+Colorectal+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00457691%3B+Docetaxel+and+Lapatinib+with+or+without+Combination+Chemotherapy+or+Docetaxel+and+Trastuzumab+with+Combination+Chemotherapy+in+Treating+Women+with+Locally+Advanced%2C+Inflammatory+or+Resectable+Breast+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00450892%3B+Chemotherapy%2C+Radiation+Therapy+and+Immunotherapy+Prior+to+Surgery+in+Operable+Esophageal+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00393068%3B+Combination+Chemotherapy+and+Radiation+therapy+with+or+without+Lapatinib+in+Treating+Patients+with+Locally+Advanced+Cancer+of+the+Larynx+or+Hypopharynx+That+Can+Be+Removed+by+Surgery%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00498953%3B+Lapatinib+%2B%2F-+Trastuzumab+in+addition+to+Standard+Neoadjuvant+Breast+Cancer+Therapy%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00524303%3B+Chemotherapy+%26+Erlotinib+in+Treating+Patients+with+Esophageal+or+Gastroesophageal+Cancer+That+Cannot+be+Removed+by+Surgery%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT0000539617%3B+A+Phase+II+Study+of+2+Doses+of+ZD6474+%28Vandetanib%29+in+combination+with+FOLFOX+vs+FOLFOX+Alone+for+the+Treatment+of+Colorectal+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00500292."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=ref30_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="ref31_1"><span>Clinical Trials - Combination of Pemetrexed with Kinase Inhibitors: A Study to Find the Best Dose of SU011248 When Given with Pemetrexed, Pemetrexed and Cisplatin or Pemetrexed and Carboplatin in Patients with Advanced Solid Tumors, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00528619?term=pemetrexed&amp;rank=1" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00528619?term=pemetrexed&rank=1</a>; Efficacy Study Comparing ZD6474 in Combination with Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients (ZEAL), <a href="http://clinicaltrials.gov/ct2/show/NCT00418886?term=pemetrexed&amp;rank=2" class="extLink">http://clinicaltrials.gov/ct2/show/NCT00418886?term=pemetrexed&rank=2</a>; Docetaxel or Pemetrexed with or Without Cetuximab in Patients with Recurrent or Progressive Non-small Cell Lung Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00095199?term=pemetrexed&amp;rank=3" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00095199?term=pemetrexed&rank=3</a>; A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) Versus Pemetrexed in Advanced Non-small Cell Lung Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00528281?term=pemetrexed&amp;rank=7" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00528281?term=pemetrexed&rank=7</a>; Study of Pemetrexed Versus Pemetrexed + Erlotinib as Treatment of Non-small Cell Lung Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00447057?term=pemetrexed&amp;rank=14" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00447057?term=pemetrexed&rank=14</a>; Cisplatin, Imatinib Mesylate, and Pemetrexed in Malignant Mesothelioma Patients, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00402766?term=pemetrexed&amp;rank=17" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00402766?term=pemetrexed&rank=17</a>; ZD6474 (Vandetanib) + Alimta Combo Study, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00506051?term=pemetrexed&amp;rank=22" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00506051?term=pemetrexed&rank=22</a>; Study of Enzastaurin Versus Placebo with Pemetrexed for Patients with Advanced or Metastatic Lung Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00530621?term=pemetrexed&amp;rank=27" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00530621?term=pemetrexed&rank=27</a>; Pemetrexed Disodium with or Without Sorafenib as Second-line Therapy in Treating Patients with Stage IIIB or Stave IV Non-small Cell Lung Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00454194?term=pemetrexed&amp;rank=31" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00454194?term=pemetrexed&rank=31</a>; AZD6244 Versus Pemetrexed (Alimta®) in Patients with Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen, <a href="http://clinicaltrials.gov/ct2/show/NCT00372788?term=pemetrexec&amp;rank=32" class="extLink">http://clinicaltrials.gov/ct2/show/NCT00372788?term=pemetrexec&rank=32</a>; Randomized Phase III Trial of Pemetrexed vs Erlotinib in Pretreated Patients with NSCLC, <a href="http://clinicaltrials.gov/ct2/show/NCT00440414?term=pemetrexed&amp;rank=34" class="extLink">http://clinicaltrials.gov/ct2/show/NCT00440414?term=pemetrexed&rank=34</a>; Vatalanib and Pemetrexed Disodium in Treating Patients with Advanced Solid Tumors, <a href="http://clinicaltrials.gov/ct2/show/NCT00390000?term=pemetrexed&amp;rank=37" class="extLink">http://clinicaltrials.gov/ct2/show/NCT00390000?term=pemetrexed&rank=37</a>; Sorafenib Combined with Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating patients with Metastatic Solid Tumors, <a href="http://clinicaltrials.gov/ct2/show/NCT00573690?term=pemetrexed&amp;rank=92" class="extLink">http://clinicaltrials.gov/ct2/show/NCT00573690?term=pemetrexed&rank=92</a>; Study in Patients with Advanced Non-small Cell Lung Cancer Treated with Pemetrexed and Carboplatin Plus or Minus Sorafenib (PECASO), <a href="http://clinicaltrials.gov/ct2/show/NCT00473486?term=pemetrexed&amp;rank=98" class="extLink">http://clinicaltrials.gov/ct2/show/NCT00473486?term=pemetrexed&rank=98</a>; Chemotherapy for patients with Non-small Cell Lung Cancer Who Are Non-smokers, <a href="http://clinicaltrials.gov/ct2/show/NCT00409006?term=pemetrexed&amp;rank=152" class="extLink">http://clinicaltrials.gov/ct2/show/NCT00409006?term=pemetrexed&rank=152</a>; Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients with Non-small Cell Lung Cancer, <a href="http://clinicaltrials.gov/ct2/show/NCT00351039?term=pemetrexed&amp;rank=202" class="extLink">http://clinicaltrials.gov/ct2/show/NCT00351039?term=pemetrexed&rank=202</a>; A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-small Cell Lung Cancer), <a href="http://clinicaltrials.gov/ct2/show/NCT00095225?term=pemetrexed&amp;rank=203" class="extLink">http://clinicaltrials.gov/ct2/show/NCT00095225?term=pemetrexed&rank=203</a>; A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients with Advanced, Recurrent or Metastatic Non-small Cell Lung Cancer (NSCLC), <a href="http://clinicaltrials.gov/ct2/show/NCT00556322?term=pemetrexed&amp;rank=206" class="extLink">http://clinicaltrials.gov/ct2/show/NCT00556322?term=pemetrexed&rank=206</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical+Trials+-+Combination+of+Pemetrexed+with+Kinase+Inhibitors%3A+A+Study+to+Find+the+Best+Dose+of+SU011248+When+Given+with+Pemetrexed%2C+Pemetrexed+and+Cisplatin+or+Pemetrexed+and+Carboplatin+in+Patients+with+Advanced+Solid+Tumors%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00528619%3Fterm%3Dpemetrexed%26rank%3D1%3B+Efficacy+Study+Comparing+ZD6474+in+Combination+with+Pemetrexed+and+Pemetrexed+Alone+in+2nd+Line+NSCLC+Patients+%28ZEAL%29%2C+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT00418886%3Fterm%3Dpemetrexed%26rank%3D2%3B+Docetaxel+or+Pemetrexed+with+or+Without+Cetuximab+in+Patients+with+Recurrent+or+Progressive+Non-small+Cell+Lung+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00095199%3Fterm%3Dpemetrexed%26rank%3D3%3B+A+Phase+II+Trial+of+Lapatinib+%28TYKERB%29+%2B+Pemetrexed+%28ALIMTA%29+Versus+Pemetrexed+in+Advanced+Non-small+Cell+Lung+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00528281%3Fterm%3Dpemetrexed%26rank%3D7%3B+Study+of+Pemetrexed+Versus+Pemetrexed+%2B+Erlotinib+as+Treatment+of+Non-small+Cell+Lung+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00447057%3Fterm%3Dpemetrexed%26rank%3D14%3B+Cisplatin%2C+Imatinib+Mesylate%2C+and+Pemetrexed+in+Malignant+Mesothelioma+Patients%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00402766%3Fterm%3Dpemetrexed%26rank%3D17%3B+ZD6474+%28Vandetanib%29+%2B+Alimta+Combo+Study%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00506051%3Fterm%3Dpemetrexed%26rank%3D22%3B+Study+of+Enzastaurin+Versus+Placebo+with+Pemetrexed+for+Patients+with+Advanced+or+Metastatic+Lung+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00530621%3Fterm%3Dpemetrexed%26rank%3D27%3B+Pemetrexed+Disodium+with+or+Without+Sorafenib+as+Second-line+Therapy+in+Treating+Patients+with+Stage+IIIB+or+Stave+IV+Non-small+Cell+Lung+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00454194%3Fterm%3Dpemetrexed%26rank%3D31%3B+AZD6244+Versus+Pemetrexed+%28Alimta%C2%AE%29+in+Patients+with+Non-small+Cell+Lung+Cancer%2C+Who+Have+Failed+One+or+Two+Prior+Chemotherapy+Regimen%2C+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT00372788%3Fterm%3Dpemetrexec%26rank%3D32%3B+Randomized+Phase+III+Trial+of+Pemetrexed+vs+Erlotinib+in+Pretreated+Patients+with+NSCLC%2C+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT00440414%3Fterm%3Dpemetrexed%26rank%3D34%3B+Vatalanib+and+Pemetrexed+Disodium+in+Treating+Patients+with+Advanced+Solid+Tumors%2C+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT00390000%3Fterm%3Dpemetrexed%26rank%3D37%3B+Sorafenib+Combined+with+Cisplatin+and+Etoposide+or+Carboplatin+and+Pemetrexed+in+Treating+patients+with+Metastatic+Solid+Tumors%2C+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT00573690%3Fterm%3Dpemetrexed%26rank%3D92%3B+Study+in+Patients+with+Advanced+Non-small+Cell+Lung+Cancer+Treated+with+Pemetrexed+and+Carboplatin+Plus+or+Minus+Sorafenib+%28PECASO%29%2C+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT00473486%3Fterm%3Dpemetrexed%26rank%3D98%3B+Chemotherapy+for+patients+with+Non-small+Cell+Lung+Cancer+Who+Are+Non-smokers%2C+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT00409006%3Fterm%3Dpemetrexed%26rank%3D152%3B+Phase+I%2FII+Trial+of+Bevacizumab%2C+Pemetrexed+and+Erlotinib+in+Elderly+Patients+with+Non-small+Cell+Lung+Cancer%2C+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT00351039%3Fterm%3Dpemetrexed%26rank%3D202%3B+A+Study+to+Evaluate+Bevacizumab+and+Chemotherapy+or+Tarceva+in+Treating+Recurrent+or+Refractory+NSCLC+%28Non-small+Cell+Lung+Cancer%29%2C+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT00095225%3Fterm%3Dpemetrexed%26rank%3D203%3B+A+Study+of+Tarceva+%28Erlotinib%29+and+Standard+of+Care+Chemotherapy+in+Patients+with+Advanced%2C+Recurrent+or+Metastatic+Non-small+Cell+Lung+Cancer+%28NSCLC%29%2C+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT00556322%3Fterm%3Dpemetrexed%26rank%3D206."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=ref31_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Huber, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bischof, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenne, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heiland, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peschke, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saffrich, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groene, H.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debus, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipson, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abdollahi, A.</span><span> </span><span class="NLM_article-title">Trimodal cancer treatment: Beneficial effects of combined antiangiogenesis, radiation, and chemotherapy</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">3643</span><span class="NLM_x">–</span> <span class="NLM_lpage">3655</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=3643-3655&author=P.+E.+Huberauthor=M.+Bischofauthor=J.+Jenneauthor=S.+Heilandauthor=P.+Peschkeauthor=R.+Saffrichauthor=H.-J.+Groeneauthor=J.+Debusauthor=K.+E.+Lipsonauthor=A.+Abdollahi&title=Trimodal+cancer+treatment%3A+Beneficial+effects+of+combined+antiangiogenesis%2C+radiation%2C+and+chemotherapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHuber%26aufirst%3DP.%2BE.%26aulast%3DBischof%26aufirst%3DM.%26aulast%3DJenne%26aufirst%3DJ.%26aulast%3DHeiland%26aufirst%3DS.%26aulast%3DPeschke%26aufirst%3DP.%26aulast%3DSaffrich%26aufirst%3DR.%26aulast%3DGroene%26aufirst%3DH.-J.%26aulast%3DDebus%26aufirst%3DJ.%26aulast%3DLipson%26aufirst%3DK.%2BE.%26aulast%3DAbdollahi%26aufirst%3DA.%26atitle%3DTrimodal%2520cancer%2520treatment%253A%2520Beneficial%2520effects%2520of%2520combined%2520antiangiogenesis%252C%2520radiation%252C%2520and%2520chemotherapy%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D3643%26epage%3D3655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Schnell, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dyson, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, P. E.</span><span> </span><span class="NLM_article-title">Structure, dynamics, and catalytic function of dihydrofolate reductase</span> <span class="citation_source-journal">Annu. Rev. Biophys. Biomol. Struct.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">119</span><span class="NLM_x">–</span> <span class="NLM_lpage">140</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2004&pages=119-140&author=J.+R.+Schnellauthor=H.+J.+Dysonauthor=P.+E.+Wright&title=Structure%2C+dynamics%2C+and+catalytic+function+of+dihydrofolate+reductase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchnell%26aufirst%3DJ.%2BR.%26aulast%3DDyson%26aufirst%3DH.%2BJ.%26aulast%3DWright%26aufirst%3DP.%2BE.%26atitle%3DStructure%252C%2520dynamics%252C%2520and%2520catalytic%2520function%2520of%2520dihydrofolate%2520reductase%26jtitle%3DAnnu.%2520Rev.%2520Biophys.%2520Biomol.%2520Struct.%26date%3D2004%26volume%3D33%26spage%3D119%26epage%3D140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Carreras, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santi, D. V.</span><span> </span><span class="NLM_article-title">The catalytic mechanism and structure of thymidylate synthase</span> <span class="citation_source-journal">Annu. Rev. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">721</span><span class="NLM_x">–</span> <span class="NLM_lpage">762</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1146%2Fannurev.bi.64.070195.003445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=7574499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADyaK2MXmsl2qtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1995&pages=721-762&author=C.+W.+Carrerasauthor=D.+V.+Santi&title=The+catalytic+mechanism+and+structure+of+thymidylate+synthase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The catalytic mechanism and structure of thymidylate synthase</span></div><div class="casAuthors">Carreras, Christopher W.; Santi, Daniel V.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">721-62</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review, with 193 refs.  Thymidylate synthase (TS, EC 2.1.1.45) catalyzes the reductive methylation of dUMP by CH2H4folate to produce dTMP and H2folate.  Knowledge of the catalytic mechanism and structure of TS has increased substantially over recent years.  Major advances were derived from crystal structures of TS bound to various ligands, the ability to overexpress TS in heterologous hosts, and the numerous mutants that have been prepd. and analyzed.  These advances, coupled with previous knowledge, have culminated in an in-depth understanding of many important mol. details of the reaction.  The authors review aspects of TS catalysis that are most pertinent to understanding the current status of the structure and catalytic mechanism of the enzyme.  Included is a discussion of available sources and assays for TS, a description of the enzyme's chem. mechanism and crystal structure, and a summary of data obtained from mutagenesis expts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO-xv6vKzvm7Vg90H21EOLACvtfcHk0liiSmZhiSG2FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXmsl2qtrg%253D&md5=3fa2b583e048196a12193b27f9533770</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1146%2Fannurev.bi.64.070195.003445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.bi.64.070195.003445%26sid%3Dliteratum%253Aachs%26aulast%3DCarreras%26aufirst%3DC.%2BW.%26aulast%3DSanti%26aufirst%3DD.%2BV.%26atitle%3DThe%2520catalytic%2520mechanism%2520and%2520structure%2520of%2520thymidylate%2520synthase%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D1995%26volume%3D64%26spage%3D721%26epage%3D762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Lehman, N. L.</span><span> </span><span class="NLM_article-title">Future potential of thymidylate synthase inhibitors in cancer therapy</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1775</span><span class="NLM_x">–</span> <span class="NLM_lpage">1787</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2002&pages=1775-1787&author=N.+L.+Lehman&title=Future+potential+of+thymidylate+synthase+inhibitors+in+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLehman%26aufirst%3DN.%2BL.%26atitle%3DFuture%2520potential%2520of%2520thymidylate%2520synthase%2520inhibitors%2520in%2520cancer%2520therapy%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2002%26volume%3D11%26spage%3D1775%26epage%3D1787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Pizzorno, G. D. R. B.; Cheng, Y.-C.</span><span> </span><span class="NLM_article-title">Pyrimidine and Purine Antimetabolites</span>. In  <span class="citation_source-book">Cancer Medicine</span>; <span class="NLM_contrib-group">Holland, J. F.,; Frei, E.,  III</span>, Eds.; <span class="NLM_publisher-name">B. C. Decker, Inc.</span>: <span class="NLM_publisher-loc">Hamilton, London</span>.<span class="NLM_x"> </span><span class="NLM_year">2003</span><span class="NLM_x">, </span>pp  <span class="NLM_fpage">739</span>− <span class="NLM_lpage">744</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&pages=739-744&author=G.+D.+R.+B.+Pizzorno&author=Y.-C.+Chengauthor=J.+F.+Holland&author=E.+Frei&title=Cancer+Medicine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DPizzorno%26aufirst%3DG.%2BD.%2BR.%2BB.%26atitle%3DPyrimidine%2520and%2520Purine%2520Antimetabolites%26btitle%3DCancer%2520Medicine%26aulast%3DHolland%26aufirst%3DJ.%2BF.%26pub%3DB.%2520C.%2520Decker%252C%2520Inc%26date%3D2003%26spage%3D739%26epage%3D744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Rollins, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindley, C.</span><span> </span><span class="NLM_article-title">Pemetrexed: A multitargeted antifolate</span> <span class="citation_source-journal">Clin. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1343</span><span class="NLM_x">–</span> <span class="NLM_lpage">1382</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1016%2Fj.clinthera.2005.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=16291410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtF2lurvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2005&pages=1343-1382&author=K.+D.+Rollinsauthor=C.+Lindley&title=Pemetrexed%3A+A+multitargeted+antifolate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Pemetrexed: A multitargeted antifolate</span></div><div class="casAuthors">Rollins, Kristan D.; Lindley, Celeste</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1343-1382</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Excerpta Medica, Inc.</span>)
        </div><div class="casAbstract">A review.  Background: The US Food and Drug Administration approved pemetrexed in Feb. 2004 for the treatment of malignant pleural mesothelioma (MPM) in combination with cisplatin in patients with unresectable disease or for whom curative surgery is not an option.  Pemetrexed is the first agent approved for the treatment of MPM.  In August 2004, pemetrexed was approved as a second-line, single-agent treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC).  Objectives: The goals of this article were to summarize the pharmacol., pharmacokinetics, efficacy, and safety of pemetrexed, and to review its current and potential roles in therapy for MPM, NSCLC, and other oncol. conditions.  Methods: Relevant English-language literature was identified through searches of PubMed (1966-Dec. 2004), International Pharmaceutical Abstrs., and the Proceedings of the American Society of Clin. Oncol. (Jan. 1995-Dec. 2004).  Search terms included pemetrexed, Alimta, MTA, multitargeted antifolate, LY231514, mesothelioma, MPM, non-small cell lung cancer, NSCLC, breast cancer, and pancreatic cancer.  In addn. to published literature, abstrs. and posters presented at national and international scientific meetings were reviewed.  Results: Myelosuppression was the predominant dose-limiting toxicity of pemetrexed reported in Phase I studies.  Identification of the correlation between poor folate status and increased pemetrexed toxicity in a multivariate anal. led to the requirement of folic acid and vitamin B12 supplementation for patients in all pemetrexed studies, with a resulting noted decrease in pemetrexed toxicity.  A single, multicenter, randomized Phase III trial compared the efficacy of pemetrexed in combination with cisplatin vs. cisplatin alone in the treatment of MPM.  Response rates were 41.3% in the pemetrexed/cisplatin combination and 16.7% with single-agent cisplatin (P < 0.001).  The median survival time for the pemetrexed/cisplatin combination was significantly longer at 12.1 mo vs. 9.3 mo for cisplatin alone (P = 0.02).  One international, multicenter, randomized Phase III trial in patients with NSCLC compared single-agent pemetrexed vs. docetaxel in patients previously treated with chemotherapy.  Overall response rates (9.1% and 8.8%) and median survival (8.3 mo and 7.9 mo) did not differ between pemetrexed and docetaxel (P = 0.105 and P = 0.226, resp.).  Hematol. adverse effects-grade 3/4 neutropenia (40.2% vs 5.3%; P < 0.001), febrile neutropenia (12.7% vs 1.9%; P < 0.001), and neutropenic infections (3.3% vs 0%; P = 0.004)-were significantly greater in the docetaxel-treated patients than in the pemetrexed-treated patients, as was alopecia (37.7% vs 6.4%; P < 0.001).  Results of an international, multicenter Phase III trial of pemetrexed in combination with gemcitabine conducted in patients with pancreatic cancer indicate that the combination is no more efficacious than single-agent gemcitabine.  Results in other disease states are still preliminary.  Conclusions: Pemetrexed is a multitargeted antifolate that has demonstrated antitumor activity in various tumor types as a single agent and in combination with other chemotherapeutic agents.  Efficacy for the treatment of MPM in combination with cisplatin has been demonstrated, and approval as a second-line agent in NSCLC was based on response rate as a surrogate end point for survival.  The addn. of folic acid and vitamin B12 supplementation markedly re-.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUS9Hvh4IAmLVg90H21EOLACvtfcHk0libK_AyBisvuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtF2lurvE&md5=44f44151b633d5595ab3ac39ad623766</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.clinthera.2005.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinthera.2005.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DRollins%26aufirst%3DK.%2BD.%26aulast%3DLindley%26aufirst%3DC.%26atitle%3DPemetrexed%253A%2520A%2520multitargeted%2520antifolate%26jtitle%3DClin.%2520Ther.%26date%3D2005%26volume%3D27%26spage%3D1343%26epage%3D1382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Clamp, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoeffski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valle, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marreaud, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Govaerts, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debois, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacombe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Twelves, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayson, G. C.</span><span> </span><span class="NLM_article-title">A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">579</span><span class="NLM_x">–</span> <span class="NLM_lpage">585</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1007%2Fs00280-007-0509-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=17520255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjsFajsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2008&pages=579-585&author=A.+R.+Clampauthor=P.+Schoeffskiauthor=J.+W.+Valleauthor=R.+H.+Wilsonauthor=S.+Marreaudauthor=A.+S.+Govaertsauthor=M.+Deboisauthor=D.+Lacombeauthor=C.+Twelvesauthor=J.+Chickauthor=G.+C.+Jayson&title=A+phase+I+and+pharmacokinetic+study+of+OSI-7904L%2C+a+liposomal+thymidylate+synthase+inhibitor+in+combination+with+oxaliplatin+in+patients+with+advanced+colorectal+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer</span></div><div class="casAuthors">Clamp, A. R.; Schoeffski, P.; Valle, J. W.; Wilson, R. H.; Marreaud, S.; Govaerts, A.-S.; Debois, M.; Lacombe, D.; Twelves, C.; Chick, J.; Jayson, G. C.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">579-585</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: OSI-7904L is a liposomal formulation of a potent thymidylate synthase (TS) inhibitor.  This phase I study evaluated the safety, tolerability and pharmacokinetics (PK) of OSI-7904L administered in combination with oxaliplatin every 21 days in patients with advanced colorectal carcinoma.  Method: A 3+3 study design was utilized at predefined dose levels.  Polymorphisms in the TS enhancer region and XPD enzyme were investigated as potential predictors of efficacy and toxicity.  Results: Fourteen patients received 76 cycles of treatment.  At the highest dose level (OSI-7904L 9 mg/m2, oxaliplatin 130 mg/m2) investigated, one of nine patients experienced dose-limiting toxicity of grade 3 oral mucositis with cycle 1 and five further patients required dose redns.  The toxicity profile of stomatitis, diarrhea, nausea, fatigue, sensory neuropathy and skin rash was consistent with that expected for a TS inhibitor/oxaliplatin combination regimen.  PK anal. showed high interpatient variability with no detectable interaction between OSI-7904L and oxaliplatin.  Partial radiol. responses were documented in two patients.  Conclusions :The recommended regimen for further investigation is OSI-7904L 9 mg/m2 and oxaliplatin 130 mg/m2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiemScdOhig7Vg90H21EOLACvtfcHk0libK_AyBisvuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjsFajsw%253D%253D&md5=710dbd51193545a24faa3d8c5b2ad1f5</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1007%2Fs00280-007-0509-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-007-0509-5%26sid%3Dliteratum%253Aachs%26aulast%3DClamp%26aufirst%3DA.%2BR.%26aulast%3DSchoeffski%26aufirst%3DP.%26aulast%3DValle%26aufirst%3DJ.%2BW.%26aulast%3DWilson%26aufirst%3DR.%2BH.%26aulast%3DMarreaud%26aufirst%3DS.%26aulast%3DGovaerts%26aufirst%3DA.%2BS.%26aulast%3DDebois%26aufirst%3DM.%26aulast%3DLacombe%26aufirst%3DD.%26aulast%3DTwelves%26aufirst%3DC.%26aulast%3DChick%26aufirst%3DJ.%26aulast%3DJayson%26aufirst%3DG.%2BC.%26atitle%3DA%2520phase%2520I%2520and%2520pharmacokinetic%2520study%2520of%2520OSI-7904L%252C%2520a%2520liposomal%2520thymidylate%2520synthase%2520inhibitor%2520in%2520combination%2520with%2520oxaliplatin%2520in%2520patients%2520with%2520advanced%2520colorectal%2520cancer%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2008%26volume%3D61%26spage%3D579%26epage%3D585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Showalter, H. D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sercel, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMichael, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 16. 6,5,6-Tricyclic benzothieno[3,2-<i>d</i>]pyrimidines and pyrimido[5,4-<i>b</i>]- and -[4,5-<i>b</i>]indoles as potent inhibitors of the epidermal growth factor receptor tyrosine kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">5464</span><span class="NLM_x">–</span> <span class="NLM_lpage">5474</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9903949" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=5464-5474&author=H.+D.+H.+Showalterauthor=A.+J.+Bridgesauthor=H.+Zhouauthor=A.+D.+Sercelauthor=A.+McMichaelauthor=D.+W.+Fry&title=Tyrosine+kinase+inhibitors.+16.+6%2C5%2C6-Tricyclic+benzothieno%5B3%2C2-d%5Dpyrimidines+and+pyrimido%5B5%2C4-b%5D-+and+-%5B4%2C5-b%5Dindoles+as+potent+inhibitors+of+the+epidermal+growth+factor+receptor+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm9903949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9903949%26sid%3Dliteratum%253Aachs%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DSercel%26aufirst%3DA.%2BD.%26aulast%3DMcMichael%26aufirst%3DA.%26aulast%3DFry%26aufirst%3DD.%2BW.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%252016.%25206%252C5%252C6-Tricyclic%2520benzothieno%255B3%252C2-d%255Dpyrimidines%2520and%2520pyrimido%255B5%252C4-b%255D-%2520and%2520-%255B4%252C5-b%255Dindoles%2520as%2520potent%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D5464%26epage%3D5474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Traxler, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mett, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lydon, N.</span><span> </span><span class="NLM_article-title">4-(Phenylamino)pyrrolopyrimidines: Potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">2285</span><span class="NLM_x">–</span> <span class="NLM_lpage">2292</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm960118j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=2285-2292&author=P.+M.+Traxlerauthor=P.+Furetauthor=H.+Mettauthor=E.+Buchdungerauthor=T.+Meyerauthor=N.+Lydon&title=4-%28Phenylamino%29pyrrolopyrimidines%3A+Potent+and+selective%2C+ATP+site+directed+inhibitors+of+the+EGF-receptor+protein+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm960118j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960118j%26sid%3Dliteratum%253Aachs%26aulast%3DTraxler%26aufirst%3DP.%2BM.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DMett%26aufirst%3DH.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DLydon%26aufirst%3DN.%26atitle%3D4-%2528Phenylamino%2529pyrrolopyrimidines%253A%2520Potent%2520and%2520selective%252C%2520ATP%2520site%2520directed%2520inhibitors%2520of%2520the%2520EGF-receptor%2520protein%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D2285%26epage%3D2292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Traxler, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span> </span><span class="NLM_article-title">Strategies toward the design of novel and selective protein tyrosine kinase inhibitors</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">195</span><span class="NLM_x">–</span> <span class="NLM_lpage">206</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1016%2FS0163-7258%2898%2900044-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=10454197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADyaK1MXjvFOht7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=1999&pages=195-206&author=P.+Traxlerauthor=P.+Furet&title=Strategies+toward+the+design+of+novel+and+selective+protein+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies toward the design of novel and selective protein tyrosine kinase inhibitors</span></div><div class="casAuthors">Traxler, Peter; Furet, Pascal</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">195-206</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review with 37 refs.  Protein tyrosine kinases play a fundamental role in signal transduction pathways.  Deregulated tyrosine kinase activity has been obsd. in many proliferative diseases (e.g., cancer, psoriasis, restenosis, etc.).  Tyrosine kinases are, therefore, attractive targets for the design of new therapeutic agents against cancer.  We have built up a pharmacophore model of the ATP-binding site of the epidermal growth factor receptor (EGFR) kinase and used it for the rational design of kinase inhibitors.  Several examples of the successful use of this model are presented in this review.  Amongst these, 4-substituted-pyrrolo[2,3-d]pyrimidines, a new class of highly potent and selective inhibitors of the EGFR kinase, have been identified and further optimized.  The most active derivs. inhibited the EGFR tyrosine kinase with IC50 values between 1 and 5 nM.  In EGF-dependent cellular systems, tyrosine phosphorylation, as well as c-fos mRNA expression, was inhibited with similar IC50 values.  Further successful application of this pharmacophore model led to the identification and optimization of phenylamino-pyrazolo[4,3-d]pyrimidines and substituted isoflavones and quinolones, other classes of potent, selective, and ATP competitive EGFR kinase inhibitors with IC50 values in the low nanomolar range.  Structure-activity relationships of both classes are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzTOVAYLwK77Vg90H21EOLACvtfcHk0lh2dGkXqDk5cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjvFOht7Y%253D&md5=26e5ed297e37b0cb188a0676e5b27f5b</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2FS0163-7258%2898%2900044-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7258%252898%252900044-8%26sid%3Dliteratum%253Aachs%26aulast%3DTraxler%26aufirst%3DP.%26aulast%3DFuret%26aufirst%3DP.%26atitle%3DStrategies%2520toward%2520the%2520design%2520of%2520novel%2520and%2520selective%2520protein%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DPharmacol.%2520Ther.%26date%3D1999%26volume%3D82%26spage%3D195%26epage%3D206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Gangjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihnat, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamat, S.</span><span> </span><span class="NLM_article-title">Antiangiogenic and antitumor agents. Design, synthesis, and evaluation of novel 2-amino-4-(3-bromoanilino)-6-benzylsubstituted pyrrolo[2,3-<i>d</i>]pyrimidines as inhibitors of receptor tyrosine kinases</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">5155</span><span class="NLM_x">–</span> <span class="NLM_lpage">5170</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=5155-5170&author=A.+Gangjeeauthor=J.+Yangauthor=M.+A.+Ihnatauthor=S.+Kamat&title=Antiangiogenic+and+antitumor+agents.+Design%2C+synthesis%2C+and+evaluation+of+novel+2-amino-4-%283-bromoanilino%29-6-benzylsubstituted+pyrrolo%5B2%2C3-d%5Dpyrimidines+as+inhibitors+of+receptor+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DIhnat%26aufirst%3DM.%2BA.%26aulast%3DKamat%26aufirst%3DS.%26atitle%3DAntiangiogenic%2520and%2520antitumor%2520agents.%2520Design%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520novel%25202-amino-4-%25283-bromoanilino%2529-6-benzylsubstituted%2520pyrrolo%255B2%252C3-d%255Dpyrimidines%2520as%2520inhibitors%2520of%2520receptor%2520tyrosine%2520kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2003%26volume%3D11%26spage%3D5155%26epage%3D5170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Laufer, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Domeyer, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scior, T. R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauser, D. R. J.</span><span> </span><span class="NLM_article-title">Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">710</span><span class="NLM_x">–</span> <span class="NLM_lpage">722</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0408767" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=710-722&author=S.+A.+Lauferauthor=D.+M.+Domeyerauthor=T.+R.+F.+Sciorauthor=W.+Albrechtauthor=D.+R.+J.+Hauser&title=Synthesis+and+biological+testing+of+purine+derivatives+as+potential+ATP-competitive+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm0408767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0408767%26sid%3Dliteratum%253Aachs%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26aulast%3DDomeyer%26aufirst%3DD.%2BM.%26aulast%3DScior%26aufirst%3DT.%2BR.%2BF.%26aulast%3DAlbrecht%26aufirst%3DW.%26aulast%3DHauser%26aufirst%3DD.%2BR.%2BJ.%26atitle%3DSynthesis%2520and%2520biological%2520testing%2520of%2520purine%2520derivatives%2520as%2520potential%2520ATP-competitive%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D710%26epage%3D722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Abu Thaher, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schattel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S.</span><span> </span><span class="NLM_article-title">Role of the hydrogen bonding heteroatom−Lys53 interaction between the p38α mitogen-activated protein (MAP) kinase and pyridinyl-substituted 5-membered heterocyclic ring inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">2613</span><span class="NLM_x">–</span> <span class="NLM_lpage">2617</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=2613-2617&author=B.+Abu+Thaherauthor=P.+Kochauthor=V.+Schattelauthor=S.+Laufer&title=Role+of+the+hydrogen+bonding+heteroatom%E2%88%92Lys53+interaction+between+the+p38%CE%B1+mitogen-activated+protein+%28MAP%29+kinase+and+pyridinyl-substituted+5-membered+heterocyclic+ring+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAbu%2BThaher%26aufirst%3DB.%26aulast%3DKoch%26aufirst%3DP.%26aulast%3DSchattel%26aufirst%3DV.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DRole%2520of%2520the%2520hydrogen%2520bonding%2520heteroatom%25E2%2588%2592Lys53%2520interaction%2520between%2520the%2520p38%25CE%25B1%2520mitogen-activated%2520protein%2520%2528MAP%2529%2520kinase%2520and%2520pyridinyl-substituted%25205-membered%2520heterocyclic%2520ring%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D2613%26epage%3D2617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Gangjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kisliuk, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGuire, J. J.</span><span> </span><span class="NLM_article-title">Synthesis of <i>N</i>-{4-[(2,4-Diamino-5-methyl-4,7-dihydro-3<i>H</i>- pyrrolo[2,3-<i>d</i>]pyrimidin-6-yl)thio]benzoyl}-<span class="smallcaps smallerCapital">l</span>-glutamic Acid and <i>N</i>-{4-[(2-Amino-4-oxo-5-methyl-4,7-dihydro-3<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin- 6-yl)thio]benzoyl}-<span class="smallcaps smallerCapital">l</span>-glutamic Acid as Dual Inhibitors of Dihydrofolate Reductase and Thymidylate Synthase and as Potential Antitumor Agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">7215</span><span class="NLM_x">–</span> <span class="NLM_lpage">7222</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm058234m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=7215-7222&author=A.+Gangjeeauthor=X.+Linauthor=R.+L.+Kisliukauthor=J.+J.+McGuire&title=Synthesis+of+N-%7B4-%5B%282%2C4-Diamino-5-methyl-4%2C7-dihydro-3H-+pyrrolo%5B2%2C3-d%5Dpyrimidin-6-yl%29thio%5Dbenzoyl%7D-l-glutamic+Acid+and+N-%7B4-%5B%282-Amino-4-oxo-5-methyl-4%2C7-dihydro-3H-pyrrolo%5B2%2C3-d%5Dpyrimidin-+6-yl%29thio%5Dbenzoyl%7D-l-glutamic+Acid+as+Dual+Inhibitors+of+Dihydrofolate+Reductase+and+Thymidylate+Synthase+and+as+Potential+Antitumor+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm058234m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058234m%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DKisliuk%26aufirst%3DR.%2BL.%26aulast%3DMcGuire%26aufirst%3DJ.%2BJ.%26atitle%3DSynthesis%2520of%2520N-%257B4-%255B%25282%252C4-Diamino-5-methyl-4%252C7-dihydro-3H-%2520pyrrolo%255B2%252C3-d%255Dpyrimidin-6-yl%2529thio%255Dbenzoyl%257D-l-glutamic%2520Acid%2520and%2520N-%257B4-%255B%25282-Amino-4-oxo-5-methyl-4%252C7-dihydro-3H-pyrrolo%255B2%252C3-d%255Dpyrimidin-%25206-yl%2529thio%255Dbenzoyl%257D-l-glutamic%2520Acid%2520as%2520Dual%2520Inhibitors%2520of%2520Dihydrofolate%2520Reductase%2520and%2520Thymidylate%2520Synthase%2520and%2520as%2520Potential%2520Antitumor%2520Agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D7215%26epage%3D7222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Rosowsky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forsch, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freisheim, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danenberg, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wick, M. M.</span><span> </span><span class="NLM_article-title">Methotrexate analogs. 29. Effect of γ-aminobutyric acid spacers between the pteroyl and glutamate moieties on enzyme binding and cell growth inhibition</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1872</span><span class="NLM_x">–</span> <span class="NLM_lpage">1876</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00160a014" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1986&pages=1872-1876&author=A.+Rosowskyauthor=R.+A.+Forschauthor=J.+H.+Freisheimauthor=P.+V.+Danenbergauthor=R.+G.+Moranauthor=M.+M.+Wick&title=Methotrexate+analogs.+29.+Effect+of+%CE%B3-aminobutyric+acid+spacers+between+the+pteroyl+and+glutamate+moieties+on+enzyme+binding+and+cell+growth+inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm00160a014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00160a014%26sid%3Dliteratum%253Aachs%26aulast%3DRosowsky%26aufirst%3DA.%26aulast%3DForsch%26aufirst%3DR.%2BA.%26aulast%3DFreisheim%26aufirst%3DJ.%2BH.%26aulast%3DDanenberg%26aufirst%3DP.%2BV.%26aulast%3DMoran%26aufirst%3DR.%2BG.%26aulast%3DWick%26aufirst%3DM.%2BM.%26atitle%3DMethotrexate%2520analogs.%252029.%2520Effect%2520of%2520%25CE%25B3-aminobutyric%2520acid%2520spacers%2520between%2520the%2520pteroyl%2520and%2520glutamate%2520moieties%2520on%2520enzyme%2520binding%2520and%2520cell%2520growth%2520inhibition%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1986%26volume%3D29%26spage%3D1872%26epage%3D1876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Gangjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurup, S.</span><span> </span><span class="NLM_article-title">Recent advances in classical and non-classical antifolates as antitumor and antiopportunistic infection agents: part I</span> <span class="citation_source-journal">Anti-Cancer Agents Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">524</span><span class="NLM_x">–</span> <span class="NLM_lpage">542</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=524-542&author=A.+Gangjeeauthor=H.+D.+Jainauthor=S.+Kurup&title=Recent+advances+in+classical+and+non-classical+antifolates+as+antitumor+and+antiopportunistic+infection+agents%3A+part+I"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DJain%26aufirst%3DH.%2BD.%26aulast%3DKurup%26aufirst%3DS.%26atitle%3DRecent%2520advances%2520in%2520classical%2520and%2520non-classical%2520antifolates%2520as%2520antitumor%2520and%2520antiopportunistic%2520infection%2520agents%253A%2520part%2520I%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D524%26epage%3D542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Gangjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kisliuk, R. L.</span><span> </span><span class="NLM_article-title">Potent dual thymidylate synthase and dihydrofolate reductase inhibitors: Classical and nonclassical 2-amino-4-oxo-5-arylthio-substituted-6-methylthieno[2,3-<i>d</i>]pyrimidine antifolates</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5789</span><span class="NLM_x">–</span> <span class="NLM_lpage">5797</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8006933" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5789-5797&author=A.+Gangjeeauthor=Y.+Qiuauthor=W.+Liauthor=R.+L.+Kisliuk&title=Potent+dual+thymidylate+synthase+and+dihydrofolate+reductase+inhibitors%3A+Classical+and+nonclassical+2-amino-4-oxo-5-arylthio-substituted-6-methylthieno%5B2%2C3-d%5Dpyrimidine+antifolates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm8006933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8006933%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DKisliuk%26aufirst%3DR.%2BL.%26atitle%3DPotent%2520dual%2520thymidylate%2520synthase%2520and%2520dihydrofolate%2520reductase%2520inhibitors%253A%2520Classical%2520and%2520nonclassical%25202-amino-4-oxo-5-arylthio-substituted-6-methylthieno%255B2%252C3-d%255Dpyrimidine%2520antifolates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5789%26epage%3D5797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Gangjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kisliuk, R. L.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of classical and nonclassical 2-amino-4-oxo-5-substituted-6-methylpyrrolo[3,2-<i>d</i>]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">68</span><span class="NLM_x">–</span> <span class="NLM_lpage">76</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm701052u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=68-76&author=A.+Gangjeeauthor=W.+Liauthor=J.+Yangauthor=R.+L.+Kisliuk&title=Design%2C+synthesis%2C+and+biological+evaluation+of+classical+and+nonclassical+2-amino-4-oxo-5-substituted-6-methylpyrrolo%5B3%2C2-d%5Dpyrimidines+as+dual+thymidylate+synthase+and+dihydrofolate+reductase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm701052u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701052u%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DKisliuk%26aufirst%3DR.%2BL.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520classical%2520and%2520nonclassical%25202-amino-4-oxo-5-substituted-6-methylpyrrolo%255B3%252C2-d%255Dpyrimidines%2520as%2520dual%2520thymidylate%2520synthase%2520and%2520dihydrofolate%2520reductase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D68%26epage%3D76" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Cody, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luft Joseph, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pangborn, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gangjee, A.</span><span> </span><span class="NLM_article-title">Analysis of three crystal structure determinations of a 5-methyl-6-<i>N</i>-methylanilino pyridopyrimidine antifolate complex with human dihydrofolate reductase</span> <span class="citation_source-journal">Acta Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">D59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1603</span><span class="NLM_x">–</span> <span class="NLM_lpage">1609</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=D59&publication_year=2003&pages=1603-1609&author=V.+Codyauthor=R.+Luft+Josephauthor=W.+Pangbornauthor=A.+Gangjee&title=Analysis+of+three+crystal+structure+determinations+of+a+5-methyl-6-N-methylanilino+pyridopyrimidine+antifolate+complex+with+human+dihydrofolate+reductase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCody%26aufirst%3DV.%26aulast%3DLuft%2BJoseph%26aufirst%3DR.%26aulast%3DPangborn%26aufirst%3DW.%26aulast%3DGangjee%26aufirst%3DA.%26atitle%3DAnalysis%2520of%2520three%2520crystal%2520structure%2520determinations%2520of%2520a%25205-methyl-6-N-methylanilino%2520pyridopyrimidine%2520antifolate%2520complex%2520with%2520human%2520dihydrofolate%2520reductase%26jtitle%3DActa%2520Crystallogr.%26date%3D2003%26volume%3DD59%26spage%3D1603%26epage%3D1609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span>Tripos Inc., 1699 South Hanley Road, St. Louis, MO 63144.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Tripos+Inc.%2C+1699+South+Hanley+Road%2C+St.+Louis%2C+MO+63144."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Davies, J. F.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delcamp, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prendergast, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashford, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freisheim, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraut, J.</span><span> </span><span class="NLM_article-title">Crystal structures of recombinant human dihydrofolate reductase complexed with folate and 5-deazafolate</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">9467</span><span class="NLM_x">–</span> <span class="NLM_lpage">9479</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi00492a021" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADyaK3cXlsVOqtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1990&pages=9467-9479&author=J.+F.+Daviesauthor=T.+J.+Delcampauthor=N.+J.+Prendergastauthor=V.+A.+Ashfordauthor=J.+H.+Freisheimauthor=J.+Kraut&title=Crystal+structures+of+recombinant+human+dihydrofolate+reductase+complexed+with+folate+and+5-deazafolate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of recombinant human dihydrofolate reductase complexed with folate and 5-deazafolate</span></div><div class="casAuthors">Davies, Jay F., II; Delcamp, Tavner J.; Prendergast, Neal J.; Ashford, Victor A.; Freisheim, James H.; Kraut, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">9467-79</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    </div><div class="casAbstract">The 2.3 Å crystal structure of recombinant human dihydrofolate reductase (EC 1.5.1.3; DHFR) was solved as a binary complex with folate (a poor substrate at neutral pH) and also as a binary complex with an inhibitor, 5-deazafolate.  The inhibitor appeared to be protonated at N8 on binding, whereas folate was not.  Rotation of the peptide plane joining I7 and V8 from its position in the folate complex permitted H-bonding of 5-deazafolate's protonated N8 to the backbone carbonyl of I7, thus contributing to the enzyme's greater affinity for 5-deazafolate than for folate.  In this respect it is likely that bound 5-deazafolate furnishes a model for 7,8-dihydrofolate binding and, in addn., resembles the transition state for folate redn.  A hypothetical transition-state model for folate redn., generated by superposition of the DHFR binary complex, human DHFR-5-deazafolate and chicken liver DHFR-NADPH, revealed a 1 Å overlap of the binding sites for folate's pteridine ring and the dihydronicotinamide ring of NADPH.  It was proposed that this binding-site overlap accelerates the redn. of both folate and 7,8-dihydrofolate by simultaneously binding substrate and cofactor with a sub-van der Waals sepn. that is optimal for hydride transfer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC_0KLfFpXWLVg90H21EOLACvtfcHk0ljuXIHTfQjEqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXlsVOqtLk%253D&md5=a27aee68329833336600b9314ee67b9b</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fbi00492a021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00492a021%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DJ.%2BF.%26aulast%3DDelcamp%26aufirst%3DT.%2BJ.%26aulast%3DPrendergast%26aufirst%3DN.%2BJ.%26aulast%3DAshford%26aufirst%3DV.%2BA.%26aulast%3DFreisheim%26aufirst%3DJ.%2BH.%26aulast%3DKraut%26aufirst%3DJ.%26atitle%3DCrystal%2520structures%2520of%2520recombinant%2520human%2520dihydrofolate%2520reductase%2520complexed%2520with%2520folate%2520and%25205-deazafolate%26jtitle%3DBiochemistry%26date%3D1990%26volume%3D29%26spage%3D9467%26epage%3D9479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Oefner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D'Arcy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winkler, F. K.</span><span> </span><span class="NLM_article-title">Crystal structure of human dihydrofolate reductase complexed with folate</span> <span class="citation_source-journal">Eur. J. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">174</span><span class="NLM_x">, </span> <span class="NLM_fpage">377</span><span class="NLM_x">–</span> <span class="NLM_lpage">385</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1111%2Fj.1432-1033.1988.tb14108.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=3383852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADyaL1cXktlCnsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=1988&pages=377-385&author=C.+Oefnerauthor=A.+D%27Arcyauthor=F.+K.+Winkler&title=Crystal+structure+of+human+dihydrofolate+reductase+complexed+with+folate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of human dihydrofolate reductase complexed with folate</span></div><div class="casAuthors">Oefner, Christian; D'Arcy, Allan; Winkler, Fritz K.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">377-85</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    </div><div class="casAbstract">The crystal structure of recombinant human dihydrofolate reductase with folate bound in the active site was detd. and the structural model refined at 0.2-nm resoln.  Preliminary studies of the binding of the inhibitors, methotrexate and trimethoprim, to the human apoenzyme were performed at 0.35-nm resoln.  The conformations of the chem. very similar ligands, folate and methotrexate, one a substrate the other a potent inhibitor, differed substantially in that their pteridine rings were in inverse orientations relative to their p-aminobenzoyl-L-glutamate moieties.  Methotrexate binding was similar to that previously obsd. in 2 bacterial enzymes but was quite different from that obsd. in the enzyme from a mouse lymphoma cell line.  The geometry of the polypeptide chain around the folate-binding site in the human enzyme was not consistent with conclusions previously drawn with regard to the species selectivity of the inhibitor, trimethoprim.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqThLSy_vselbVg90H21EOLACvtfcHk0lhA16a3hGr8Kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXktlCnsLs%253D&md5=84c62c6d99c9a0892c9c1b794327c72d</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1111%2Fj.1432-1033.1988.tb14108.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1432-1033.1988.tb14108.x%26sid%3Dliteratum%253Aachs%26aulast%3DOefner%26aufirst%3DC.%26aulast%3DD%2527Arcy%26aufirst%3DA.%26aulast%3DWinkler%26aufirst%3DF.%2BK.%26atitle%3DCrystal%2520structure%2520of%2520human%2520dihydrofolate%2520reductase%2520complexed%2520with%2520folate%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D1988%26volume%3D174%26spage%3D377%26epage%3D385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Sayre, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finer-Moore, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritz, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biermann, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gates, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacKellar, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stroud, R. M.</span><span> </span><span class="NLM_article-title">Multi-targeted antifolates aimed at avoiding drug resistance form covalent closed inhibitory complexes with human and <i>Escherichia coli</i> thymidylate synthases</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">313</span><span class="NLM_x">, </span> <span class="NLM_fpage">813</span><span class="NLM_x">–</span> <span class="NLM_lpage">829</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=2001&pages=813-829&author=P.+H.+Sayreauthor=J.+S.+Finer-Mooreauthor=T.+A.+Fritzauthor=D.+Biermannauthor=S.+B.+Gatesauthor=W.+C.+MacKellarauthor=V.+F.+Patelauthor=R.+M.+Stroud&title=Multi-targeted+antifolates+aimed+at+avoiding+drug+resistance+form+covalent+closed+inhibitory+complexes+with+human+and+Escherichia+coli+thymidylate+synthases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSayre%26aufirst%3DP.%2BH.%26aulast%3DFiner-Moore%26aufirst%3DJ.%2BS.%26aulast%3DFritz%26aufirst%3DT.%2BA.%26aulast%3DBiermann%26aufirst%3DD.%26aulast%3DGates%26aufirst%3DS.%2BB.%26aulast%3DMacKellar%26aufirst%3DW.%2BC.%26aulast%3DPatel%26aufirst%3DV.%2BF.%26aulast%3DStroud%26aufirst%3DR.%2BM.%26atitle%3DMulti-targeted%2520antifolates%2520aimed%2520at%2520avoiding%2520drug%2520resistance%2520form%2520covalent%2520closed%2520inhibitory%2520complexes%2520with%2520human%2520and%2520Escherichia%2520coli%2520thymidylate%2520synthases%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2001%26volume%3D313%26spage%3D813%26epage%3D829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Miyazaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsunaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philippe, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibahara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolte, R. T.</span><span> </span><span class="NLM_article-title">Novel 4-aminofuro[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">2203</span><span class="NLM_x">–</span> <span class="NLM_lpage">2207</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=2203-2207&author=Y.+Miyazakiauthor=S.+Matsunagaauthor=J.+Tangauthor=Y.+Maedaauthor=M.+Nakanoauthor=R.+J.+Philippeauthor=M.+Shibaharaauthor=W.+Liuauthor=H.+Satoauthor=L.+Wangauthor=R.+T.+Nolte&title=Novel+4-aminofuro%5B2%2C3-d%5Dpyrimidines+as+Tie-2+and+VEGFR2+dual+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiyazaki%26aufirst%3DY.%26aulast%3DMatsunaga%26aufirst%3DS.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DMaeda%26aufirst%3DY.%26aulast%3DNakano%26aufirst%3DM.%26aulast%3DPhilippe%26aufirst%3DR.%2BJ.%26aulast%3DShibahara%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DSato%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DNolte%26aufirst%3DR.%2BT.%26atitle%3DNovel%25204-aminofuro%255B2%252C3-d%255Dpyrimidines%2520as%2520Tie-2%2520and%2520VEGFR2%2520dual%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D2203%26epage%3D2207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Mol, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sridhar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chien, E. Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, B.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nowakowski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kassel, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cronin, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McRee, D. E.</span><span> </span><span class="NLM_article-title">Structure of a c-Kit product complex reveals the basis for kinase transactivation</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">31461</span><span class="NLM_x">–</span> <span class="NLM_lpage">31464</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1074%2Fjbc.C300186200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=12824176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmsVOnsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=31461-31464&author=C.+D.+Molauthor=K.+B.+Limauthor=V.+Sridharauthor=H.+Zouauthor=E.+Y.+T.+Chienauthor=B.-C.+Sangauthor=J.+Nowakowskiauthor=D.+B.+Kasselauthor=C.+N.+Croninauthor=D.+E.+McRee&title=Structure+of+a+c-Kit+product+complex+reveals+the+basis+for+kinase+transactivation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of a c-Kit Product Complex Reveals the Basis for Kinase Transactivation</span></div><div class="casAuthors">Mol, Clifford D.; Lim, Kheng B.; Sridhar, Vandana; Zou, Hua; Chien, Ellen Y. T.; Sang, Bi-Ching; Nowakowski, Jacek; Kassel, Daniel B.; Cronin, Ciaran N.; McRee, Duncan E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">31461-31464</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The c-Kit proto-oncogene is a receptor protein-tyrosine kinase assocd. with several highly malignant human cancers.  Upon binding its ligand, stem cell factor (SCF), c-Kit forms an active dimer that autophosphorylates itself and activates a signaling cascade that induces cell growth.  Disease-causing human mutations that activate SCF-independent constitutive expression of c-Kit are found in acute myelogenous leukemia, human mast cell disease, and gastrointestinal stromal tumors.  We report on the phosphorylation state and crystal structure of a c-Kit product complex.  The c-Kit structure is in a fully active form, with ordered kinase activation and phosphate-binding loops.  These results provide key insights into the mol. basis for c-Kit kinase transactivation to assist in the design of new competitive inhibitors targeting activated mutant forms of c-Kit that are resistant to current chemotherapy regimes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv0eZJ9UHNILVg90H21EOLACvtfcHk0lhA16a3hGr8Kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmsVOnsb0%253D&md5=f537b5c9903adb6cc057406bd20f0f5a</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1074%2Fjbc.C300186200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.C300186200%26sid%3Dliteratum%253Aachs%26aulast%3DMol%26aufirst%3DC.%2BD.%26aulast%3DLim%26aufirst%3DK.%2BB.%26aulast%3DSridhar%26aufirst%3DV.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChien%26aufirst%3DE.%2BY.%2BT.%26aulast%3DSang%26aufirst%3DB.-C.%26aulast%3DNowakowski%26aufirst%3DJ.%26aulast%3DKassel%26aufirst%3DD.%2BB.%26aulast%3DCronin%26aufirst%3DC.%2BN.%26aulast%3DMcRee%26aufirst%3DD.%2BE.%26atitle%3DStructure%2520of%2520a%2520c-Kit%2520product%2520complex%2520reveals%2520the%2520basis%2520for%2520kinase%2520transactivation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D31461%26epage%3D31464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span>Molecular Operating environment (MOE 2007.09), C. C. G., Inc., 1255 University Street, Suite 1600, Montreal, Quebec, Canada, H3B 3X3.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Molecular+Operating+environment+%28MOE+2007.09%29%2C+C.+C.+G.%2C+Inc.%2C+1255+University+Street%2C+Suite+1600%2C+Montreal%2C+Quebec%2C+Canada%2C+H3B+3X3."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Operating%2520environment%2520%2528MOE%25202007.09%2529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Altschul, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koonin, E. V.</span><span> </span><span class="NLM_article-title">Iterated profile searches with PSI-BLAST - a tool for discovery in protein databases</span> <span class="citation_source-journal">Trends Biochem. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">444</span><span class="NLM_x">–</span> <span class="NLM_lpage">447</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1998&pages=444-447&author=S.+F.+Altschulauthor=E.+V.+Koonin&title=Iterated+profile+searches+with+PSI-BLAST+-+a+tool+for+discovery+in+protein+databases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAltschul%26aufirst%3DS.%2BF.%26aulast%3DKoonin%26aufirst%3DE.%2BV.%26atitle%3DIterated%2520profile%2520searches%2520with%2520PSI-BLAST%2520-%2520a%2520tool%2520for%2520discovery%2520in%2520protein%2520databases%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D1998%26volume%3D23%26spage%3D444%26epage%3D447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Gallivan, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dougherty, D. A.</span><span> </span><span class="NLM_article-title">Cation-pi interactions in structural biology</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">9459</span><span class="NLM_x">–</span> <span class="NLM_lpage">9464</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1073%2Fpnas.96.17.9459" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=10449714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADyaK1MXlsVymsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=9459-9464&author=J.+P.+Gallivanauthor=D.+A.+Dougherty&title=Cation-pi+interactions+in+structural+biology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Cation-π interactions in structural biology</span></div><div class="casAuthors">Gallivan, Justin P.; Dougherty, Dennis A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">9459-9464</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Cation-π interactions in protein structures are identified and evaluated by using an energy-based criterion for selecting significant side-chain pairs.  Cation-π interactions are found to be common among structures in the Protein Data Bank, and it is clearly demonstrated that, when a cationic side-chain (Lys or Arg) is near an arom. side-chain (Phe, Tyr, or Trp), the geometry is biased toward one that would experience a favorable cation-π interaction.  The side-chain of Arg is more likely than that of Lys to be in a cation-π interaction.  Among the aroms., a strong bias toward Trp is clear, such that over one-fourth of all tryptophans in the data bank experience an energetically significant cation-π interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7r9RXU9TpNbVg90H21EOLACvtfcHk0lgW1j3KtwehOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlsVymsr8%253D&md5=515e9cf97e9e5dcedbd13ce9f4dfdfb5</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1073%2Fpnas.96.17.9459&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.96.17.9459%26sid%3Dliteratum%253Aachs%26aulast%3DGallivan%26aufirst%3DJ.%2BP.%26aulast%3DDougherty%26aufirst%3DD.%2BA.%26atitle%3DCation-pi%2520interactions%2520in%2520structural%2520biology%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1999%26volume%3D96%26spage%3D9459%26epage%3D9464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Mahboobi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uecker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellmer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cenac, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoecher, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pongratz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eichhorn, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hufsky, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truempler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sicker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heidel, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stocking, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boehmer, F.-D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dove, S.</span><span> </span><span class="NLM_article-title">Novel bis(1h-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">3101</span><span class="NLM_x">–</span> <span class="NLM_lpage">3115</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm058033i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=3101-3115&author=S.+Mahboobiauthor=A.+Ueckerauthor=A.+Sellmerauthor=C.+Cenacauthor=H.+Hoecherauthor=H.+Pongratzauthor=E.+Eichhornauthor=H.+Hufskyauthor=A.+Truemplerauthor=M.+Sickerauthor=F.+Heidelauthor=T.+Fischerauthor=C.+Stockingauthor=S.+Elzauthor=F.-D.+Boehmerauthor=S.+Dove&title=Novel+bis%281h-indol-2-yl%29methanones+as+potent+inhibitors+of+FLT3+and+platelet-derived+growth+factor+receptor+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fjm058033i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058033i%26sid%3Dliteratum%253Aachs%26aulast%3DMahboobi%26aufirst%3DS.%26aulast%3DUecker%26aufirst%3DA.%26aulast%3DSellmer%26aufirst%3DA.%26aulast%3DCenac%26aufirst%3DC.%26aulast%3DHoecher%26aufirst%3DH.%26aulast%3DPongratz%26aufirst%3DH.%26aulast%3DEichhorn%26aufirst%3DE.%26aulast%3DHufsky%26aufirst%3DH.%26aulast%3DTruempler%26aufirst%3DA.%26aulast%3DSicker%26aufirst%3DM.%26aulast%3DHeidel%26aufirst%3DF.%26aulast%3DFischer%26aufirst%3DT.%26aulast%3DStocking%26aufirst%3DC.%26aulast%3DElz%26aufirst%3DS.%26aulast%3DBoehmer%26aufirst%3DF.-D.%26aulast%3DDove%26aufirst%3DS.%26atitle%3DNovel%2520bis%25281h-indol-2-yl%2529methanones%2520as%2520potent%2520inhibitors%2520of%2520FLT3%2520and%2520platelet-derived%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D3101%26epage%3D3115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Henderson, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bavetsias, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theti, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clauss, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackman, A. L.</span><span> </span><span class="NLM_article-title">Targeting the a-folate receptor with cyclopenta[g]quinazoline-based inhibitors of thymidylate synthase</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">5020</span><span class="NLM_x">–</span> <span class="NLM_lpage">5042</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=5020-5042&author=E.+A.+Hendersonauthor=V.+Bavetsiasauthor=D.+S.+Thetiauthor=S.+C.+Wilsonauthor=R.+Claussauthor=A.+L.+Jackman&title=Targeting+the+a-folate+receptor+with+cyclopenta%5Bg%5Dquinazoline-based+inhibitors+of+thymidylate+synthase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHenderson%26aufirst%3DE.%2BA.%26aulast%3DBavetsias%26aufirst%3DV.%26aulast%3DTheti%26aufirst%3DD.%2BS.%26aulast%3DWilson%26aufirst%3DS.%2BC.%26aulast%3DClauss%26aufirst%3DR.%26aulast%3DJackman%26aufirst%3DA.%2BL.%26atitle%3DTargeting%2520the%2520a-folate%2520receptor%2520with%2520cyclopenta%255Bg%255Dquinazoline-based%2520inhibitors%2520of%2520thymidylate%2520synthase%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26spage%3D5020%26epage%3D5042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Griffith, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faerman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swenson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wynn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippke, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saxena, K.</span><span> </span><span class="NLM_article-title">The structural basis for autoinhibition of FLT3 by the juxtamembrane domain</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">178</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1016%2FS1097-2765%2803%2900505-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=14759363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFOiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2004&pages=169-178&author=J.+Griffithauthor=J.+Blackauthor=C.+Faermanauthor=L.+Swensonauthor=M.+Wynnauthor=F.+Luauthor=J.+Lippkeauthor=K.+Saxena&title=The+structural+basis+for+autoinhibition+of+FLT3+by+the+juxtamembrane+domain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">The structural basis for autoinhibition of FLT3 by the juxtamembrane domain</span></div><div class="casAuthors">Griffith, James; Black, James; Faerman, Carlos; Swenson, Lora; Wynn, Michael; Lu, Fan; Lippke, Judith; Saxena, Kumkum</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">169-178</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">FLT3 is a type III receptor tyrosine kinase that is thought to play a key role in hematopoiesis.  Certain classes of FLT3 mutations cause constitutively activated forms of the receptor that are found in significant nos. of patients with acute myelogenous leukemia (AML).  The mutations occur either in the activation loop, for example, as point mutations of Asp835 or as internal tandem duplication (ITD) sequences in the juxtamembrane (JM) domain.  To further understand the nature of FLT3 autoinhibition and regulation, we have detd. the crystal structure of the autoinhibited form of FLT3.  This structure shows the autoinhibitory conformation of a complete JM domain in this class of receptor tyrosine kinases.  The detailed inhibitory mechanism of the JM domain is revealed, which is likely utilized by other members of type III receptor tyrosine kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJAabT6TBxpLVg90H21EOLACvtfcHk0lgW1j3KtwehOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFOiu7g%253D&md5=d1df4a37aac59f5b59ca242fc8ccd6da</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2803%2900505-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252803%252900505-7%26sid%3Dliteratum%253Aachs%26aulast%3DGriffith%26aufirst%3DJ.%26aulast%3DBlack%26aufirst%3DJ.%26aulast%3DFaerman%26aufirst%3DC.%26aulast%3DSwenson%26aufirst%3DL.%26aulast%3DWynn%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DF.%26aulast%3DLippke%26aufirst%3DJ.%26aulast%3DSaxena%26aufirst%3DK.%26atitle%3DThe%2520structural%2520basis%2520for%2520autoinhibition%2520of%2520FLT3%2520by%2520the%2520juxtamembrane%2520domain%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D13%26spage%3D169%26epage%3D178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Hennessy, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ram, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, G. B.</span><span> </span><span class="NLM_article-title">Exploiting the PI3K/AKT pathway for cancer drug discovery</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">988</span><span class="NLM_x">–</span> <span class="NLM_lpage">1004</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1038%2Fnrd1902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=16341064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1yktbjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=988-1004&author=B.+T.+Hennessyauthor=D.+L.+Smithauthor=P.+T.+Ramauthor=Y.+Luauthor=G.+B.+Mills&title=Exploiting+the+PI3K%2FAKT+pathway+for+cancer+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery</span></div><div class="casAuthors">Hennessy, Bryan T.; Smith, Debra L.; Ram, Prahlad T.; Lu, Yiling; Mills, Gordon B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">988-1004</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Evolving studies with several different targeted therapeutic agents are demonstrating that patients with genomic alterations of the target, including amplification, translocation and mutation, are more likely to respond to the therapy.  Recent studies indicate that numerous components of the phosphatidylinositol-3-kinase (PI3K)/AKT pathway are targeted by amplification, mutation and translocation more frequently than any other pathway in cancer patients, with resultant activation of the pathway.  This warrants exploiting the PI3K/AKT pathway for cancer drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq40Fg-hLrrMbVg90H21EOLACvtfcHk0lhoUKIllfpYWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1yktbjI&md5=faecabc3a6799137d133afb37d139ceb</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1038%2Fnrd1902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1902%26sid%3Dliteratum%253Aachs%26aulast%3DHennessy%26aufirst%3DB.%2BT.%26aulast%3DSmith%26aufirst%3DD.%2BL.%26aulast%3DRam%26aufirst%3DP.%2BT.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DMills%26aufirst%3DG.%2BB.%26atitle%3DExploiting%2520the%2520PI3K%252FAKT%2520pathway%2520for%2520cancer%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2005%26volume%3D4%26spage%3D988%26epage%3D1004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Ihnat, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaltreider, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorpe, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamat, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeper, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shanner, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warnke, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piconi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceriello, A.</span><span> </span><span class="NLM_article-title">Attenuated superoxide dismutase induction in retinal cells in response to intermittent high versus continuous high glucose</span> <span class="citation_source-journal">Am. J. Biochem. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">16</span><span class="NLM_x">–</span> <span class="NLM_lpage">23</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.3844%2Fajbbsp.2007.16.23" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVCktbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=16-23&author=M.+A.+Ihnatauthor=R.+C.+Kaltreiderauthor=J.+E.+Thorpeauthor=D.+E.+Greenauthor=C.+D.+Kamatauthor=M.+Leeperauthor=A.+C.+Shannerauthor=L.+A.+Warnkeauthor=L.+Piconiauthor=A.+Ceriello&title=Attenuated+superoxide+dismutase+induction+in+retinal+cells+in+response+to+intermittent+high+versus+continuous+high+glucose"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Attenuated superoxide dismutase induction in retinal cells in response to intermittent high versus continuous high glucose</span></div><div class="casAuthors">Ihnat, Michael A.; Kaltreider, Ronald C.; Thorpe, Jessica E.; Green, Dixy E.; Kamat, Chandrashekhar D.; Leeper, Melissa; Shanner, Amanda C.; Warnke, Linda A.; Piconi, Ludovica; Ceriello, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Biochemistry and Biotechnology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16-23</span>CODEN:
                <span class="NLM_cas:coden">AJBBA5</span>;
        ISSN:<span class="NLM_cas:issn">1553-3468</span>.
    
            (<span class="NLM_cas:orgname">Science Publications</span>)
        </div><div class="casAbstract">High glucose, particularly in oscillating conditions, produces an increase in oxidative stress and has been shown to result in an increase in diabetic complications, retinopathy in particular.  The hypothesis of this work was that chronic exposure to intermittent high glucose results in an attenuated induction of an antioxidant response as compared to continuous high glucose exposure in isolated retinal cells In this work, human retinal pericytes and ARPE-19 cells were exposed to 5 mM or 30 mM continuous high glucose or to 5 mM oscillating daily with 30 mM glucose for 14 days.  Levels of antioxidant proteins and activity and levels of reactive species protein adducts were measured.  We demonstrate that the induction of total cellular superoxide dismutase (SOD) activity in isolated retinal pericytes and ARPE-19 cells is significantly attenuated in response to oscillating glucose as compared to continuous high glucose.  We also show that a marker of nitrosative stress, 3-nitrotyrosine and a general marker of oxidized proteins, OxyBlot, were significantly increased in both cell types exposed to intermittent high glucose as compared to continuous high glucose.  Finally, we show that levels of nitrated MnSOD were increased in response to intermittent high vs. continuous high glucose and that the addn. of a reactive nitrogen species scavenger to oscillating glucose resulted in significantly increased levels of SOD activity.  In conclusion, our results demonstrate for the first time a link between intermittent high glucose and a decreased induction of an antioxidant response of SOD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCThEyRZGfArVg90H21EOLACvtfcHk0lhoUKIllfpYWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVCktbo%253D&md5=f68f2f1d1e039e5e0492b7e1317573b2</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.3844%2Fajbbsp.2007.16.23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3844%252Fajbbsp.2007.16.23%26sid%3Dliteratum%253Aachs%26aulast%3DIhnat%26aufirst%3DM.%2BA.%26aulast%3DKaltreider%26aufirst%3DR.%2BC.%26aulast%3DThorpe%26aufirst%3DJ.%2BE.%26aulast%3DGreen%26aufirst%3DD.%2BE.%26aulast%3DKamat%26aufirst%3DC.%2BD.%26aulast%3DLeeper%26aufirst%3DM.%26aulast%3DShanner%26aufirst%3DA.%2BC.%26aulast%3DWarnke%26aufirst%3DL.%2BA.%26aulast%3DPiconi%26aufirst%3DL.%26aulast%3DCeriello%26aufirst%3DA.%26atitle%3DAttenuated%2520superoxide%2520dismutase%2520induction%2520in%2520retinal%2520cells%2520in%2520response%2520to%2520intermittent%2520high%2520versus%2520continuous%2520high%2520glucose%26jtitle%3DAm.%2520J.%2520Biochem.%2520Biotechnol.%26date%3D2007%26volume%3D3%26spage%3D16%26epage%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Schroeder, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamby, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connolly, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grohar, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winters, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barvian, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boushelle, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crean, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Driscoll, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batley, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahring, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Major, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panek, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D.</span><span> </span><span class="NLM_article-title">Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">1915</span><span class="NLM_x">–</span> <span class="NLM_lpage">1926</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0004291" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=1915-1926&author=M.+C.+Schroederauthor=J.+M.+Hambyauthor=C.+J.+Connollyauthor=P.+J.+Groharauthor=R.+T.+Wintersauthor=M.+R.+Barvianauthor=C.+W.+Mooreauthor=S.+L.+Boushelleauthor=S.+M.+Creanauthor=A.+J.+Krakerauthor=D.+L.+Driscollauthor=P.+W.+Vincentauthor=W.+L.+Elliottauthor=G.+H.+Luauthor=B.+L.+Batleyauthor=T.+K.+Dahringauthor=T.+C.+Majorauthor=R.+L.+Panekauthor=A.+M.+Dohertyauthor=H.+D.+Showalter&title=Soluble+2-substituted+aminopyrido%5B2%2C3-d%5Dpyrimidin-7-yl+ureas.+Structure-activity+relationships+against+selected+tyrosine+kinases+and+exploration+of+in+vitro+and+in+vivo+anticancer+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fjm0004291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0004291%26sid%3Dliteratum%253Aachs%26aulast%3DSchroeder%26aufirst%3DM.%2BC.%26aulast%3DHamby%26aufirst%3DJ.%2BM.%26aulast%3DConnolly%26aufirst%3DC.%2BJ.%26aulast%3DGrohar%26aufirst%3DP.%2BJ.%26aulast%3DWinters%26aufirst%3DR.%2BT.%26aulast%3DBarvian%26aufirst%3DM.%2BR.%26aulast%3DMoore%26aufirst%3DC.%2BW.%26aulast%3DBoushelle%26aufirst%3DS.%2BL.%26aulast%3DCrean%26aufirst%3DS.%2BM.%26aulast%3DKraker%26aufirst%3DA.%2BJ.%26aulast%3DDriscoll%26aufirst%3DD.%2BL.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DLu%26aufirst%3DG.%2BH.%26aulast%3DBatley%26aufirst%3DB.%2BL.%26aulast%3DDahring%26aufirst%3DT.%2BK.%26aulast%3DMajor%26aufirst%3DT.%2BC.%26aulast%3DPanek%26aufirst%3DR.%2BL.%26aulast%3DDoherty%26aufirst%3DA.%2BM.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%26atitle%3DSoluble%25202-substituted%2520aminopyrido%255B2%252C3-d%255Dpyrimidin-7-yl%2520ureas.%2520Structure-activity%2520relationships%2520against%2520selected%2520tyrosine%2520kinases%2520and%2520exploration%2520of%2520in%2520vitro%2520and%2520in%2520vivo%2520anticancer%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D1915%26epage%3D1926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Zaman, G. J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vink, P. M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van den Doelen, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veeneman, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theunissen, H. J. M.</span><span> </span><span class="NLM_article-title">Tyrosine kinase activity of purified recombinant cytoplasmic domain of platelet-derived growth factor β-receptor (β-PDGFR) and discovery of a novel inhibitor of receptor tyrosine kinases</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">57</span><span class="NLM_x">–</span> <span class="NLM_lpage">64</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1999&pages=57-64&author=G.+J.+R.+Zamanauthor=P.+M.+F.+Vinkauthor=A.+A.+van+den+Doelenauthor=G.+H.+Veenemanauthor=H.+J.+M.+Theunissen&title=Tyrosine+kinase+activity+of+purified+recombinant+cytoplasmic+domain+of+platelet-derived+growth+factor+%CE%B2-receptor+%28%CE%B2-PDGFR%29+and+discovery+of+a+novel+inhibitor+of+receptor+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZaman%26aufirst%3DG.%2BJ.%2BR.%26aulast%3DVink%26aufirst%3DP.%2BM.%2BF.%26aulast%3Dvan%2Bden%2BDoelen%26aufirst%3DA.%2BA.%26aulast%3DVeeneman%26aufirst%3DG.%2BH.%26aulast%3DTheunissen%26aufirst%3DH.%2BJ.%2BM.%26atitle%3DTyrosine%2520kinase%2520activity%2520of%2520purified%2520recombinant%2520cytoplasmic%2520domain%2520of%2520platelet-derived%2520growth%2520factor%2520%25CE%25B2-receptor%2520%2528%25CE%25B2-PDGFR%2529%2520and%2520discovery%2520of%2520a%2520novel%2520inhibitor%2520of%2520receptor%2520tyrosine%2520kinases%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1999%26volume%3D57%26spage%3D57%26epage%3D64" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Mori, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirokawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satomi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aburada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyamoto, K.-i.</span><span> </span><span class="NLM_article-title">Structure activity relationships of quinoxalin-2-one derivatives as platelet-derived growth factor-β receptor (PDGF β R) inhibitors, derived from molecular modeling</span> <span class="citation_source-journal">Chem. Pharm. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">682</span><span class="NLM_x">–</span> <span class="NLM_lpage">687</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2008&pages=682-687&author=Y.+Moriauthor=T.+Hirokawaauthor=K.+Aokiauthor=H.+Satomiauthor=S.+Takedaauthor=M.+Aburadaauthor=K.-i.+Miyamoto&title=Structure+activity+relationships+of+quinoxalin-2-one+derivatives+as+platelet-derived+growth+factor-%CE%B2+receptor+%28PDGF+%CE%B2+R%29+inhibitors%2C+derived+from+molecular+modeling"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DY.%26aulast%3DHirokawa%26aufirst%3DT.%26aulast%3DAoki%26aufirst%3DK.%26aulast%3DSatomi%26aufirst%3DH.%26aulast%3DTakeda%26aufirst%3DS.%26aulast%3DAburada%26aufirst%3DM.%26aulast%3DMiyamoto%26aufirst%3DK.-i.%26atitle%3DStructure%2520activity%2520relationships%2520of%2520quinoxalin-2-one%2520derivatives%2520as%2520platelet-derived%2520growth%2520factor-%25CE%25B2%2520receptor%2520%2528PDGF%2520%25CE%25B2%2520R%2529%2520inhibitors%252C%2520derived%2520from%2520molecular%2520modeling%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D2008%26volume%3D56%26spage%3D682%26epage%3D687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">Ward, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGuffin, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buxton, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D. T.</span><span> </span><span class="NLM_article-title">The DISOPRED server for the prediction of protein disorder</span> <span class="citation_source-journal">Bioinformatics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">2138</span><span class="NLM_x">–</span> <span class="NLM_lpage">2139</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1093%2Fbioinformatics%2Fbth195" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=15044227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsVyitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2004&pages=2138-2139&author=J.+J.+Wardauthor=L.+J.+McGuffinauthor=K.+Brysonauthor=B.+F.+Buxtonauthor=D.+T.+Jones&title=The+DISOPRED+server+for+the+prediction+of+protein+disorder"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">The DISOPRED server for the prediction of protein disorder</span></div><div class="casAuthors">Ward, Jonathan J.; McGuffin, Liam J.; Bryson, Kevin; Buxton, Bernard F.; Jones, David T.</div><div class="citationInfo"><span class="NLM_cas:title">Bioinformatics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2138-2139</span>CODEN:
                <span class="NLM_cas:coden">BOINFP</span>;
        ISSN:<span class="NLM_cas:issn">1367-4803</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Dynamically disordered regions appear to be relatively abundant in eukaryotic proteomes.  The DISOPRED server allows users to submit a protein sequence, and returns a probability est. of each residue in the sequence being disordered.  The results are sent in both plain text and graphical formats, and the server can also supply predictions of secondary structure to provide further structural information.  The server can be accessed by non-com. users at http://bioinf.cs.ucl.ac.uk/disopred/.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo73X8S8FYxj7Vg90H21EOLACvtfcHk0lhHPEjR43J2Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsVyitLs%253D&md5=aa675b1ed2c09ffd30ae54cd0d1b3ce5</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1093%2Fbioinformatics%2Fbth195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbioinformatics%252Fbth195%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DJ.%2BJ.%26aulast%3DMcGuffin%26aufirst%3DL.%2BJ.%26aulast%3DBryson%26aufirst%3DK.%26aulast%3DBuxton%26aufirst%3DB.%2BF.%26aulast%3DJones%26aufirst%3DD.%2BT.%26atitle%3DThe%2520DISOPRED%2520server%2520for%2520the%2520prediction%2520of%2520protein%2520disorder%26jtitle%3DBioinformatics%26date%3D2004%26volume%3D20%26spage%3D2138%26epage%3D2139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group">Wilson, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barsoum, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pappone, P. A.</span><span> </span><span class="NLM_article-title">Purine nucleotides modulate proliferation of brown fat preadipocytes</span> <span class="citation_source-journal">Cell Proliferation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">–</span> <span class="NLM_lpage">140</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1999&pages=131-140&author=S.+M.+Wilsonauthor=M.+J.+Barsoumauthor=B.+W.+Wilsonauthor=P.+A.+Pappone&title=Purine+nucleotides+modulate+proliferation+of+brown+fat+preadipocytes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DS.%2BM.%26aulast%3DBarsoum%26aufirst%3DM.%2BJ.%26aulast%3DWilson%26aufirst%3DB.%2BW.%26aulast%3DPappone%26aufirst%3DP.%2BA.%26atitle%3DPurine%2520nucleotides%2520modulate%2520proliferation%2520of%2520brown%2520fat%2520preadipocytes%26jtitle%3DCell%2520Proliferation%26date%3D1999%26volume%3D32%26spage%3D131%26epage%3D140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group">Maurer, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihnat, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pullman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Brien, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasey, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornwell, M. M.</span><span> </span><span class="NLM_article-title">Growth of human tumor cells in macroporous microcarriers results in p53-independent, decreased cisplatin sensitivity relative to monolayers</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">938</span><span class="NLM_x">–</span> <span class="NLM_lpage">947</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1999&pages=938-947&author=B.+J.+Maurerauthor=M.+A.+Ihnatauthor=C.+Morganauthor=J.+Pullmanauthor=C.+O%27Brienauthor=S.+W.+Johnsonauthor=J.+S.+Raseyauthor=M.+M.+Cornwell&title=Growth+of+human+tumor+cells+in+macroporous+microcarriers+results+in+p53-independent%2C+decreased+cisplatin+sensitivity+relative+to+monolayers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMaurer%26aufirst%3DB.%2BJ.%26aulast%3DIhnat%26aufirst%3DM.%2BA.%26aulast%3DMorgan%26aufirst%3DC.%26aulast%3DPullman%26aufirst%3DJ.%26aulast%3DO%2527Brien%26aufirst%3DC.%26aulast%3DJohnson%26aufirst%3DS.%2BW.%26aulast%3DRasey%26aufirst%3DJ.%2BS.%26aulast%3DCornwell%26aufirst%3DM.%2BM.%26atitle%3DGrowth%2520of%2520human%2520tumor%2520cells%2520in%2520macroporous%2520microcarriers%2520results%2520in%2520p53-independent%252C%2520decreased%2520cisplatin%2520sensitivity%2520relative%2520to%2520monolayers%26jtitle%3DMol.%2520Pharmacol.%26date%3D1999%26volume%3D55%26spage%3D938%26epage%3D947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group">Fong, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shawver, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">App, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreck, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risau, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirth, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMahon, G.</span><span> </span><span class="NLM_article-title">SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">99</span><span class="NLM_x">–</span> <span class="NLM_lpage">106</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=9892193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADyaK1MXmsFOgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1999&pages=99-106&author=T.+A.+Fongauthor=L.+K.+Shawverauthor=L.+Sunauthor=C.+Tangauthor=H.+Appauthor=T.+J.+Powellauthor=Y.+H.+Kimauthor=R.+Schreckauthor=X.+Wangauthor=W.+Risauauthor=A.+Ullrichauthor=K.+P.+Hirthauthor=G.+McMahon&title=SU5416+is+a+potent+and+selective+inhibitor+of+the+vascular+endothelial+growth+factor+receptor+%28Flk-1%2FKDR%29+that+inhibits+tyrosine+kinase+catalysis%2C+tumor+vascularization%2C+and+growth+of+multiple+tumor+types"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types</span></div><div class="casAuthors">Fong, T. Annie T.; Shawver, Laura K.; Sun, Li; Tang, Cho; App, Harald; Powell, T. Jeff; Kim, Young H.; Schreck, Randall; Wang, Xueyan; Risau, Werner; Ullrich, Axel; Hirth, K. Peter; McMahon, Gerald</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">99-106</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">AACR Subscription Office</span>)
        </div><div class="casAbstract">SU5416, a novel synthetic compd., is a potent and selective inhibitor of the Flk-1/KDR receptor tyrosine kinase that is presently under evaluation in Phase I clin. studies for the treatment of human cancers.  SU5416 was shown to inhibit vascular endothelial growth factor-dependent mitogenesis of human endothelial cells without inhibiting the growth of a variety of tumor cells in vitro.  In contrast, systemic administration of SU5416 at nontoxic doses in mice resulted in inhibition of s.c. tumor growth of cells derived from various tissue origins.  The antitumor effect of SU5416 was accompanied by the appearance of pale white tumors that were resected from drug-treated animals, supporting the antiangiogenic property of this agent.  These findings support that pharmacol. inhibition of the enzymic activity of the vascular endothelial growth factor receptor represents a novel strategy for limiting the growth of a wide variety of tumor types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiq1KqJ-CsCrVg90H21EOLACvtfcHk0lhHPEjR43J2Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmsFOgug%253D%253D&md5=92a2610ecfcdc996a6a79b0b559c4852</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFong%26aufirst%3DT.%2BA.%26aulast%3DShawver%26aufirst%3DL.%2BK.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DApp%26aufirst%3DH.%26aulast%3DPowell%26aufirst%3DT.%2BJ.%26aulast%3DKim%26aufirst%3DY.%2BH.%26aulast%3DSchreck%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DRisau%26aufirst%3DW.%26aulast%3DUllrich%26aufirst%3DA.%26aulast%3DHirth%26aufirst%3DK.%2BP.%26aulast%3DMcMahon%26aufirst%3DG.%26atitle%3DSU5416%2520is%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520the%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520%2528Flk-1%252FKDR%2529%2520that%2520inhibits%2520tyrosine%2520kinase%2520catalysis%252C%2520tumor%2520vascularization%252C%2520and%2520growth%2520of%2520multiple%2520tumor%2520types%26jtitle%3DCancer%2520Res.%26date%3D1999%26volume%3D59%26spage%3D99%26epage%3D106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group">Stockwell, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haggarty, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreiber, S. L.</span><span> </span><span class="NLM_article-title">High-throughput screening of small molecules in miniaturized mammalian cell-based assays involving post-translational modifications</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">71</span><span class="NLM_x">–</span> <span class="NLM_lpage">83</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1016%2FS1074-5521%2899%2980004-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=10021420" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADyaK1MXhs1yru7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1999&pages=71-83&author=B.+R.+Stockwellauthor=S.+J.+Haggartyauthor=S.+L.+Schreiber&title=High-throughput+screening+of+small+molecules+in+miniaturized+mammalian+cell-based+assays+involving+post-translational+modifications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">High-throughput screening of small molecules in miniaturized mammalian cell-based assays involving post-translational modifications</span></div><div class="casAuthors">Stockwell, Brent R.; Haggarty, Stephen J.; Schreiber, Stuart L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">71-83</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Current Biology Publications</span>)
        </div><div class="casAbstract">Fully adapting a forward genetic approach to mammalian systems requires efficient methods to alter systematically gene products without prior knowledge of gene sequences, while allowing for the subsequent characterization of these alterations.  Ideally, these methods would also allow function to be altered in a temporally controlled manner.  We report the development of a miniaturized cell-based assay format that enables a genetic-like approach to understanding cellular pathways in mammalian systems using small mols., rather than mutations, as the source of gene-product alterations.  This whole-cell immunodetection assay can sensitively detect changes in specific cellular macromols. in high-d. arrays of mammalian cells.  Furthermore, it is compatible with screening large nos. of small mols. in nanoliter to microliter culture vols.  We refer to this assay format as a "cytoblot", and demonstrate the use of cytoblotting to monitor biosynthetic processes such as DNA synthesis, and post-translational processes such as acetylation and phosphorylation.  Finally, we demonstrate the applicability of these assays to natural-product screening through the identification of marine sponge exts. exhibiting genotype-specific inhibition of 5-bromodeoxyuridine incorporation and suppression of the anti-proliferative effect of rapamycin.  We show that cytoblots can be used for high-throughout screening of small mols. in cell-based assays.  Together with small-mol. libraries, the cytoblot assay can be used to perform chem. genetic screens analogous to those used in classical genetics and thus should be applicable to understanding a wide variety of cellular processes, esp. those involving post-transitional modifications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrR0KGn09XQ0LVg90H21EOLACvtfcHk0ljg1SJpaA4G3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhs1yru7o%253D&md5=681b3a056d86ca5df5902eb420e0f8a1</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2FS1074-5521%2899%2980004-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1074-5521%252899%252980004-0%26sid%3Dliteratum%253Aachs%26aulast%3DStockwell%26aufirst%3DB.%2BR.%26aulast%3DHaggarty%26aufirst%3DS.%2BJ.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26atitle%3DHigh-throughput%2520screening%2520of%2520small%2520molecules%2520in%2520miniaturized%2520mammalian%2520cell-based%2520assays%2520involving%2520post-translational%2520modifications%26jtitle%3DChem.%2520Biol.%26date%3D1999%26volume%3D6%26spage%3D71%26epage%3D83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group">Gangjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Namjoshi, O. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihnat, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorpe, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warnke, L. A.</span><span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agents</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">5514</span><span class="NLM_x">–</span> <span class="NLM_lpage">5528</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=5514-5528&author=A.+Gangjeeauthor=O.+A.+Namjoshiauthor=J.+Yuauthor=M.+A.+Ihnatauthor=J.+E.+Thorpeauthor=L.+A.+Warnke&title=Design%2C+synthesis+and+biological+evaluation+of+substituted+pyrrolo%5B2%2C3-d%5Dpyrimidines+as+multiple+receptor+tyrosine+kinase+inhibitors+and+antiangiogenic+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DNamjoshi%26aufirst%3DO.%2BA.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DIhnat%26aufirst%3DM.%2BA.%26aulast%3DThorpe%26aufirst%3DJ.%2BE.%26aulast%3DWarnke%26aufirst%3DL.%2BA.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520substituted%2520pyrrolo%255B2%252C3-d%255Dpyrimidines%2520as%2520multiple%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520and%2520antiangiogenic%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2008%26volume%3D16%26spage%3D5514%26epage%3D5528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">Rosenzweig, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youmell, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palayoor, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, B. D.</span><span> </span><span class="NLM_article-title">Radiosensitization of human tumor cells by the phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1149</span><span class="NLM_x">–</span> <span class="NLM_lpage">1156</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=9815794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADyaK2sXkvFCgsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1997&pages=1149-1156&author=K.+E.+Rosenzweigauthor=M.+B.+Youmellauthor=S.+T.+Palayoorauthor=B.+D.+Price&title=Radiosensitization+of+human+tumor+cells+by+the+phosphatidylinositol+3-kinase+inhibitors+wortmannin+and+LY294002+correlates+with+inhibition+of+DNA-dependent+protein+kinase+and+prolonged+G2-M+delay"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Radiosensitization of human tumor cells by the phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay</span></div><div class="casAuthors">Rosenzweig, Kenneth E.; Youmell, Matthew B.; Palayoor, Sanjewani T.; Price, Brendan D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1149-1156</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Members of the phosphatidylinositol (PI) 3-kinase gene family, including the ataxia telangiectasia gene and the DNA-dependent protein kinase (DNA-PK), are involved in regulating cellular radiosensitivity.  We have investigated two structurally unrelated PI 3-kinase inhibitors, wortmannin and LY294002, to det. whether they inhibit DNA-PK and increase cellular radiosensitivity.  The PI 3-kinase inhibitors wortmannin and LY294002 were effective radiosensitizers of human tumor cells, with sensitizer enhancement ratios (at 10% survival) of 2.8 and 1.9, resp., in SW480 cells.  Wortmannin and LY294002 inhibited the kinase activity of purified DNA-PK and inactivated cellular DNA-PK kinase activity.  Inhibition of cellular DNA-PK activity occurred at the same concns. of wortmannin that caused radiosensitization, and this correlation was found in a range of tumor cell lines.  However, cells deficient in either DNA-PK (scid cells) or the ataxia telangiectasia protein were also partly sensitized to radiation by wortmannin, indicating the involvement of more than one protein kinase in the mechanism of action of wortmannin.  Wortmannin also affected the G2-M checkpoint.  SW480 cells had a reversible G2-M delay of 20 h following irradn.  However, wortmannin-treated SW480 cells had a prolonged G2-M delay; more than 75% of cells were arrested in G2 at 50 h postirradn.  This suggests the accumulation of significant unrepaired DNA damage following inhibition of PI 3-kinase family members.  Therefore, PI 3-kinase inhibitors may represent a new class of radiosensitizers that inhibit the repair of DNA damage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrO-sYwY5NMarVg90H21EOLACvtfcHk0ljg1SJpaA4G3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXkvFCgsLg%253D&md5=06668de6331a6890d7cbc700dad58317</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRosenzweig%26aufirst%3DK.%2BE.%26aulast%3DYoumell%26aufirst%3DM.%2BB.%26aulast%3DPalayoor%26aufirst%3DS.%2BT.%26aulast%3DPrice%26aufirst%3DB.%2BD.%26atitle%3DRadiosensitization%2520of%2520human%2520tumor%2520cells%2520by%2520the%2520phosphatidylinositol%25203-kinase%2520inhibitors%2520wortmannin%2520and%2520LY294002%2520correlates%2520with%2520inhibition%2520of%2520DNA-dependent%2520protein%2520kinase%2520and%2520prolonged%2520G2-M%2520delay%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D1997%26volume%3D3%26spage%3D1149%26epage%3D1156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group">Kisliuk, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strumpf, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaumont, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leary, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plante, L.</span><span> </span><span class="NLM_article-title">Diastereoisomers of 5,10-methylene-5,6,7,8-tetrahydropteroyl-<span class="smallcaps smallerCapital">d</span>-glutamic acid</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1531</span><span class="NLM_x">–</span> <span class="NLM_lpage">1533</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00221a038" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1977&pages=1531-1533&author=R.+L.+Kisliukauthor=D.+Strumpfauthor=Y.+Gaumontauthor=R.+P.+Learyauthor=L.+Plante&title=Diastereoisomers+of+5%2C10-methylene-5%2C6%2C7%2C8-tetrahydropteroyl-d-glutamic+acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1021%2Fjm00221a038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00221a038%26sid%3Dliteratum%253Aachs%26aulast%3DKisliuk%26aufirst%3DR.%2BL.%26aulast%3DStrumpf%26aufirst%3DD.%26aulast%3DGaumont%26aufirst%3DY.%26aulast%3DLeary%26aufirst%3DR.%2BP.%26aulast%3DPlante%26aufirst%3DL.%26atitle%3DDiastereoisomers%2520of%25205%252C10-methylene-5%252C6%252C7%252C8-tetrahydropteroyl-d-glutamic%2520acid%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1977%26volume%3D20%26spage%3D1531%26epage%3D1533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group">Wahba, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedkin, M.</span><span> </span><span class="NLM_article-title">Enzymic synthesis of thymidylate. I. Early steps in the purification of thymidylate synthetase of <i>Escherichia coli</i></span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1962</span><span class="NLM_x">, </span> <span class="NLM_volume">237</span><span class="NLM_x">, </span> <span class="NLM_fpage">3794</span><span class="NLM_x">–</span> <span class="NLM_lpage">3801</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=237&publication_year=1962&pages=3794-3801&author=A.+J.+Wahbaauthor=M.+Friedkin&title=Enzymic+synthesis+of+thymidylate.+I.+Early+steps+in+the+purification+of+thymidylate+synthetase+of+Escherichia+coli"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWahba%26aufirst%3DA.%2BJ.%26aulast%3DFriedkin%26aufirst%3DM.%26atitle%3DEnzymic%2520synthesis%2520of%2520thymidylate.%2520I.%2520Early%2520steps%2520in%2520the%2520purification%2520of%2520thymidylate%2520synthetase%2520of%2520Escherichia%2520coli%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1962%26volume%3D237%26spage%3D3794%26epage%3D3801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">Davisson, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirawaraporn, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santi, D. V.</span><span> </span><span class="NLM_article-title">Expression of human thymidylate synthase in <i>Escherichia coli</i></span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">264</span><span class="NLM_x">, </span> <span class="NLM_fpage">9145</span><span class="NLM_x">–</span> <span class="NLM_lpage">9148</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=264&publication_year=1989&pages=9145-9148&author=V.+J.+Davissonauthor=W.+Sirawarapornauthor=D.+V.+Santi&title=Expression+of+human+thymidylate+synthase+in+Escherichia+coli"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDavisson%26aufirst%3DV.%2BJ.%26aulast%3DSirawaraporn%26aufirst%3DW.%26aulast%3DSanti%26aufirst%3DD.%2BV.%26atitle%3DExpression%2520of%2520human%2520thymidylate%2520synthase%2520in%2520Escherichia%2520coli%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1989%26volume%3D264%26spage%3D9145%26epage%3D9148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group">Tsuda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakaguchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawakita, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakazawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takatsuki, K.</span><span> </span><span class="NLM_article-title">Alteration of cell cycle progression in human leukemia cell line (KOPM-28) induced by 12-o-tetradecanoylphorbol-13-acetate</span> <span class="citation_source-journal">Int. J. Cell Cloning</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">209</span><span class="NLM_x">–</span> <span class="NLM_lpage">220</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1002%2Fstem.5530060306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=3397593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A280%3ADyaL1c3osFymtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1988&pages=209-220&author=H.+Tsudaauthor=M.+Sakaguchiauthor=M.+Kawakitaauthor=S.+Nakazawaauthor=T.+Moriauthor=K.+Takatsuki&title=Alteration+of+cell+cycle+progression+in+human+leukemia+cell+line+%28KOPM-28%29+induced+by+12-o-tetradecanoylphorbol-13-acetate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Alteration of cell cycle progression in human leukemia cell line (KOPM-28) induced by 12-o-tetradecanoylphorbol-13-acetate</span></div><div class="casAuthors">Tsuda H; Sakaguchi M; Kawakita M; Nakazawa S; Mori T; Takatsuki K</div><div class="citationInfo"><span class="NLM_cas:title">International journal of cell cloning</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">209-20</span>
        ISSN:<span class="NLM_cas:issn">0737-1454</span>.
    </div><div class="casAbstract">Terminal cell differentiation usually results in an irreversible arrest in the G1 phase of the cell cycle and loss of cell renewal ability.  Human promyelocytic leukemia HL-60 cells induced with 12-o-tetradecanoylphorbol-13-acetate (TPA) differentiate into monocytes/macrophages and accumulate in G1.  We determined the effect of TPA on the growth kinetics of a human leukemia cell line (KOPM-28), which developed several of the characteristics of megakaryocytes in response to TPA, such as the surface antigen complex IIb/IIIa, platelet peroxidase and polyploidy.  Cell growth was immediately and completely inhibited by TPA.  Flow cytometric analysis of cellular DNA content revealed a gradual decrease in cells in G1 and an accumulation of cells in G2.  These data suggest that TPA prolonged G1 and rapidly arrested the cells in G2.  Synchronized cells were utilized to further analyze the rapid G2 arrest.  Cells arrested with aphidicolin at the G1/S interphase were released, and the effects of TPA (added at different intervals) on cell cycle progression were examined 14 h after release.  The results showed that TPA added at the end of the S phase, as well as at the G1/S interphase incompletely but distinctly arrested cells in G2.  Moreover, G2 arrest was observed when TPA was added to cells released from a colcemid-induced G2/M block, suggesting that cells already in G2 were inhibited by TPA from moving through M to G1.  Since some cells became multi-nucleated in the course of incubation with TPA, this G2 accumulation may have resulted at least in part from a prolongation of the phase or a transient G2 block.  These changes in cell cycle progression induced by TPA may be characteristic of and/or related to megakaryocytic differentiation of hemopoietic precursor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSFqM8kfPuu9mK_SFaaT9INfW6udTcc2ebh4I0aBIbu87ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL1c3osFymtw%253D%253D&md5=9871d0cd87c86b19c6f186db89d6aace</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1002%2Fstem.5530060306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fstem.5530060306%26sid%3Dliteratum%253Aachs%26aulast%3DTsuda%26aufirst%3DH.%26aulast%3DSakaguchi%26aufirst%3DM.%26aulast%3DKawakita%26aufirst%3DM.%26aulast%3DNakazawa%26aufirst%3DS.%26aulast%3DMori%26aufirst%3DT.%26aulast%3DTakatsuki%26aufirst%3DK.%26atitle%3DAlteration%2520of%2520cell%2520cycle%2520progression%2520in%2520human%2520leukemia%2520cell%2520line%2520%2528KOPM-28%2529%2520induced%2520by%252012-o-tetradecanoylphorbol-13-acetate%26jtitle%3DInt.%2520J.%2520Cell%2520Cloning%26date%3D1988%26volume%3D6%26spage%3D209%26epage%3D220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group">Iliakis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nusse, M.</span><span> </span><span class="NLM_article-title">Arrest of irradiated G1, S, or G2 cells at mitosis using nocodazole promotes repair of potentially lethal damage</span> <span class="citation_source-journal">Radiat. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">346</span><span class="NLM_x">–</span> <span class="NLM_lpage">351</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.2307%2F3576377" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=6463212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADyaL2cXltVKmtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=1984&pages=346-351&author=G.+Iliakisauthor=M.+Nusse&title=Arrest+of+irradiated+G1%2C+S%2C+or+G2+cells+at+mitosis+using+nocodazole+promotes+repair+of+potentially+lethal+damage"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Arrest of irradiated G1, S, or G2 cells at mitosis using nocodazole promotes repair of potentially lethal damage</span></div><div class="casAuthors">Iliakis, George; Nusse, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Radiation Research</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">346-51</span>CODEN:
                <span class="NLM_cas:coden">RAREAE</span>;
        ISSN:<span class="NLM_cas:issn">0033-7587</span>.
    </div><div class="casAbstract">The ability of synchronized Ehrlich ascites tumor cells, x-irradiated in G1, S, and G2 phases, to repair potentially lethal damage when arrested at mitosis by using nocodazole, a specific inhibitor of microtubule polymn., (0.4 μg/mL) was studied.  Cells irradiated in these phases repaired potentially lethal damage at mitosis.  The extent of this repair was similar to that obsd. for cells irradiated at the same stages in the cell cycle but allowed to repair potentially lethal damage by incubating in balanced salt soln. for 6 h after x-irradn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpieml_uESMprVg90H21EOLACvtfcHk0ljcUeVlhbKnSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXltVKmtb0%253D&md5=17db8a1f8d235325c161251807fb98e1</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.2307%2F3576377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2307%252F3576377%26sid%3Dliteratum%253Aachs%26aulast%3DIliakis%26aufirst%3DG.%26aulast%3DNusse%26aufirst%3DM.%26atitle%3DArrest%2520of%2520irradiated%2520G1%252C%2520S%252C%2520or%2520G2%2520cells%2520at%2520mitosis%2520using%2520nocodazole%2520promotes%2520repair%2520of%2520potentially%2520lethal%2520damage%26jtitle%3DRadiat.%2520Res.%26date%3D1984%26volume%3D99%26spage%3D346%26epage%3D351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group">Lucarelli, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sangiorgi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benassi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donati, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gobbi, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picci, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacca, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribatti, D.</span><span> </span><span class="NLM_article-title">Angiogenesis in lipoma: An experimental study in the chick embryo chorioallantoic membrane</span> <span class="citation_source-journal">Int. J. Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">593</span><span class="NLM_x">–</span> <span class="NLM_lpage">596</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=10567667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A280%3ADC%252BD3c%252Fjs12mtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1999&pages=593-596&author=E.+Lucarelliauthor=L.+Sangiorgiauthor=S.+Benassiauthor=D.+Donatiauthor=G.+A.+Gobbiauthor=P.+Picciauthor=A.+Vaccaauthor=D.+Ribatti&title=Angiogenesis+in+lipoma%3A+An+experimental+study+in+the+chick+embryo+chorioallantoic+membrane"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Angiogenesis in lipoma: An experimental study in the chick embryo chorioallantoic membrane</span></div><div class="casAuthors">Lucarelli E; Sangiorgi L; Benassi S; Donati D; Gobbi G A; Picci P; Vacca A; Ribatti D</div><div class="citationInfo"><span class="NLM_cas:title">International journal of molecular medicine</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">593-6</span>
        ISSN:<span class="NLM_cas:issn">1107-3756</span>.
    </div><div class="casAbstract">Lipoma is one of the most common benign mesenchymal tumors.  Its ability to trigger an angiogenic response is a critical step for its growth.  Because adipose tissue serves as an important conduit for the vasculature, it is conceivable that the angiogenic properties of this tissue may modulate the growth of the vasculature in a paracrine manner.  We investigated in vivo the angiogenic potential of bioptic fragments of human lipoma by using the chick embryo chorioallantoic membrane (CAM), a useful model for such an investigation.  The angiogenic response in pathological and control implants was assessed on histologic sections by a morphometric method, 96 h after grafting.  Results showed that pathological samples were surrounded by numerous allantoic vessels with a radially arranged pattern around the implant.  The vascular counts in the CAMs treated with lipoma implants were comparable to that of FGF-2.  The role played in vasoproliferative response by angiogenic cytokines (FGF-2, VEGF) released by adipocytes, by endogenous cytokines, such as FGF-2, stored in the CAM extracellular matrix and by angiogenic growth factors released by perivascular mononuclear cells around the newly-formed blood vessels, were supported by this study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR8BDkSiue04f69nzq6467DfW6udTcc2ebh4I0aBIbu87ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c%252Fjs12mtg%253D%253D&md5=624b9230c8167312f01641c6f7732b20</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLucarelli%26aufirst%3DE.%26aulast%3DSangiorgi%26aufirst%3DL.%26aulast%3DBenassi%26aufirst%3DS.%26aulast%3DDonati%26aufirst%3DD.%26aulast%3DGobbi%26aufirst%3DG.%2BA.%26aulast%3DPicci%26aufirst%3DP.%26aulast%3DVacca%26aufirst%3DA.%26aulast%3DRibatti%26aufirst%3DD.%26atitle%3DAngiogenesis%2520in%2520lipoma%253A%2520An%2520experimental%2520study%2520in%2520the%2520chick%2520embryo%2520chorioallantoic%2520membrane%26jtitle%3DInt.%2520J.%2520Mol.%2520Med.%26date%3D1999%26volume%3D4%26spage%3D593%26epage%3D596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group">Romanoff, A. L.</span> <span class="citation_source-book">Biochemistry of the Avian Embryo: A Quantitative Analysis of Prenatal Development</span>; <span class="NLM_publisher-name">Interscience</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">1967</span><span class="NLM_x">; </span>398 pp.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1967&author=A.+L.+Romanoff&title=Biochemistry+of+the+Avian+Embryo%3A+A+Quantitative+Analysis+of+Prenatal+Development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DRomanoff%26aufirst%3DA.%2BL.%26btitle%3DBiochemistry%2520of%2520the%2520Avian%2520Embryo%253A%2520A%2520Quantitative%2520Analysis%2520of%2520Prenatal%2520Development%26pub%3DInterscience%26date%3D1967" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group">Hanna, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidler, I. J.</span><span> </span><span class="NLM_article-title">Role of natural killer cells in the destruction of circulating tumor emboli</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">801</span><span class="NLM_x">–</span> <span class="NLM_lpage">809</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=6932529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A280%3ADyaL3M%252FivVOgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=1980&pages=801-809&author=N.+Hannaauthor=I.+J.+Fidler&title=Role+of+natural+killer+cells+in+the+destruction+of+circulating+tumor+emboli"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Role of natural killer cells in the destruction of circulating tumor emboli</span></div><div class="casAuthors">Hanna N; Fidler I J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">801-9</span>
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    </div><div class="casAbstract">A close correlation was demonstrated between levels of host natural cytotoxic (NC) and/or natural killer (NK) cell activity and capacity to eliminate blood-borne tumor cells.  The outcome of experimental metastasis of several tumors with defined biologic behavior was studied in syngeneic mice exhibiting low NK cell activity [3-wk-old normal mice and cyclophosphamide (Cy)-treated adult mice] and high NK cell activity (normal adult mice).  An iv injection of metastatic tumor cells into 3-week-old or Cy-treated mice markedly enhanced experimental pulmonary metastasis.  The increased incidence of metastasis in mice exhibiting low activity of NK cells was not due to enhanced tumor cell arrest in the lung but rather to increased tumor cell survival.  Boosting the NK activity of 3-week-old, but not Cy-treated, mice with interferon inducers inhibited metastasis formation.  The adoptive transfer of spleen cells from syngeneic mice or allogeneic nude mice that have high NK activity shortly before (but not after) iv tumor challenge abrogated the Cy-induced enhancement of metastasis.  The reactive lymphoid cells were non-T, nonadherent to nylon wool, sensitive to Cy treatment, and endowed with a natural ability to kill tumor cells during a short (12-24 hr) period.  The conclusions were that NC-NK cells are important in host defense against circulating tumor cells and therefore can prevent the development of tumor cells into metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT4JYPfiC_AeWgRQsDqrjW_fW6udTcc2eb_xI-0lSsrFbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL3M%252FivVOgsQ%253D%253D&md5=466b8b538686edf88fe7b3406b4e7e1e</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHanna%26aufirst%3DN.%26aulast%3DFidler%26aufirst%3DI.%2BJ.%26atitle%3DRole%2520of%2520natural%2520killer%2520cells%2520in%2520the%2520destruction%2520of%2520circulating%2520tumor%2520emboli%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D1980%26volume%3D65%26spage%3D801%26epage%3D809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group">Hanna, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidler, I. J.</span><span> </span><span class="NLM_article-title">Environmental and genetic factors determine the level of NK activity of nude mice and affect their suitability as models for experimental metastasis</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">371</span><span class="NLM_x">–</span> <span class="NLM_lpage">376</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1002%2Fijc.2910300319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=7129682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A280%3ADyaL3s%252FivFynsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1982&pages=371-376&author=N.+Hannaauthor=T.+W.+Davisauthor=I.+J.+Fidler&title=Environmental+and+genetic+factors+determine+the+level+of+NK+activity+of+nude+mice+and+affect+their+suitability+as+models+for+experimental+metastasis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Environmental and genetic factors determine the level of NK activity of nude mice and affect their suitability as models for experimental metastasis</span></div><div class="casAuthors">Hanna N; Davis T W; Fidler I J</div><div class="citationInfo"><span class="NLM_cas:title">International journal of cancer. Journal international du cancer</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">371-6</span>
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    </div><div class="casAbstract">In these studies we have evaluated the effects of age, genetic background, and housing conditions on the NK-cell activity of nude mice measured in vitro and resistance to tumor metastasis in vivo.  BALB/cAnN nude mice exhibited lower levels of NK-cell-mediated cytotoxicity than age-matched N:NIH(S) nude mice maintained under similar housing conditions.  The stronger response of N:NIH(S) nude mice was observed also after experimental activation of NK cells by Corynebacterium parvum.  Nude mice maintained under barrier conditions have weaker NK-cell activity than mice maintained under conventional conditions.  The incidence of experimental pulmonary metastases of allogeneic tumors injected into nude mice was inversely correlated with the levels of NK-cell-mediated cytotoxicity.  Thus, 3-week-old BALB/cAnN nude mice raised under barrier conditions were more sensitive to development of experimental metastasis than age-matched N:NIH(S) nude mice maintained under barrier conditions or nude mice of either strain maintained under conventional conditions.  In both strains, however, the relative differences in metastatic potential among the tumor cell lines observed in syngeneic recipients were maintained.  We conclude that young BALB/cAnN nude mice raised under barrier conditions may provide a valuable in vivo model for studying metastasis of neoplasms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7JdJmeKDCkzDnmmyUf5qOfW6udTcc2eb_xI-0lSsrFbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL3s%252FivFynsQ%253D%253D&md5=48efc4bef602a01b8686a29e0a14883b</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1002%2Fijc.2910300319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.2910300319%26sid%3Dliteratum%253Aachs%26aulast%3DHanna%26aufirst%3DN.%26aulast%3DDavis%26aufirst%3DT.%2BW.%26aulast%3DFidler%26aufirst%3DI.%2BJ.%26atitle%3DEnvironmental%2520and%2520genetic%2520factors%2520determine%2520the%2520level%2520of%2520NK%2520activity%2520of%2520nude%2520mice%2520and%2520affect%2520their%2520suitability%2520as%2520models%2520for%2520experimental%2520metastasis%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D1982%26volume%3D30%26spage%3D371%26epage%3D376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27a','cit27b'],'ref28':['ref28_1'],'ref29':['cit29'],'ref30':['ref30_1'],'ref31':['ref31_1'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 40 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yibin Xu, Ding Xue, Armand Bankhead, III, <span class="NLM_string-name hlFld-ContribAuthor">Nouri Neamati</span>. </span><span class="cited-content_cbyCitation_article-title">Why All the Fuss about Oxidative Phosphorylation (OXPHOS)?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (23)
                                     , 14276-14307. <a href="https://doi.org/10.1021/acs.jmedchem.0c01013" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01013%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DWhy%252BAll%252Bthe%252BFuss%252Babout%252BOxidative%252BPhosphorylation%252B%252528OXPHOS%252529%25253F%26aulast%3DXu%26aufirst%3DYibin%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D14062020%26date%3D26102020%26volume%3D63%26issue%3D23%26spage%3D14276%26epage%3D14307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Lucia Veselovská, Radek Pohl, Eva Tloušt′ová, Soňa Gurská, Petr Džubák, Marián Hajdúch, <span class="NLM_string-name hlFld-ContribAuthor">Michal Hocek</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrido-Fused Deazapurine Bases: Synthesis and Glycosylation of 4-Substituted 9H-Pyrido[2′,3′:4,5]- and Pyrido[4′,3′:4,5]pyrrolo[2,3-d]pyrimidines. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2020,</strong> <em>5 </em>
                                    (40)
                                     , 26278-26286. <a href="https://doi.org/10.1021/acsomega.0c04302" title="DOI URL">https://doi.org/10.1021/acsomega.0c04302</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.0c04302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.0c04302%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DPyrido-Fused%252BDeazapurine%252BBases%25253A%252BSynthesis%252Band%252BGlycosylation%252Bof%252B4-Substituted%252B9H-Pyrido%25255B2%2525E2%252580%2525B2%25252C3%2525E2%252580%2525B2%25253A4%25252C5%25255D-%252Band%252BPyrido%25255B4%2525E2%252580%2525B2%25252C3%2525E2%252580%2525B2%25253A4%25252C5%25255Dpyrrolo%25255B2%25252C3-d%25255Dpyrimidines%26aulast%3DVeselovsk%25C3%25A1%26aufirst%3DLucia%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D03092020%26date%3D24092020%26date%3D02102020%26volume%3D5%26issue%3D40%26spage%3D26278%26epage%3D26286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Marianne Fleuti, Kateřina Bártová, Lenka Poštová Slavětínská, Eva Tloušt’ová, Michal Tichý, Soňa Gurská, Petr Pavliš, Petr Džubák, Marián Hajdúch, <span class="NLM_string-name hlFld-ContribAuthor">Michal Hocek</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Biological Profiling of Pyrazolo-Fused 7-Deazapurine Nucleosides. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (16)
                                     , 10539-10551. <a href="https://doi.org/10.1021/acs.joc.0c00928" title="DOI URL">https://doi.org/10.1021/acs.joc.0c00928</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c00928&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c00928%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Band%252BBiological%252BProfiling%252Bof%252BPyrazolo-Fused%252B7-Deazapurine%252BNucleosides%26aulast%3DFleuti%26aufirst%3DMarianne%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D15042020%26date%3D06082020%26date%3D21072020%26volume%3D85%26issue%3D16%26spage%3D10539%26epage%3D10551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chao Yang, Radek Pohl, Michal Tichý, Soňa Gurská, Petr Pavliš, Petr Džubák, Marián Hajdúch, <span class="NLM_string-name hlFld-ContribAuthor">Michal Hocek</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, Photophysical Properties, and Biological Profiling of Benzothieno-Fused 7-Deazapurine Ribonucleosides. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (12)
                                     , 8085-8101. <a href="https://doi.org/10.1021/acs.joc.0c00927" title="DOI URL">https://doi.org/10.1021/acs.joc.0c00927</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c00927&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c00927%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%25252C%252BPhotophysical%252BProperties%25252C%252Band%252BBiological%252BProfiling%252Bof%252BBenzothieno-Fused%252B7-Deazapurine%252BRibonucleosides%26aulast%3DYang%26aufirst%3DChao%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D15042020%26date%3D04062020%26date%3D20052020%26volume%3D85%26issue%3D12%26spage%3D8085%26epage%3D8101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michal  Tichý</span>, <span class="hlFld-ContribAuthor ">Sabina  Smoleń</span>, <span class="hlFld-ContribAuthor ">Eva  Tloušt’ová</span>, <span class="hlFld-ContribAuthor ">Radek  Pohl</span>, <span class="hlFld-ContribAuthor ">Tomáš  Oždian</span>, <span class="hlFld-ContribAuthor ">Klára  Hejtmánková</span>, <span class="hlFld-ContribAuthor ">Barbora  Lišková</span>, <span class="hlFld-ContribAuthor ">Soňa  Gurská</span>, <span class="hlFld-ContribAuthor ">Petr  Džubák</span>, <span class="hlFld-ContribAuthor ">Marián  Hajdúch</span>, and <span class="hlFld-ContribAuthor ">Michal  Hocek</span>  . </span><span class="cited-content_cbyCitation_article-title">Synthesis and Cytostatic and Antiviral Profiling of Thieno-Fused 7-Deazapurine Ribonucleosides. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (6)
                                     , 2411-2424. <a href="https://doi.org/10.1021/acs.jmedchem.6b01766" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01766</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01766%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252BCytostatic%252Band%252BAntiviral%252BProfiling%252Bof%252BThieno-Fused%252B7-Deazapurine%252BRibonucleosides%26aulast%3DTich%25C3%25BD%26aufirst%3DMichal%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D03122016%26date%3D03032017%26date%3D23032017%26date%3D21022017%26volume%3D60%26issue%3D6%26spage%3D2411%26epage%3D2424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aleem  Gangjee</span>, <span class="hlFld-ContribAuthor ">Roheeth Kumar  Pavana</span>, <span class="hlFld-ContribAuthor ">Michael A.  Ihnat</span>, <span class="hlFld-ContribAuthor ">Jessica E.  Thorpe</span>, <span class="hlFld-ContribAuthor ">Bryan C.  Disch</span>, <span class="hlFld-ContribAuthor ">Anja  Bastian</span>, <span class="hlFld-ContribAuthor ">Lora C.  Bailey-Downs</span>, <span class="hlFld-ContribAuthor ">Ernest  Hamel</span>, and <span class="hlFld-ContribAuthor ">Rouli  Bai</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Antitubulin Agents with Antiangiogenic Activity as Single Entities with Multitarget Chemotherapy Potential. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2014,</strong> <em>5 </em>
                                    (5)
                                     , 480-484. <a href="https://doi.org/10.1021/ml4004793" title="DOI URL">https://doi.org/10.1021/ml4004793</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ml4004793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fml4004793%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BAntitubulin%252BAgents%252Bwith%252BAntiangiogenic%252BActivity%252Bas%252BSingle%252BEntities%252Bwith%252BMultitarget%252BChemotherapy%252BPotential%26aulast%3DGangjee%26aufirst%3DAleem%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D2013%26date%3D21112013%26date%3D27022014%26date%3D05032014%26date%3D08052014%26date%3D27022014%26volume%3D5%26issue%3D5%26spage%3D480%26epage%3D484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nilesh  Zaware</span>, <span class="hlFld-ContribAuthor ">Hitesh  Sharma</span>, <span class="hlFld-ContribAuthor ">Jie  Yang</span>, <span class="hlFld-ContribAuthor ">Ravi Kumar Vyas  Devambatla</span>, <span class="hlFld-ContribAuthor ">Sherry F.  Queener</span>, <span class="hlFld-ContribAuthor ">Karen S.  Anderson</span>, and <span class="hlFld-ContribAuthor ">Aleem  Gangjee</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Potent and Selective Inhibitors of Toxoplasma gondii Thymidylate Synthase for Opportunistic Infections. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2013,</strong> <em>4 </em>
                                    (12)
                                     , 1148-1151. <a href="https://doi.org/10.1021/ml400208v" title="DOI URL">https://doi.org/10.1021/ml400208v</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ml400208v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fml400208v%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BPotent%252Band%252BSelective%252BInhibitors%252Bof%252BToxoplasma%252Bgondii%252BThymidylate%252BSynthase%252Bfor%252BOpportunistic%252BInfections%26aulast%3DZaware%26aufirst%3DNilesh%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D29052013%26date%3D04102013%26date%3D15102013%26date%3D12122013%26date%3D04102013%26volume%3D4%26issue%3D12%26spage%3D1148%26epage%3D1151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sergei A.  Shipilovskikh</span>, <span class="hlFld-ContribAuthor ">Irina A.  Gorbunova</span>, <span class="hlFld-ContribAuthor ">Aleksandr E.  Rubtsov</span>. </span><span class="cited-content_cbyCitation_article-title">E/Z isomerization of ethyl 2-amino-1-(3-(ethoxycarbonyl)-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)-4-oxo-5-(2-oxo-2-phenylethylidene)-4,5-dihydro-1H-pyrrole-3-carboxylate. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 030017. <a href="https://doi.org/10.1063/5.0018490" title="DOI URL">https://doi.org/10.1063/5.0018490</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1063/5.0018490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1063%2F5.0018490%26sid%3Dliteratum%253Aachs%26atitle%3DE%25252FZ%252Bisomerization%252Bof%252Bethyl%252B2-amino-1-%2525283-%252528ethoxycarbonyl%252529-4%25252C5%25252C6%25252C7-tetrahydrobenzo%25255Bb%25255Dthiophen-2-yl%252529-4-oxo-5-%2525282-oxo-2-phenylethylidene%252529-4%25252C5-dihydro-1H-pyrrole-3-carboxylate%26aulast%3DShipilovskikh%26aufirst%3DSergei%2BA.%26date%3D2020%26spage%3D030017%26pub%3DAIP%2520Publishing%26date%3D2020%26volume%3D2283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amol A.  Nagargoje</span>, <span class="hlFld-ContribAuthor ">Satish V.  Akolkar</span>, <span class="hlFld-ContribAuthor ">Madiha M.  Siddiqui</span>, <span class="hlFld-ContribAuthor ">Aditi V.  Bagade</span>, <span class="hlFld-ContribAuthor ">Kisan M.  Kodam</span>, <span class="hlFld-ContribAuthor ">Jaiprakash N.  Sangshetti</span>, <span class="hlFld-ContribAuthor ">Manoj G.  Damale</span>, <span class="hlFld-ContribAuthor ">Bapurao B.  Shingate</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and evaluation of pyrazole‐incorporated monocarbonyl curcumin analogues as antiproliferative and antioxidant agents. </span><span class="cited-content_cbyCitation_journal-name">Journal of the Chinese Chemical Society</span><span> <strong>2019,</strong> <em>66 </em>
                                    (12)
                                     , 1658-1665. <a href="https://doi.org/10.1002/jccs.201800405" title="DOI URL">https://doi.org/10.1002/jccs.201800405</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jccs.201800405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjccs.201800405%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520Chinese%2520Chemical%2520Society%26atitle%3DSynthesis%252Band%252Bevaluation%252Bof%252Bpyrazole%2525E2%252580%252590incorporated%252Bmonocarbonyl%252Bcurcumin%252Banalogues%252Bas%252Bantiproliferative%252Band%252Bantioxidant%252Bagents%26aulast%3DNagargoje%26aufirst%3DAmol%2BA.%26date%3D2019%26date%3D2019%26volume%3D66%26issue%3D12%26spage%3D1658%26epage%3D1665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">S. Christopher  Jeyaseelan</span>, <span class="hlFld-ContribAuthor ">R.  Premkumar</span>, <span class="hlFld-ContribAuthor ">K.  Kaviyarasu</span>, <span class="hlFld-ContribAuthor ">A. Milton  Franklin Benial</span>. </span><span class="cited-content_cbyCitation_article-title">Spectroscopic, quantum chemical, molecular docking and in vitro anticancer activity studies on 5-Methoxyindole-3-carboxaldehyde. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Structure</span><span> <strong>2019,</strong> <em>1197 </em>, 134-146. <a href="https://doi.org/10.1016/j.molstruc.2019.07.042" title="DOI URL">https://doi.org/10.1016/j.molstruc.2019.07.042</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molstruc.2019.07.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molstruc.2019.07.042%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Structure%26atitle%3DSpectroscopic%25252C%252Bquantum%252Bchemical%25252C%252Bmolecular%252Bdocking%252Band%252Bin%2525C2%2525A0vitro%252Banticancer%252Bactivity%252Bstudies%252Bon%252B5-Methoxyindole-3-carboxaldehyde%26aulast%3DJeyaseelan%26aufirst%3DS.%2BChristopher%26date%3D2019%26volume%3D1197%26spage%3D134%26epage%3D146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ravi Kumar Vyas  Devambatla</span>, <span class="hlFld-ContribAuthor ">Shruti  Choudhary</span>, <span class="hlFld-ContribAuthor ">Michael  Ihnat</span>, <span class="hlFld-ContribAuthor ">Ernest  Hamel</span>, <span class="hlFld-ContribAuthor ">Susan L.  Mooberry</span>, <span class="hlFld-ContribAuthor ">Aleem  Gangjee</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and preclinical evaluation of 5-methyl-N4-aryl-furo[2,3-d]pyrimidines as single agents with combination chemotherapy potential. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>28 </em>
                                    (18)
                                     , 3085-3093. <a href="https://doi.org/10.1016/j.bmcl.2018.07.039" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.07.039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.07.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.07.039%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bpreclinical%252Bevaluation%252Bof%252B5-methyl-N4-aryl-furo%25255B2%25252C3-d%25255Dpyrimidines%252Bas%252Bsingle%252Bagents%252Bwith%252Bcombination%252Bchemotherapy%252Bpotential%26aulast%3DDevambatla%26aufirst%3DRavi%2BKumar%2BVyas%26date%3D2018%26volume%3D28%26issue%3D18%26spage%3D3085%26epage%3D3093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michal  Tichý</span>, <span class="hlFld-ContribAuthor ">Sabina  Smoleń</span>, <span class="hlFld-ContribAuthor ">Tomáš  Deingruber</span>, <span class="hlFld-ContribAuthor ">Petr  Džubák</span>, <span class="hlFld-ContribAuthor ">Radek  Pohl</span>, <span class="hlFld-ContribAuthor ">Lenka Poštová  Slavětínská</span>, <span class="hlFld-ContribAuthor ">Marián  Hajdúch</span>, <span class="hlFld-ContribAuthor ">Michal  Hocek</span>. </span><span class="cited-content_cbyCitation_article-title">Thienopyrrolo[2, 3-
              d
              ]pyrimidines, New Tricyclic Nucleobase Analogues: Synthesis and Biological Activities. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2018,</strong> <em>3 </em>
                                    (31)
                                     , 9144-9149. <a href="https://doi.org/10.1002/slct.201802190" title="DOI URL">https://doi.org/10.1002/slct.201802190</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.201802190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.201802190%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DThienopyrrolo%25255B2%25252C%2525E2%252580%2525893-%252Bd%252B%25255Dpyrimidines%25252C%252BNew%252BTricyclic%252BNucleobase%252BAnalogues%25253A%252BSynthesis%252Band%252BBiological%252BActivities%26aulast%3DTich%25C3%25BD%26aufirst%3DMichal%26date%3D2018%26date%3D2018%26volume%3D3%26issue%3D31%26spage%3D9144%26epage%3D9149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shailee  Tiwari</span>, <span class="hlFld-ContribAuthor ">Nawaz  Sharif</span>, <span class="hlFld-ContribAuthor ">Rekha  Gajare</span>, <span class="hlFld-ContribAuthor ">Julio  Vazquez</span>, <span class="hlFld-ContribAuthor ">Jaiprakash  Sangshetti</span>, <span class="hlFld-ContribAuthor ">Manoj  Damale</span>, <span class="hlFld-ContribAuthor ">Anna  Nikalje</span>. </span><span class="cited-content_cbyCitation_article-title">New 2-Oxoindolin Phosphonates as Novel Agents to Treat Cancer: A Green Synthesis and Molecular Modeling. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2018,</strong> <em>23 </em>
                                    (8)
                                     , 1981. <a href="https://doi.org/10.3390/molecules23081981" title="DOI URL">https://doi.org/10.3390/molecules23081981</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules23081981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules23081981%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DNew%252B2-Oxoindolin%252BPhosphonates%252Bas%252BNovel%252BAgents%252Bto%252BTreat%252BCancer%25253A%252BA%252BGreen%252BSynthesis%252Band%252BMolecular%252BModeling%26aulast%3DTiwari%26aufirst%3DShailee%26date%3D2018%26date%3D2018%26volume%3D23%26issue%3D8%26spage%3D1981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anna Pratima G.  Nikalje</span>, <span class="hlFld-ContribAuthor ">Shailee V.  Tiwari</span>, <span class="hlFld-ContribAuthor ">Jaiprakash N.  Sangshetti</span>, <span class="hlFld-ContribAuthor ">Manoj D.  Damale</span>. </span><span class="cited-content_cbyCitation_article-title">Ultrasound-mediated synthesis, biological evaluation, docking and in vivo acute oral toxicity study of novel indolin-2-one coupled pyrimidine derivatives. </span><span class="cited-content_cbyCitation_journal-name">Research on Chemical Intermediates</span><span> <strong>2018,</strong> <em>44 </em>
                                    (5)
                                     , 3031-3059. <a href="https://doi.org/10.1007/s11164-018-3292-5" title="DOI URL">https://doi.org/10.1007/s11164-018-3292-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11164-018-3292-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11164-018-3292-5%26sid%3Dliteratum%253Aachs%26jtitle%3DResearch%2520on%2520Chemical%2520Intermediates%26atitle%3DUltrasound-mediated%252Bsynthesis%25252C%252Bbiological%252Bevaluation%25252C%252Bdocking%252Band%252Bin%252Bvivo%252Bacute%252Boral%252Btoxicity%252Bstudy%252Bof%252Bnovel%252Bindolin-2-one%252Bcoupled%252Bpyrimidine%252Bderivatives%26aulast%3DNikalje%26aufirst%3DAnna%2BPratima%2BG.%26date%3D2018%26date%3D2018%26volume%3D44%26issue%3D5%26spage%3D3031%26epage%3D3059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ding  Xia</span>, <span class="hlFld-ContribAuthor ">Doan V.  Lai</span>, <span class="hlFld-ContribAuthor ">Weijuan  Wu</span>, <span class="hlFld-ContribAuthor ">Zachary D.  Webb</span>, <span class="hlFld-ContribAuthor ">Qing  Yang</span>, <span class="hlFld-ContribAuthor ">Lichao  Zhao</span>, <span class="hlFld-ContribAuthor ">Zhongxin  Yu</span>, <span class="hlFld-ContribAuthor ">Jessica E.  Thorpe</span>, <span class="hlFld-ContribAuthor ">Bryan C.  Disch</span>, <span class="hlFld-ContribAuthor ">Michael A.  Ihnat</span>, <span class="hlFld-ContribAuthor ">Muralidharan  Jayaraman</span>, <span class="hlFld-ContribAuthor ">Danny N.  Dhanasekaran</span>, <span class="hlFld-ContribAuthor ">Kelly L.  Stratton</span>, <span class="hlFld-ContribAuthor ">Michael S.  Cookson</span>, <span class="hlFld-ContribAuthor ">Kar-Ming  Fung</span>, <span class="hlFld-ContribAuthor ">Hsueh-Kung  Lin</span>. </span><span class="cited-content_cbyCitation_article-title">Transition from androgenic to neurosteroidal action of 5α-androstane-3α, 17β-diol through the type A γ-aminobutyric acid receptor in prostate cancer progression. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Steroid Biochemistry and Molecular Biology</span><span> <strong>2018,</strong> <em>178 </em>, 89-98. <a href="https://doi.org/10.1016/j.jsbmb.2017.11.006" title="DOI URL">https://doi.org/10.1016/j.jsbmb.2017.11.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jsbmb.2017.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jsbmb.2017.11.006%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Steroid%2520Biochemistry%2520and%2520Molecular%2520Biology%26atitle%3DTransition%252Bfrom%252Bandrogenic%252Bto%252Bneurosteroidal%252Baction%252Bof%252B5%2525CE%2525B1-androstane-3%2525CE%2525B1%25252C%252B17%2525CE%2525B2-diol%252Bthrough%252Bthe%252Btype%252BA%252B%2525CE%2525B3-aminobutyric%252Bacid%252Breceptor%252Bin%252Bprostate%252Bcancer%252Bprogression%26aulast%3DXia%26aufirst%3DDing%26date%3D2018%26volume%3D178%26spage%3D89%26epage%3D98" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicolas  Biteau</span>, <span class="hlFld-ContribAuthor ">Vincent  Hervin</span>, <span class="hlFld-ContribAuthor ">Vincent  Roy</span>, <span class="hlFld-ContribAuthor ">Luigi A.  Agrofoglio</span>. </span><span class="cited-content_cbyCitation_article-title">Suzuki-Miyaura Cross-Coupling as a Synthetic Tool for Nucleoside and Nucleotide Modification. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 37-74. <a href="https://doi.org/10.1016/B978-0-12-811292-2.00003-9" title="DOI URL">https://doi.org/10.1016/B978-0-12-811292-2.00003-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-811292-2.00003-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-811292-2.00003-9%26sid%3Dliteratum%253Aachs%26atitle%3DSuzuki-Miyaura%252BCross-Coupling%252Bas%252Ba%252BSynthetic%252BTool%252Bfor%252BNucleoside%252Band%252BNucleotide%252BModification%26aulast%3DBiteau%26aufirst%3DNicolas%26date%3D2018%26spage%3D37%26epage%3D74%26pub%3DElsevier%26atitle%3DPalladium-Catalyzed%252BModification%252Bof%252BNucleosides%25252C%252BNucleotides%252Band%252BOligonucleotides%26date%3D2018%26volume%3D48" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Luca  Costantino</span>, <span class="hlFld-ContribAuthor ">Daniela  Barlocco</span>. </span><span class="cited-content_cbyCitation_article-title">Designing Approaches to Multitarget Drugs. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 161-205. <a href="https://doi.org/10.1002/9783527674381.ch7" title="DOI URL">https://doi.org/10.1002/9783527674381.ch7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9783527674381.ch7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9783527674381.ch7%26sid%3Dliteratum%253Aachs%26atitle%3DDesigning%252BApproaches%252Bto%252BMultitarget%252BDrugs%26aulast%3DCostantino%26aufirst%3DLuca%26date%3D2017%26date%3D2017%26spage%3D161%26epage%3D205%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26atitle%3DDrug%252BSelectivity%26aulast%3DHandler%26aufirst%3DNorbert%26date%3D2017%26volume%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ravi Kumar Vyas  Devambatla</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Nilesh  Zaware</span>, <span class="hlFld-ContribAuthor ">Shruti  Choudhary</span>, <span class="hlFld-ContribAuthor ">Ernest  Hamel</span>, <span class="hlFld-ContribAuthor ">Susan L.  Mooberry</span>, <span class="hlFld-ContribAuthor ">Aleem  Gangjee</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and structure–activity relationships of pyrimido[4,5- b ]indole-4-amines as microtubule depolymerizing agents that are effective against multidrug resistant cells. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (15)
                                     , 3423-3430. <a href="https://doi.org/10.1016/j.bmcl.2017.05.085" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.05.085</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.05.085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.05.085%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bstructure%2525E2%252580%252593activity%252Brelationships%252Bof%252Bpyrimido%25255B4%25252C5-%252Bb%252B%25255Dindole-4-amines%252Bas%252Bmicrotubule%252Bdepolymerizing%252Bagents%252Bthat%252Bare%252Beffective%252Bagainst%252Bmultidrug%252Bresistant%252Bcells%26aulast%3DDevambatla%26aufirst%3DRavi%2BKumar%2BVyas%26date%3D2017%26volume%3D27%26issue%3D15%26spage%3D3423%26epage%3D3430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nilesh  Zaware</span>, <span class="hlFld-ContribAuthor ">Roy  Kisliuk</span>, <span class="hlFld-ContribAuthor ">Anja  Bastian</span>, <span class="hlFld-ContribAuthor ">Michael A.  Ihnat</span>, <span class="hlFld-ContribAuthor ">Aleem  Gangjee</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and evaluation of 5-(arylthio)-9 H -pyrimido[4,5- b ]indole-2,4-diamines as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (7)
                                     , 1602-1607. <a href="https://doi.org/10.1016/j.bmcl.2017.02.018" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.02.018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.02.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.02.018%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252Bevaluation%252Bof%252B5-%252528arylthio%252529-9%252BH%252B-pyrimido%25255B4%25252C5-%252Bb%252B%25255Dindole-2%25252C4-diamines%252Bas%252Breceptor%252Btyrosine%252Bkinase%252Band%252Bthymidylate%252Bsynthase%252Binhibitors%252Band%252Bas%252Bantitumor%252Bagents%26aulast%3DZaware%26aufirst%3DNilesh%26date%3D2017%26volume%3D27%26issue%3D7%26spage%3D1602%26epage%3D1607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anja  Bastian</span>, <span class="hlFld-ContribAuthor ">Satoshi  Matsuzaki</span>, <span class="hlFld-ContribAuthor ">Kenneth M.  Humphries</span>, <span class="hlFld-ContribAuthor ">Gavin A.  Pharaoh</span>, <span class="hlFld-ContribAuthor ">Arpit  Doshi</span>, <span class="hlFld-ContribAuthor ">Nilesh  Zaware</span>, <span class="hlFld-ContribAuthor ">Aleem  Gangjee</span>, <span class="hlFld-ContribAuthor ">Michael A.  Ihnat</span>. </span><span class="cited-content_cbyCitation_article-title">AG311, a small molecule inhibitor of complex I and hypoxia-induced HIF-1α stabilization. </span><span class="cited-content_cbyCitation_journal-name">Cancer Letters</span><span> <strong>2017,</strong> <em>388 </em>, 149-157. <a href="https://doi.org/10.1016/j.canlet.2016.11.040" title="DOI URL">https://doi.org/10.1016/j.canlet.2016.11.040</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.canlet.2016.11.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.canlet.2016.11.040%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Letters%26atitle%3DAG311%25252C%252Ba%252Bsmall%252Bmolecule%252Binhibitor%252Bof%252Bcomplex%252BI%252Band%252Bhypoxia-induced%252BHIF-1%2525CE%2525B1%252Bstabilization%26aulast%3DBastian%26aufirst%3DAnja%26date%3D2017%26volume%3D388%26spage%3D149%26epage%3D157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Roheeth Kumar  Pavana</span>, <span class="hlFld-ContribAuthor ">Shruti  Choudhary</span>, <span class="hlFld-ContribAuthor ">Anja  Bastian</span>, <span class="hlFld-ContribAuthor ">Michael A.  Ihnat</span>, <span class="hlFld-ContribAuthor ">Ruoli  Bai</span>, <span class="hlFld-ContribAuthor ">Ernest  Hamel</span>, <span class="hlFld-ContribAuthor ">Aleem  Gangjee</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2017,</strong> <em>25 </em>
                                    (2)
                                     , 545-556. <a href="https://doi.org/10.1016/j.bmc.2016.11.026" title="DOI URL">https://doi.org/10.1016/j.bmc.2016.11.026</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2016.11.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2016.11.026%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252Bpreclinical%252Bevaluation%252Bof%252B7-benzyl-N-%252528substituted%252529-pyrrolo%25255B3%25252C2-d%25255Dpyrimidin-4-amines%252Bas%252Bsingle%252Bagents%252Bwith%252Bmicrotubule%252Btargeting%252Beffects%252Balong%252Bwith%252Btriple-acting%252Bangiokinase%252Binhibition%252Bas%252Bantitumor%252Bagents%26aulast%3DPavana%26aufirst%3DRoheeth%2BKumar%26date%3D2017%26volume%3D25%26issue%3D2%26spage%3D545%26epage%3D556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cristina  Rohena</span>, <span class="hlFld-ContribAuthor ">April  Risinger</span>, <span class="hlFld-ContribAuthor ">Ravi  Devambatla</span>, <span class="hlFld-ContribAuthor ">Nicholas  Dybdal-Hargreaves</span>, <span class="hlFld-ContribAuthor ">Roma  Kaul</span>, <span class="hlFld-ContribAuthor ">Shruti  Choudhary</span>, <span class="hlFld-ContribAuthor ">Aleem  Gangjee</span>, <span class="hlFld-ContribAuthor ">Susan  Mooberry</span>. </span><span class="cited-content_cbyCitation_article-title">Janus Compounds, 5-Chloro-N4-methyl-N4-aryl-9H-pyrimido[4,5-b]indole-2,4-diamines, Cause Both Microtubule Depolymerizing and Stabilizing Effects. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2016,</strong> <em>21 </em>
                                    (12)
                                     , 1661. <a href="https://doi.org/10.3390/molecules21121661" title="DOI URL">https://doi.org/10.3390/molecules21121661</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules21121661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules21121661%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DJanus%252BCompounds%25252C%252B5-Chloro-N4-methyl-N4-aryl-9H-pyrimido%25255B4%25252C5-b%25255Dindole-2%25252C4-diamines%25252C%252BCause%252BBoth%252BMicrotubule%252BDepolymerizing%252Band%252BStabilizing%252BEffects%26aulast%3DRohena%26aufirst%3DCristina%26date%3D2016%26date%3D2016%26volume%3D21%26issue%3D12%26spage%3D1661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rui-Xia  Yang</span>, <span class="hlFld-ContribAuthor ">Yu-Cheng  Zhao</span>, <span class="hlFld-ContribAuthor ">Ling-Bin  Kong</span>, <span class="hlFld-ContribAuthor ">Sheng-Jiao  Yan</span>, <span class="hlFld-ContribAuthor ">Jun  Lin</span>. </span><span class="cited-content_cbyCitation_article-title">Simple Synthesis of Multi-Halogen Pyrazino[1,2-
              a
              ]indole-1,8(2
              H
              ,5
              aH
              )-diones. </span><span class="cited-content_cbyCitation_journal-name">Bulletin of the Korean Chemical Society</span><span> <strong>2016,</strong> <em>37 </em>
                                    (10)
                                     , 1593-1599. <a href="https://doi.org/10.1002/bkcs.10909" title="DOI URL">https://doi.org/10.1002/bkcs.10909</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/bkcs.10909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fbkcs.10909%26sid%3Dliteratum%253Aachs%26jtitle%3DBulletin%2520of%2520the%2520Korean%2520Chemical%2520Society%26atitle%3DSimple%252BSynthesis%252Bof%252BMulti-Halogen%252BPyrazino%25255B1%25252C2-%252Ba%252B%25255Dindole-1%25252C8%2525282%252BH%252B%25252C5%252BaH%252B%252529-diones%26aulast%3DYang%26aufirst%3DRui-Xia%26date%3D2016%26date%3D2016%26volume%3D37%26issue%3D10%26spage%3D1593%26epage%3D1599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xin  Zhang</span>, <span class="hlFld-ContribAuthor ">Sudhir  Raghavan</span>, <span class="hlFld-ContribAuthor ">Michael  Ihnat</span>, <span class="hlFld-ContribAuthor ">Ernest  Hamel</span>, <span class="hlFld-ContribAuthor ">Cynthia  Zammiello</span>, <span class="hlFld-ContribAuthor ">Anja  Bastian</span>, <span class="hlFld-ContribAuthor ">Susan L.  Mooberry</span>, <span class="hlFld-ContribAuthor ">Aleem  Gangjee</span>. </span><span class="cited-content_cbyCitation_article-title">The design, synthesis and biological evaluation of conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase and microtubule inhibitors as potential antitumor agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2015,</strong> <em>23 </em>
                                    (10)
                                     , 2408-2423. <a href="https://doi.org/10.1016/j.bmc.2015.03.061" title="DOI URL">https://doi.org/10.1016/j.bmc.2015.03.061</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2015.03.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2015.03.061%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DThe%252Bdesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bconformationally%252Brestricted%252B4-substituted-2%25252C6-dimethylfuro%25255B2%25252C3-d%25255Dpyrimidines%252Bas%252Bmulti-targeted%252Breceptor%252Btyrosine%252Bkinase%252Band%252Bmicrotubule%252Binhibitors%252Bas%252Bpotential%252Bantitumor%252Bagents%26aulast%3DZhang%26aufirst%3DXin%26date%3D2015%26volume%3D23%26issue%3D10%26spage%3D2408%26epage%3D2423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anja  Bastian</span>, <span class="hlFld-ContribAuthor ">Jessica E.  Thorpe</span>, <span class="hlFld-ContribAuthor ">Bryan C.  Disch</span>, <span class="hlFld-ContribAuthor ">Lora C.  Bailey-Downs</span>, <span class="hlFld-ContribAuthor ">Aleem  Gangjee</span>, <span class="hlFld-ContribAuthor ">Ravi K. V.  Devambatla</span>, <span class="hlFld-ContribAuthor ">Jim  Henthorn</span>, <span class="hlFld-ContribAuthor ">Kenneth M.  Humphries</span>, <span class="hlFld-ContribAuthor ">Shraddha S.  Vadvalkar</span>, <span class="hlFld-ContribAuthor ">Michael A.  Ihnat</span>. </span><span class="cited-content_cbyCitation_article-title">A Small Molecule with Anticancer and Antimetastatic Activities Induces Rapid Mitochondrial-Associated Necrosis in Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmacology and Experimental Therapeutics</span><span> <strong>2015,</strong> <em>353 </em>
                                    (2)
                                     , 392-404. <a href="https://doi.org/10.1124/jpet.114.220335" title="DOI URL">https://doi.org/10.1124/jpet.114.220335</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/jpet.114.220335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fjpet.114.220335%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmacology%2520and%2520Experimental%2520Therapeutics%26atitle%3DA%252BSmall%252BMolecule%252Bwith%252BAnticancer%252Band%252BAntimetastatic%252BActivities%252BInduces%252BRapid%252BMitochondrial-Associated%252BNecrosis%252Bin%252BBreast%252BCancer%26aulast%3DBastian%26aufirst%3DAnja%26date%3D2015%26date%3D2015%26volume%3D353%26issue%3D2%26spage%3D392%26epage%3D404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shaoying  Tan</span>, <span class="hlFld-ContribAuthor ">Kun  Han</span>, <span class="hlFld-ContribAuthor ">Qiang  Li</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Yiqi  Yang</span>, <span class="hlFld-ContribAuthor ">Zhuo  Chen</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Xuhong  Qian</span>, <span class="hlFld-ContribAuthor ">Yufang  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Novel metal complexes of naphthalimide–cyclam conjugates as potential multi-target receptor tyrosine kinase (RTK) inhibitors: Synthesis and biological evaluation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>85 </em>, 207-214. <a href="https://doi.org/10.1016/j.ejmech.2014.07.068" title="DOI URL">https://doi.org/10.1016/j.ejmech.2014.07.068</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2014.07.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2014.07.068%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252Bmetal%252Bcomplexes%252Bof%252Bnaphthalimide%2525E2%252580%252593cyclam%252Bconjugates%252Bas%252Bpotential%252Bmulti-target%252Breceptor%252Btyrosine%252Bkinase%252B%252528RTK%252529%252Binhibitors%25253A%252BSynthesis%252Band%252Bbiological%252Bevaluation%26aulast%3DTan%26aufirst%3DShaoying%26date%3D2014%26volume%3D85%26spage%3D207%26epage%3D214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xin  Zhang</span>, <span class="hlFld-ContribAuthor ">Sudhir  Raghavan</span>, <span class="hlFld-ContribAuthor ">Michael  Ihnat</span>, <span class="hlFld-ContribAuthor ">Jessica E.  Thorpe</span>, <span class="hlFld-ContribAuthor ">Bryan C.  Disch</span>, <span class="hlFld-ContribAuthor ">Anja  Bastian</span>, <span class="hlFld-ContribAuthor ">Lora C.  Bailey-Downs</span>, <span class="hlFld-ContribAuthor ">Nicholas F.  Dybdal-Hargreaves</span>, <span class="hlFld-ContribAuthor ">Cristina C.  Rohena</span>, <span class="hlFld-ContribAuthor ">Ernest  Hamel</span>, <span class="hlFld-ContribAuthor ">Susan L.  Mooberry</span>, <span class="hlFld-ContribAuthor ">Aleem  Gangjee</span>. </span><span class="cited-content_cbyCitation_article-title">The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2014,</strong> <em>22 </em>
                                    (14)
                                     , 3753-3772. <a href="https://doi.org/10.1016/j.bmc.2014.04.049" title="DOI URL">https://doi.org/10.1016/j.bmc.2014.04.049</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2014.04.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2014.04.049%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DThe%252Bdesign%252Band%252Bdiscovery%252Bof%252Bwater%252Bsoluble%252B4-substituted-2%25252C6-dimethylfuro%25255B2%25252C3-d%25255Dpyrimidines%252Bas%252Bmultitargeted%252Breceptor%252Btyrosine%252Bkinase%252Binhibitors%252Band%252Bmicrotubule%252Btargeting%252Bantitumor%252Bagents%26aulast%3DZhang%26aufirst%3DXin%26date%3D2014%26volume%3D22%26issue%3D14%26spage%3D3753%26epage%3D3772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fei  Jia</span>, <span class="hlFld-ContribAuthor ">Juan  Hong</span>, <span class="hlFld-ContribAuthor ">Ping-Hua  Sun</span>, <span class="hlFld-ContribAuthor ">Jian-Xin  Chen</span>, <span class="hlFld-ContribAuthor ">Wei-Min  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Facile Synthesis of the Neuraminidase Inhibitor Peramivir. </span><span class="cited-content_cbyCitation_journal-name">Synthetic Communications</span><span> <strong>2013,</strong> <em>43 </em>
                                    (19)
                                     , 2641-2647. <a href="https://doi.org/10.1080/00397911.2012.729279" title="DOI URL">https://doi.org/10.1080/00397911.2012.729279</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/00397911.2012.729279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F00397911.2012.729279%26sid%3Dliteratum%253Aachs%26jtitle%3DSynthetic%2520Communications%26atitle%3DFacile%252BSynthesis%252Bof%252Bthe%252BNeuraminidase%252BInhibitor%252BPeramivir%26aulast%3DJia%26aufirst%3DFei%26date%3D2013%26date%3D2013%26volume%3D43%26issue%3D19%26spage%3D2641%26epage%3D2647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michal  Tichý</span>, <span class="hlFld-ContribAuthor ">Radek  Pohl</span>, <span class="hlFld-ContribAuthor ">Eva  Tloušt’ová</span>, <span class="hlFld-ContribAuthor ">Jan  Weber</span>, <span class="hlFld-ContribAuthor ">Gina  Bahador</span>, <span class="hlFld-ContribAuthor ">Yu-Jen  Lee</span>, <span class="hlFld-ContribAuthor ">Michal  Hocek</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological activity of benzo-fused 7-deazaadenosine analogues. 5- and 6-substituted 4-amino- or 4-alkylpyrimido[4,5-b]indole ribonucleosides. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2013,</strong> <em>21 </em>
                                    (17)
                                     , 5362-5372. <a href="https://doi.org/10.1016/j.bmc.2013.06.011" title="DOI URL">https://doi.org/10.1016/j.bmc.2013.06.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2013.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2013.06.011%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bactivity%252Bof%252Bbenzo-fused%252B7-deazaadenosine%252Banalogues.%252B5-%252Band%252B6-substituted%252B4-amino-%252Bor%252B4-alkylpyrimido%25255B4%25252C5-b%25255Dindole%252Bribonucleosides%26aulast%3DTich%25C3%25BD%26aufirst%3DMichal%26date%3D2013%26volume%3D21%26issue%3D17%26spage%3D5362%26epage%3D5372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xin  Wang</span>, <span class="hlFld-ContribAuthor ">Zhuo  Chen</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Shaoying  Tan</span>, <span class="hlFld-ContribAuthor ">Wei  Zhou</span>, <span class="hlFld-ContribAuthor ">Ting  Peng</span>, <span class="hlFld-ContribAuthor ">Kun  Han</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Yufang  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Naphthalimides exhibit in vitro antiproliferative and antiangiogenic activities by inhibiting both topoisomerase II (topo II) and receptor tyrosine kinases (RTKs). </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>65 </em>, 477-486. <a href="https://doi.org/10.1016/j.ejmech.2013.05.002" title="DOI URL">https://doi.org/10.1016/j.ejmech.2013.05.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2013.05.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2013.05.002%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNaphthalimides%252Bexhibit%252Bin%2525C2%2525A0vitro%252Bantiproliferative%252Band%252Bantiangiogenic%252Bactivities%252Bby%252Binhibiting%252Bboth%252Btopoisomerase%252BII%252B%252528topo%252BII%252529%252Band%252Breceptor%252Btyrosine%252Bkinases%252B%252528RTKs%252529%26aulast%3DWang%26aufirst%3DXin%26date%3D2013%26volume%3D65%26spage%3D477%26epage%3D486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aleem  Gangjee</span>, <span class="hlFld-ContribAuthor ">Nilesh  Zaware</span>, <span class="hlFld-ContribAuthor ">Sudhir  Raghavan</span>, <span class="hlFld-ContribAuthor ">Bryan C.  Disch</span>, <span class="hlFld-ContribAuthor ">Jessica E.  Thorpe</span>, <span class="hlFld-ContribAuthor ">Anja  Bastian</span>, <span class="hlFld-ContribAuthor ">Michael A.  Ihnat</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological activity of 5-chloro-N4-substituted phenyl-9H-pyrimido[4,5-b]indole-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2013,</strong> <em>21 </em>
                                    (7)
                                     , 1857-1864. <a href="https://doi.org/10.1016/j.bmc.2013.01.040" title="DOI URL">https://doi.org/10.1016/j.bmc.2013.01.040</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2013.01.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2013.01.040%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bactivity%252Bof%252B5-chloro-N4-substituted%252Bphenyl-9H-pyrimido%25255B4%25252C5-b%25255Dindole-2%25252C4-diamines%252Bas%252Bvascular%252Bendothelial%252Bgrowth%252Bfactor%252Breceptor-2%252Binhibitors%252Band%252Bantiangiogenic%252Bagents%26aulast%3DGangjee%26aufirst%3DAleem%26date%3D2013%26volume%3D21%26issue%3D7%26spage%3D1857%26epage%3D1864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qian-Ru  Du</span>, <span class="hlFld-ContribAuthor ">Dong-Dong  Li</span>, <span class="hlFld-ContribAuthor ">Ya-Zhou  Pi</span>, <span class="hlFld-ContribAuthor ">Jing-Ran  Li</span>, <span class="hlFld-ContribAuthor ">Jian  Sun</span>, <span class="hlFld-ContribAuthor ">Fei  Fang</span>, <span class="hlFld-ContribAuthor ">Wei-Qing  Zhong</span>, <span class="hlFld-ContribAuthor ">Hai-Bin  Gong</span>, <span class="hlFld-ContribAuthor ">Hai-Liang  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Novel 1,3,4-oxadiazole thioether derivatives targeting thymidylate synthase as dual anticancer/antimicrobial agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2013,</strong> <em>21 </em>
                                    (8)
                                     , 2286-2297. <a href="https://doi.org/10.1016/j.bmc.2013.02.008" title="DOI URL">https://doi.org/10.1016/j.bmc.2013.02.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2013.02.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2013.02.008%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DNovel%252B1%25252C3%25252C4-oxadiazole%252Bthioether%252Bderivatives%252Btargeting%252Bthymidylate%252Bsynthase%252Bas%252Bdual%252Banticancer%25252Fantimicrobial%252Bagents%26aulast%3DDu%26aufirst%3DQian-Ru%26date%3D2013%26volume%3D21%26issue%3D8%26spage%3D2286%26epage%3D2297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michal  Tichý</span>, <span class="hlFld-ContribAuthor ">Radek  Pohl</span>, <span class="hlFld-ContribAuthor ">Hao Ying  Xu</span>, <span class="hlFld-ContribAuthor ">Yen-Liang  Chen</span>, <span class="hlFld-ContribAuthor ">Fumiaki  Yokokawa</span>, <span class="hlFld-ContribAuthor ">Pei-Yong  Shi</span>, <span class="hlFld-ContribAuthor ">Michal  Hocek</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and antiviral activity of 4,6-disubstituted pyrimido[4,5-b]indole ribonucleosides. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2012,</strong> <em>20 </em>
                                    (20)
                                     , 6123-6133. <a href="https://doi.org/10.1016/j.bmc.2012.08.021" title="DOI URL">https://doi.org/10.1016/j.bmc.2012.08.021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2012.08.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2012.08.021%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bantiviral%252Bactivity%252Bof%252B4%25252C6-disubstituted%252Bpyrimido%25255B4%25252C5-b%25255Dindole%252Bribonucleosides%26aulast%3DTich%25C3%25BD%26aufirst%3DMichal%26date%3D2012%26volume%3D20%26issue%3D20%26spage%3D6123%26epage%3D6133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aleem  Gangjee</span>, <span class="hlFld-ContribAuthor ">Ying  Zhao</span>, <span class="hlFld-ContribAuthor ">Michael A.  Ihnat</span>, <span class="hlFld-ContribAuthor ">Jessica E.  Thorpe</span>, <span class="hlFld-ContribAuthor ">Lora C.  Bailey-Downs</span>, <span class="hlFld-ContribAuthor ">Roy L.  Kisliuk</span>. </span><span class="cited-content_cbyCitation_article-title">Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2012,</strong> <em>20 </em>
                                    (14)
                                     , 4217-4225. <a href="https://doi.org/10.1016/j.bmc.2012.05.068" title="DOI URL">https://doi.org/10.1016/j.bmc.2012.05.068</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2012.05.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2012.05.068%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DNovel%252Btricyclic%252Bindeno%25255B2%25252C1-d%25255Dpyrimidines%252Bwith%252Bdual%252Bantiangiogenic%252Band%252Bcytotoxic%252Bactivities%252Bas%252Bpotent%252Bantitumor%252Bagents%26aulast%3DGangjee%26aufirst%3DAleem%26date%3D2012%26volume%3D20%26issue%3D14%26spage%3D4217%26epage%3D4225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bartolo  Gabriele</span>, <span class="hlFld-ContribAuthor ">Lucia  Veltri</span>, <span class="hlFld-ContribAuthor ">Raffaella  Mancuso</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Salerno</span>, <span class="hlFld-ContribAuthor ">Mirco  Costa</span>. </span><span class="cited-content_cbyCitation_article-title">A General Synthesis of Indole-3-carboxylic Esters by Palladium-Catalyzed Direct Oxidative Carbonylation of 2-Alkynylaniline Derivatives. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2012,</strong> <em>2012 </em>
                                    (13)
                                     , 2549-2559. <a href="https://doi.org/10.1002/ejoc.201200120" title="DOI URL">https://doi.org/10.1002/ejoc.201200120</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201200120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201200120%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DA%252BGeneral%252BSynthesis%252Bof%252BIndole-3-carboxylic%252BEsters%252Bby%252BPalladium-Catalyzed%252BDirect%252BOxidative%252BCarbonylation%252Bof%252B2-Alkynylaniline%252BDerivatives%26aulast%3DGabriele%26aufirst%3DBartolo%26date%3D2012%26date%3D2012%26volume%3D2012%26issue%3D13%26spage%3D2549%26epage%3D2559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aleem  Gangjee</span>, <span class="hlFld-ContribAuthor ">Nilesh  Zaware</span>, <span class="hlFld-ContribAuthor ">Sudhir  Raghavan</span>, <span class="hlFld-ContribAuthor ">Jie  Yang</span>, <span class="hlFld-ContribAuthor ">Jessica E.  Thorpe</span>, <span class="hlFld-ContribAuthor ">Michael A.  Ihnat</span>. </span><span class="cited-content_cbyCitation_article-title">N4-(3-Bromophenyl)-7-(substituted benzyl) pyrrolo[2,3-d]pyrimidines as potent multiple receptor tyrosine kinase inhibitors: Design, synthesis, and in vivo evaluation. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2012,</strong> <em>20 </em>
                                    (7)
                                     , 2444-2454. <a href="https://doi.org/10.1016/j.bmc.2012.01.029" title="DOI URL">https://doi.org/10.1016/j.bmc.2012.01.029</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2012.01.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2012.01.029%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DN4-%2525283-Bromophenyl%252529-7-%252528substituted%252Bbenzyl%252529%252Bpyrrolo%25255B2%25252C3-d%25255Dpyrimidines%252Bas%252Bpotent%252Bmultiple%252Breceptor%252Btyrosine%252Bkinase%252Binhibitors%25253A%252BDesign%25252C%252Bsynthesis%25252C%252Band%252Bin%252Bvivo%252Bevaluation%26aulast%3DGangjee%26aufirst%3DAleem%26date%3D2012%26volume%3D20%26issue%3D7%26spage%3D2444%26epage%3D2454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xudong  Luan</span>, <span class="hlFld-ContribAuthor ">Chunmei  Gao</span>, <span class="hlFld-ContribAuthor ">Nannan  Zhang</span>, <span class="hlFld-ContribAuthor ">Yuzong  Chen</span>, <span class="hlFld-ContribAuthor ">Qinsheng  Sun</span>, <span class="hlFld-ContribAuthor ">Chunyan  Tan</span>, <span class="hlFld-ContribAuthor ">Hongxia  Liu</span>, <span class="hlFld-ContribAuthor ">Yibao  Jin</span>, <span class="hlFld-ContribAuthor ">Yuyang  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Exploration of acridine scaffold as a potentially interesting scaffold for discovering novel multi-target VEGFR-2 and Src kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2011,</strong> <em>19 </em>
                                    (11)
                                     , 3312-3319. <a href="https://doi.org/10.1016/j.bmc.2011.04.053" title="DOI URL">https://doi.org/10.1016/j.bmc.2011.04.053</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2011.04.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2011.04.053%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DExploration%252Bof%252Bacridine%252Bscaffold%252Bas%252Ba%252Bpotentially%252Binteresting%252Bscaffold%252Bfor%252Bdiscovering%252Bnovel%252Bmulti-target%252BVEGFR-2%252Band%252BSrc%252Bkinase%252Binhibitors%26aulast%3DLuan%26aufirst%3DXudong%26date%3D2011%26volume%3D19%26issue%3D11%26spage%3D3312%26epage%3D3319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mingzhang  Gao</span>, <span class="hlFld-ContribAuthor ">Christian M.  Lola</span>, <span class="hlFld-ContribAuthor ">Min  Wang</span>, <span class="hlFld-ContribAuthor ">Kathy D.  Miller</span>, <span class="hlFld-ContribAuthor ">George W.  Sledge</span>, <span class="hlFld-ContribAuthor ">Qi-Huang  Zheng</span>. </span><span class="cited-content_cbyCitation_article-title">Radiosynthesis of [11C]Vandetanib and [11C]chloro-Vandetanib as new potential PET agents for imaging of VEGFR in cancer. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2011,</strong> <em>21 </em>
                                    (11)
                                     , 3222-3226. <a href="https://doi.org/10.1016/j.bmcl.2011.04.049" title="DOI URL">https://doi.org/10.1016/j.bmcl.2011.04.049</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2011.04.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2011.04.049%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DRadiosynthesis%252Bof%252B%25255B11C%25255DVandetanib%252Band%252B%25255B11C%25255Dchloro-Vandetanib%252Bas%252Bnew%252Bpotential%252BPET%252Bagents%252Bfor%252Bimaging%252Bof%252BVEGFR%252Bin%252Bcancer%26aulast%3DGao%26aufirst%3DMingzhang%26date%3D2011%26volume%3D21%26issue%3D11%26spage%3D3222%26epage%3D3226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ragini  Gupta</span>, <span class="hlFld-ContribAuthor ">Anshu  Jain</span>, <span class="hlFld-ContribAuthor ">Rahul  Joshi</span>, <span class="hlFld-ContribAuthor ">Meenakshi  Jain</span>. </span><span class="cited-content_cbyCitation_article-title">Eco-friendly Solventless Synthesis of 5-Indolylpyrimido[4,5-d]pyrimidinones and Their Antimicrobial Activity. </span><span class="cited-content_cbyCitation_journal-name">Bulletin of the Korean Chemical Society</span><span> <strong>2011,</strong> <em>32 </em>
                                    (3)
                                     , 899-904. <a href="https://doi.org/10.5012/bkcs.2011.32.3.899" title="DOI URL">https://doi.org/10.5012/bkcs.2011.32.3.899</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.5012/bkcs.2011.32.3.899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.5012%2Fbkcs.2011.32.3.899%26sid%3Dliteratum%253Aachs%26jtitle%3DBulletin%2520of%2520the%2520Korean%2520Chemical%2520Society%26atitle%3DEco-friendly%252BSolventless%252BSynthesis%252Bof%252B5-Indolylpyrimido%25255B4%25252C5-d%25255Dpyrimidinones%252Band%252BTheir%252BAntimicrobial%252BActivity%26aulast%3DGupta%26aufirst%3DRagini%26date%3D2011%26volume%3D32%26issue%3D3%26spage%3D899%26epage%3D904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aleem  Gangjee</span>, <span class="hlFld-ContribAuthor ">Ying  Zhao</span>, <span class="hlFld-ContribAuthor ">Sudhir  Raghavan</span>, <span class="hlFld-ContribAuthor ">Michael A.  Ihnat</span>, <span class="hlFld-ContribAuthor ">Bryan C.  Disch</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and evaluation of 2-amino-4-m-bromoanilino-6-arylmethyl-7H-pyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors and antiangiogenic agents1. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2010,</strong> <em>18 </em>
                                    (14)
                                     , 5261-5273. <a href="https://doi.org/10.1016/j.bmc.2010.05.049" title="DOI URL">https://doi.org/10.1016/j.bmc.2010.05.049</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2010.05.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2010.05.049%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bevaluation%252Bof%252B2-amino-4-m-bromoanilino-6-arylmethyl-7H-pyrrolo%25255B2%25252C3-d%25255Dpyrimidines%252Bas%252Btyrosine%252Bkinase%252Binhibitors%252Band%252Bantiangiogenic%252Bagents1%26aulast%3DGangjee%26aufirst%3DAleem%26date%3D2010%26volume%3D18%26issue%3D14%26spage%3D5261%26epage%3D5273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/medium/jm-2009-011142_0005.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9011142&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/medium/jm-2009-011142_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0006.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Single and multitargeted RTK inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9011142&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/medium/jm-2009-011142_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0007.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Target compounds <b>1</b> and <b>2</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9011142&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/medium/jm-2009-011142_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0008.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Dihydrofolate reductase and thymidylate synthase inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9011142&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/medium/jm-2009-011142_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0009.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Rationale for the synthesis of target molecules.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9011142&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/medium/jm-2009-011142_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0010.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Stereoview (SYBYL7.3) of the pyrimidine ring of <b>1</b> superimposed on the pyrimidine ring of the DHFR inhibitor in the X-ray crystal structure of hDHFR (<a href="https://" class="ext-link">1PDB</a>).<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9011142&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/medium/jm-2009-011142_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0011.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Stereoview (SYBYL7.3) of <b>1</b> superimposed on the X-ray crystal structure of pemetrexed (green) in hTS. (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1JU6">1JU6</a>).<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9011142&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/medium/jm-2009-011142_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0012.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Stereoview (SYBYL7.3) of <b>1</b> superimposed on furo[2,3-<i>d</i>]pyrimidine X-ray crystal structure (not shown) in VEGFR2. Hinge region, 4NH<sub>2</sub>−Glu915 (C═O), N3−Cys917 (N−H), 2NH<sub>2</sub>−Cys917 (C═O); hydrophobic region 1, 5-thiophenyl−(Leu1033, Cys1043) (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1YWN">1YWN</a>).<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9011142&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/medium/jm-2009-011142_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0013.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Stereoview of a docked pose of <b>1</b> in the putative PDGFR-β active site model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9011142&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/medium/jm-2009-011142_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0014.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. <sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9011142&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) EtO<sub>2</sub>CCH<sub>2</sub>CN, <i>t</i>-BuOK, THF, reflux, 48 h; (b) Zn, HOAc, 50−55 °C, 2 h, 30 min; (c) methyl sulfone, 110 °C, 30 min; (d) 2,2-dimethylpropanoic anhydride, DMAP, NEt<sub>3</sub>, DMF, 60 °C, 48 h; (e) POCl<sub>3</sub>, reflux, 4 h; (f) NH<sub>3</sub>/CH<sub>3</sub>OH, sealed vessel, 130 °C, 48 h; (g) K<sub>2</sub>CO<sub>3</sub>, NMP, microwave, 250 °C, 30 min.</p></p></figure><figure data-id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/medium/jm-2009-011142_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0015.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Standard drugs and control agents.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9011142&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/medium/jm-2009-011142_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0016.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Cell viability assay after 48 h treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9011142&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/medium/jm-2009-011142_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0001.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Cell cycle analysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9011142&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/medium/jm-2009-011142_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0002.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Cell signaling.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9011142&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/medium/jm-2009-011142_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0003.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. MDA-MB-435 CAM 72 h xenograft.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9011142&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/medium/jm-2009-011142_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0004.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Tumor growth: (A) primary tumor volume, (B) primary tumor growth rate, (C) primary tumor vascularity, and (D) liver metastasis of COLO-205 tumor xenografts after various treatments. COLO-205 cells were implanted into male athymic mice as in the <a class="ref internalNav" href="#sec6" aria-label="Detailed Methods">Detailed Methods</a> section. Compounds were administered at the listed doses three times weekly, and tumor growth was measured using calipers. At the experiment end, tumors were stained for vascularity and livers were stained for metastases as in the <a class="ref internalNav" href="#sec6" aria-label="Detailed Methods">Detailed Methods</a> section. Data represent the average ± SD of 7−11 animals: ∗, <i>P</i> > 0.05; ∗∗, <i>P</i> < 0.01; ∗∗∗, <i>P</i> < 0.001 by one-way ANOVA and Neuman−Keuls post-test. The average tumor growth rate for control treated animals (B) is 58.9 mm<sup>3</sup>/day, average number of tumor vessels in control-treated animals (C) is 11.2/field, and average metastases in control treated animals (D) are 0.65/lobe.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-4/jm9011142/production/images/large/jm-2009-011142_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm9011142&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i35">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42473" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42473" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 83 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Davis, D. W.; Herbst, R. S.; Abbruzzese, J. L.</span> <span class="citation_source-book">Antiangiogenic Cancer Therapy</span>; <span class="NLM_publisher-name">CRC Press, Taylor and Francis Group</span>: <span class="NLM_publisher-loc">Boca Raton, FL</span>:<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span>p  <span class="NLM_fpage">841</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=841&author=D.+W.+Davis&author=R.+S.+Herbst&author=J.+L.+Abbruzzese&title=Antiangiogenic+Cancer+Therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DD.%2BW.%26btitle%3DAntiangiogenic%2520Cancer%2520Therapy%26pub%3DCRC%2520Press%252C%2520Taylor%2520and%2520Francis%2520Group%26date%3D2008%26spage%3D841" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Folkman, J.</span><span> </span><span class="NLM_article-title">Angiogenesis</span> <span class="citation_source-journal">Annu. Rev. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">18</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2006&pages=1-18&author=J.+Folkman&title=Angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFolkman%26aufirst%3DJ.%26atitle%3DAngiogenesis%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2006%26volume%3D57%26spage%3D1%26epage%3D18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Fabbro, D.; McCormick, F.</span>, Eds.  <span class="citation_source-book">Protein Tyrosine Kinases: From Inhibitors to Useful Drugs</span>; <span class="NLM_publisher-name">Humana Press</span>, <span class="NLM_publisher-loc">Totowa, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">2006</span><span class="NLM_x">; </span>290 pp.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=D.+Fabbro&author=F.+McCormick&title=Protein+Tyrosine+Kinases%3A+From+Inhibitors+to+Useful+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DFabbro%26aufirst%3DD.%26btitle%3DProtein%2520Tyrosine%2520Kinases%253A%2520From%2520Inhibitors%2520to%2520Useful%2520Drugs%26pub%3DHumana%2520Press%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Gschwind, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span> </span><span class="NLM_article-title">Timeline: The discovery of receptor tyrosine kinases: Targets for cancer therapy</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">361</span><span class="NLM_x">–</span> <span class="NLM_lpage">370</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1038%2Fnrc1360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=15122207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsFSlu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=361-370&author=A.+Gschwindauthor=O.+M.+Fischerauthor=A.+Ullrich&title=Timeline%3A+The+discovery+of+receptor+tyrosine+kinases%3A+Targets+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Timeline: The discovery of receptor tyrosine kinases: targets for cancer therapy</span></div><div class="casAuthors">Gschwind, Andreas; Fischer, Oliver M.; Ullrich, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">361-370</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinases are a subclass of cell-surface growth-factor receptors with an intrinsic, ligand-controlled tyrosine-kinase activity.  They regulate diverse functions in normal cells and have a crucial role in oncogenesis.  Twenty years ago, the 1st primary structure of a receptor Tyr kinase, the epidermal growth factor receptor, was elucidated.  The characterization of both the mol. architecture of receptor Tyr kinases and the main functions of these proteins and their ligands in tumorigenesis opened the door to a new era in mol. oncol. and paved the way to the development of the 1st target-specific cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1NLVNn4dw37Vg90H21EOLACvtfcHk0ljn5QF25-gMCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsFSlu7g%253D&md5=ea24c0ccaea68b743b5da9587ed19406</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrc1360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1360%26sid%3Dliteratum%253Aachs%26aulast%3DGschwind%26aufirst%3DA.%26aulast%3DFischer%26aufirst%3DO.%2BM.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DTimeline%253A%2520The%2520discovery%2520of%2520receptor%2520tyrosine%2520kinases%253A%2520Targets%2520for%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D361%26epage%3D370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Carmeliet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, R. K.</span><span> </span><span class="NLM_article-title">Angiogenesis in cancer and other diseases</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">407</span><span class="NLM_x">, </span> <span class="NLM_fpage">249</span><span class="NLM_x">–</span> <span class="NLM_lpage">257</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1038%2F35025220" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=11001068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmvVSls74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=407&publication_year=2000&pages=249-257&author=P.+Carmelietauthor=R.+K.+Jain&title=Angiogenesis+in+cancer+and+other+diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Angiogenesis in cancer and other diseases</span></div><div class="casAuthors">Carmeliet, Peter; Jain, Rakesh K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">407</span>
        (<span class="NLM_cas:issue">6801</span>),
    <span class="NLM_cas:pages">249-257</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with 75 refs.  Pathol. angiogenesis is a hallmark of cancer and various ischemic and inflammatory diseases.  Concd. efforts in this area of research are leading to the discovery of a growing no. of pro- and anti-angiogenic mols., some of which are already in clin. trials.  The complex interactions among these mols. and how they affect vascular structure and function in different environments are now beginning to be elucidated.  This integrated understanding is leading to the development of a no. of exciting and bold approaches to treat cancer and other diseases.  But owing to several unanswered questions, caution is needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPQMelW0OMYbVg90H21EOLACvtfcHk0lhzxSUM8b2Ynw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmvVSls74%253D&md5=703cbcdbd32292a9238f0394220c853c</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2F35025220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35025220%26sid%3Dliteratum%253Aachs%26aulast%3DCarmeliet%26aufirst%3DP.%26aulast%3DJain%26aufirst%3DR.%2BK.%26atitle%3DAngiogenesis%2520in%2520cancer%2520and%2520other%2520diseases%26jtitle%3DNature%26date%3D2000%26volume%3D407%26spage%3D249%26epage%3D257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Gorre, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammed, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellwood, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquette, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">293</span><span class="NLM_x">, </span> <span class="NLM_fpage">876</span><span class="NLM_x">–</span> <span class="NLM_lpage">880</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=293&publication_year=2001&pages=876-880&author=M.+E.+Gorreauthor=M.+Mohammedauthor=K.+Ellwoodauthor=N.+Hsuauthor=R.+Paquetteauthor=P.+N.+Raoauthor=C.+L.+Sawyers&title=Clinical+resistance+to+STI-571+cancer+therapy+caused+by+BCR-ABL+gene+mutation+or+amplification"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGorre%26aufirst%3DM.%2BE.%26aulast%3DMohammed%26aufirst%3DM.%26aulast%3DEllwood%26aufirst%3DK.%26aulast%3DHsu%26aufirst%3DN.%26aulast%3DPaquette%26aufirst%3DR.%26aulast%3DRao%26aufirst%3DP.%2BN.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DClinical%2520resistance%2520to%2520STI-571%2520cancer%2520therapy%2520caused%2520by%2520BCR-ABL%2520gene%2520mutation%2520or%2520amplification%26jtitle%3DScience%26date%3D2001%26volume%3D293%26spage%3D876%26epage%3D880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Gorre, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia</span> <span class="citation_source-journal">Curr. Opin. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">303</span><span class="NLM_x">–</span> <span class="NLM_lpage">307</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1097%2F00062752-200207000-00007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=12042704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A280%3ADC%252BD38zgtFSgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2002&pages=303-307&author=M.+E.+Gorreauthor=C.+L.+Sawyers&title=Molecular+mechanisms+of+resistance+to+STI571+in+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia</span></div><div class="casAuthors">Gorre Mercedes E; Sawyers Charles L</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in hematology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">303-7</span>
        ISSN:<span class="NLM_cas:issn">1065-6251</span>.
    </div><div class="casAbstract">Therapeutic use of the recently FDA-approved drug STI571 has been successful in the treatment of Philadelphia chromosome-positive leukemias.  STI571 is a small molecule inhibitor with activity against BCR-ABL, the deregulated tyrosine kinase responsible for initiation and maintenance of the disease in the chronic phase of chronic myeloid leukemia (CML).  Clinical trials demonstrated the ability of STI571 to induce remissions in patients with chronic phase CML with only rare relapses after 18 months of follow-up.  However, in patients with more advanced stages of disease, responses to STI571 were less common and often transient.  Studies investigating the molecular mechanisms of resistance to this novel compound have progressed rapidly and point to the continued importance of BCR-ABL in disease maintenance even at its latest stages.  Here the authors review recent work aimed at elucidating the nature of STI51 resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQFpKjX-b8FPSsZ1x6zOs0vfW6udTcc2eamZ5N79XnoWbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38zgtFSgtQ%253D%253D&md5=63a02d15bd7f0917778618d4835d9aa3</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1097%2F00062752-200207000-00007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00062752-200207000-00007%26sid%3Dliteratum%253Aachs%26aulast%3DGorre%26aufirst%3DM.%2BE.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DMolecular%2520mechanisms%2520of%2520resistance%2520to%2520STI571%2520in%2520chronic%2520myeloid%2520leukemia%26jtitle%3DCurr.%2520Opin.%2520Hematol.%26date%3D2002%26volume%3D9%26spage%3D303%26epage%3D307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Hurwitz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fehrenbacher, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novotny, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cartwright, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hainsworth, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heim, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berlin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffing, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmgren, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fyfe, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kabbinavar, F.</span><span> </span><span class="NLM_article-title">Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x">, </span> <span class="NLM_fpage">2335</span><span class="NLM_x">–</span> <span class="NLM_lpage">2342</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1056%2FNEJMoa032691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=15175435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD2cXks1Gjt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2004&pages=2335-2342&author=H.+Hurwitzauthor=L.+Fehrenbacherauthor=W.+Novotnyauthor=T.+Cartwrightauthor=J.+Hainsworthauthor=W.+Heimauthor=J.+Berlinauthor=A.+Baronauthor=S.+Griffingauthor=E.+Holmgrenauthor=N.+Ferraraauthor=G.+Fyfeauthor=B.+Rogersauthor=R.+Rossauthor=F.+Kabbinavar&title=Bevacizumab+plus+irinotecan%2C+fluorouracil%2C+and+leucovorin+for+metastatic+colorectal+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer</span></div><div class="casAuthors">Hurwitz, Herbert; Fehrenbacher, Louis; Novotny, William; Cartwright, Thomas; Hainsworth, John; Heim, William; Berlin, Jordan; Baron, Ari; Griffing, Susan; Holmgren, Eric; Ferrara, Napoleone; Fyfe, Gwen; Rogers, Beth; Ross, Robert; Kabbinavar, Fairooz</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2335-2342</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclin. and clin. activity against metastatic colorectal cancer, particularly in combination with chemotherapy.  Of 813 patients with previously untreated metastatic colorectal cancer, we randomly assigned 402 to receive irinotecan, bolus fluorouracil, and leucovorin (IFL) plus bevacizumab (5 mg per kg of body wt. every two weeks) and 411 to receive IFL plus placebo.  The primary end point was overall survival.  Secondary end points were progression-free survival, the response rate, the duration of the response, safety, and the quality of life.  The median duration of survival was 20.3 mo in the group given IFL plus bevacizumab, as compared with 15.6 mo in the group given IFL plus placebo, corresponding to a hazard ratio for death of 0.66 (P<0.001).  The median duration of progression-free survival was 10.6 mo in the group given IFL plus bevacizumab, as compared with 6.2 mo in the group given IFL plus placebo (hazard ratio for disease progression, 0.54; P<0.001); the corresponding rates of response were 44.8 % and 34.8 % (P = 0.004).  The median duration of the response was 10.4 mo in the group given IFL plus bevacizumab, as compared with 7.1 mo in the group given IFL plus placebo (hazard ratio for progression, 0.62; P = 0.001).  Grade 3 hypertension was more common during treatment with IFL plus bevacizumab than with IFL plus placebo (11.0 % vs. 2.3 %) but was easily managed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5r6uP5oxZU7Vg90H21EOLACvtfcHk0lgbX8-yD_mo-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXks1Gjt74%253D&md5=6a1289cdbf1501f121eb0482e5a1f536</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa032691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa032691%26sid%3Dliteratum%253Aachs%26aulast%3DHurwitz%26aufirst%3DH.%26aulast%3DFehrenbacher%26aufirst%3DL.%26aulast%3DNovotny%26aufirst%3DW.%26aulast%3DCartwright%26aufirst%3DT.%26aulast%3DHainsworth%26aufirst%3DJ.%26aulast%3DHeim%26aufirst%3DW.%26aulast%3DBerlin%26aufirst%3DJ.%26aulast%3DBaron%26aufirst%3DA.%26aulast%3DGriffing%26aufirst%3DS.%26aulast%3DHolmgren%26aufirst%3DE.%26aulast%3DFerrara%26aufirst%3DN.%26aulast%3DFyfe%26aufirst%3DG.%26aulast%3DRogers%26aufirst%3DB.%26aulast%3DRoss%26aufirst%3DR.%26aulast%3DKabbinavar%26aufirst%3DF.%26atitle%3DBevacizumab%2520plus%2520irinotecan%252C%2520fluorouracil%252C%2520and%2520leucovorin%2520for%2520metastatic%2520colorectal%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D350%26spage%3D2335%26epage%3D2342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Oestman, A.</span><span> </span><span class="NLM_article-title">PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma</span> <span class="citation_source-journal">Cytokine Growth Factor Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">275</span><span class="NLM_x">–</span> <span class="NLM_lpage">286</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1016%2Fj.cytogfr.2004.03.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=15207817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltVKhtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2004&pages=275-286&author=A.+Oestman&title=PDGF+receptors-mediators+of+autocrine+tumor+growth+and+regulators+of+tumor+vasculature+and+stroma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma</span></div><div class="casAuthors">Oestman, Arne</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">275-286</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review with refs.  PDGFs and their cognate tyrosine kinase α- and β-receptors are involved in multiple tumor-assocd. processes including autocrine growth stimulation of tumor cells, stimulation of tumor angiogenesis and recruitment and regulation of tumor fibroblasts.  The recent development of clin. useful PDGF antagonists, like STI571/Glivec, has increased the interest in PDGF receptors as cancer drug targets.  Autocrine PDGF receptor signaling occurs in certain malignancies characterized by mutational activation of PDGF or PDGF receptors, for instance, dermatofibrosarcoma protuberans, gastrointestinal stromal tumors, and hypereosinophilic syndrome.  The roles of PDGF in regulation of tumor angiogenesis and tumor fibroblasts are more general, and probably occur in most common solid tumors.  Concerning tumor angiogenesis recent studies have predominantly focused on the importance of PDGF receptor signaling for tumor pericyte recruitment.  PDGF receptors in the tumor stroma have also attracted attention as interesting drug targets because of their function as regulators of tumor interstitial fluid pressure, tumor trans-vascular transport and tumor drug uptake.  In summary, the improved understanding of the role of PDGF signaling in tumor biol., and the introduction of PDGF antagonists, has set the stage for a continued development of PDGF antagonists as novel cancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8-4CVipxax7Vg90H21EOLACvtfcHk0lgbX8-yD_mo-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltVKhtLw%253D&md5=1acb20873a7a3b8e18799bb255792a46</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.cytogfr.2004.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cytogfr.2004.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DOestman%26aufirst%3DA.%26atitle%3DPDGF%2520receptors-mediators%2520of%2520autocrine%2520tumor%2520growth%2520and%2520regulators%2520of%2520tumor%2520vasculature%2520and%2520stroma%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2004%26volume%3D15%26spage%3D275%26epage%3D286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Pearson, M.; Garcia-Echeverria, C.; Fabbro, D.</span><span> </span><span class="NLM_article-title">Protein Tyrosine Kinases as Targets for Cancer and Other Indications in Protein Tyrosine Kinases</span>. In  <span class="citation_source-book">From Inhibitors to Useful Drugs</span>; <span class="NLM_contrib-group">Fabbro, D.,; McCormick, F.</span>, Eds.; <span class="NLM_publisher-name">Human Press</span>, <span class="NLM_publisher-loc">Totowa, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">2005</span><span class="NLM_x">, </span>pp  <span class="NLM_fpage">1</span>− <span class="NLM_lpage">29</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&pages=1-29&author=M.+Pearson&author=C.+Garcia-Echeverria&author=D.+Fabbroauthor=D.+Fabbro&author=F.+McCormick&title=From+Inhibitors+to+Useful+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DPearson%26aufirst%3DM.%26atitle%3DProtein%2520Tyrosine%2520Kinases%2520as%2520Targets%2520for%2520Cancer%2520and%2520Other%2520Indications%2520in%2520Protein%2520Tyrosine%2520Kinases%26btitle%3DFrom%2520Inhibitors%2520to%2520Useful%2520Drugs%26aulast%3DFabbro%26aufirst%3DD.%26pub%3DHuman%2520Press%26date%3D2005%26spage%3D1%26epage%3D29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Stein, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span> </span><span class="NLM_article-title">CCR drug updates: Sorafenib and sunitinib in renal cell carcinoma</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">3765</span><span class="NLM_x">–</span> <span class="NLM_lpage">3770</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1158%2F1078-0432.CCR-06-2844" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=17606705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD2sXntFymsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=3765-3770&author=M.+N.+Steinauthor=K.+T.+Flaherty&title=CCR+drug+updates%3A+Sorafenib+and+sunitinib+in+renal+cell+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">CCR drug updates: Sorafenib and sunitinib in renal cell carcinoma</span></div><div class="casAuthors">Stein, Mark N.; Flaherty, Keith T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3765-3770</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The role of sorafenib and sunitinib antagonize VEGF receptor tyrosine kinases of these agents as VEGFR inhibitors in renal cell carcinoma (RCC) and their unique spectra of activity are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqchkyOioqfkLVg90H21EOLACvtfcHk0lgbX8-yD_mo-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXntFymsb4%253D&md5=45c121fccb373ff7784a48cd33380383</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-2844&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-2844%26sid%3Dliteratum%253Aachs%26aulast%3DStein%26aufirst%3DM.%2BN.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26atitle%3DCCR%2520drug%2520updates%253A%2520Sorafenib%2520and%2520sunitinib%2520in%2520renal%2520cell%2520carcinoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D3765%26epage%3D3770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Tabernero, J.</span><span> </span><span class="NLM_article-title">The role of VEGF and EGFR inhibition: Implications for combining anti-VEGF and anti-EGFR agents</span> <span class="citation_source-journal">Mol. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">203</span><span class="NLM_x">–</span> <span class="NLM_lpage">220</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1158%2F1541-7786.MCR-06-0404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=17374728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjt1Srsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2007&pages=203-220&author=J.+Tabernero&title=The+role+of+VEGF+and+EGFR+inhibition%3A+Implications+for+combining+anti-VEGF+and+anti-EGFR+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of VEGF and EGFR Inhibition: Implications for Combining Anti-VEGF and Anti-EGFR Agents</span></div><div class="casAuthors">Tabernero, Josep</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">203-220</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Multiple cellular pathways influence the growth and metastatic potential of tumors.  This creates heterogeneity, redundancy, and the potential for tumors to bypass signaling pathway blockade, resulting in primary or acquired resistance.  Combining therapies that inhibit different signaling pathways has the potential to be more effective than inhibition of a single pathway and to overcome tumor resistance.  Vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) inhibitors have become key therapies in several tumor types.  Close relationships between these factors exist: VEGF signaling is up-regulated by EGFR expression and, conversely, VEGF up-regulation independent of EGFR signaling seems to contribute to resistance to EGFR inhibition.  Therefore, inhibition of both pathways could improve antitumor efficacy and overcome resistance to EGFR inhibition.  Preclin. studies have shown that VEGF and EGFR inhibitors can have additive effects and that combined inhibition is effective in EGFR inhibitor-resistant cell lines.  Clin. trials have also produced promising data: combining the anti-VEGF monoclonal antibody bevacizumab with the anti-EGFR antibody cetuximab or the EGFR tyrosine kinase inhibitor erlotinib increases benefit compared with either of these anti-EGFR agents alone or combined with chemotherapy.  The potential of this novel approach to anticancer therapy will be elucidated by large, ongoing clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgvbskfTKTarVg90H21EOLACvtfcHk0lgvxL_XVjNdyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjt1Srsbo%253D&md5=af3b3a51f6836322379eac8e1427cec4</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-06-0404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-06-0404%26sid%3Dliteratum%253Aachs%26aulast%3DTabernero%26aufirst%3DJ.%26atitle%3DThe%2520role%2520of%2520VEGF%2520and%2520EGFR%2520inhibition%253A%2520Implications%2520for%2520combining%2520anti-VEGF%2520and%2520anti-EGFR%2520agents%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2007%26volume%3D5%26spage%3D203%26epage%3D220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Jain, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duda, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loeffler, J. S.</span><span> </span><span class="NLM_article-title">Lessons from phase III clinical trials on anti-VEGF therapy for cancer</span> <span class="citation_source-journal">Nat. Clin. Pract. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">24</span><span class="NLM_x">–</span> <span class="NLM_lpage">40</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1038%2Fncponc0403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=16407877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVynsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2006&pages=24-40&author=R.+K.+Jainauthor=D.+G.+Dudaauthor=J.+W.+Clarkauthor=J.+S.+Loeffler&title=Lessons+from+phase+III+clinical+trials+on+anti-VEGF+therapy+for+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons from phase III clinical trials on anti-VEGF therapy for cancer</span></div><div class="casAuthors">Jain, Rakesh K.; Duda, Dan G.; Clark, Jeffrey W.; Loeffler, Jay S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Clinical Practice Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">24-40</span>CODEN:
                <span class="NLM_cas:coden">NCPOB5</span>;
        ISSN:<span class="NLM_cas:issn">1743-4254</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In randomized phase III trials two anti-vascular endothelial growth factor (VEGF) approaches have yielded survival benefit in patients with metastatic cancer.  In one approach, the addn. of bevacizumab, a VEGF-specific antibody, to std. chemotherapy improved overall survival in colorectal and lung cancer patients and progression-free survival in breast cancer patients.  In the second approach, multitargeted tyrosine kinase inhibitors that block VEGF receptor and other kinases in both endothelial and cancer cells, demonstrated survival benefit in gastrointestinal stromal tumor and renal-cell-carcinoma patients.  By contrast, adding bevacizumab to chemotherapy failed to increase survival in patients with previously treated and refractory metastatic breast cancer.  Furthermore, addn. of vatalanib, a kinase inhibitor developed as a VEGF receptor-selective agent, to chemotherapy did not show a similar benefit in metastatic colorectal cancer patients.  These contrasting responses raise crit. questions about how these agents work and how to combine them optimally.  We summarize three of the many potential mechanisms of action of anti-VEGF agents, and also discuss progress relating to the identification of potential biomarkers for anti-VEGF-agent efficacy in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzdONgbUWNUrVg90H21EOLACvtfcHk0lgvxL_XVjNdyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVynsL0%253D&md5=dfcfbf8ab8060df6b65c359b0bf8ef77</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fncponc0403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncponc0403%26sid%3Dliteratum%253Aachs%26aulast%3DJain%26aufirst%3DR.%2BK.%26aulast%3DDuda%26aufirst%3DD.%2BG.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DLoeffler%26aufirst%3DJ.%2BS.%26atitle%3DLessons%2520from%2520phase%2520III%2520clinical%2520trials%2520on%2520anti-VEGF%2520therapy%2520for%2520cancer%26jtitle%3DNat.%2520Clin.%2520Pract.%2520Oncol.%26date%3D2006%26volume%3D3%26spage%3D24%26epage%3D40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Slamon, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leyland-Jones, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shak, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuchs, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paton, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajamonde, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleming, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiermann, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pegram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norton, L.</span><span> </span><span class="NLM_article-title">Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">344</span><span class="NLM_x">, </span> <span class="NLM_fpage">783</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1056%2FNEJM200103153441101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=11248153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD3MXisVGktrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2001&pages=783-792&author=D.+J.+Slamonauthor=B.+Leyland-Jonesauthor=S.+Shakauthor=H.+Fuchsauthor=V.+Patonauthor=A.+Bajamondeauthor=T.+Flemingauthor=W.+Eiermannauthor=J.+Wolterauthor=M.+Pegramauthor=J.+Baselgaauthor=L.+Norton&title=Use+of+chemotherapy+plus+a+monoclonal+antibody+against+HER2+for+metastatic+breast+cancer+that+overexpresses+HER2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2</span></div><div class="casAuthors">Slamon, Dennis J.; Leyland-Jones, Brian; Shak, Steven; Fuchs, Hank; Paton, Virginia; Bajamonde, Alex; Fleming, Thomas; Eiermann, Wolfgang; Wolter, Janet; Pegram, Mark; Baselga, Jose; Norton, Larry</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">783-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The HER2 gene, which encodes the growth factor receptor HER2, is amplified and HER2 is overexpressed in 25 to 30 % of breast cancers, increasing the aggressiveness of the tumor.  We evaluated the efficacy and safety of trastuzumab, a recombinant monoclonal antibody against HER2, in women with metastatic breast cancer that overexpressed HER2.  We randomly assigned 234 patients to receive std. chemotherapy plus trastuzumab.  Patients who had not previously received adjuvant (postoperative) therapy with an anthracycline were treated with doxorubicin (or epirubicin in the case of 36 women) and cyclophosphamide with (143 women) or without trastuzumab (138 women).  Patients who had previously received adjuvant anthracycline were treated with paclitaxel alone (96 women) or paclitaxel with trastuzumab (92 women).  The addn. of trastuzumab to chemotherapy was assocd. with a longer time to disease progression (median, 7.4 vs. 4.6 mo; P<0.001), a higher rate of objective response (50 % vs. 32 %, P<0.001), a longer duration of response (median, 9.1 vs. 6.1 mo; P<0.001), a lower rate of death at 1 yr (22 % vs. 33 %, P=0.008), longer survival (median survival, 25.1 vs. 20.3 mo; P=0.046), and a 20 % redn. in the risk of death.  The most important adverse event was cardiac dysfunction, which occurred in 27 % of the group given an anthracycline, cyclophosphamide, and trastuzumab; 8 % of the group given an anthracycline and cyclophosphamide alone; 13 % of the group given paclitaxel and trastuzumab; and 1 % of the group given paclitaxel alone.  Although the cardiotoxicity was potentially severe and, in some cases, life-threatening, the symptoms generally improved with std. medical management.  Trastuzumab increases the clin. benefit of first-line chemotherapy in metastatic breast cancer that overexpresses HER2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGK_4WWRZLKLVg90H21EOLACvtfcHk0lgvxL_XVjNdyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXisVGktrc%253D&md5=81112f11ffc66fc3a898b61e104322b6</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1056%2FNEJM200103153441101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200103153441101%26sid%3Dliteratum%253Aachs%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26aulast%3DLeyland-Jones%26aufirst%3DB.%26aulast%3DShak%26aufirst%3DS.%26aulast%3DFuchs%26aufirst%3DH.%26aulast%3DPaton%26aufirst%3DV.%26aulast%3DBajamonde%26aufirst%3DA.%26aulast%3DFleming%26aufirst%3DT.%26aulast%3DEiermann%26aufirst%3DW.%26aulast%3DWolter%26aufirst%3DJ.%26aulast%3DPegram%26aufirst%3DM.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DNorton%26aufirst%3DL.%26atitle%3DUse%2520of%2520chemotherapy%2520plus%2520a%2520monoclonal%2520antibody%2520against%2520HER2%2520for%2520metastatic%2520breast%2520cancer%2520that%2520overexpresses%2520HER2%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2001%26volume%3D344%26spage%3D783%26epage%3D792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Bergers, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer-Morse, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergsland, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanahan, D.</span><span> </span><span class="NLM_article-title">Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">1287</span><span class="NLM_x">–</span> <span class="NLM_lpage">1295</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2003&pages=1287-1295&author=G.+Bergersauthor=S.+Songauthor=N.+Meyer-Morseauthor=E.+Bergslandauthor=D.+Hanahan&title=Benefits+of+targeting+both+pericytes+and+endothelial+cells+in+the+tumor+vasculature+with+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBergers%26aufirst%3DG.%26aulast%3DSong%26aufirst%3DS.%26aulast%3DMeyer-Morse%26aufirst%3DN.%26aulast%3DBergsland%26aufirst%3DE.%26aulast%3DHanahan%26aufirst%3DD.%26atitle%3DBenefits%2520of%2520targeting%2520both%2520pericytes%2520and%2520endothelial%2520cells%2520in%2520the%2520tumor%2520vasculature%2520with%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2003%26volume%3D111%26spage%3D1287%26epage%3D1295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Carmeliet, P.</span><span> </span><span class="NLM_article-title">Angiogenesis in life, disease and medicine</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">438</span><span class="NLM_x">, </span> <span class="NLM_fpage">932</span><span class="NLM_x">–</span> <span class="NLM_lpage">936</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1038%2Fnature04478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=16355210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSksrjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=438&publication_year=2005&pages=932-936&author=P.+Carmeliet&title=Angiogenesis+in+life%2C+disease+and+medicine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Angiogenesis in life, disease and medicine</span></div><div class="casAuthors">Carmeliet, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">438</span>
        (<span class="NLM_cas:issue">7070</span>),
    <span class="NLM_cas:pages">932-936</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The growth of blood vessels (a process known as angiogenesis) is essential for organ growth and repair.  An imbalance in this process contributes to numerous malignant, inflammatory, ischemic, infectious and immune disorders.  Recently, the first anti-angiogenic agents have been approved for the treatment of cancer and blindness.  Angiogenesis research will probably change the face of medicine in the next decades, with more than 500 million people worldwide predicted to benefit from pro- or anti-angiogenesis treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor5NqkaUGRfrVg90H21EOLACvtfcHk0lit1nEUcFSQ_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSksrjF&md5=e196d7203fa60d5ecd9182fa023cd30e</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnature04478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04478%26sid%3Dliteratum%253Aachs%26aulast%3DCarmeliet%26aufirst%3DP.%26atitle%3DAngiogenesis%2520in%2520life%252C%2520disease%2520and%2520medicine%26jtitle%3DNature%26date%3D2005%26volume%3D438%26spage%3D932%26epage%3D936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Gasparini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teicher, B. A.</span><span> </span><span class="NLM_article-title">Combination of antiangiogenic therapy with other anticancer therapies: Results, challenges, and open questions</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1295</span><span class="NLM_x">–</span> <span class="NLM_lpage">1311</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1200%2FJCO.2005.10.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=15718328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitl2gu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=1295-1311&author=G.+Gaspariniauthor=R.+Longoauthor=M.+Fanelliauthor=B.+A.+Teicher&title=Combination+of+antiangiogenic+therapy+with+other+anticancer+therapies%3A+Results%2C+challenges%2C+and+open+questions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of antiangiogenic therapy with other anticancer therapies: Results, challenges, and open questions</span></div><div class="casAuthors">Gasparini, Giampietro; Longo, Raffaele; Fanelli, Massimo; Teicher, Beverly A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1295-1311</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Angiogenesis is necessary for tumor growth.  Drug discovery efforts have identified several potential therapeutic targets on endothelial cells and selective inhibitors capable of slowing tumor growth or producing tumor regression by blocking angiogenesis in in vivo tumor models.  Certain antiangiogenic therapeutics increase the activity of cytotoxic anticancer treatments in preclin. models.  More than 75 antiangiogenic compds. have entered clin. trials.  Most of the early clin. testing was conducted in patients with advanced disease resistant to std. therapies.  Several phase III trials have been undertaken to compare the efficacy of std. chemotherapy vs. the same in combination with an exptl. angiogenesis inhibitor.  Preliminary results of the clin. studies suggest that single-agent antiangiogenic therapy is poorly active in advanced tumors.  Although some of the results of combination trials are controversial, recent pos. outcomes with an antivascular endothelial growth factor antibody combined with chemotherapy as front-line therapy of metastatic colorectal cancer have renewed enthusiasm for this therapeutic strategy.  This article presents an overview of exptl. and clin. studies of combined therapy with antiangiogenic agents and highlights the challenges related to the appropriate strategies for selection of the patients, study design, and choice of proper end points for preclin. and clin. studies using these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi3tg_F1HebrVg90H21EOLACvtfcHk0lit1nEUcFSQ_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitl2gu74%253D&md5=7d365a736bcd2aabc130d9d5f9c60eed</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.10.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.10.022%26sid%3Dliteratum%253Aachs%26aulast%3DGasparini%26aufirst%3DG.%26aulast%3DLongo%26aufirst%3DR.%26aulast%3DFanelli%26aufirst%3DM.%26aulast%3DTeicher%26aufirst%3DB.%2BA.%26atitle%3DCombination%2520of%2520antiangiogenic%2520therapy%2520with%2520other%2520anticancer%2520therapies%253A%2520Results%252C%2520challenges%252C%2520and%2520open%2520questions%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D1295%26epage%3D1311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Casanovas, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicklin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergers, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanahan, D.</span><span> </span><span class="NLM_article-title">Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">299</span><span class="NLM_x">–</span> <span class="NLM_lpage">309</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2005&pages=299-309&author=O.+Casanovasauthor=D.+J.+Hicklinauthor=G.+Bergersauthor=D.+Hanahan&title=Drug+resistance+by+evasion+of+antiangiogenic+targeting+of+VEGF+signaling+in+late-stage+pancreatic+islet+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCasanovas%26aufirst%3DO.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26aulast%3DBergers%26aufirst%3DG.%26aulast%3DHanahan%26aufirst%3DD.%26atitle%3DDrug%2520resistance%2520by%2520evasion%2520of%2520antiangiogenic%2520targeting%2520of%2520VEGF%2520signaling%2520in%2520late-stage%2520pancreatic%2520islet%2520tumors%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D8%26spage%3D299%26epage%3D309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Mancuso, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norberg, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Brien, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sennino, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakahara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freimark, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shalinsky, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu-Lowe, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, D. M.</span><span> </span><span class="NLM_article-title">Rapid vascular regrowth in tumors after reversal of VEGF inhibition</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">2610</span><span class="NLM_x">–</span> <span class="NLM_lpage">2621</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2006&pages=2610-2621&author=M.+R.+Mancusoauthor=R.+Davisauthor=S.+M.+Norbergauthor=S.+O%27Brienauthor=B.+Senninoauthor=T.+Nakaharaauthor=V.+J.+Yaoauthor=T.+Inaiauthor=P.+Brooksauthor=B.+Freimarkauthor=D.+R.+Shalinskyauthor=D.+D.+Hu-Loweauthor=D.+M.+McDonald&title=Rapid+vascular+regrowth+in+tumors+after+reversal+of+VEGF+inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMancuso%26aufirst%3DM.%2BR.%26aulast%3DDavis%26aufirst%3DR.%26aulast%3DNorberg%26aufirst%3DS.%2BM.%26aulast%3DO%2527Brien%26aufirst%3DS.%26aulast%3DSennino%26aufirst%3DB.%26aulast%3DNakahara%26aufirst%3DT.%26aulast%3DYao%26aufirst%3DV.%2BJ.%26aulast%3DInai%26aufirst%3DT.%26aulast%3DBrooks%26aufirst%3DP.%26aulast%3DFreimark%26aufirst%3DB.%26aulast%3DShalinsky%26aufirst%3DD.%2BR.%26aulast%3DHu-Lowe%26aufirst%3DD.%2BD.%26aulast%3DMcDonald%26aufirst%3DD.%2BM.%26atitle%3DRapid%2520vascular%2520regrowth%2520in%2520tumors%2520after%2520reversal%2520of%2520VEGF%2520inhibition%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2006%26volume%3D116%26spage%3D2610%26epage%3D2621" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Ma, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waxman, D. J.</span><span> </span><span class="NLM_article-title">Combination of antiangiogenesis with chemotherapy for more effective cancer treatment</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">3670</span><span class="NLM_x">–</span> <span class="NLM_lpage">3684</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1158%2F1535-7163.MCT-08-0715" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=19074844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsV2iurnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=3670-3684&author=J.+Maauthor=D.+J.+Waxman&title=Combination+of+antiangiogenesis+with+chemotherapy+for+more+effective+cancer+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of antiangiogenesis with chemotherapy for more effective cancer treatment</span></div><div class="casAuthors">Ma, Jie; Waxman, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3670-3684</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Angiogenesis is a hallmark of tumor development and metastasis and is now a validated target for cancer treatment.  However, the survival benefits of antiangiogenic drugs have thus far been rather modest, stimulating interest in developing more effective ways to combine antiangiogenic drugs with established chemotherapies.  This review discusses recent progress and emerging challenges in this field; interactions between antiangiogenic drugs and conventional chemotherapeutic agents are examd., and strategies for the optimization of combination therapies are discussed.  Antiangiogenic drugs such as the anti-vascular endothelial growth factor antibody bevacizumab can induce a functional normalization of the tumor vasculature that is transient and can potentiate the activity of coadministered chemoradiotherapies.  However, chronic angiogenesis inhibition typically reduces tumor uptake of coadministered chemotherapeutics, indicating a need to explore new approaches, including intermittent treatment schedules and provascular strategies to increase chemotherapeutic drug exposure.  In cases where antiangiogenesis-induced tumor cell starvation augments the intrinsic cytotoxic effects of a conventional chemotherapeutic drug, combination therapy may increase antitumor activity despite a decrease in cytotoxic drug exposure.  As new angiogenesis inhibitors enter the clinic, reliable surrogate markers are needed to monitor the progress of antiangiogenic therapies and to identify responsive patients.  New targets for antiangiogenesis continue to be discovered, increasing the opportunities to interdict tumor angiogenesis and circumvent resistance mechanisms that may emerge with chronic use of these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFuKsU4WlEmLVg90H21EOLACvtfcHk0lit1nEUcFSQ_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsV2iurnN&md5=187b65f71cce4580756ae01973ca758f</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-0715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-0715%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DWaxman%26aufirst%3DD.%2BJ.%26atitle%3DCombination%2520of%2520antiangiogenesis%2520with%2520chemotherapy%2520for%2520more%2520effective%2520cancer%2520treatment%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D3670%26epage%3D3684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Gangjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihnat, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warnke, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kisliuk, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, F.-T.</span><span> </span><span class="NLM_article-title">Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">5475</span><span class="NLM_x">–</span> <span class="NLM_lpage">5491</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2005&pages=5475-5491&author=A.+Gangjeeauthor=Y.+Zengauthor=M.+Ihnatauthor=L.+A.+Warnkeauthor=D.+W.+Greenauthor=R.+L.+Kisliukauthor=F.-T.+Lin&title=Novel+5-substituted%2C+2%2C4-diaminofuro%5B2%2C3-d%5Dpyrimidines+as+multireceptor+tyrosine+kinase+and+dihydrofolate+reductase+inhibitors+with+antiangiogenic+and+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DZeng%26aufirst%3DY.%26aulast%3DIhnat%26aufirst%3DM.%26aulast%3DWarnke%26aufirst%3DL.%2BA.%26aulast%3DGreen%26aufirst%3DD.%2BW.%26aulast%3DKisliuk%26aufirst%3DR.%2BL.%26aulast%3DLin%26aufirst%3DF.-T.%26atitle%3DNovel%25205-substituted%252C%25202%252C4-diaminofuro%255B2%252C3-d%255Dpyrimidines%2520as%2520multireceptor%2520tyrosine%2520kinase%2520and%2520dihydrofolate%2520reductase%2520inhibitors%2520with%2520antiangiogenic%2520and%2520antitumor%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2005%26volume%3D13%26spage%3D5475%26epage%3D5491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Fukumura, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, R. K.</span><span> </span><span class="NLM_article-title">Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalization</span> <span class="citation_source-journal">Microvasc. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">72</span><span class="NLM_x">–</span> <span class="NLM_lpage">84</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1016%2Fj.mvr.2007.05.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=17560615" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1ykur7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2007&pages=72-84&author=D.+Fukumuraauthor=R.+K.+Jain&title=Tumor+microvasculature+and+microenvironment%3A+Targets+for+anti-angiogenesis+and+normalization"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalization</span></div><div class="casAuthors">Fukumura, Dai; Jain, Rakesh K.</div><div class="citationInfo"><span class="NLM_cas:title">Microvascular Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">72-84</span>CODEN:
                <span class="NLM_cas:coden">MIVRA6</span>;
        ISSN:<span class="NLM_cas:issn">0026-2862</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  A solid tumor forms an organ-like entity comprised of neoplastic cells and non-transformed host stromal cells embedded in an extracellular matrix.  Similar to normal tissues, blood vessels nourish cells residing in tumors.  However, unlike normal blood vessels, tumor vasculature has abnormal organization, structure, and function.  Tumor vessels are leaky and blood flow is heterogeneous and often compromised.  Vascular hyperpermeability and the lack of functional lymphatic vessels inside tumors cause elevation of interstitial fluid pressure in solid tumors.  Each of these abnormalities forms a physiol. barrier to the delivery of therapeutic agents to tumors.  Furthermore, elevated tumor interstitial fluid pressure increases fluid flow from the tumor margin into the peri-tumor area and may facilitate peri-tumor lymphatic hyperplasia and metastasis.  Abnormal microcirculation in tumors also leads to a hostile microenvironment characterized by hypoxia and acidosis, which hinder the effectiveness of anti-tumor treatments such as radiation therapy and chemotherapy.  In addn., host-tumor interactions regulate expression of pro- and anti-angiogenic factors and hence contribute to their imbalance and resulting pathophysiol. characteristics of the tumor.  Restoration of pro- and anti-angiogenic balance in tumors may "normalize" tumor vasculature and thus improve its function.  Indeed, anti-angiogenic treatments directly targeting angiogenic signaling pathways as well as indirectly modulating angiogenesis show normalization of tumor vasculature and microenvironment at least transiently in both preclin. and clin. settings.  Combination of cytotoxic therapy and anti-angiogenic treatment during the vascular normalization exhibits synergistic effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDTVgfrwwDFLVg90H21EOLACvtfcHk0ljSbsJnr52NMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1ykur7E&md5=c5d718292cb56e9762af981656db45bf</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.mvr.2007.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mvr.2007.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DFukumura%26aufirst%3DD.%26aulast%3DJain%26aufirst%3DR.%2BK.%26atitle%3DTumor%2520microvasculature%2520and%2520microenvironment%253A%2520Targets%2520for%2520anti-angiogenesis%2520and%2520normalization%26jtitle%3DMicrovasc.%2520Res.%26date%3D2007%26volume%3D74%26spage%3D72%26epage%3D84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Browder, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butterfield, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraling, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Reilly, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folkman, J.</span><span> </span><span class="NLM_article-title">Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">1878</span><span class="NLM_x">–</span> <span class="NLM_lpage">1886</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=1878-1886&author=T.+Browderauthor=C.+E.+Butterfieldauthor=B.+M.+Kralingauthor=B.+Shiauthor=B.+Marshallauthor=M.+S.+O%27Reillyauthor=J.+Folkman&title=Antiangiogenic+scheduling+of+chemotherapy+improves+efficacy+against+experimental+drug-resistant+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrowder%26aufirst%3DT.%26aulast%3DButterfield%26aufirst%3DC.%2BE.%26aulast%3DKraling%26aufirst%3DB.%2BM.%26aulast%3DShi%26aufirst%3DB.%26aulast%3DMarshall%26aufirst%3DB.%26aulast%3DO%2527Reilly%26aufirst%3DM.%2BS.%26aulast%3DFolkman%26aufirst%3DJ.%26atitle%3DAntiangiogenic%2520scheduling%2520of%2520chemotherapy%2520improves%2520efficacy%2520against%2520experimental%2520drug-resistant%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2000%26volume%3D60%26spage%3D1878%26epage%3D1886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Ferrara, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerbel, R. S.</span><span> </span><span class="NLM_article-title">Angiogenesis as a therapeutic target</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">438</span><span class="NLM_x">, </span> <span class="NLM_fpage">967</span><span class="NLM_x">–</span> <span class="NLM_lpage">974</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1038%2Fnature04483" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=16355214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSksrnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=438&publication_year=2005&pages=967-974&author=N.+Ferraraauthor=R.+S.+Kerbel&title=Angiogenesis+as+a+therapeutic+target"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Angiogenesis as a therapeutic target</span></div><div class="casAuthors">Ferrara, Napoleone; Kerbel, Robert S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">438</span>
        (<span class="NLM_cas:issue">7070</span>),
    <span class="NLM_cas:pages">967-974</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Inhibiting angiogenesis is a promising strategy for treatment of cancer and several other disorders, including age-related macular degeneration.  Major progress towards a treatment has been achieved over the past few years, and the first antiangiogenic agents have been recently approved for use in several countries.  Therapeutic angiogenesis (promoting new vessel growth to treat ischemic disorders) is an exciting frontier of cardiovascular medicine, but further understanding of the mechanisms of vascular morphogenesis is needed first.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdP_T905faXLVg90H21EOLACvtfcHk0ljSbsJnr52NMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSksrnI&md5=05a90bd29a0fb34f9c20a825f899d04c</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnature04483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature04483%26sid%3Dliteratum%253Aachs%26aulast%3DFerrara%26aufirst%3DN.%26aulast%3DKerbel%26aufirst%3DR.%2BS.%26atitle%3DAngiogenesis%2520as%2520a%2520therapeutic%2520target%26jtitle%3DNature%26date%3D2005%26volume%3D438%26spage%3D967%26epage%3D974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Klement, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baruchel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Man, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicklin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohlen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerbel, R. S.</span><span> </span><span class="NLM_article-title">Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">R15</span><span class="NLM_x">–</span> <span class="NLM_lpage">R24</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2000&pages=R15-R24&author=G.+Klementauthor=S.+Baruchelauthor=J.+Rakauthor=S.+Manauthor=K.+Clarkauthor=D.+J.+Hicklinauthor=P.+Bohlenauthor=R.+S.+Kerbel&title=Continuous+low-dose+therapy+with+vinblastine+and+VEGF+receptor-2+antibody+induces+sustained+tumor+regression+without+overt+toxicity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKlement%26aufirst%3DG.%26aulast%3DBaruchel%26aufirst%3DS.%26aulast%3DRak%26aufirst%3DJ.%26aulast%3DMan%26aufirst%3DS.%26aulast%3DClark%26aufirst%3DK.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26aulast%3DBohlen%26aufirst%3DP.%26aulast%3DKerbel%26aufirst%3DR.%2BS.%26atitle%3DContinuous%2520low-dose%2520therapy%2520with%2520vinblastine%2520and%2520VEGF%2520receptor-2%2520antibody%2520induces%2520sustained%2520tumor%2520regression%2520without%2520overt%2520toxicity%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2000%26volume%3D105%26spage%3DR15%26epage%3DR24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Ho, Q. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, C. J.</span><span> </span><span class="NLM_article-title">Vascular endothelial growth factor: Biology and therapeutic applications</span> <span class="citation_source-journal">Int. J. Biochem. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1349</span><span class="NLM_x">–</span> <span class="NLM_lpage">1357</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1016%2Fj.biocel.2007.04.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=17537667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2007&pages=1349-1357&author=Q.+T.+Hoauthor=C.+J.+Kuo&title=Vascular+endothelial+growth+factor%3A+Biology+and+therapeutic+applications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular endothelial growth factor: Biology and therapeutic applications</span></div><div class="casAuthors">Ho, Quoc T.; Kuo, Calvin J.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry & Cell Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">1349-1357</span>CODEN:
                <span class="NLM_cas:coden">IJBBFU</span>;
        ISSN:<span class="NLM_cas:issn">1357-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  While the development of anti-angiogenic therapy, as it pertains to cancer treatment, may still be in its infancy relative to well-established modalities such as chemotherapy, radiation, and surgery, major strides made in the past several decades have allowed translation of basic science discoveries in this field into clin. reality.  The discovery of key mol. modulators of angiogenesis, notably vascular endothelial growth factor (VEGF), has catalyzed the development of numerous neutralizing therapeutic agents.  The validity of VEGF inhibition as a therapeutic strategy has been well supported in randomized clin. trials, as well as U.S.  Food and Drug Administration approval of the VEGF antagonists bevacizumab, sunitinib malate, sorafenib, pegaptinib and ranibizumab.  Accordingly, this review will (1) briefly review the basic mol. biol. of VEGF and (2) summarize recent progress in targeting the VEGF mol. pathway as therapy for angiogenic diseases such as cancer and age-related macular degeneration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraJnUIpAfpmbVg90H21EOLACvtfcHk0lioJbvVyCSrwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWltLs%253D&md5=b802e1610699a5619e56f3720ef17bac</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.biocel.2007.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biocel.2007.04.010%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DQ.%2BT.%26aulast%3DKuo%26aufirst%3DC.%2BJ.%26atitle%3DVascular%2520endothelial%2520growth%2520factor%253A%2520Biology%2520and%2520therapeutic%2520applications%26jtitle%3DInt.%2520J.%2520Biochem.%2520Cell%2520Biol.%26date%3D2007%26volume%3D39%26spage%3D1349%26epage%3D1357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27a"><span><span class="NLM_contrib-group">Lindahl, P. J. B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levéen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Betsholtz, C.</span><span> </span><span class="NLM_article-title">Pericyte Loss and Microaneurysm Formation in PDGF-B-Deficient Mice</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x"> (</span><span class="NLM_issue">5323</span><span class="NLM_x">) </span> <span class="NLM_fpage">242</span><span class="NLM_x">–</span> <span class="NLM_lpage">245</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=1997&pages=242-245&issue=5323&author=P.+J.+B.+R.+Lindahlauthor=P.+Lev%C3%A9enauthor=C.+Betsholtz&title=Pericyte+Loss+and+Microaneurysm+Formation+in+PDGF-B-Deficient+Mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLindahl%26aufirst%3DP.%2BJ.%2BB.%2BR.%26aulast%3DLev%25C3%25A9en%26aufirst%3DP.%26aulast%3DBetsholtz%26aufirst%3DC.%26atitle%3DPericyte%2520Loss%2520and%2520Microaneurysm%2520Formation%2520in%2520PDGF-B-Deficient%2520Mice%26jtitle%3DScience%26date%3D1997%26volume%3D277%26issue%3D5323%26spage%3D242%26epage%3D245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit27b"><span><span class="NLM_contrib-group">Sjöblom, T. P., K.; Östman, A.; Heldin, C.-H.</span><span> </span><span class="NLM_article-title">Platelet-derived growth factor. Normal function, role in disease and application of PDGF antagonists</span>. In  <span class="citation_source-book">Protein Tyrosine Kinases: From Inhibitors to Useful Drugs</span>; <span class="NLM_contrib-group">Fabbra, D., ; McCormick, F.</span>, Eds.; <span class="NLM_publisher-name">Humana Press</span>, <span class="NLM_publisher-loc">Totowa, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">2006</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">161</span>− <span class="NLM_lpage">186</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=161-186&author=T.+P.%2C+K.+Sj%C3%B6blom&author=A.+%C3%96stman&author=C.-H.+Heldinauthor=D.+Fabbra&author=F.+McCormick&title=Protein+Tyrosine+Kinases%3A+From+Inhibitors+to+Useful+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DSj%25C3%25B6blom%26aufirst%3DT.%2BP.%252C%2BK.%26atitle%3DPlatelet-derived%2520growth%2520factor.%2520Normal%2520function%252C%2520role%2520in%2520disease%2520and%2520application%2520of%2520PDGF%2520antagonists%26btitle%3DProtein%2520Tyrosine%2520Kinases%253A%2520From%2520Inhibitors%2520to%2520Useful%2520Drugs%26aulast%3DFabbra%26aufirst%3DD.%26pub%3DHumana%2520Press%26date%3D2006%26spage%3D161%26epage%3D186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-ref28_1"><span>Clinical Trials: Combination of Capecitabine with Kinase Inhibitors: Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer. <a href="http://www.clinicaltrials.gov/ct2/show/NCT00496366?term=capecitabine&amp;rank=4" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00496366?term=capecitabine&rank=4</a>; <a href="http://www.clinicaltrials.gov/ct2/show/NCT00496366?term=capecitabine&amp;rank=4" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00496366?term=capecitabine&rank=4</a>; A study of Sunitinib in Combination with Capecitabine Compared with Capecitabine in Patients with Breast Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00435409?term=capecitabine&amp;rank=5" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00435409?term=capecitabine&rank=5</a>; Study of Sunitinib in Combination with Cisplatin/Capecitabine or Oxaliplatin/Capecitabine in Patients with Advanced Gastric Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00555620?term=capecitabine&amp;rank=6" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00555620?term=capecitabine&rank=6</a>; Bevacizumab, Erlotinib and Capecitabine for Locally Advanced Rectal Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00543842?term=capecitabine&amp;rank=15" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00543842?term=capecitabine&rank=15</a>; Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabinie/Erlotnib Followed of Capecitabine, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00440167" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00440167</a>; A Phase I Trial of Capecitabine in Combination with Gemcitabine and Erlotinib for Advanced Pancreatic Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00480584" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00480584</a>; Gemcitabine/Vinorelbine versus Gemcitabine/Cisplatin versus Gemcitabine/Capecitabine in Metastatic Breast Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00480597" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00480597</a>; A Phase II Trial of Gemcitabine, Capecitabine and Bevacizumab in Metastatic Renal Cell Carcinoma, <a href="http://www.clinicaltrials.gov/ct2/show/NCT0000523640" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT0000523640</a>; Brain Mets - Capecitabine and WBRT, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00570908?term=capecitabine&amp;rank=19" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00570908?term=capecitabine&rank=19</a>; Combination Study of Capecitabine and Erlotinib Concurrent with Radiotherapy for Non-operable Advanced Pancreatic Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00565487?term=capecitabine&amp;rank=30" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00565487?term=capecitabine&rank=30</a>; Phase I Vandetanib Plau Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00532909?term=capecitabine&amp;rank=44" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00532909?term=capecitabine&rank=44</a>; Phase I Study of Lapatinib in combination with Oxaliplatin and Capecitabine in Sugjects with Advanced Colorectal Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00536809?term=capecitabine&amp;rank=74" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00536809?term=capecitabine&rank=74</a>; Enzastaurin in combination of Capecitabine to Treat Breat Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00437294?term=capecitabine&amp;rank=92" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00437294?term=capecitabine&rank=92</a>; Imatinib Mesylate, Gemcitabine and Capecitabine in Treating Patients with Advanced Solid Tumors, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00483366?term=capecitabine&amp;rank=93" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00483366?term=capecitabine&rank=93</a>; Lapatinib + Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women from China, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00508274?term=capecitabine&amp;rank=101" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00508274?term=capecitabine&rank=101</a>; A Clinical Trial Comparing Efficacy and Safety of Sunitinib and Capecitabine, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00373113?term=capecitabine&amp;rank=150" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00373113?term=capecitabine&rank=150</a>; Study for Patients with Untreated Gastric Cancer Who Will Receive Capecitabine and Lapatinib, <a href="http://www.clinicaltrials.gov/ct2/show/NCT0000570908?term=capecitabine&amp;rank=152" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT0000570908?term=capecitabine&rank=152</a>; EAP (Expanded Access Protocol) of Lapatinib Combinied with Capecitabine in Metastatic Breast Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00338247?term=capecitabine&amp;rank=167" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00338247?term=capecitabine&rank=167</a>; Phase I/II XP + Sorafenib in AGC, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00565370?term=capecitabine&amp;rank=250" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00565370?term=capecitabine&rank=250</a>. A Brain Metastases in ErbB2-Positive Breast Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00437073?term=capecitabine&amp;rank=267" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00437073?term=capecitabine&rank=267</a>; Lapatinib in Combination with Capecitabine in Japanese Patients with Metastatic Breast Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00477464?term=capecitabine&amp;rank=309" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00477464?term=capecitabine&rank=309</a>; Clinical Trial on the Mixture of Gemcitabine, Capecitabine and Sorafenib (Bay 43-9006) in the Treatment of Patients with Renal Cell Carcinoma (RCC) (SOGUG-02-06), <a href="http://www.clinicaltrials.gov/ct2/show/NCT00496301?term=capecitabine&amp;rank=311" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00496301?term=capecitabine&rank=311</a>; Erlotinib, Combination Chemotherapy and Radiation Therapy in Treating Patients with Stage I or Stage II Pancreatic Cancer that can be Removed by Surgery, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00313560?term=capecitabine&amp;rank=352" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00313560?term=capecitabine&rank=352</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical+Trials%3A+Combination+of+Capecitabine+with+Kinase+Inhibitors%3A+Capecitabine+%28Xeloda%29+and+Lapatinib+%28Tykerb%29+as+First-line+Therapy+in+HER2%2FNeu-positive+Breast+Cancer.+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00496366%3Fterm%3Dcapecitabine%26rank%3D4%3B+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00496366%3Fterm%3Dcapecitabine%26rank%3D4%3B+A+study+of+Sunitinib+in+Combination+with+Capecitabine+Compared+with+Capecitabine+in+Patients+with+Breast+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00435409%3Fterm%3Dcapecitabine%26rank%3D5%3B+Study+of+Sunitinib+in+Combination+with+Cisplatin%2FCapecitabine+or+Oxaliplatin%2FCapecitabine+in+Patients+with+Advanced+Gastric+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00555620%3Fterm%3Dcapecitabine%26rank%3D6%3B+Bevacizumab%2C+Erlotinib+and+Capecitabine+for+Locally+Advanced+Rectal+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00543842%3Fterm%3Dcapecitabine%26rank%3D15%3B+Capecitabine%2FErlotinib+Followed+of+Gemcitabine+Versus+Gemcitabinie%2FErlotnib+Followed+of+Capecitabine%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00440167%3B+A+Phase+I+Trial+of+Capecitabine+in+Combination+with+Gemcitabine+and+Erlotinib+for+Advanced+Pancreatic+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00480584%3B+Gemcitabine%2FVinorelbine+versus+Gemcitabine%2FCisplatin+versus+Gemcitabine%2FCapecitabine+in+Metastatic+Breast+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00480597%3B+A+Phase+II+Trial+of+Gemcitabine%2C+Capecitabine+and+Bevacizumab+in+Metastatic+Renal+Cell+Carcinoma%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT0000523640%3B+Brain+Mets+-+Capecitabine+and+WBRT%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00570908%3Fterm%3Dcapecitabine%26rank%3D19%3B+Combination+Study+of+Capecitabine+and+Erlotinib+Concurrent+with+Radiotherapy+for+Non-operable+Advanced+Pancreatic+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00565487%3Fterm%3Dcapecitabine%26rank%3D30%3B+Phase+I+Vandetanib+Plau+Capecitabine%2C+Oxaliplatin+and+Bevacizumab+for+Metastatic+Colorectal+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00532909%3Fterm%3Dcapecitabine%26rank%3D44%3B+Phase+I+Study+of+Lapatinib+in+combination+with+Oxaliplatin+and+Capecitabine+in+Sugjects+with+Advanced+Colorectal+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00536809%3Fterm%3Dcapecitabine%26rank%3D74%3B+Enzastaurin+in+combination+of+Capecitabine+to+Treat+Breat+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00437294%3Fterm%3Dcapecitabine%26rank%3D92%3B+Imatinib+Mesylate%2C+Gemcitabine+and+Capecitabine+in+Treating+Patients+with+Advanced+Solid+Tumors%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00483366%3Fterm%3Dcapecitabine%26rank%3D93%3B+Lapatinib+%2B+Capecitabine+Treatment+for+Advanced+Metastatic+Breast+Cancer+in+Women+from+China%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00508274%3Fterm%3Dcapecitabine%26rank%3D101%3B+A+Clinical+Trial+Comparing+Efficacy+and+Safety+of+Sunitinib+and+Capecitabine%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00373113%3Fterm%3Dcapecitabine%26rank%3D150%3B+Study+for+Patients+with+Untreated+Gastric+Cancer+Who+Will+Receive+Capecitabine+and+Lapatinib%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT0000570908%3Fterm%3Dcapecitabine%26rank%3D152%3B+EAP+%28Expanded+Access+Protocol%29+of+Lapatinib+Combinied+with+Capecitabine+in+Metastatic+Breast+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00338247%3Fterm%3Dcapecitabine%26rank%3D167%3B+Phase+I%2FII+XP+%2B+Sorafenib+in+AGC%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00565370%3Fterm%3Dcapecitabine%26rank%3D250.+A+Brain+Metastases+in+ErbB2-Positive+Breast+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00437073%3Fterm%3Dcapecitabine%26rank%3D267%3B+Lapatinib+in+Combination+with+Capecitabine+in+Japanese+Patients+with+Metastatic+Breast+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00477464%3Fterm%3Dcapecitabine%26rank%3D309%3B+Clinical+Trial+on+the+Mixture+of+Gemcitabine%2C+Capecitabine+and+Sorafenib+%28Bay+43-9006%29+in+the+Treatment+of+Patients+with+Renal+Cell+Carcinoma+%28RCC%29+%28SOGUG-02-06%29%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00496301%3Fterm%3Dcapecitabine%26rank%3D311%3B+Erlotinib%2C+Combination+Chemotherapy+and+Radiation+Therapy+in+Treating+Patients+with+Stage+I+or+Stage+II+Pancreatic+Cancer+that+can+be+Removed+by+Surgery%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00313560%3Fterm%3Dcapecitabine%26rank%3D352."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=ref28_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Tripathy, D.</span><span> </span><span class="NLM_article-title">Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: underlying rationale and results of clinical trials</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">375</span><span class="NLM_x">–</span> <span class="NLM_lpage">389</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=375-389&author=D.+Tripathy&title=Capecitabine+in+combination+with+novel+targeted+agents+in+the+management+of+metastatic+breast+cancer%3A+underlying+rationale+and+results+of+clinical+trials"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTripathy%26aufirst%3DD.%26atitle%3DCapecitabine%2520in%2520combination%2520with%2520novel%2520targeted%2520agents%2520in%2520the%2520management%2520of%2520metastatic%2520breast%2520cancer%253A%2520underlying%2520rationale%2520and%2520results%2520of%2520clinical%2520trials%26jtitle%3DOncologist%26date%3D2007%26volume%3D12%26spage%3D375%26epage%3D389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-ref30_1"><span>Clinical Trials Combination of 5-FU with Kinase Inhibitors: Bevacizumab, Erlotinib and 5-Fluorouracil with External Beam Radiation Therapy in Locally Advanced Rectal Cancer,. <a href="http://www.clinicaltrials.gov/ct2/show/NCT00307736" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00307736</a>; Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00591123" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00591123</a>; Sunitinib, Irinotecan, Fluorouracil and Leucovorini in Treating Patients with Advanced Stomach Cancer or Gastroesophageal Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00524186" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00524186</a>; A Phase I Study of Sunitinib in combination with Cisplatin and 5-Fluorouracil in Patients with Advanced Gastric Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00555672" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00555672</a>; Oxaliplatin, Fluorouracil, Erlotinib and Radiation Therapy before Surgery and Erlotinib After Sursery in Treating Patients with Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00499564" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00499564</a>; Cisplatin, Fluorouracil, Gefitinib and Radiation Therapy in Treating Patients with Locally Advanced Head and Neck Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00352105" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00352105</a>; Study of FOLFIRI Chemotherapy with or without Sunitinib in Patients with Metastatic Colorectal Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00457691" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00457691</a>; Docetaxel and Lapatinib with or without Combination Chemotherapy or Docetaxel and Trastuzumab with Combination Chemotherapy in Treating Women with Locally Advanced, Inflammatory or Resectable Breast Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00450892" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00450892</a>; Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00393068" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00393068</a>; Combination Chemotherapy and Radiation therapy with or without Lapatinib in Treating Patients with Locally Advanced Cancer of the Larynx or Hypopharynx That Can Be Removed by Surgery, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00498953" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00498953</a>; Lapatinib +/- Trastuzumab in addition to Standard Neoadjuvant Breast Cancer Therapy, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00524303" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00524303</a>; Chemotherapy & Erlotinib in Treating Patients with Esophageal or Gastroesophageal Cancer That Cannot be Removed by Surgery, <a href="http://www.clinicaltrials.gov/ct2/show/NCT0000539617" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT0000539617</a>; A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in combination with FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00500292" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00500292</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical+Trials+Combination+of+5-FU+with+Kinase+Inhibitors%3A+Bevacizumab%2C+Erlotinib+and+5-Fluorouracil+with+External+Beam+Radiation+Therapy+in+Locally+Advanced+Rectal+Cancer%2C.+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00307736%3B+Study+of+Erlotinib+and+Chemotherapy+for+Unresectable+or+Metastatic+Cancer+of+the+Esophagus+and+Gastric+Cardia%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00591123%3B+Sunitinib%2C+Irinotecan%2C+Fluorouracil+and+Leucovorini+in+Treating+Patients+with+Advanced+Stomach+Cancer+or+Gastroesophageal+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00524186%3B+A+Phase+I+Study+of+Sunitinib+in+combination+with+Cisplatin+and+5-Fluorouracil+in+Patients+with+Advanced+Gastric+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00555672%3B+Oxaliplatin%2C+Fluorouracil%2C+Erlotinib+and+Radiation+Therapy+before+Surgery+and+Erlotinib+After+Sursery+in+Treating+Patients+with+Locally+Advanced+Cancer+of+the+Esophagus+or+Gastroesophageal+Junction%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00499564%3B+Cisplatin%2C+Fluorouracil%2C+Gefitinib+and+Radiation+Therapy+in+Treating+Patients+with+Locally+Advanced+Head+and+Neck+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00352105%3B+Study+of+FOLFIRI+Chemotherapy+with+or+without+Sunitinib+in+Patients+with+Metastatic+Colorectal+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00457691%3B+Docetaxel+and+Lapatinib+with+or+without+Combination+Chemotherapy+or+Docetaxel+and+Trastuzumab+with+Combination+Chemotherapy+in+Treating+Women+with+Locally+Advanced%2C+Inflammatory+or+Resectable+Breast+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00450892%3B+Chemotherapy%2C+Radiation+Therapy+and+Immunotherapy+Prior+to+Surgery+in+Operable+Esophageal+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00393068%3B+Combination+Chemotherapy+and+Radiation+therapy+with+or+without+Lapatinib+in+Treating+Patients+with+Locally+Advanced+Cancer+of+the+Larynx+or+Hypopharynx+That+Can+Be+Removed+by+Surgery%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00498953%3B+Lapatinib+%2B%2F-+Trastuzumab+in+addition+to+Standard+Neoadjuvant+Breast+Cancer+Therapy%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00524303%3B+Chemotherapy+%26+Erlotinib+in+Treating+Patients+with+Esophageal+or+Gastroesophageal+Cancer+That+Cannot+be+Removed+by+Surgery%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT0000539617%3B+A+Phase+II+Study+of+2+Doses+of+ZD6474+%28Vandetanib%29+in+combination+with+FOLFOX+vs+FOLFOX+Alone+for+the+Treatment+of+Colorectal+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00500292."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=ref30_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-ref31_1"><span>Clinical Trials - Combination of Pemetrexed with Kinase Inhibitors: A Study to Find the Best Dose of SU011248 When Given with Pemetrexed, Pemetrexed and Cisplatin or Pemetrexed and Carboplatin in Patients with Advanced Solid Tumors, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00528619?term=pemetrexed&amp;rank=1" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00528619?term=pemetrexed&rank=1</a>; Efficacy Study Comparing ZD6474 in Combination with Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients (ZEAL), <a href="http://clinicaltrials.gov/ct2/show/NCT00418886?term=pemetrexed&amp;rank=2" class="extLink">http://clinicaltrials.gov/ct2/show/NCT00418886?term=pemetrexed&rank=2</a>; Docetaxel or Pemetrexed with or Without Cetuximab in Patients with Recurrent or Progressive Non-small Cell Lung Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00095199?term=pemetrexed&amp;rank=3" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00095199?term=pemetrexed&rank=3</a>; A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) Versus Pemetrexed in Advanced Non-small Cell Lung Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00528281?term=pemetrexed&amp;rank=7" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00528281?term=pemetrexed&rank=7</a>; Study of Pemetrexed Versus Pemetrexed + Erlotinib as Treatment of Non-small Cell Lung Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00447057?term=pemetrexed&amp;rank=14" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00447057?term=pemetrexed&rank=14</a>; Cisplatin, Imatinib Mesylate, and Pemetrexed in Malignant Mesothelioma Patients, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00402766?term=pemetrexed&amp;rank=17" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00402766?term=pemetrexed&rank=17</a>; ZD6474 (Vandetanib) + Alimta Combo Study, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00506051?term=pemetrexed&amp;rank=22" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00506051?term=pemetrexed&rank=22</a>; Study of Enzastaurin Versus Placebo with Pemetrexed for Patients with Advanced or Metastatic Lung Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00530621?term=pemetrexed&amp;rank=27" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00530621?term=pemetrexed&rank=27</a>; Pemetrexed Disodium with or Without Sorafenib as Second-line Therapy in Treating Patients with Stage IIIB or Stave IV Non-small Cell Lung Cancer, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00454194?term=pemetrexed&amp;rank=31" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00454194?term=pemetrexed&rank=31</a>; AZD6244 Versus Pemetrexed (Alimta®) in Patients with Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen, <a href="http://clinicaltrials.gov/ct2/show/NCT00372788?term=pemetrexec&amp;rank=32" class="extLink">http://clinicaltrials.gov/ct2/show/NCT00372788?term=pemetrexec&rank=32</a>; Randomized Phase III Trial of Pemetrexed vs Erlotinib in Pretreated Patients with NSCLC, <a href="http://clinicaltrials.gov/ct2/show/NCT00440414?term=pemetrexed&amp;rank=34" class="extLink">http://clinicaltrials.gov/ct2/show/NCT00440414?term=pemetrexed&rank=34</a>; Vatalanib and Pemetrexed Disodium in Treating Patients with Advanced Solid Tumors, <a href="http://clinicaltrials.gov/ct2/show/NCT00390000?term=pemetrexed&amp;rank=37" class="extLink">http://clinicaltrials.gov/ct2/show/NCT00390000?term=pemetrexed&rank=37</a>; Sorafenib Combined with Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating patients with Metastatic Solid Tumors, <a href="http://clinicaltrials.gov/ct2/show/NCT00573690?term=pemetrexed&amp;rank=92" class="extLink">http://clinicaltrials.gov/ct2/show/NCT00573690?term=pemetrexed&rank=92</a>; Study in Patients with Advanced Non-small Cell Lung Cancer Treated with Pemetrexed and Carboplatin Plus or Minus Sorafenib (PECASO), <a href="http://clinicaltrials.gov/ct2/show/NCT00473486?term=pemetrexed&amp;rank=98" class="extLink">http://clinicaltrials.gov/ct2/show/NCT00473486?term=pemetrexed&rank=98</a>; Chemotherapy for patients with Non-small Cell Lung Cancer Who Are Non-smokers, <a href="http://clinicaltrials.gov/ct2/show/NCT00409006?term=pemetrexed&amp;rank=152" class="extLink">http://clinicaltrials.gov/ct2/show/NCT00409006?term=pemetrexed&rank=152</a>; Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients with Non-small Cell Lung Cancer, <a href="http://clinicaltrials.gov/ct2/show/NCT00351039?term=pemetrexed&amp;rank=202" class="extLink">http://clinicaltrials.gov/ct2/show/NCT00351039?term=pemetrexed&rank=202</a>; A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-small Cell Lung Cancer), <a href="http://clinicaltrials.gov/ct2/show/NCT00095225?term=pemetrexed&amp;rank=203" class="extLink">http://clinicaltrials.gov/ct2/show/NCT00095225?term=pemetrexed&rank=203</a>; A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients with Advanced, Recurrent or Metastatic Non-small Cell Lung Cancer (NSCLC), <a href="http://clinicaltrials.gov/ct2/show/NCT00556322?term=pemetrexed&amp;rank=206" class="extLink">http://clinicaltrials.gov/ct2/show/NCT00556322?term=pemetrexed&rank=206</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical+Trials+-+Combination+of+Pemetrexed+with+Kinase+Inhibitors%3A+A+Study+to+Find+the+Best+Dose+of+SU011248+When+Given+with+Pemetrexed%2C+Pemetrexed+and+Cisplatin+or+Pemetrexed+and+Carboplatin+in+Patients+with+Advanced+Solid+Tumors%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00528619%3Fterm%3Dpemetrexed%26rank%3D1%3B+Efficacy+Study+Comparing+ZD6474+in+Combination+with+Pemetrexed+and+Pemetrexed+Alone+in+2nd+Line+NSCLC+Patients+%28ZEAL%29%2C+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT00418886%3Fterm%3Dpemetrexed%26rank%3D2%3B+Docetaxel+or+Pemetrexed+with+or+Without+Cetuximab+in+Patients+with+Recurrent+or+Progressive+Non-small+Cell+Lung+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00095199%3Fterm%3Dpemetrexed%26rank%3D3%3B+A+Phase+II+Trial+of+Lapatinib+%28TYKERB%29+%2B+Pemetrexed+%28ALIMTA%29+Versus+Pemetrexed+in+Advanced+Non-small+Cell+Lung+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00528281%3Fterm%3Dpemetrexed%26rank%3D7%3B+Study+of+Pemetrexed+Versus+Pemetrexed+%2B+Erlotinib+as+Treatment+of+Non-small+Cell+Lung+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00447057%3Fterm%3Dpemetrexed%26rank%3D14%3B+Cisplatin%2C+Imatinib+Mesylate%2C+and+Pemetrexed+in+Malignant+Mesothelioma+Patients%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00402766%3Fterm%3Dpemetrexed%26rank%3D17%3B+ZD6474+%28Vandetanib%29+%2B+Alimta+Combo+Study%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00506051%3Fterm%3Dpemetrexed%26rank%3D22%3B+Study+of+Enzastaurin+Versus+Placebo+with+Pemetrexed+for+Patients+with+Advanced+or+Metastatic+Lung+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00530621%3Fterm%3Dpemetrexed%26rank%3D27%3B+Pemetrexed+Disodium+with+or+Without+Sorafenib+as+Second-line+Therapy+in+Treating+Patients+with+Stage+IIIB+or+Stave+IV+Non-small+Cell+Lung+Cancer%2C+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00454194%3Fterm%3Dpemetrexed%26rank%3D31%3B+AZD6244+Versus+Pemetrexed+%28Alimta%C2%AE%29+in+Patients+with+Non-small+Cell+Lung+Cancer%2C+Who+Have+Failed+One+or+Two+Prior+Chemotherapy+Regimen%2C+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT00372788%3Fterm%3Dpemetrexec%26rank%3D32%3B+Randomized+Phase+III+Trial+of+Pemetrexed+vs+Erlotinib+in+Pretreated+Patients+with+NSCLC%2C+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT00440414%3Fterm%3Dpemetrexed%26rank%3D34%3B+Vatalanib+and+Pemetrexed+Disodium+in+Treating+Patients+with+Advanced+Solid+Tumors%2C+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT00390000%3Fterm%3Dpemetrexed%26rank%3D37%3B+Sorafenib+Combined+with+Cisplatin+and+Etoposide+or+Carboplatin+and+Pemetrexed+in+Treating+patients+with+Metastatic+Solid+Tumors%2C+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT00573690%3Fterm%3Dpemetrexed%26rank%3D92%3B+Study+in+Patients+with+Advanced+Non-small+Cell+Lung+Cancer+Treated+with+Pemetrexed+and+Carboplatin+Plus+or+Minus+Sorafenib+%28PECASO%29%2C+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT00473486%3Fterm%3Dpemetrexed%26rank%3D98%3B+Chemotherapy+for+patients+with+Non-small+Cell+Lung+Cancer+Who+Are+Non-smokers%2C+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT00409006%3Fterm%3Dpemetrexed%26rank%3D152%3B+Phase+I%2FII+Trial+of+Bevacizumab%2C+Pemetrexed+and+Erlotinib+in+Elderly+Patients+with+Non-small+Cell+Lung+Cancer%2C+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT00351039%3Fterm%3Dpemetrexed%26rank%3D202%3B+A+Study+to+Evaluate+Bevacizumab+and+Chemotherapy+or+Tarceva+in+Treating+Recurrent+or+Refractory+NSCLC+%28Non-small+Cell+Lung+Cancer%29%2C+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT00095225%3Fterm%3Dpemetrexed%26rank%3D203%3B+A+Study+of+Tarceva+%28Erlotinib%29+and+Standard+of+Care+Chemotherapy+in+Patients+with+Advanced%2C+Recurrent+or+Metastatic+Non-small+Cell+Lung+Cancer+%28NSCLC%29%2C+http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT00556322%3Fterm%3Dpemetrexed%26rank%3D206."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=ref31_1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Huber, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bischof, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenne, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heiland, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peschke, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saffrich, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groene, H.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debus, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipson, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abdollahi, A.</span><span> </span><span class="NLM_article-title">Trimodal cancer treatment: Beneficial effects of combined antiangiogenesis, radiation, and chemotherapy</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">3643</span><span class="NLM_x">–</span> <span class="NLM_lpage">3655</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=3643-3655&author=P.+E.+Huberauthor=M.+Bischofauthor=J.+Jenneauthor=S.+Heilandauthor=P.+Peschkeauthor=R.+Saffrichauthor=H.-J.+Groeneauthor=J.+Debusauthor=K.+E.+Lipsonauthor=A.+Abdollahi&title=Trimodal+cancer+treatment%3A+Beneficial+effects+of+combined+antiangiogenesis%2C+radiation%2C+and+chemotherapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHuber%26aufirst%3DP.%2BE.%26aulast%3DBischof%26aufirst%3DM.%26aulast%3DJenne%26aufirst%3DJ.%26aulast%3DHeiland%26aufirst%3DS.%26aulast%3DPeschke%26aufirst%3DP.%26aulast%3DSaffrich%26aufirst%3DR.%26aulast%3DGroene%26aufirst%3DH.-J.%26aulast%3DDebus%26aufirst%3DJ.%26aulast%3DLipson%26aufirst%3DK.%2BE.%26aulast%3DAbdollahi%26aufirst%3DA.%26atitle%3DTrimodal%2520cancer%2520treatment%253A%2520Beneficial%2520effects%2520of%2520combined%2520antiangiogenesis%252C%2520radiation%252C%2520and%2520chemotherapy%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D3643%26epage%3D3655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Schnell, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dyson, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, P. E.</span><span> </span><span class="NLM_article-title">Structure, dynamics, and catalytic function of dihydrofolate reductase</span> <span class="citation_source-journal">Annu. Rev. Biophys. Biomol. Struct.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">119</span><span class="NLM_x">–</span> <span class="NLM_lpage">140</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2004&pages=119-140&author=J.+R.+Schnellauthor=H.+J.+Dysonauthor=P.+E.+Wright&title=Structure%2C+dynamics%2C+and+catalytic+function+of+dihydrofolate+reductase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchnell%26aufirst%3DJ.%2BR.%26aulast%3DDyson%26aufirst%3DH.%2BJ.%26aulast%3DWright%26aufirst%3DP.%2BE.%26atitle%3DStructure%252C%2520dynamics%252C%2520and%2520catalytic%2520function%2520of%2520dihydrofolate%2520reductase%26jtitle%3DAnnu.%2520Rev.%2520Biophys.%2520Biomol.%2520Struct.%26date%3D2004%26volume%3D33%26spage%3D119%26epage%3D140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Carreras, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santi, D. V.</span><span> </span><span class="NLM_article-title">The catalytic mechanism and structure of thymidylate synthase</span> <span class="citation_source-journal">Annu. Rev. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">721</span><span class="NLM_x">–</span> <span class="NLM_lpage">762</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1146%2Fannurev.bi.64.070195.003445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=7574499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADyaK2MXmsl2qtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1995&pages=721-762&author=C.+W.+Carrerasauthor=D.+V.+Santi&title=The+catalytic+mechanism+and+structure+of+thymidylate+synthase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The catalytic mechanism and structure of thymidylate synthase</span></div><div class="casAuthors">Carreras, Christopher W.; Santi, Daniel V.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">721-62</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review, with 193 refs.  Thymidylate synthase (TS, EC 2.1.1.45) catalyzes the reductive methylation of dUMP by CH2H4folate to produce dTMP and H2folate.  Knowledge of the catalytic mechanism and structure of TS has increased substantially over recent years.  Major advances were derived from crystal structures of TS bound to various ligands, the ability to overexpress TS in heterologous hosts, and the numerous mutants that have been prepd. and analyzed.  These advances, coupled with previous knowledge, have culminated in an in-depth understanding of many important mol. details of the reaction.  The authors review aspects of TS catalysis that are most pertinent to understanding the current status of the structure and catalytic mechanism of the enzyme.  Included is a discussion of available sources and assays for TS, a description of the enzyme's chem. mechanism and crystal structure, and a summary of data obtained from mutagenesis expts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO-xv6vKzvm7Vg90H21EOLACvtfcHk0lgrLPn4xGo_Gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXmsl2qtrg%253D&md5=3fa2b583e048196a12193b27f9533770</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1146%2Fannurev.bi.64.070195.003445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.bi.64.070195.003445%26sid%3Dliteratum%253Aachs%26aulast%3DCarreras%26aufirst%3DC.%2BW.%26aulast%3DSanti%26aufirst%3DD.%2BV.%26atitle%3DThe%2520catalytic%2520mechanism%2520and%2520structure%2520of%2520thymidylate%2520synthase%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D1995%26volume%3D64%26spage%3D721%26epage%3D762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Lehman, N. L.</span><span> </span><span class="NLM_article-title">Future potential of thymidylate synthase inhibitors in cancer therapy</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1775</span><span class="NLM_x">–</span> <span class="NLM_lpage">1787</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2002&pages=1775-1787&author=N.+L.+Lehman&title=Future+potential+of+thymidylate+synthase+inhibitors+in+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLehman%26aufirst%3DN.%2BL.%26atitle%3DFuture%2520potential%2520of%2520thymidylate%2520synthase%2520inhibitors%2520in%2520cancer%2520therapy%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2002%26volume%3D11%26spage%3D1775%26epage%3D1787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Pizzorno, G. D. R. B.; Cheng, Y.-C.</span><span> </span><span class="NLM_article-title">Pyrimidine and Purine Antimetabolites</span>. In  <span class="citation_source-book">Cancer Medicine</span>; <span class="NLM_contrib-group">Holland, J. F.,; Frei, E.,  III</span>, Eds.; <span class="NLM_publisher-name">B. C. Decker, Inc.</span>: <span class="NLM_publisher-loc">Hamilton, London</span>.<span class="NLM_x"> </span><span class="NLM_year">2003</span><span class="NLM_x">, </span>pp  <span class="NLM_fpage">739</span>− <span class="NLM_lpage">744</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&pages=739-744&author=G.+D.+R.+B.+Pizzorno&author=Y.-C.+Chengauthor=J.+F.+Holland&author=E.+Frei&title=Cancer+Medicine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DPizzorno%26aufirst%3DG.%2BD.%2BR.%2BB.%26atitle%3DPyrimidine%2520and%2520Purine%2520Antimetabolites%26btitle%3DCancer%2520Medicine%26aulast%3DHolland%26aufirst%3DJ.%2BF.%26pub%3DB.%2520C.%2520Decker%252C%2520Inc%26date%3D2003%26spage%3D739%26epage%3D744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Rollins, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindley, C.</span><span> </span><span class="NLM_article-title">Pemetrexed: A multitargeted antifolate</span> <span class="citation_source-journal">Clin. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1343</span><span class="NLM_x">–</span> <span class="NLM_lpage">1382</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1016%2Fj.clinthera.2005.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=16291410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtF2lurvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2005&pages=1343-1382&author=K.+D.+Rollinsauthor=C.+Lindley&title=Pemetrexed%3A+A+multitargeted+antifolate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Pemetrexed: A multitargeted antifolate</span></div><div class="casAuthors">Rollins, Kristan D.; Lindley, Celeste</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1343-1382</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Excerpta Medica, Inc.</span>)
        </div><div class="casAbstract">A review.  Background: The US Food and Drug Administration approved pemetrexed in Feb. 2004 for the treatment of malignant pleural mesothelioma (MPM) in combination with cisplatin in patients with unresectable disease or for whom curative surgery is not an option.  Pemetrexed is the first agent approved for the treatment of MPM.  In August 2004, pemetrexed was approved as a second-line, single-agent treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC).  Objectives: The goals of this article were to summarize the pharmacol., pharmacokinetics, efficacy, and safety of pemetrexed, and to review its current and potential roles in therapy for MPM, NSCLC, and other oncol. conditions.  Methods: Relevant English-language literature was identified through searches of PubMed (1966-Dec. 2004), International Pharmaceutical Abstrs., and the Proceedings of the American Society of Clin. Oncol. (Jan. 1995-Dec. 2004).  Search terms included pemetrexed, Alimta, MTA, multitargeted antifolate, LY231514, mesothelioma, MPM, non-small cell lung cancer, NSCLC, breast cancer, and pancreatic cancer.  In addn. to published literature, abstrs. and posters presented at national and international scientific meetings were reviewed.  Results: Myelosuppression was the predominant dose-limiting toxicity of pemetrexed reported in Phase I studies.  Identification of the correlation between poor folate status and increased pemetrexed toxicity in a multivariate anal. led to the requirement of folic acid and vitamin B12 supplementation for patients in all pemetrexed studies, with a resulting noted decrease in pemetrexed toxicity.  A single, multicenter, randomized Phase III trial compared the efficacy of pemetrexed in combination with cisplatin vs. cisplatin alone in the treatment of MPM.  Response rates were 41.3% in the pemetrexed/cisplatin combination and 16.7% with single-agent cisplatin (P < 0.001).  The median survival time for the pemetrexed/cisplatin combination was significantly longer at 12.1 mo vs. 9.3 mo for cisplatin alone (P = 0.02).  One international, multicenter, randomized Phase III trial in patients with NSCLC compared single-agent pemetrexed vs. docetaxel in patients previously treated with chemotherapy.  Overall response rates (9.1% and 8.8%) and median survival (8.3 mo and 7.9 mo) did not differ between pemetrexed and docetaxel (P = 0.105 and P = 0.226, resp.).  Hematol. adverse effects-grade 3/4 neutropenia (40.2% vs 5.3%; P < 0.001), febrile neutropenia (12.7% vs 1.9%; P < 0.001), and neutropenic infections (3.3% vs 0%; P = 0.004)-were significantly greater in the docetaxel-treated patients than in the pemetrexed-treated patients, as was alopecia (37.7% vs 6.4%; P < 0.001).  Results of an international, multicenter Phase III trial of pemetrexed in combination with gemcitabine conducted in patients with pancreatic cancer indicate that the combination is no more efficacious than single-agent gemcitabine.  Results in other disease states are still preliminary.  Conclusions: Pemetrexed is a multitargeted antifolate that has demonstrated antitumor activity in various tumor types as a single agent and in combination with other chemotherapeutic agents.  Efficacy for the treatment of MPM in combination with cisplatin has been demonstrated, and approval as a second-line agent in NSCLC was based on response rate as a surrogate end point for survival.  The addn. of folic acid and vitamin B12 supplementation markedly re-.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUS9Hvh4IAmLVg90H21EOLACvtfcHk0lgq8ahbxVZChA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtF2lurvE&md5=44f44151b633d5595ab3ac39ad623766</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.clinthera.2005.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinthera.2005.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DRollins%26aufirst%3DK.%2BD.%26aulast%3DLindley%26aufirst%3DC.%26atitle%3DPemetrexed%253A%2520A%2520multitargeted%2520antifolate%26jtitle%3DClin.%2520Ther.%26date%3D2005%26volume%3D27%26spage%3D1343%26epage%3D1382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Clamp, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoeffski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valle, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marreaud, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Govaerts, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debois, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacombe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Twelves, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayson, G. C.</span><span> </span><span class="NLM_article-title">A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">579</span><span class="NLM_x">–</span> <span class="NLM_lpage">585</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1007%2Fs00280-007-0509-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=17520255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjsFajsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2008&pages=579-585&author=A.+R.+Clampauthor=P.+Schoeffskiauthor=J.+W.+Valleauthor=R.+H.+Wilsonauthor=S.+Marreaudauthor=A.+S.+Govaertsauthor=M.+Deboisauthor=D.+Lacombeauthor=C.+Twelvesauthor=J.+Chickauthor=G.+C.+Jayson&title=A+phase+I+and+pharmacokinetic+study+of+OSI-7904L%2C+a+liposomal+thymidylate+synthase+inhibitor+in+combination+with+oxaliplatin+in+patients+with+advanced+colorectal+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer</span></div><div class="casAuthors">Clamp, A. R.; Schoeffski, P.; Valle, J. W.; Wilson, R. H.; Marreaud, S.; Govaerts, A.-S.; Debois, M.; Lacombe, D.; Twelves, C.; Chick, J.; Jayson, G. C.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">579-585</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: OSI-7904L is a liposomal formulation of a potent thymidylate synthase (TS) inhibitor.  This phase I study evaluated the safety, tolerability and pharmacokinetics (PK) of OSI-7904L administered in combination with oxaliplatin every 21 days in patients with advanced colorectal carcinoma.  Method: A 3+3 study design was utilized at predefined dose levels.  Polymorphisms in the TS enhancer region and XPD enzyme were investigated as potential predictors of efficacy and toxicity.  Results: Fourteen patients received 76 cycles of treatment.  At the highest dose level (OSI-7904L 9 mg/m2, oxaliplatin 130 mg/m2) investigated, one of nine patients experienced dose-limiting toxicity of grade 3 oral mucositis with cycle 1 and five further patients required dose redns.  The toxicity profile of stomatitis, diarrhea, nausea, fatigue, sensory neuropathy and skin rash was consistent with that expected for a TS inhibitor/oxaliplatin combination regimen.  PK anal. showed high interpatient variability with no detectable interaction between OSI-7904L and oxaliplatin.  Partial radiol. responses were documented in two patients.  Conclusions :The recommended regimen for further investigation is OSI-7904L 9 mg/m2 and oxaliplatin 130 mg/m2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiemScdOhig7Vg90H21EOLACvtfcHk0lgq8ahbxVZChA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjsFajsw%253D%253D&md5=710dbd51193545a24faa3d8c5b2ad1f5</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1007%2Fs00280-007-0509-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-007-0509-5%26sid%3Dliteratum%253Aachs%26aulast%3DClamp%26aufirst%3DA.%2BR.%26aulast%3DSchoeffski%26aufirst%3DP.%26aulast%3DValle%26aufirst%3DJ.%2BW.%26aulast%3DWilson%26aufirst%3DR.%2BH.%26aulast%3DMarreaud%26aufirst%3DS.%26aulast%3DGovaerts%26aufirst%3DA.%2BS.%26aulast%3DDebois%26aufirst%3DM.%26aulast%3DLacombe%26aufirst%3DD.%26aulast%3DTwelves%26aufirst%3DC.%26aulast%3DChick%26aufirst%3DJ.%26aulast%3DJayson%26aufirst%3DG.%2BC.%26atitle%3DA%2520phase%2520I%2520and%2520pharmacokinetic%2520study%2520of%2520OSI-7904L%252C%2520a%2520liposomal%2520thymidylate%2520synthase%2520inhibitor%2520in%2520combination%2520with%2520oxaliplatin%2520in%2520patients%2520with%2520advanced%2520colorectal%2520cancer%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2008%26volume%3D61%26spage%3D579%26epage%3D585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Showalter, H. D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sercel, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMichael, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 16. 6,5,6-Tricyclic benzothieno[3,2-<i>d</i>]pyrimidines and pyrimido[5,4-<i>b</i>]- and -[4,5-<i>b</i>]indoles as potent inhibitors of the epidermal growth factor receptor tyrosine kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">5464</span><span class="NLM_x">–</span> <span class="NLM_lpage">5474</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9903949" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=5464-5474&author=H.+D.+H.+Showalterauthor=A.+J.+Bridgesauthor=H.+Zhouauthor=A.+D.+Sercelauthor=A.+McMichaelauthor=D.+W.+Fry&title=Tyrosine+kinase+inhibitors.+16.+6%2C5%2C6-Tricyclic+benzothieno%5B3%2C2-d%5Dpyrimidines+and+pyrimido%5B5%2C4-b%5D-+and+-%5B4%2C5-b%5Dindoles+as+potent+inhibitors+of+the+epidermal+growth+factor+receptor+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm9903949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9903949%26sid%3Dliteratum%253Aachs%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DSercel%26aufirst%3DA.%2BD.%26aulast%3DMcMichael%26aufirst%3DA.%26aulast%3DFry%26aufirst%3DD.%2BW.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%252016.%25206%252C5%252C6-Tricyclic%2520benzothieno%255B3%252C2-d%255Dpyrimidines%2520and%2520pyrimido%255B5%252C4-b%255D-%2520and%2520-%255B4%252C5-b%255Dindoles%2520as%2520potent%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D5464%26epage%3D5474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Traxler, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mett, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lydon, N.</span><span> </span><span class="NLM_article-title">4-(Phenylamino)pyrrolopyrimidines: Potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">2285</span><span class="NLM_x">–</span> <span class="NLM_lpage">2292</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm960118j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=2285-2292&author=P.+M.+Traxlerauthor=P.+Furetauthor=H.+Mettauthor=E.+Buchdungerauthor=T.+Meyerauthor=N.+Lydon&title=4-%28Phenylamino%29pyrrolopyrimidines%3A+Potent+and+selective%2C+ATP+site+directed+inhibitors+of+the+EGF-receptor+protein+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm960118j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960118j%26sid%3Dliteratum%253Aachs%26aulast%3DTraxler%26aufirst%3DP.%2BM.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DMett%26aufirst%3DH.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DLydon%26aufirst%3DN.%26atitle%3D4-%2528Phenylamino%2529pyrrolopyrimidines%253A%2520Potent%2520and%2520selective%252C%2520ATP%2520site%2520directed%2520inhibitors%2520of%2520the%2520EGF-receptor%2520protein%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D2285%26epage%3D2292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Traxler, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span> </span><span class="NLM_article-title">Strategies toward the design of novel and selective protein tyrosine kinase inhibitors</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">195</span><span class="NLM_x">–</span> <span class="NLM_lpage">206</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1016%2FS0163-7258%2898%2900044-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=10454197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADyaK1MXjvFOht7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=1999&pages=195-206&author=P.+Traxlerauthor=P.+Furet&title=Strategies+toward+the+design+of+novel+and+selective+protein+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies toward the design of novel and selective protein tyrosine kinase inhibitors</span></div><div class="casAuthors">Traxler, Peter; Furet, Pascal</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">195-206</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review with 37 refs.  Protein tyrosine kinases play a fundamental role in signal transduction pathways.  Deregulated tyrosine kinase activity has been obsd. in many proliferative diseases (e.g., cancer, psoriasis, restenosis, etc.).  Tyrosine kinases are, therefore, attractive targets for the design of new therapeutic agents against cancer.  We have built up a pharmacophore model of the ATP-binding site of the epidermal growth factor receptor (EGFR) kinase and used it for the rational design of kinase inhibitors.  Several examples of the successful use of this model are presented in this review.  Amongst these, 4-substituted-pyrrolo[2,3-d]pyrimidines, a new class of highly potent and selective inhibitors of the EGFR kinase, have been identified and further optimized.  The most active derivs. inhibited the EGFR tyrosine kinase with IC50 values between 1 and 5 nM.  In EGF-dependent cellular systems, tyrosine phosphorylation, as well as c-fos mRNA expression, was inhibited with similar IC50 values.  Further successful application of this pharmacophore model led to the identification and optimization of phenylamino-pyrazolo[4,3-d]pyrimidines and substituted isoflavones and quinolones, other classes of potent, selective, and ATP competitive EGFR kinase inhibitors with IC50 values in the low nanomolar range.  Structure-activity relationships of both classes are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzTOVAYLwK77Vg90H21EOLACvtfcHk0liRBS3bD3w94w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjvFOht7Y%253D&md5=26e5ed297e37b0cb188a0676e5b27f5b</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2FS0163-7258%2898%2900044-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7258%252898%252900044-8%26sid%3Dliteratum%253Aachs%26aulast%3DTraxler%26aufirst%3DP.%26aulast%3DFuret%26aufirst%3DP.%26atitle%3DStrategies%2520toward%2520the%2520design%2520of%2520novel%2520and%2520selective%2520protein%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DPharmacol.%2520Ther.%26date%3D1999%26volume%3D82%26spage%3D195%26epage%3D206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Gangjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihnat, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamat, S.</span><span> </span><span class="NLM_article-title">Antiangiogenic and antitumor agents. Design, synthesis, and evaluation of novel 2-amino-4-(3-bromoanilino)-6-benzylsubstituted pyrrolo[2,3-<i>d</i>]pyrimidines as inhibitors of receptor tyrosine kinases</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">5155</span><span class="NLM_x">–</span> <span class="NLM_lpage">5170</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=5155-5170&author=A.+Gangjeeauthor=J.+Yangauthor=M.+A.+Ihnatauthor=S.+Kamat&title=Antiangiogenic+and+antitumor+agents.+Design%2C+synthesis%2C+and+evaluation+of+novel+2-amino-4-%283-bromoanilino%29-6-benzylsubstituted+pyrrolo%5B2%2C3-d%5Dpyrimidines+as+inhibitors+of+receptor+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DIhnat%26aufirst%3DM.%2BA.%26aulast%3DKamat%26aufirst%3DS.%26atitle%3DAntiangiogenic%2520and%2520antitumor%2520agents.%2520Design%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520novel%25202-amino-4-%25283-bromoanilino%2529-6-benzylsubstituted%2520pyrrolo%255B2%252C3-d%255Dpyrimidines%2520as%2520inhibitors%2520of%2520receptor%2520tyrosine%2520kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2003%26volume%3D11%26spage%3D5155%26epage%3D5170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Laufer, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Domeyer, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scior, T. R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauser, D. R. J.</span><span> </span><span class="NLM_article-title">Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">710</span><span class="NLM_x">–</span> <span class="NLM_lpage">722</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0408767" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=710-722&author=S.+A.+Lauferauthor=D.+M.+Domeyerauthor=T.+R.+F.+Sciorauthor=W.+Albrechtauthor=D.+R.+J.+Hauser&title=Synthesis+and+biological+testing+of+purine+derivatives+as+potential+ATP-competitive+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm0408767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0408767%26sid%3Dliteratum%253Aachs%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26aulast%3DDomeyer%26aufirst%3DD.%2BM.%26aulast%3DScior%26aufirst%3DT.%2BR.%2BF.%26aulast%3DAlbrecht%26aufirst%3DW.%26aulast%3DHauser%26aufirst%3DD.%2BR.%2BJ.%26atitle%3DSynthesis%2520and%2520biological%2520testing%2520of%2520purine%2520derivatives%2520as%2520potential%2520ATP-competitive%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D710%26epage%3D722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Abu Thaher, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schattel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S.</span><span> </span><span class="NLM_article-title">Role of the hydrogen bonding heteroatom−Lys53 interaction between the p38α mitogen-activated protein (MAP) kinase and pyridinyl-substituted 5-membered heterocyclic ring inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">2613</span><span class="NLM_x">–</span> <span class="NLM_lpage">2617</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=2613-2617&author=B.+Abu+Thaherauthor=P.+Kochauthor=V.+Schattelauthor=S.+Laufer&title=Role+of+the+hydrogen+bonding+heteroatom%E2%88%92Lys53+interaction+between+the+p38%CE%B1+mitogen-activated+protein+%28MAP%29+kinase+and+pyridinyl-substituted+5-membered+heterocyclic+ring+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAbu%2BThaher%26aufirst%3DB.%26aulast%3DKoch%26aufirst%3DP.%26aulast%3DSchattel%26aufirst%3DV.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DRole%2520of%2520the%2520hydrogen%2520bonding%2520heteroatom%25E2%2588%2592Lys53%2520interaction%2520between%2520the%2520p38%25CE%25B1%2520mitogen-activated%2520protein%2520%2528MAP%2529%2520kinase%2520and%2520pyridinyl-substituted%25205-membered%2520heterocyclic%2520ring%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D2613%26epage%3D2617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Gangjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kisliuk, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGuire, J. J.</span><span> </span><span class="NLM_article-title">Synthesis of <i>N</i>-{4-[(2,4-Diamino-5-methyl-4,7-dihydro-3<i>H</i>- pyrrolo[2,3-<i>d</i>]pyrimidin-6-yl)thio]benzoyl}-<span class="smallcaps smallerCapital">l</span>-glutamic Acid and <i>N</i>-{4-[(2-Amino-4-oxo-5-methyl-4,7-dihydro-3<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin- 6-yl)thio]benzoyl}-<span class="smallcaps smallerCapital">l</span>-glutamic Acid as Dual Inhibitors of Dihydrofolate Reductase and Thymidylate Synthase and as Potential Antitumor Agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">7215</span><span class="NLM_x">–</span> <span class="NLM_lpage">7222</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm058234m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=7215-7222&author=A.+Gangjeeauthor=X.+Linauthor=R.+L.+Kisliukauthor=J.+J.+McGuire&title=Synthesis+of+N-%7B4-%5B%282%2C4-Diamino-5-methyl-4%2C7-dihydro-3H-+pyrrolo%5B2%2C3-d%5Dpyrimidin-6-yl%29thio%5Dbenzoyl%7D-l-glutamic+Acid+and+N-%7B4-%5B%282-Amino-4-oxo-5-methyl-4%2C7-dihydro-3H-pyrrolo%5B2%2C3-d%5Dpyrimidin-+6-yl%29thio%5Dbenzoyl%7D-l-glutamic+Acid+as+Dual+Inhibitors+of+Dihydrofolate+Reductase+and+Thymidylate+Synthase+and+as+Potential+Antitumor+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm058234m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058234m%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DKisliuk%26aufirst%3DR.%2BL.%26aulast%3DMcGuire%26aufirst%3DJ.%2BJ.%26atitle%3DSynthesis%2520of%2520N-%257B4-%255B%25282%252C4-Diamino-5-methyl-4%252C7-dihydro-3H-%2520pyrrolo%255B2%252C3-d%255Dpyrimidin-6-yl%2529thio%255Dbenzoyl%257D-l-glutamic%2520Acid%2520and%2520N-%257B4-%255B%25282-Amino-4-oxo-5-methyl-4%252C7-dihydro-3H-pyrrolo%255B2%252C3-d%255Dpyrimidin-%25206-yl%2529thio%255Dbenzoyl%257D-l-glutamic%2520Acid%2520as%2520Dual%2520Inhibitors%2520of%2520Dihydrofolate%2520Reductase%2520and%2520Thymidylate%2520Synthase%2520and%2520as%2520Potential%2520Antitumor%2520Agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D7215%26epage%3D7222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Rosowsky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forsch, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freisheim, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danenberg, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wick, M. M.</span><span> </span><span class="NLM_article-title">Methotrexate analogs. 29. Effect of γ-aminobutyric acid spacers between the pteroyl and glutamate moieties on enzyme binding and cell growth inhibition</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1872</span><span class="NLM_x">–</span> <span class="NLM_lpage">1876</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00160a014" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1986&pages=1872-1876&author=A.+Rosowskyauthor=R.+A.+Forschauthor=J.+H.+Freisheimauthor=P.+V.+Danenbergauthor=R.+G.+Moranauthor=M.+M.+Wick&title=Methotrexate+analogs.+29.+Effect+of+%CE%B3-aminobutyric+acid+spacers+between+the+pteroyl+and+glutamate+moieties+on+enzyme+binding+and+cell+growth+inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm00160a014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00160a014%26sid%3Dliteratum%253Aachs%26aulast%3DRosowsky%26aufirst%3DA.%26aulast%3DForsch%26aufirst%3DR.%2BA.%26aulast%3DFreisheim%26aufirst%3DJ.%2BH.%26aulast%3DDanenberg%26aufirst%3DP.%2BV.%26aulast%3DMoran%26aufirst%3DR.%2BG.%26aulast%3DWick%26aufirst%3DM.%2BM.%26atitle%3DMethotrexate%2520analogs.%252029.%2520Effect%2520of%2520%25CE%25B3-aminobutyric%2520acid%2520spacers%2520between%2520the%2520pteroyl%2520and%2520glutamate%2520moieties%2520on%2520enzyme%2520binding%2520and%2520cell%2520growth%2520inhibition%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1986%26volume%3D29%26spage%3D1872%26epage%3D1876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Gangjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurup, S.</span><span> </span><span class="NLM_article-title">Recent advances in classical and non-classical antifolates as antitumor and antiopportunistic infection agents: part I</span> <span class="citation_source-journal">Anti-Cancer Agents Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">524</span><span class="NLM_x">–</span> <span class="NLM_lpage">542</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=524-542&author=A.+Gangjeeauthor=H.+D.+Jainauthor=S.+Kurup&title=Recent+advances+in+classical+and+non-classical+antifolates+as+antitumor+and+antiopportunistic+infection+agents%3A+part+I"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DJain%26aufirst%3DH.%2BD.%26aulast%3DKurup%26aufirst%3DS.%26atitle%3DRecent%2520advances%2520in%2520classical%2520and%2520non-classical%2520antifolates%2520as%2520antitumor%2520and%2520antiopportunistic%2520infection%2520agents%253A%2520part%2520I%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D524%26epage%3D542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Gangjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kisliuk, R. L.</span><span> </span><span class="NLM_article-title">Potent dual thymidylate synthase and dihydrofolate reductase inhibitors: Classical and nonclassical 2-amino-4-oxo-5-arylthio-substituted-6-methylthieno[2,3-<i>d</i>]pyrimidine antifolates</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5789</span><span class="NLM_x">–</span> <span class="NLM_lpage">5797</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8006933" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5789-5797&author=A.+Gangjeeauthor=Y.+Qiuauthor=W.+Liauthor=R.+L.+Kisliuk&title=Potent+dual+thymidylate+synthase+and+dihydrofolate+reductase+inhibitors%3A+Classical+and+nonclassical+2-amino-4-oxo-5-arylthio-substituted-6-methylthieno%5B2%2C3-d%5Dpyrimidine+antifolates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm8006933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8006933%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DKisliuk%26aufirst%3DR.%2BL.%26atitle%3DPotent%2520dual%2520thymidylate%2520synthase%2520and%2520dihydrofolate%2520reductase%2520inhibitors%253A%2520Classical%2520and%2520nonclassical%25202-amino-4-oxo-5-arylthio-substituted-6-methylthieno%255B2%252C3-d%255Dpyrimidine%2520antifolates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5789%26epage%3D5797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Gangjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kisliuk, R. L.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of classical and nonclassical 2-amino-4-oxo-5-substituted-6-methylpyrrolo[3,2-<i>d</i>]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">68</span><span class="NLM_x">–</span> <span class="NLM_lpage">76</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm701052u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=68-76&author=A.+Gangjeeauthor=W.+Liauthor=J.+Yangauthor=R.+L.+Kisliuk&title=Design%2C+synthesis%2C+and+biological+evaluation+of+classical+and+nonclassical+2-amino-4-oxo-5-substituted-6-methylpyrrolo%5B3%2C2-d%5Dpyrimidines+as+dual+thymidylate+synthase+and+dihydrofolate+reductase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm701052u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701052u%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DKisliuk%26aufirst%3DR.%2BL.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520classical%2520and%2520nonclassical%25202-amino-4-oxo-5-substituted-6-methylpyrrolo%255B3%252C2-d%255Dpyrimidines%2520as%2520dual%2520thymidylate%2520synthase%2520and%2520dihydrofolate%2520reductase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D68%26epage%3D76" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Cody, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luft Joseph, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pangborn, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gangjee, A.</span><span> </span><span class="NLM_article-title">Analysis of three crystal structure determinations of a 5-methyl-6-<i>N</i>-methylanilino pyridopyrimidine antifolate complex with human dihydrofolate reductase</span> <span class="citation_source-journal">Acta Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">D59</span><span class="NLM_x">, </span> <span class="NLM_fpage">1603</span><span class="NLM_x">–</span> <span class="NLM_lpage">1609</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=D59&publication_year=2003&pages=1603-1609&author=V.+Codyauthor=R.+Luft+Josephauthor=W.+Pangbornauthor=A.+Gangjee&title=Analysis+of+three+crystal+structure+determinations+of+a+5-methyl-6-N-methylanilino+pyridopyrimidine+antifolate+complex+with+human+dihydrofolate+reductase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCody%26aufirst%3DV.%26aulast%3DLuft%2BJoseph%26aufirst%3DR.%26aulast%3DPangborn%26aufirst%3DW.%26aulast%3DGangjee%26aufirst%3DA.%26atitle%3DAnalysis%2520of%2520three%2520crystal%2520structure%2520determinations%2520of%2520a%25205-methyl-6-N-methylanilino%2520pyridopyrimidine%2520antifolate%2520complex%2520with%2520human%2520dihydrofolate%2520reductase%26jtitle%3DActa%2520Crystallogr.%26date%3D2003%26volume%3DD59%26spage%3D1603%26epage%3D1609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span>Tripos Inc., 1699 South Hanley Road, St. Louis, MO 63144.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Tripos+Inc.%2C+1699+South+Hanley+Road%2C+St.+Louis%2C+MO+63144."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Davies, J. F.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delcamp, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prendergast, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashford, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freisheim, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraut, J.</span><span> </span><span class="NLM_article-title">Crystal structures of recombinant human dihydrofolate reductase complexed with folate and 5-deazafolate</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">9467</span><span class="NLM_x">–</span> <span class="NLM_lpage">9479</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi00492a021" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADyaK3cXlsVOqtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1990&pages=9467-9479&author=J.+F.+Daviesauthor=T.+J.+Delcampauthor=N.+J.+Prendergastauthor=V.+A.+Ashfordauthor=J.+H.+Freisheimauthor=J.+Kraut&title=Crystal+structures+of+recombinant+human+dihydrofolate+reductase+complexed+with+folate+and+5-deazafolate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of recombinant human dihydrofolate reductase complexed with folate and 5-deazafolate</span></div><div class="casAuthors">Davies, Jay F., II; Delcamp, Tavner J.; Prendergast, Neal J.; Ashford, Victor A.; Freisheim, James H.; Kraut, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">9467-79</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    </div><div class="casAbstract">The 2.3 Å crystal structure of recombinant human dihydrofolate reductase (EC 1.5.1.3; DHFR) was solved as a binary complex with folate (a poor substrate at neutral pH) and also as a binary complex with an inhibitor, 5-deazafolate.  The inhibitor appeared to be protonated at N8 on binding, whereas folate was not.  Rotation of the peptide plane joining I7 and V8 from its position in the folate complex permitted H-bonding of 5-deazafolate's protonated N8 to the backbone carbonyl of I7, thus contributing to the enzyme's greater affinity for 5-deazafolate than for folate.  In this respect it is likely that bound 5-deazafolate furnishes a model for 7,8-dihydrofolate binding and, in addn., resembles the transition state for folate redn.  A hypothetical transition-state model for folate redn., generated by superposition of the DHFR binary complex, human DHFR-5-deazafolate and chicken liver DHFR-NADPH, revealed a 1 Å overlap of the binding sites for folate's pteridine ring and the dihydronicotinamide ring of NADPH.  It was proposed that this binding-site overlap accelerates the redn. of both folate and 7,8-dihydrofolate by simultaneously binding substrate and cofactor with a sub-van der Waals sepn. that is optimal for hydride transfer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC_0KLfFpXWLVg90H21EOLACvtfcHk0lisy0c_Rti9pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXlsVOqtLk%253D&md5=a27aee68329833336600b9314ee67b9b</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fbi00492a021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00492a021%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DJ.%2BF.%26aulast%3DDelcamp%26aufirst%3DT.%2BJ.%26aulast%3DPrendergast%26aufirst%3DN.%2BJ.%26aulast%3DAshford%26aufirst%3DV.%2BA.%26aulast%3DFreisheim%26aufirst%3DJ.%2BH.%26aulast%3DKraut%26aufirst%3DJ.%26atitle%3DCrystal%2520structures%2520of%2520recombinant%2520human%2520dihydrofolate%2520reductase%2520complexed%2520with%2520folate%2520and%25205-deazafolate%26jtitle%3DBiochemistry%26date%3D1990%26volume%3D29%26spage%3D9467%26epage%3D9479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Oefner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D'Arcy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winkler, F. K.</span><span> </span><span class="NLM_article-title">Crystal structure of human dihydrofolate reductase complexed with folate</span> <span class="citation_source-journal">Eur. J. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">174</span><span class="NLM_x">, </span> <span class="NLM_fpage">377</span><span class="NLM_x">–</span> <span class="NLM_lpage">385</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1111%2Fj.1432-1033.1988.tb14108.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=3383852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADyaL1cXktlCnsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=1988&pages=377-385&author=C.+Oefnerauthor=A.+D%27Arcyauthor=F.+K.+Winkler&title=Crystal+structure+of+human+dihydrofolate+reductase+complexed+with+folate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of human dihydrofolate reductase complexed with folate</span></div><div class="casAuthors">Oefner, Christian; D'Arcy, Allan; Winkler, Fritz K.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">377-85</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    </div><div class="casAbstract">The crystal structure of recombinant human dihydrofolate reductase with folate bound in the active site was detd. and the structural model refined at 0.2-nm resoln.  Preliminary studies of the binding of the inhibitors, methotrexate and trimethoprim, to the human apoenzyme were performed at 0.35-nm resoln.  The conformations of the chem. very similar ligands, folate and methotrexate, one a substrate the other a potent inhibitor, differed substantially in that their pteridine rings were in inverse orientations relative to their p-aminobenzoyl-L-glutamate moieties.  Methotrexate binding was similar to that previously obsd. in 2 bacterial enzymes but was quite different from that obsd. in the enzyme from a mouse lymphoma cell line.  The geometry of the polypeptide chain around the folate-binding site in the human enzyme was not consistent with conclusions previously drawn with regard to the species selectivity of the inhibitor, trimethoprim.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqThLSy_vselbVg90H21EOLACvtfcHk0lgU3FJEvM0w-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXktlCnsLs%253D&md5=84c62c6d99c9a0892c9c1b794327c72d</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1111%2Fj.1432-1033.1988.tb14108.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1432-1033.1988.tb14108.x%26sid%3Dliteratum%253Aachs%26aulast%3DOefner%26aufirst%3DC.%26aulast%3DD%2527Arcy%26aufirst%3DA.%26aulast%3DWinkler%26aufirst%3DF.%2BK.%26atitle%3DCrystal%2520structure%2520of%2520human%2520dihydrofolate%2520reductase%2520complexed%2520with%2520folate%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D1988%26volume%3D174%26spage%3D377%26epage%3D385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Sayre, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finer-Moore, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritz, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biermann, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gates, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacKellar, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stroud, R. M.</span><span> </span><span class="NLM_article-title">Multi-targeted antifolates aimed at avoiding drug resistance form covalent closed inhibitory complexes with human and <i>Escherichia coli</i> thymidylate synthases</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">313</span><span class="NLM_x">, </span> <span class="NLM_fpage">813</span><span class="NLM_x">–</span> <span class="NLM_lpage">829</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=2001&pages=813-829&author=P.+H.+Sayreauthor=J.+S.+Finer-Mooreauthor=T.+A.+Fritzauthor=D.+Biermannauthor=S.+B.+Gatesauthor=W.+C.+MacKellarauthor=V.+F.+Patelauthor=R.+M.+Stroud&title=Multi-targeted+antifolates+aimed+at+avoiding+drug+resistance+form+covalent+closed+inhibitory+complexes+with+human+and+Escherichia+coli+thymidylate+synthases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSayre%26aufirst%3DP.%2BH.%26aulast%3DFiner-Moore%26aufirst%3DJ.%2BS.%26aulast%3DFritz%26aufirst%3DT.%2BA.%26aulast%3DBiermann%26aufirst%3DD.%26aulast%3DGates%26aufirst%3DS.%2BB.%26aulast%3DMacKellar%26aufirst%3DW.%2BC.%26aulast%3DPatel%26aufirst%3DV.%2BF.%26aulast%3DStroud%26aufirst%3DR.%2BM.%26atitle%3DMulti-targeted%2520antifolates%2520aimed%2520at%2520avoiding%2520drug%2520resistance%2520form%2520covalent%2520closed%2520inhibitory%2520complexes%2520with%2520human%2520and%2520Escherichia%2520coli%2520thymidylate%2520synthases%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2001%26volume%3D313%26spage%3D813%26epage%3D829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Miyazaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsunaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philippe, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibahara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolte, R. T.</span><span> </span><span class="NLM_article-title">Novel 4-aminofuro[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">2203</span><span class="NLM_x">–</span> <span class="NLM_lpage">2207</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=2203-2207&author=Y.+Miyazakiauthor=S.+Matsunagaauthor=J.+Tangauthor=Y.+Maedaauthor=M.+Nakanoauthor=R.+J.+Philippeauthor=M.+Shibaharaauthor=W.+Liuauthor=H.+Satoauthor=L.+Wangauthor=R.+T.+Nolte&title=Novel+4-aminofuro%5B2%2C3-d%5Dpyrimidines+as+Tie-2+and+VEGFR2+dual+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiyazaki%26aufirst%3DY.%26aulast%3DMatsunaga%26aufirst%3DS.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DMaeda%26aufirst%3DY.%26aulast%3DNakano%26aufirst%3DM.%26aulast%3DPhilippe%26aufirst%3DR.%2BJ.%26aulast%3DShibahara%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DSato%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DNolte%26aufirst%3DR.%2BT.%26atitle%3DNovel%25204-aminofuro%255B2%252C3-d%255Dpyrimidines%2520as%2520Tie-2%2520and%2520VEGFR2%2520dual%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D2203%26epage%3D2207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Mol, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sridhar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chien, E. Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, B.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nowakowski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kassel, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cronin, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McRee, D. E.</span><span> </span><span class="NLM_article-title">Structure of a c-Kit product complex reveals the basis for kinase transactivation</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">31461</span><span class="NLM_x">–</span> <span class="NLM_lpage">31464</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1074%2Fjbc.C300186200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=12824176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmsVOnsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=31461-31464&author=C.+D.+Molauthor=K.+B.+Limauthor=V.+Sridharauthor=H.+Zouauthor=E.+Y.+T.+Chienauthor=B.-C.+Sangauthor=J.+Nowakowskiauthor=D.+B.+Kasselauthor=C.+N.+Croninauthor=D.+E.+McRee&title=Structure+of+a+c-Kit+product+complex+reveals+the+basis+for+kinase+transactivation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of a c-Kit Product Complex Reveals the Basis for Kinase Transactivation</span></div><div class="casAuthors">Mol, Clifford D.; Lim, Kheng B.; Sridhar, Vandana; Zou, Hua; Chien, Ellen Y. T.; Sang, Bi-Ching; Nowakowski, Jacek; Kassel, Daniel B.; Cronin, Ciaran N.; McRee, Duncan E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">31461-31464</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The c-Kit proto-oncogene is a receptor protein-tyrosine kinase assocd. with several highly malignant human cancers.  Upon binding its ligand, stem cell factor (SCF), c-Kit forms an active dimer that autophosphorylates itself and activates a signaling cascade that induces cell growth.  Disease-causing human mutations that activate SCF-independent constitutive expression of c-Kit are found in acute myelogenous leukemia, human mast cell disease, and gastrointestinal stromal tumors.  We report on the phosphorylation state and crystal structure of a c-Kit product complex.  The c-Kit structure is in a fully active form, with ordered kinase activation and phosphate-binding loops.  These results provide key insights into the mol. basis for c-Kit kinase transactivation to assist in the design of new competitive inhibitors targeting activated mutant forms of c-Kit that are resistant to current chemotherapy regimes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv0eZJ9UHNILVg90H21EOLACvtfcHk0lgU3FJEvM0w-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmsVOnsb0%253D&md5=f537b5c9903adb6cc057406bd20f0f5a</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1074%2Fjbc.C300186200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.C300186200%26sid%3Dliteratum%253Aachs%26aulast%3DMol%26aufirst%3DC.%2BD.%26aulast%3DLim%26aufirst%3DK.%2BB.%26aulast%3DSridhar%26aufirst%3DV.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChien%26aufirst%3DE.%2BY.%2BT.%26aulast%3DSang%26aufirst%3DB.-C.%26aulast%3DNowakowski%26aufirst%3DJ.%26aulast%3DKassel%26aufirst%3DD.%2BB.%26aulast%3DCronin%26aufirst%3DC.%2BN.%26aulast%3DMcRee%26aufirst%3DD.%2BE.%26atitle%3DStructure%2520of%2520a%2520c-Kit%2520product%2520complex%2520reveals%2520the%2520basis%2520for%2520kinase%2520transactivation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D31461%26epage%3D31464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span>Molecular Operating environment (MOE 2007.09), C. C. G., Inc., 1255 University Street, Suite 1600, Montreal, Quebec, Canada, H3B 3X3.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Molecular+Operating+environment+%28MOE+2007.09%29%2C+C.+C.+G.%2C+Inc.%2C+1255+University+Street%2C+Suite+1600%2C+Montreal%2C+Quebec%2C+Canada%2C+H3B+3X3."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Operating%2520environment%2520%2528MOE%25202007.09%2529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Altschul, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koonin, E. V.</span><span> </span><span class="NLM_article-title">Iterated profile searches with PSI-BLAST - a tool for discovery in protein databases</span> <span class="citation_source-journal">Trends Biochem. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">444</span><span class="NLM_x">–</span> <span class="NLM_lpage">447</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1998&pages=444-447&author=S.+F.+Altschulauthor=E.+V.+Koonin&title=Iterated+profile+searches+with+PSI-BLAST+-+a+tool+for+discovery+in+protein+databases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAltschul%26aufirst%3DS.%2BF.%26aulast%3DKoonin%26aufirst%3DE.%2BV.%26atitle%3DIterated%2520profile%2520searches%2520with%2520PSI-BLAST%2520-%2520a%2520tool%2520for%2520discovery%2520in%2520protein%2520databases%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D1998%26volume%3D23%26spage%3D444%26epage%3D447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Gallivan, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dougherty, D. A.</span><span> </span><span class="NLM_article-title">Cation-pi interactions in structural biology</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">9459</span><span class="NLM_x">–</span> <span class="NLM_lpage">9464</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1073%2Fpnas.96.17.9459" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=10449714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADyaK1MXlsVymsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=9459-9464&author=J.+P.+Gallivanauthor=D.+A.+Dougherty&title=Cation-pi+interactions+in+structural+biology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Cation-π interactions in structural biology</span></div><div class="casAuthors">Gallivan, Justin P.; Dougherty, Dennis A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">9459-9464</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Cation-π interactions in protein structures are identified and evaluated by using an energy-based criterion for selecting significant side-chain pairs.  Cation-π interactions are found to be common among structures in the Protein Data Bank, and it is clearly demonstrated that, when a cationic side-chain (Lys or Arg) is near an arom. side-chain (Phe, Tyr, or Trp), the geometry is biased toward one that would experience a favorable cation-π interaction.  The side-chain of Arg is more likely than that of Lys to be in a cation-π interaction.  Among the aroms., a strong bias toward Trp is clear, such that over one-fourth of all tryptophans in the data bank experience an energetically significant cation-π interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7r9RXU9TpNbVg90H21EOLACvtfcHk0liT5J4ktG3Wzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlsVymsr8%253D&md5=515e9cf97e9e5dcedbd13ce9f4dfdfb5</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1073%2Fpnas.96.17.9459&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.96.17.9459%26sid%3Dliteratum%253Aachs%26aulast%3DGallivan%26aufirst%3DJ.%2BP.%26aulast%3DDougherty%26aufirst%3DD.%2BA.%26atitle%3DCation-pi%2520interactions%2520in%2520structural%2520biology%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1999%26volume%3D96%26spage%3D9459%26epage%3D9464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Mahboobi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uecker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellmer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cenac, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoecher, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pongratz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eichhorn, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hufsky, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truempler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sicker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heidel, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stocking, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boehmer, F.-D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dove, S.</span><span> </span><span class="NLM_article-title">Novel bis(1h-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">3101</span><span class="NLM_x">–</span> <span class="NLM_lpage">3115</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm058033i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=3101-3115&author=S.+Mahboobiauthor=A.+Ueckerauthor=A.+Sellmerauthor=C.+Cenacauthor=H.+Hoecherauthor=H.+Pongratzauthor=E.+Eichhornauthor=H.+Hufskyauthor=A.+Truemplerauthor=M.+Sickerauthor=F.+Heidelauthor=T.+Fischerauthor=C.+Stockingauthor=S.+Elzauthor=F.-D.+Boehmerauthor=S.+Dove&title=Novel+bis%281h-indol-2-yl%29methanones+as+potent+inhibitors+of+FLT3+and+platelet-derived+growth+factor+receptor+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fjm058033i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058033i%26sid%3Dliteratum%253Aachs%26aulast%3DMahboobi%26aufirst%3DS.%26aulast%3DUecker%26aufirst%3DA.%26aulast%3DSellmer%26aufirst%3DA.%26aulast%3DCenac%26aufirst%3DC.%26aulast%3DHoecher%26aufirst%3DH.%26aulast%3DPongratz%26aufirst%3DH.%26aulast%3DEichhorn%26aufirst%3DE.%26aulast%3DHufsky%26aufirst%3DH.%26aulast%3DTruempler%26aufirst%3DA.%26aulast%3DSicker%26aufirst%3DM.%26aulast%3DHeidel%26aufirst%3DF.%26aulast%3DFischer%26aufirst%3DT.%26aulast%3DStocking%26aufirst%3DC.%26aulast%3DElz%26aufirst%3DS.%26aulast%3DBoehmer%26aufirst%3DF.-D.%26aulast%3DDove%26aufirst%3DS.%26atitle%3DNovel%2520bis%25281h-indol-2-yl%2529methanones%2520as%2520potent%2520inhibitors%2520of%2520FLT3%2520and%2520platelet-derived%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D3101%26epage%3D3115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Henderson, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bavetsias, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theti, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clauss, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackman, A. L.</span><span> </span><span class="NLM_article-title">Targeting the a-folate receptor with cyclopenta[g]quinazoline-based inhibitors of thymidylate synthase</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">5020</span><span class="NLM_x">–</span> <span class="NLM_lpage">5042</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=5020-5042&author=E.+A.+Hendersonauthor=V.+Bavetsiasauthor=D.+S.+Thetiauthor=S.+C.+Wilsonauthor=R.+Claussauthor=A.+L.+Jackman&title=Targeting+the+a-folate+receptor+with+cyclopenta%5Bg%5Dquinazoline-based+inhibitors+of+thymidylate+synthase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHenderson%26aufirst%3DE.%2BA.%26aulast%3DBavetsias%26aufirst%3DV.%26aulast%3DTheti%26aufirst%3DD.%2BS.%26aulast%3DWilson%26aufirst%3DS.%2BC.%26aulast%3DClauss%26aufirst%3DR.%26aulast%3DJackman%26aufirst%3DA.%2BL.%26atitle%3DTargeting%2520the%2520a-folate%2520receptor%2520with%2520cyclopenta%255Bg%255Dquinazoline-based%2520inhibitors%2520of%2520thymidylate%2520synthase%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26spage%3D5020%26epage%3D5042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Griffith, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faerman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swenson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wynn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippke, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saxena, K.</span><span> </span><span class="NLM_article-title">The structural basis for autoinhibition of FLT3 by the juxtamembrane domain</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">178</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1016%2FS1097-2765%2803%2900505-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=14759363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFOiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2004&pages=169-178&author=J.+Griffithauthor=J.+Blackauthor=C.+Faermanauthor=L.+Swensonauthor=M.+Wynnauthor=F.+Luauthor=J.+Lippkeauthor=K.+Saxena&title=The+structural+basis+for+autoinhibition+of+FLT3+by+the+juxtamembrane+domain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">The structural basis for autoinhibition of FLT3 by the juxtamembrane domain</span></div><div class="casAuthors">Griffith, James; Black, James; Faerman, Carlos; Swenson, Lora; Wynn, Michael; Lu, Fan; Lippke, Judith; Saxena, Kumkum</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">169-178</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">FLT3 is a type III receptor tyrosine kinase that is thought to play a key role in hematopoiesis.  Certain classes of FLT3 mutations cause constitutively activated forms of the receptor that are found in significant nos. of patients with acute myelogenous leukemia (AML).  The mutations occur either in the activation loop, for example, as point mutations of Asp835 or as internal tandem duplication (ITD) sequences in the juxtamembrane (JM) domain.  To further understand the nature of FLT3 autoinhibition and regulation, we have detd. the crystal structure of the autoinhibited form of FLT3.  This structure shows the autoinhibitory conformation of a complete JM domain in this class of receptor tyrosine kinases.  The detailed inhibitory mechanism of the JM domain is revealed, which is likely utilized by other members of type III receptor tyrosine kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJAabT6TBxpLVg90H21EOLACvtfcHk0liT5J4ktG3Wzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFOiu7g%253D&md5=d1df4a37aac59f5b59ca242fc8ccd6da</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2803%2900505-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252803%252900505-7%26sid%3Dliteratum%253Aachs%26aulast%3DGriffith%26aufirst%3DJ.%26aulast%3DBlack%26aufirst%3DJ.%26aulast%3DFaerman%26aufirst%3DC.%26aulast%3DSwenson%26aufirst%3DL.%26aulast%3DWynn%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DF.%26aulast%3DLippke%26aufirst%3DJ.%26aulast%3DSaxena%26aufirst%3DK.%26atitle%3DThe%2520structural%2520basis%2520for%2520autoinhibition%2520of%2520FLT3%2520by%2520the%2520juxtamembrane%2520domain%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D13%26spage%3D169%26epage%3D178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Hennessy, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ram, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, G. B.</span><span> </span><span class="NLM_article-title">Exploiting the PI3K/AKT pathway for cancer drug discovery</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">988</span><span class="NLM_x">–</span> <span class="NLM_lpage">1004</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1038%2Fnrd1902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=16341064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1yktbjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=988-1004&author=B.+T.+Hennessyauthor=D.+L.+Smithauthor=P.+T.+Ramauthor=Y.+Luauthor=G.+B.+Mills&title=Exploiting+the+PI3K%2FAKT+pathway+for+cancer+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery</span></div><div class="casAuthors">Hennessy, Bryan T.; Smith, Debra L.; Ram, Prahlad T.; Lu, Yiling; Mills, Gordon B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">988-1004</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Evolving studies with several different targeted therapeutic agents are demonstrating that patients with genomic alterations of the target, including amplification, translocation and mutation, are more likely to respond to the therapy.  Recent studies indicate that numerous components of the phosphatidylinositol-3-kinase (PI3K)/AKT pathway are targeted by amplification, mutation and translocation more frequently than any other pathway in cancer patients, with resultant activation of the pathway.  This warrants exploiting the PI3K/AKT pathway for cancer drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq40Fg-hLrrMbVg90H21EOLACvtfcHk0lgS9wFX9PfXxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1yktbjI&md5=faecabc3a6799137d133afb37d139ceb</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1038%2Fnrd1902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1902%26sid%3Dliteratum%253Aachs%26aulast%3DHennessy%26aufirst%3DB.%2BT.%26aulast%3DSmith%26aufirst%3DD.%2BL.%26aulast%3DRam%26aufirst%3DP.%2BT.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DMills%26aufirst%3DG.%2BB.%26atitle%3DExploiting%2520the%2520PI3K%252FAKT%2520pathway%2520for%2520cancer%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2005%26volume%3D4%26spage%3D988%26epage%3D1004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Ihnat, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaltreider, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorpe, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamat, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeper, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shanner, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warnke, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piconi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceriello, A.</span><span> </span><span class="NLM_article-title">Attenuated superoxide dismutase induction in retinal cells in response to intermittent high versus continuous high glucose</span> <span class="citation_source-journal">Am. J. Biochem. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">16</span><span class="NLM_x">–</span> <span class="NLM_lpage">23</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.3844%2Fajbbsp.2007.16.23" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVCktbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=16-23&author=M.+A.+Ihnatauthor=R.+C.+Kaltreiderauthor=J.+E.+Thorpeauthor=D.+E.+Greenauthor=C.+D.+Kamatauthor=M.+Leeperauthor=A.+C.+Shannerauthor=L.+A.+Warnkeauthor=L.+Piconiauthor=A.+Ceriello&title=Attenuated+superoxide+dismutase+induction+in+retinal+cells+in+response+to+intermittent+high+versus+continuous+high+glucose"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Attenuated superoxide dismutase induction in retinal cells in response to intermittent high versus continuous high glucose</span></div><div class="casAuthors">Ihnat, Michael A.; Kaltreider, Ronald C.; Thorpe, Jessica E.; Green, Dixy E.; Kamat, Chandrashekhar D.; Leeper, Melissa; Shanner, Amanda C.; Warnke, Linda A.; Piconi, Ludovica; Ceriello, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Biochemistry and Biotechnology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16-23</span>CODEN:
                <span class="NLM_cas:coden">AJBBA5</span>;
        ISSN:<span class="NLM_cas:issn">1553-3468</span>.
    
            (<span class="NLM_cas:orgname">Science Publications</span>)
        </div><div class="casAbstract">High glucose, particularly in oscillating conditions, produces an increase in oxidative stress and has been shown to result in an increase in diabetic complications, retinopathy in particular.  The hypothesis of this work was that chronic exposure to intermittent high glucose results in an attenuated induction of an antioxidant response as compared to continuous high glucose exposure in isolated retinal cells In this work, human retinal pericytes and ARPE-19 cells were exposed to 5 mM or 30 mM continuous high glucose or to 5 mM oscillating daily with 30 mM glucose for 14 days.  Levels of antioxidant proteins and activity and levels of reactive species protein adducts were measured.  We demonstrate that the induction of total cellular superoxide dismutase (SOD) activity in isolated retinal pericytes and ARPE-19 cells is significantly attenuated in response to oscillating glucose as compared to continuous high glucose.  We also show that a marker of nitrosative stress, 3-nitrotyrosine and a general marker of oxidized proteins, OxyBlot, were significantly increased in both cell types exposed to intermittent high glucose as compared to continuous high glucose.  Finally, we show that levels of nitrated MnSOD were increased in response to intermittent high vs. continuous high glucose and that the addn. of a reactive nitrogen species scavenger to oscillating glucose resulted in significantly increased levels of SOD activity.  In conclusion, our results demonstrate for the first time a link between intermittent high glucose and a decreased induction of an antioxidant response of SOD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCThEyRZGfArVg90H21EOLACvtfcHk0lgS9wFX9PfXxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVCktbo%253D&md5=f68f2f1d1e039e5e0492b7e1317573b2</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.3844%2Fajbbsp.2007.16.23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3844%252Fajbbsp.2007.16.23%26sid%3Dliteratum%253Aachs%26aulast%3DIhnat%26aufirst%3DM.%2BA.%26aulast%3DKaltreider%26aufirst%3DR.%2BC.%26aulast%3DThorpe%26aufirst%3DJ.%2BE.%26aulast%3DGreen%26aufirst%3DD.%2BE.%26aulast%3DKamat%26aufirst%3DC.%2BD.%26aulast%3DLeeper%26aufirst%3DM.%26aulast%3DShanner%26aufirst%3DA.%2BC.%26aulast%3DWarnke%26aufirst%3DL.%2BA.%26aulast%3DPiconi%26aufirst%3DL.%26aulast%3DCeriello%26aufirst%3DA.%26atitle%3DAttenuated%2520superoxide%2520dismutase%2520induction%2520in%2520retinal%2520cells%2520in%2520response%2520to%2520intermittent%2520high%2520versus%2520continuous%2520high%2520glucose%26jtitle%3DAm.%2520J.%2520Biochem.%2520Biotechnol.%26date%3D2007%26volume%3D3%26spage%3D16%26epage%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Schroeder, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamby, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connolly, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grohar, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winters, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barvian, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boushelle, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crean, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Driscoll, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batley, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahring, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Major, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panek, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D.</span><span> </span><span class="NLM_article-title">Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">1915</span><span class="NLM_x">–</span> <span class="NLM_lpage">1926</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0004291" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=1915-1926&author=M.+C.+Schroederauthor=J.+M.+Hambyauthor=C.+J.+Connollyauthor=P.+J.+Groharauthor=R.+T.+Wintersauthor=M.+R.+Barvianauthor=C.+W.+Mooreauthor=S.+L.+Boushelleauthor=S.+M.+Creanauthor=A.+J.+Krakerauthor=D.+L.+Driscollauthor=P.+W.+Vincentauthor=W.+L.+Elliottauthor=G.+H.+Luauthor=B.+L.+Batleyauthor=T.+K.+Dahringauthor=T.+C.+Majorauthor=R.+L.+Panekauthor=A.+M.+Dohertyauthor=H.+D.+Showalter&title=Soluble+2-substituted+aminopyrido%5B2%2C3-d%5Dpyrimidin-7-yl+ureas.+Structure-activity+relationships+against+selected+tyrosine+kinases+and+exploration+of+in+vitro+and+in+vivo+anticancer+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fjm0004291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0004291%26sid%3Dliteratum%253Aachs%26aulast%3DSchroeder%26aufirst%3DM.%2BC.%26aulast%3DHamby%26aufirst%3DJ.%2BM.%26aulast%3DConnolly%26aufirst%3DC.%2BJ.%26aulast%3DGrohar%26aufirst%3DP.%2BJ.%26aulast%3DWinters%26aufirst%3DR.%2BT.%26aulast%3DBarvian%26aufirst%3DM.%2BR.%26aulast%3DMoore%26aufirst%3DC.%2BW.%26aulast%3DBoushelle%26aufirst%3DS.%2BL.%26aulast%3DCrean%26aufirst%3DS.%2BM.%26aulast%3DKraker%26aufirst%3DA.%2BJ.%26aulast%3DDriscoll%26aufirst%3DD.%2BL.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DLu%26aufirst%3DG.%2BH.%26aulast%3DBatley%26aufirst%3DB.%2BL.%26aulast%3DDahring%26aufirst%3DT.%2BK.%26aulast%3DMajor%26aufirst%3DT.%2BC.%26aulast%3DPanek%26aufirst%3DR.%2BL.%26aulast%3DDoherty%26aufirst%3DA.%2BM.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%26atitle%3DSoluble%25202-substituted%2520aminopyrido%255B2%252C3-d%255Dpyrimidin-7-yl%2520ureas.%2520Structure-activity%2520relationships%2520against%2520selected%2520tyrosine%2520kinases%2520and%2520exploration%2520of%2520in%2520vitro%2520and%2520in%2520vivo%2520anticancer%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D1915%26epage%3D1926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Zaman, G. J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vink, P. M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van den Doelen, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veeneman, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theunissen, H. J. M.</span><span> </span><span class="NLM_article-title">Tyrosine kinase activity of purified recombinant cytoplasmic domain of platelet-derived growth factor β-receptor (β-PDGFR) and discovery of a novel inhibitor of receptor tyrosine kinases</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">57</span><span class="NLM_x">–</span> <span class="NLM_lpage">64</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1999&pages=57-64&author=G.+J.+R.+Zamanauthor=P.+M.+F.+Vinkauthor=A.+A.+van+den+Doelenauthor=G.+H.+Veenemanauthor=H.+J.+M.+Theunissen&title=Tyrosine+kinase+activity+of+purified+recombinant+cytoplasmic+domain+of+platelet-derived+growth+factor+%CE%B2-receptor+%28%CE%B2-PDGFR%29+and+discovery+of+a+novel+inhibitor+of+receptor+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZaman%26aufirst%3DG.%2BJ.%2BR.%26aulast%3DVink%26aufirst%3DP.%2BM.%2BF.%26aulast%3Dvan%2Bden%2BDoelen%26aufirst%3DA.%2BA.%26aulast%3DVeeneman%26aufirst%3DG.%2BH.%26aulast%3DTheunissen%26aufirst%3DH.%2BJ.%2BM.%26atitle%3DTyrosine%2520kinase%2520activity%2520of%2520purified%2520recombinant%2520cytoplasmic%2520domain%2520of%2520platelet-derived%2520growth%2520factor%2520%25CE%25B2-receptor%2520%2528%25CE%25B2-PDGFR%2529%2520and%2520discovery%2520of%2520a%2520novel%2520inhibitor%2520of%2520receptor%2520tyrosine%2520kinases%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1999%26volume%3D57%26spage%3D57%26epage%3D64" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Mori, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirokawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satomi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aburada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyamoto, K.-i.</span><span> </span><span class="NLM_article-title">Structure activity relationships of quinoxalin-2-one derivatives as platelet-derived growth factor-β receptor (PDGF β R) inhibitors, derived from molecular modeling</span> <span class="citation_source-journal">Chem. Pharm. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">682</span><span class="NLM_x">–</span> <span class="NLM_lpage">687</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2008&pages=682-687&author=Y.+Moriauthor=T.+Hirokawaauthor=K.+Aokiauthor=H.+Satomiauthor=S.+Takedaauthor=M.+Aburadaauthor=K.-i.+Miyamoto&title=Structure+activity+relationships+of+quinoxalin-2-one+derivatives+as+platelet-derived+growth+factor-%CE%B2+receptor+%28PDGF+%CE%B2+R%29+inhibitors%2C+derived+from+molecular+modeling"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DY.%26aulast%3DHirokawa%26aufirst%3DT.%26aulast%3DAoki%26aufirst%3DK.%26aulast%3DSatomi%26aufirst%3DH.%26aulast%3DTakeda%26aufirst%3DS.%26aulast%3DAburada%26aufirst%3DM.%26aulast%3DMiyamoto%26aufirst%3DK.-i.%26atitle%3DStructure%2520activity%2520relationships%2520of%2520quinoxalin-2-one%2520derivatives%2520as%2520platelet-derived%2520growth%2520factor-%25CE%25B2%2520receptor%2520%2528PDGF%2520%25CE%25B2%2520R%2529%2520inhibitors%252C%2520derived%2520from%2520molecular%2520modeling%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D2008%26volume%3D56%26spage%3D682%26epage%3D687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">Ward, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGuffin, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buxton, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D. T.</span><span> </span><span class="NLM_article-title">The DISOPRED server for the prediction of protein disorder</span> <span class="citation_source-journal">Bioinformatics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">2138</span><span class="NLM_x">–</span> <span class="NLM_lpage">2139</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1093%2Fbioinformatics%2Fbth195" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=15044227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsVyitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2004&pages=2138-2139&author=J.+J.+Wardauthor=L.+J.+McGuffinauthor=K.+Brysonauthor=B.+F.+Buxtonauthor=D.+T.+Jones&title=The+DISOPRED+server+for+the+prediction+of+protein+disorder"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">The DISOPRED server for the prediction of protein disorder</span></div><div class="casAuthors">Ward, Jonathan J.; McGuffin, Liam J.; Bryson, Kevin; Buxton, Bernard F.; Jones, David T.</div><div class="citationInfo"><span class="NLM_cas:title">Bioinformatics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2138-2139</span>CODEN:
                <span class="NLM_cas:coden">BOINFP</span>;
        ISSN:<span class="NLM_cas:issn">1367-4803</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Dynamically disordered regions appear to be relatively abundant in eukaryotic proteomes.  The DISOPRED server allows users to submit a protein sequence, and returns a probability est. of each residue in the sequence being disordered.  The results are sent in both plain text and graphical formats, and the server can also supply predictions of secondary structure to provide further structural information.  The server can be accessed by non-com. users at http://bioinf.cs.ucl.ac.uk/disopred/.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo73X8S8FYxj7Vg90H21EOLACvtfcHk0liynDEdeHkLXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsVyitLs%253D&md5=aa675b1ed2c09ffd30ae54cd0d1b3ce5</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1093%2Fbioinformatics%2Fbth195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbioinformatics%252Fbth195%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DJ.%2BJ.%26aulast%3DMcGuffin%26aufirst%3DL.%2BJ.%26aulast%3DBryson%26aufirst%3DK.%26aulast%3DBuxton%26aufirst%3DB.%2BF.%26aulast%3DJones%26aufirst%3DD.%2BT.%26atitle%3DThe%2520DISOPRED%2520server%2520for%2520the%2520prediction%2520of%2520protein%2520disorder%26jtitle%3DBioinformatics%26date%3D2004%26volume%3D20%26spage%3D2138%26epage%3D2139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group">Wilson, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barsoum, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pappone, P. A.</span><span> </span><span class="NLM_article-title">Purine nucleotides modulate proliferation of brown fat preadipocytes</span> <span class="citation_source-journal">Cell Proliferation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">–</span> <span class="NLM_lpage">140</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1999&pages=131-140&author=S.+M.+Wilsonauthor=M.+J.+Barsoumauthor=B.+W.+Wilsonauthor=P.+A.+Pappone&title=Purine+nucleotides+modulate+proliferation+of+brown+fat+preadipocytes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DS.%2BM.%26aulast%3DBarsoum%26aufirst%3DM.%2BJ.%26aulast%3DWilson%26aufirst%3DB.%2BW.%26aulast%3DPappone%26aufirst%3DP.%2BA.%26atitle%3DPurine%2520nucleotides%2520modulate%2520proliferation%2520of%2520brown%2520fat%2520preadipocytes%26jtitle%3DCell%2520Proliferation%26date%3D1999%26volume%3D32%26spage%3D131%26epage%3D140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group">Maurer, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihnat, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pullman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Brien, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasey, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornwell, M. M.</span><span> </span><span class="NLM_article-title">Growth of human tumor cells in macroporous microcarriers results in p53-independent, decreased cisplatin sensitivity relative to monolayers</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">938</span><span class="NLM_x">–</span> <span class="NLM_lpage">947</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1999&pages=938-947&author=B.+J.+Maurerauthor=M.+A.+Ihnatauthor=C.+Morganauthor=J.+Pullmanauthor=C.+O%27Brienauthor=S.+W.+Johnsonauthor=J.+S.+Raseyauthor=M.+M.+Cornwell&title=Growth+of+human+tumor+cells+in+macroporous+microcarriers+results+in+p53-independent%2C+decreased+cisplatin+sensitivity+relative+to+monolayers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMaurer%26aufirst%3DB.%2BJ.%26aulast%3DIhnat%26aufirst%3DM.%2BA.%26aulast%3DMorgan%26aufirst%3DC.%26aulast%3DPullman%26aufirst%3DJ.%26aulast%3DO%2527Brien%26aufirst%3DC.%26aulast%3DJohnson%26aufirst%3DS.%2BW.%26aulast%3DRasey%26aufirst%3DJ.%2BS.%26aulast%3DCornwell%26aufirst%3DM.%2BM.%26atitle%3DGrowth%2520of%2520human%2520tumor%2520cells%2520in%2520macroporous%2520microcarriers%2520results%2520in%2520p53-independent%252C%2520decreased%2520cisplatin%2520sensitivity%2520relative%2520to%2520monolayers%26jtitle%3DMol.%2520Pharmacol.%26date%3D1999%26volume%3D55%26spage%3D938%26epage%3D947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group">Fong, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shawver, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">App, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreck, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Risau, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirth, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMahon, G.</span><span> </span><span class="NLM_article-title">SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">99</span><span class="NLM_x">–</span> <span class="NLM_lpage">106</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=9892193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADyaK1MXmsFOgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1999&pages=99-106&author=T.+A.+Fongauthor=L.+K.+Shawverauthor=L.+Sunauthor=C.+Tangauthor=H.+Appauthor=T.+J.+Powellauthor=Y.+H.+Kimauthor=R.+Schreckauthor=X.+Wangauthor=W.+Risauauthor=A.+Ullrichauthor=K.+P.+Hirthauthor=G.+McMahon&title=SU5416+is+a+potent+and+selective+inhibitor+of+the+vascular+endothelial+growth+factor+receptor+%28Flk-1%2FKDR%29+that+inhibits+tyrosine+kinase+catalysis%2C+tumor+vascularization%2C+and+growth+of+multiple+tumor+types"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types</span></div><div class="casAuthors">Fong, T. Annie T.; Shawver, Laura K.; Sun, Li; Tang, Cho; App, Harald; Powell, T. Jeff; Kim, Young H.; Schreck, Randall; Wang, Xueyan; Risau, Werner; Ullrich, Axel; Hirth, K. Peter; McMahon, Gerald</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">99-106</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">AACR Subscription Office</span>)
        </div><div class="casAbstract">SU5416, a novel synthetic compd., is a potent and selective inhibitor of the Flk-1/KDR receptor tyrosine kinase that is presently under evaluation in Phase I clin. studies for the treatment of human cancers.  SU5416 was shown to inhibit vascular endothelial growth factor-dependent mitogenesis of human endothelial cells without inhibiting the growth of a variety of tumor cells in vitro.  In contrast, systemic administration of SU5416 at nontoxic doses in mice resulted in inhibition of s.c. tumor growth of cells derived from various tissue origins.  The antitumor effect of SU5416 was accompanied by the appearance of pale white tumors that were resected from drug-treated animals, supporting the antiangiogenic property of this agent.  These findings support that pharmacol. inhibition of the enzymic activity of the vascular endothelial growth factor receptor represents a novel strategy for limiting the growth of a wide variety of tumor types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiq1KqJ-CsCrVg90H21EOLACvtfcHk0liynDEdeHkLXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmsFOgug%253D%253D&md5=92a2610ecfcdc996a6a79b0b559c4852</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFong%26aufirst%3DT.%2BA.%26aulast%3DShawver%26aufirst%3DL.%2BK.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DApp%26aufirst%3DH.%26aulast%3DPowell%26aufirst%3DT.%2BJ.%26aulast%3DKim%26aufirst%3DY.%2BH.%26aulast%3DSchreck%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DRisau%26aufirst%3DW.%26aulast%3DUllrich%26aufirst%3DA.%26aulast%3DHirth%26aufirst%3DK.%2BP.%26aulast%3DMcMahon%26aufirst%3DG.%26atitle%3DSU5416%2520is%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520the%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520%2528Flk-1%252FKDR%2529%2520that%2520inhibits%2520tyrosine%2520kinase%2520catalysis%252C%2520tumor%2520vascularization%252C%2520and%2520growth%2520of%2520multiple%2520tumor%2520types%26jtitle%3DCancer%2520Res.%26date%3D1999%26volume%3D59%26spage%3D99%26epage%3D106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group">Stockwell, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haggarty, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreiber, S. L.</span><span> </span><span class="NLM_article-title">High-throughput screening of small molecules in miniaturized mammalian cell-based assays involving post-translational modifications</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">71</span><span class="NLM_x">–</span> <span class="NLM_lpage">83</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1016%2FS1074-5521%2899%2980004-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=10021420" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADyaK1MXhs1yru7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1999&pages=71-83&author=B.+R.+Stockwellauthor=S.+J.+Haggartyauthor=S.+L.+Schreiber&title=High-throughput+screening+of+small+molecules+in+miniaturized+mammalian+cell-based+assays+involving+post-translational+modifications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">High-throughput screening of small molecules in miniaturized mammalian cell-based assays involving post-translational modifications</span></div><div class="casAuthors">Stockwell, Brent R.; Haggarty, Stephen J.; Schreiber, Stuart L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">71-83</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Current Biology Publications</span>)
        </div><div class="casAbstract">Fully adapting a forward genetic approach to mammalian systems requires efficient methods to alter systematically gene products without prior knowledge of gene sequences, while allowing for the subsequent characterization of these alterations.  Ideally, these methods would also allow function to be altered in a temporally controlled manner.  We report the development of a miniaturized cell-based assay format that enables a genetic-like approach to understanding cellular pathways in mammalian systems using small mols., rather than mutations, as the source of gene-product alterations.  This whole-cell immunodetection assay can sensitively detect changes in specific cellular macromols. in high-d. arrays of mammalian cells.  Furthermore, it is compatible with screening large nos. of small mols. in nanoliter to microliter culture vols.  We refer to this assay format as a "cytoblot", and demonstrate the use of cytoblotting to monitor biosynthetic processes such as DNA synthesis, and post-translational processes such as acetylation and phosphorylation.  Finally, we demonstrate the applicability of these assays to natural-product screening through the identification of marine sponge exts. exhibiting genotype-specific inhibition of 5-bromodeoxyuridine incorporation and suppression of the anti-proliferative effect of rapamycin.  We show that cytoblots can be used for high-throughout screening of small mols. in cell-based assays.  Together with small-mol. libraries, the cytoblot assay can be used to perform chem. genetic screens analogous to those used in classical genetics and thus should be applicable to understanding a wide variety of cellular processes, esp. those involving post-transitional modifications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrR0KGn09XQ0LVg90H21EOLACvtfcHk0liH1jneD0sJiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhs1yru7o%253D&md5=681b3a056d86ca5df5902eb420e0f8a1</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2FS1074-5521%2899%2980004-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1074-5521%252899%252980004-0%26sid%3Dliteratum%253Aachs%26aulast%3DStockwell%26aufirst%3DB.%2BR.%26aulast%3DHaggarty%26aufirst%3DS.%2BJ.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26atitle%3DHigh-throughput%2520screening%2520of%2520small%2520molecules%2520in%2520miniaturized%2520mammalian%2520cell-based%2520assays%2520involving%2520post-translational%2520modifications%26jtitle%3DChem.%2520Biol.%26date%3D1999%26volume%3D6%26spage%3D71%26epage%3D83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group">Gangjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Namjoshi, O. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihnat, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorpe, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warnke, L. A.</span><span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agents</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">5514</span><span class="NLM_x">–</span> <span class="NLM_lpage">5528</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=5514-5528&author=A.+Gangjeeauthor=O.+A.+Namjoshiauthor=J.+Yuauthor=M.+A.+Ihnatauthor=J.+E.+Thorpeauthor=L.+A.+Warnke&title=Design%2C+synthesis+and+biological+evaluation+of+substituted+pyrrolo%5B2%2C3-d%5Dpyrimidines+as+multiple+receptor+tyrosine+kinase+inhibitors+and+antiangiogenic+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGangjee%26aufirst%3DA.%26aulast%3DNamjoshi%26aufirst%3DO.%2BA.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DIhnat%26aufirst%3DM.%2BA.%26aulast%3DThorpe%26aufirst%3DJ.%2BE.%26aulast%3DWarnke%26aufirst%3DL.%2BA.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520substituted%2520pyrrolo%255B2%252C3-d%255Dpyrimidines%2520as%2520multiple%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520and%2520antiangiogenic%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2008%26volume%3D16%26spage%3D5514%26epage%3D5528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">Rosenzweig, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youmell, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palayoor, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, B. D.</span><span> </span><span class="NLM_article-title">Radiosensitization of human tumor cells by the phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1149</span><span class="NLM_x">–</span> <span class="NLM_lpage">1156</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=9815794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADyaK2sXkvFCgsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1997&pages=1149-1156&author=K.+E.+Rosenzweigauthor=M.+B.+Youmellauthor=S.+T.+Palayoorauthor=B.+D.+Price&title=Radiosensitization+of+human+tumor+cells+by+the+phosphatidylinositol+3-kinase+inhibitors+wortmannin+and+LY294002+correlates+with+inhibition+of+DNA-dependent+protein+kinase+and+prolonged+G2-M+delay"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Radiosensitization of human tumor cells by the phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay</span></div><div class="casAuthors">Rosenzweig, Kenneth E.; Youmell, Matthew B.; Palayoor, Sanjewani T.; Price, Brendan D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1149-1156</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Members of the phosphatidylinositol (PI) 3-kinase gene family, including the ataxia telangiectasia gene and the DNA-dependent protein kinase (DNA-PK), are involved in regulating cellular radiosensitivity.  We have investigated two structurally unrelated PI 3-kinase inhibitors, wortmannin and LY294002, to det. whether they inhibit DNA-PK and increase cellular radiosensitivity.  The PI 3-kinase inhibitors wortmannin and LY294002 were effective radiosensitizers of human tumor cells, with sensitizer enhancement ratios (at 10% survival) of 2.8 and 1.9, resp., in SW480 cells.  Wortmannin and LY294002 inhibited the kinase activity of purified DNA-PK and inactivated cellular DNA-PK kinase activity.  Inhibition of cellular DNA-PK activity occurred at the same concns. of wortmannin that caused radiosensitization, and this correlation was found in a range of tumor cell lines.  However, cells deficient in either DNA-PK (scid cells) or the ataxia telangiectasia protein were also partly sensitized to radiation by wortmannin, indicating the involvement of more than one protein kinase in the mechanism of action of wortmannin.  Wortmannin also affected the G2-M checkpoint.  SW480 cells had a reversible G2-M delay of 20 h following irradn.  However, wortmannin-treated SW480 cells had a prolonged G2-M delay; more than 75% of cells were arrested in G2 at 50 h postirradn.  This suggests the accumulation of significant unrepaired DNA damage following inhibition of PI 3-kinase family members.  Therefore, PI 3-kinase inhibitors may represent a new class of radiosensitizers that inhibit the repair of DNA damage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrO-sYwY5NMarVg90H21EOLACvtfcHk0liH1jneD0sJiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXkvFCgsLg%253D&md5=06668de6331a6890d7cbc700dad58317</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRosenzweig%26aufirst%3DK.%2BE.%26aulast%3DYoumell%26aufirst%3DM.%2BB.%26aulast%3DPalayoor%26aufirst%3DS.%2BT.%26aulast%3DPrice%26aufirst%3DB.%2BD.%26atitle%3DRadiosensitization%2520of%2520human%2520tumor%2520cells%2520by%2520the%2520phosphatidylinositol%25203-kinase%2520inhibitors%2520wortmannin%2520and%2520LY294002%2520correlates%2520with%2520inhibition%2520of%2520DNA-dependent%2520protein%2520kinase%2520and%2520prolonged%2520G2-M%2520delay%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D1997%26volume%3D3%26spage%3D1149%26epage%3D1156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group">Kisliuk, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strumpf, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaumont, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leary, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plante, L.</span><span> </span><span class="NLM_article-title">Diastereoisomers of 5,10-methylene-5,6,7,8-tetrahydropteroyl-<span class="smallcaps smallerCapital">d</span>-glutamic acid</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1531</span><span class="NLM_x">–</span> <span class="NLM_lpage">1533</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00221a038" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1977&pages=1531-1533&author=R.+L.+Kisliukauthor=D.+Strumpfauthor=Y.+Gaumontauthor=R.+P.+Learyauthor=L.+Plante&title=Diastereoisomers+of+5%2C10-methylene-5%2C6%2C7%2C8-tetrahydropteroyl-d-glutamic+acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1021%2Fjm00221a038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00221a038%26sid%3Dliteratum%253Aachs%26aulast%3DKisliuk%26aufirst%3DR.%2BL.%26aulast%3DStrumpf%26aufirst%3DD.%26aulast%3DGaumont%26aufirst%3DY.%26aulast%3DLeary%26aufirst%3DR.%2BP.%26aulast%3DPlante%26aufirst%3DL.%26atitle%3DDiastereoisomers%2520of%25205%252C10-methylene-5%252C6%252C7%252C8-tetrahydropteroyl-d-glutamic%2520acid%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1977%26volume%3D20%26spage%3D1531%26epage%3D1533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group">Wahba, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedkin, M.</span><span> </span><span class="NLM_article-title">Enzymic synthesis of thymidylate. I. Early steps in the purification of thymidylate synthetase of <i>Escherichia coli</i></span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1962</span><span class="NLM_x">, </span> <span class="NLM_volume">237</span><span class="NLM_x">, </span> <span class="NLM_fpage">3794</span><span class="NLM_x">–</span> <span class="NLM_lpage">3801</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=237&publication_year=1962&pages=3794-3801&author=A.+J.+Wahbaauthor=M.+Friedkin&title=Enzymic+synthesis+of+thymidylate.+I.+Early+steps+in+the+purification+of+thymidylate+synthetase+of+Escherichia+coli"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWahba%26aufirst%3DA.%2BJ.%26aulast%3DFriedkin%26aufirst%3DM.%26atitle%3DEnzymic%2520synthesis%2520of%2520thymidylate.%2520I.%2520Early%2520steps%2520in%2520the%2520purification%2520of%2520thymidylate%2520synthetase%2520of%2520Escherichia%2520coli%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1962%26volume%3D237%26spage%3D3794%26epage%3D3801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">Davisson, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirawaraporn, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santi, D. V.</span><span> </span><span class="NLM_article-title">Expression of human thymidylate synthase in <i>Escherichia coli</i></span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">264</span><span class="NLM_x">, </span> <span class="NLM_fpage">9145</span><span class="NLM_x">–</span> <span class="NLM_lpage">9148</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=264&publication_year=1989&pages=9145-9148&author=V.+J.+Davissonauthor=W.+Sirawarapornauthor=D.+V.+Santi&title=Expression+of+human+thymidylate+synthase+in+Escherichia+coli"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDavisson%26aufirst%3DV.%2BJ.%26aulast%3DSirawaraporn%26aufirst%3DW.%26aulast%3DSanti%26aufirst%3DD.%2BV.%26atitle%3DExpression%2520of%2520human%2520thymidylate%2520synthase%2520in%2520Escherichia%2520coli%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1989%26volume%3D264%26spage%3D9145%26epage%3D9148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group">Tsuda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakaguchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawakita, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakazawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takatsuki, K.</span><span> </span><span class="NLM_article-title">Alteration of cell cycle progression in human leukemia cell line (KOPM-28) induced by 12-o-tetradecanoylphorbol-13-acetate</span> <span class="citation_source-journal">Int. J. Cell Cloning</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">209</span><span class="NLM_x">–</span> <span class="NLM_lpage">220</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1002%2Fstem.5530060306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=3397593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A280%3ADyaL1c3osFymtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1988&pages=209-220&author=H.+Tsudaauthor=M.+Sakaguchiauthor=M.+Kawakitaauthor=S.+Nakazawaauthor=T.+Moriauthor=K.+Takatsuki&title=Alteration+of+cell+cycle+progression+in+human+leukemia+cell+line+%28KOPM-28%29+induced+by+12-o-tetradecanoylphorbol-13-acetate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Alteration of cell cycle progression in human leukemia cell line (KOPM-28) induced by 12-o-tetradecanoylphorbol-13-acetate</span></div><div class="casAuthors">Tsuda H; Sakaguchi M; Kawakita M; Nakazawa S; Mori T; Takatsuki K</div><div class="citationInfo"><span class="NLM_cas:title">International journal of cell cloning</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">209-20</span>
        ISSN:<span class="NLM_cas:issn">0737-1454</span>.
    </div><div class="casAbstract">Terminal cell differentiation usually results in an irreversible arrest in the G1 phase of the cell cycle and loss of cell renewal ability.  Human promyelocytic leukemia HL-60 cells induced with 12-o-tetradecanoylphorbol-13-acetate (TPA) differentiate into monocytes/macrophages and accumulate in G1.  We determined the effect of TPA on the growth kinetics of a human leukemia cell line (KOPM-28), which developed several of the characteristics of megakaryocytes in response to TPA, such as the surface antigen complex IIb/IIIa, platelet peroxidase and polyploidy.  Cell growth was immediately and completely inhibited by TPA.  Flow cytometric analysis of cellular DNA content revealed a gradual decrease in cells in G1 and an accumulation of cells in G2.  These data suggest that TPA prolonged G1 and rapidly arrested the cells in G2.  Synchronized cells were utilized to further analyze the rapid G2 arrest.  Cells arrested with aphidicolin at the G1/S interphase were released, and the effects of TPA (added at different intervals) on cell cycle progression were examined 14 h after release.  The results showed that TPA added at the end of the S phase, as well as at the G1/S interphase incompletely but distinctly arrested cells in G2.  Moreover, G2 arrest was observed when TPA was added to cells released from a colcemid-induced G2/M block, suggesting that cells already in G2 were inhibited by TPA from moving through M to G1.  Since some cells became multi-nucleated in the course of incubation with TPA, this G2 accumulation may have resulted at least in part from a prolongation of the phase or a transient G2 block.  These changes in cell cycle progression induced by TPA may be characteristic of and/or related to megakaryocytic differentiation of hemopoietic precursor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSFqM8kfPuu9mK_SFaaT9INfW6udTcc2eZ8Ozch2hkBPbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL1c3osFymtw%253D%253D&md5=9871d0cd87c86b19c6f186db89d6aace</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1002%2Fstem.5530060306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fstem.5530060306%26sid%3Dliteratum%253Aachs%26aulast%3DTsuda%26aufirst%3DH.%26aulast%3DSakaguchi%26aufirst%3DM.%26aulast%3DKawakita%26aufirst%3DM.%26aulast%3DNakazawa%26aufirst%3DS.%26aulast%3DMori%26aufirst%3DT.%26aulast%3DTakatsuki%26aufirst%3DK.%26atitle%3DAlteration%2520of%2520cell%2520cycle%2520progression%2520in%2520human%2520leukemia%2520cell%2520line%2520%2528KOPM-28%2529%2520induced%2520by%252012-o-tetradecanoylphorbol-13-acetate%26jtitle%3DInt.%2520J.%2520Cell%2520Cloning%26date%3D1988%26volume%3D6%26spage%3D209%26epage%3D220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group">Iliakis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nusse, M.</span><span> </span><span class="NLM_article-title">Arrest of irradiated G1, S, or G2 cells at mitosis using nocodazole promotes repair of potentially lethal damage</span> <span class="citation_source-journal">Radiat. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">346</span><span class="NLM_x">–</span> <span class="NLM_lpage">351</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.2307%2F3576377" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=6463212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A528%3ADyaL2cXltVKmtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=1984&pages=346-351&author=G.+Iliakisauthor=M.+Nusse&title=Arrest+of+irradiated+G1%2C+S%2C+or+G2+cells+at+mitosis+using+nocodazole+promotes+repair+of+potentially+lethal+damage"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Arrest of irradiated G1, S, or G2 cells at mitosis using nocodazole promotes repair of potentially lethal damage</span></div><div class="casAuthors">Iliakis, George; Nusse, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Radiation Research</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">346-51</span>CODEN:
                <span class="NLM_cas:coden">RAREAE</span>;
        ISSN:<span class="NLM_cas:issn">0033-7587</span>.
    </div><div class="casAbstract">The ability of synchronized Ehrlich ascites tumor cells, x-irradiated in G1, S, and G2 phases, to repair potentially lethal damage when arrested at mitosis by using nocodazole, a specific inhibitor of microtubule polymn., (0.4 μg/mL) was studied.  Cells irradiated in these phases repaired potentially lethal damage at mitosis.  The extent of this repair was similar to that obsd. for cells irradiated at the same stages in the cell cycle but allowed to repair potentially lethal damage by incubating in balanced salt soln. for 6 h after x-irradn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpieml_uESMprVg90H21EOLACvtfcHk0liuhOv3gGjurw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXltVKmtb0%253D&md5=17db8a1f8d235325c161251807fb98e1</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.2307%2F3576377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2307%252F3576377%26sid%3Dliteratum%253Aachs%26aulast%3DIliakis%26aufirst%3DG.%26aulast%3DNusse%26aufirst%3DM.%26atitle%3DArrest%2520of%2520irradiated%2520G1%252C%2520S%252C%2520or%2520G2%2520cells%2520at%2520mitosis%2520using%2520nocodazole%2520promotes%2520repair%2520of%2520potentially%2520lethal%2520damage%26jtitle%3DRadiat.%2520Res.%26date%3D1984%26volume%3D99%26spage%3D346%26epage%3D351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group">Lucarelli, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sangiorgi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benassi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donati, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gobbi, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Picci, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacca, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribatti, D.</span><span> </span><span class="NLM_article-title">Angiogenesis in lipoma: An experimental study in the chick embryo chorioallantoic membrane</span> <span class="citation_source-journal">Int. J. Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">593</span><span class="NLM_x">–</span> <span class="NLM_lpage">596</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=10567667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A280%3ADC%252BD3c%252Fjs12mtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1999&pages=593-596&author=E.+Lucarelliauthor=L.+Sangiorgiauthor=S.+Benassiauthor=D.+Donatiauthor=G.+A.+Gobbiauthor=P.+Picciauthor=A.+Vaccaauthor=D.+Ribatti&title=Angiogenesis+in+lipoma%3A+An+experimental+study+in+the+chick+embryo+chorioallantoic+membrane"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Angiogenesis in lipoma: An experimental study in the chick embryo chorioallantoic membrane</span></div><div class="casAuthors">Lucarelli E; Sangiorgi L; Benassi S; Donati D; Gobbi G A; Picci P; Vacca A; Ribatti D</div><div class="citationInfo"><span class="NLM_cas:title">International journal of molecular medicine</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">593-6</span>
        ISSN:<span class="NLM_cas:issn">1107-3756</span>.
    </div><div class="casAbstract">Lipoma is one of the most common benign mesenchymal tumors.  Its ability to trigger an angiogenic response is a critical step for its growth.  Because adipose tissue serves as an important conduit for the vasculature, it is conceivable that the angiogenic properties of this tissue may modulate the growth of the vasculature in a paracrine manner.  We investigated in vivo the angiogenic potential of bioptic fragments of human lipoma by using the chick embryo chorioallantoic membrane (CAM), a useful model for such an investigation.  The angiogenic response in pathological and control implants was assessed on histologic sections by a morphometric method, 96 h after grafting.  Results showed that pathological samples were surrounded by numerous allantoic vessels with a radially arranged pattern around the implant.  The vascular counts in the CAMs treated with lipoma implants were comparable to that of FGF-2.  The role played in vasoproliferative response by angiogenic cytokines (FGF-2, VEGF) released by adipocytes, by endogenous cytokines, such as FGF-2, stored in the CAM extracellular matrix and by angiogenic growth factors released by perivascular mononuclear cells around the newly-formed blood vessels, were supported by this study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR8BDkSiue04f69nzq6467DfW6udTcc2eZ8Ozch2hkBPbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c%252Fjs12mtg%253D%253D&md5=624b9230c8167312f01641c6f7732b20</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLucarelli%26aufirst%3DE.%26aulast%3DSangiorgi%26aufirst%3DL.%26aulast%3DBenassi%26aufirst%3DS.%26aulast%3DDonati%26aufirst%3DD.%26aulast%3DGobbi%26aufirst%3DG.%2BA.%26aulast%3DPicci%26aufirst%3DP.%26aulast%3DVacca%26aufirst%3DA.%26aulast%3DRibatti%26aufirst%3DD.%26atitle%3DAngiogenesis%2520in%2520lipoma%253A%2520An%2520experimental%2520study%2520in%2520the%2520chick%2520embryo%2520chorioallantoic%2520membrane%26jtitle%3DInt.%2520J.%2520Mol.%2520Med.%26date%3D1999%26volume%3D4%26spage%3D593%26epage%3D596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group">Romanoff, A. L.</span> <span class="citation_source-book">Biochemistry of the Avian Embryo: A Quantitative Analysis of Prenatal Development</span>; <span class="NLM_publisher-name">Interscience</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">1967</span><span class="NLM_x">; </span>398 pp.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1967&author=A.+L.+Romanoff&title=Biochemistry+of+the+Avian+Embryo%3A+A+Quantitative+Analysis+of+Prenatal+Development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DRomanoff%26aufirst%3DA.%2BL.%26btitle%3DBiochemistry%2520of%2520the%2520Avian%2520Embryo%253A%2520A%2520Quantitative%2520Analysis%2520of%2520Prenatal%2520Development%26pub%3DInterscience%26date%3D1967" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group">Hanna, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidler, I. J.</span><span> </span><span class="NLM_article-title">Role of natural killer cells in the destruction of circulating tumor emboli</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">801</span><span class="NLM_x">–</span> <span class="NLM_lpage">809</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=6932529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A280%3ADyaL3M%252FivVOgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=1980&pages=801-809&author=N.+Hannaauthor=I.+J.+Fidler&title=Role+of+natural+killer+cells+in+the+destruction+of+circulating+tumor+emboli"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Role of natural killer cells in the destruction of circulating tumor emboli</span></div><div class="casAuthors">Hanna N; Fidler I J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">801-9</span>
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    </div><div class="casAbstract">A close correlation was demonstrated between levels of host natural cytotoxic (NC) and/or natural killer (NK) cell activity and capacity to eliminate blood-borne tumor cells.  The outcome of experimental metastasis of several tumors with defined biologic behavior was studied in syngeneic mice exhibiting low NK cell activity [3-wk-old normal mice and cyclophosphamide (Cy)-treated adult mice] and high NK cell activity (normal adult mice).  An iv injection of metastatic tumor cells into 3-week-old or Cy-treated mice markedly enhanced experimental pulmonary metastasis.  The increased incidence of metastasis in mice exhibiting low activity of NK cells was not due to enhanced tumor cell arrest in the lung but rather to increased tumor cell survival.  Boosting the NK activity of 3-week-old, but not Cy-treated, mice with interferon inducers inhibited metastasis formation.  The adoptive transfer of spleen cells from syngeneic mice or allogeneic nude mice that have high NK activity shortly before (but not after) iv tumor challenge abrogated the Cy-induced enhancement of metastasis.  The reactive lymphoid cells were non-T, nonadherent to nylon wool, sensitive to Cy treatment, and endowed with a natural ability to kill tumor cells during a short (12-24 hr) period.  The conclusions were that NC-NK cells are important in host defense against circulating tumor cells and therefore can prevent the development of tumor cells into metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT4JYPfiC_AeWgRQsDqrjW_fW6udTcc2eZD-5gI-UecZ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL3M%252FivVOgsQ%253D%253D&md5=466b8b538686edf88fe7b3406b4e7e1e</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHanna%26aufirst%3DN.%26aulast%3DFidler%26aufirst%3DI.%2BJ.%26atitle%3DRole%2520of%2520natural%2520killer%2520cells%2520in%2520the%2520destruction%2520of%2520circulating%2520tumor%2520emboli%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D1980%26volume%3D65%26spage%3D801%26epage%3D809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group">Hanna, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidler, I. J.</span><span> </span><span class="NLM_article-title">Environmental and genetic factors determine the level of NK activity of nude mice and affect their suitability as models for experimental metastasis</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">371</span><span class="NLM_x">–</span> <span class="NLM_lpage">376</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Fjm9011142&amp;key=10.1002%2Fijc.2910300319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Fjm9011142&amp;key=7129682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Fjm9011142&amp;key=1%3ACAS%3A280%3ADyaL3s%252FivFynsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1982&pages=371-376&author=N.+Hannaauthor=T.+W.+Davisauthor=I.+J.+Fidler&title=Environmental+and+genetic+factors+determine+the+level+of+NK+activity+of+nude+mice+and+affect+their+suitability+as+models+for+experimental+metastasis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Environmental and genetic factors determine the level of NK activity of nude mice and affect their suitability as models for experimental metastasis</span></div><div class="casAuthors">Hanna N; Davis T W; Fidler I J</div><div class="citationInfo"><span class="NLM_cas:title">International journal of cancer. Journal international du cancer</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">371-6</span>
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    </div><div class="casAbstract">In these studies we have evaluated the effects of age, genetic background, and housing conditions on the NK-cell activity of nude mice measured in vitro and resistance to tumor metastasis in vivo.  BALB/cAnN nude mice exhibited lower levels of NK-cell-mediated cytotoxicity than age-matched N:NIH(S) nude mice maintained under similar housing conditions.  The stronger response of N:NIH(S) nude mice was observed also after experimental activation of NK cells by Corynebacterium parvum.  Nude mice maintained under barrier conditions have weaker NK-cell activity than mice maintained under conventional conditions.  The incidence of experimental pulmonary metastases of allogeneic tumors injected into nude mice was inversely correlated with the levels of NK-cell-mediated cytotoxicity.  Thus, 3-week-old BALB/cAnN nude mice raised under barrier conditions were more sensitive to development of experimental metastasis than age-matched N:NIH(S) nude mice maintained under barrier conditions or nude mice of either strain maintained under conventional conditions.  In both strains, however, the relative differences in metastatic potential among the tumor cell lines observed in syngeneic recipients were maintained.  We conclude that young BALB/cAnN nude mice raised under barrier conditions may provide a valuable in vivo model for studying metastasis of neoplasms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7JdJmeKDCkzDnmmyUf5qOfW6udTcc2eZD-5gI-UecZ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL3s%252FivFynsQ%253D%253D&md5=48efc4bef602a01b8686a29e0a14883b</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1002%2Fijc.2910300319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.2910300319%26sid%3Dliteratum%253Aachs%26aulast%3DHanna%26aufirst%3DN.%26aulast%3DDavis%26aufirst%3DT.%2BW.%26aulast%3DFidler%26aufirst%3DI.%2BJ.%26atitle%3DEnvironmental%2520and%2520genetic%2520factors%2520determine%2520the%2520level%2520of%2520NK%2520activity%2520of%2520nude%2520mice%2520and%2520affect%2520their%2520suitability%2520as%2520models%2520for%2520experimental%2520metastasis%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D1982%26volume%3D30%26spage%3D371%26epage%3D376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1JU6" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1JU6','PDB','1JU6'); return false;">PDB: 1JU6</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1YWN" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1YWN','PDB','1YWN'); return false;">PDB: 1YWN</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PKG" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1PKG','PDB','1PKG'); return false;">PDB: 1PKG</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i34"><a href="/doi/suppl/10.1021/jm9011142">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_31415"></div></div></div></div></div><hr /></hr><p class="last">Results from elemental analysis and high-resolution mass spectrometry. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm9011142/suppl_file/jm9011142_si_001.pdf">jm9011142_si_001.pdf (33.02 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm9011142&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3A10.1021%2Fjm9011142%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2010.53.issue-4%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm9011142" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799e688d9fe1969","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
